BayBio Members
Filter by
Please register to view the complete BayBio Member Directory
Does your organization's profile need to updated?
Service Providers click here.
R&D organizations click here.
Partners
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
|
| ||||||
Members
Abbott
http://www.abbott.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Medical Devices
Therapeutic
http://www.abbott.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Medical Devices
Therapeutic
Accenture
560 Mission Street
San Francisco, CA, United States, 94105
415-537-5000
http://www.accenture.com/Primary Contacts
Bill Annett
Partner, West Coast Life Sciences
415-537-4613
Company Profile
Accenture™'s Life Sciences practice works with pharmaceuticals, biotechnology, medical products, medical technology, regulators, distributors, wholesalers and other companies to help bring life-enhancing health solutions to people around the globe. Accenture provides consulting, technology and outsourcing services across the entire life sciences value chain, from large-scale business and technology transformation to post-merger integration. Key offerings include: Research and Development, including pharmacovigilance and regulatory outsourcing; Supply Chain and Manufacturing Optimization; and Marketing and Sales, including commercial services, analytics and digital marketing. With more than 10,000 professionals dedicated to life sciences working in more than 50 countries, Accenture helps companies overcome industry challenges, achieve business objectives and drive sustainable growth.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
560 Mission Street
San Francisco, CA, United States, 94105
415-537-5000
http://www.accenture.com/Primary Contacts
Bill Annett
Partner, West Coast Life Sciences
415-537-4613
Company Profile
Accenture™'s Life Sciences practice works with pharmaceuticals, biotechnology, medical products, medical technology, regulators, distributors, wholesalers and other companies to help bring life-enhancing health solutions to people around the globe. Accenture provides consulting, technology and outsourcing services across the entire life sciences value chain, from large-scale business and technology transformation to post-merger integration. Key offerings include: Research and Development, including pharmacovigilance and regulatory outsourcing; Supply Chain and Manufacturing Optimization; and Marketing and Sales, including commercial services, analytics and digital marketing. With more than 10,000 professionals dedicated to life sciences working in more than 50 countries, Accenture helps companies overcome industry challenges, achieve business objectives and drive sustainable growth.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Alexandria Real Estate Equities, Inc.
1700 Owens Street, Suite 590
San Francisco, CA, United States, 94158
415-554-8844
http://www.labspace.comPrimary Contacts
Stephen Richardson
Executive Vice President - Regional Market Director
Company Profile
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest REIT focused principally on providing high-quality real estate for the life science industry. Since 1994, Alexandria has created first-in-class life science clusters that foster innovative and collaborative environments in key locations immediately proximate to leading research institutions. Alexandria’s broad and diverse tenant base includes internationally renowned academic and medical institutions, multinational pharmaceutical companies, leading private and public biotechnology entities, non-profit institutions, government agencies, medical device companies, biofuels companies, research tools and service companies, and venture capitalists. Located in the top life science markets around the globe, Alexandria’s world-class properties, highly specialized operations, and expansive network assist the life science industry in translating promising discoveries into important, safe, and effective products that benefit humankind.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
1700 Owens Street, Suite 590
San Francisco, CA, United States, 94158
415-554-8844
http://www.labspace.comPrimary Contacts
Stephen Richardson
Executive Vice President - Regional Market Director
Company Profile
Alexandria Real Estate Equities, Inc., Landlord of Choice to the Life Science Industry®, is the largest REIT focused principally on providing high-quality real estate for the life science industry. Since 1994, Alexandria has created first-in-class life science clusters that foster innovative and collaborative environments in key locations immediately proximate to leading research institutions. Alexandria’s broad and diverse tenant base includes internationally renowned academic and medical institutions, multinational pharmaceutical companies, leading private and public biotechnology entities, non-profit institutions, government agencies, medical device companies, biofuels companies, research tools and service companies, and venture capitalists. Located in the top life science markets around the globe, Alexandria’s world-class properties, highly specialized operations, and expansive network assist the life science industry in translating promising discoveries into important, safe, and effective products that benefit humankind.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
Amgen Inc.
1120 Veteran's Blvd
South San Francisco, CA, 94080
650-244-1000
http://www.amgen.com/Primary Contacts
Dr. Terry Rosen
Vice President, Research; ASF Site Head
Company Profile
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
1120 Veteran's Blvd
South San Francisco, CA, 94080
650-244-1000
http://www.amgen.com/Primary Contacts
Dr. Terry Rosen
Vice President, Research; ASF Site Head
Company Profile
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Barney & Barney LLC
1999 Harrision Street, Suite 1230
Oakland, CA, United States, 94612
510-273-8888
http://www.barneyandbarney.comPrimary Contacts
Kevin Mirsky
Principal, Tech & Life Science Practice
510 466 6058
Company Profile
Barney & Barney is one of the largest insurance brokerage firms in the United States. Barney & Barney provides clients with commerical insuance and employee benefit brokerage services, risk management, personal insurance, wealth management and compensation consulting. The firm's largest concentration of clients is within its Technology & Life Science Practice Group.Company Classification
Associate/Service ProvidersOrganization Type
Insurance
1999 Harrision Street, Suite 1230
Oakland, CA, United States, 94612
510-273-8888
http://www.barneyandbarney.comPrimary Contacts
Kevin Mirsky
Principal, Tech & Life Science Practice
510 466 6058
Company Profile
Barney & Barney is one of the largest insurance brokerage firms in the United States. Barney & Barney provides clients with commerical insuance and employee benefit brokerage services, risk management, personal insurance, wealth management and compensation consulting. The firm's largest concentration of clients is within its Technology & Life Science Practice Group.Company Classification
Associate/Service ProvidersOrganization Type
Insurance
Baxter Healthcare Corporation
One Baxter Drive
Deerfield, IL, 60015
847.948.2000
http://www.baxter.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Medical Devices
TherapeuticClinical Development Stage
Phase I
Phase II
Phase III
Approved
One Baxter Drive
Deerfield, IL, 60015
847.948.2000
http://www.baxter.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Medical Devices
TherapeuticClinical Development Stage
Phase I
Phase II
Phase III
Approved
Bayer Healthcare
800 Dwight Way
Berkeley, CA, 94710
510-705-5000
http://www.biotech.bayerhealthcare.comPrimary Contacts
Joerg Heidrich
Sr. Vice President, Product Supply Biotech
Olivia Krampe
Vice President and Site Head, Emeryville Supply Center
Terry Hermiston
Vice President, US Biologics Research; Head, U.S. Innovation Center
Company Profile
Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Genetic Diseases
Kidneys & Genito-Urinary System
Ophthalmology
Respiratory Disorders
Womens HealthPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
800 Dwight Way
Berkeley, CA, 94710
510-705-5000
http://www.biotech.bayerhealthcare.comPrimary Contacts
Joerg Heidrich
Sr. Vice President, Product Supply Biotech
Olivia Krampe
Vice President and Site Head, Emeryville Supply Center
Terry Hermiston
Vice President, US Biologics Research; Head, U.S. Innovation Center
Company Profile
Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Genetic Diseases
Kidneys & Genito-Urinary System
Ophthalmology
Respiratory Disorders
Womens HealthPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
BioMed Realty Trust
7677 Gateway Blvd. Suite 100
Newark, CA, 94560
510-505-6064
http://www.biomedrealty.comPrimary Contacts
Luyen Pham
Associate
510-505-6064
Scott Altick
Associate
510-505-6044
Anne Hoffman
Senior Vice President, Development
510 505 6046
Company Profile
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. We acquire, develop, own and operate laboratory and office space. Our properties are designed to effectively support the demanding needs of a wide range of pharmaceutical, biotechnology and research institutions. We currently own or have interests in 85 properties, which comprise 147 buildings with approximately 12.2 million rentable square feet.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
7677 Gateway Blvd. Suite 100
Newark, CA, 94560
510-505-6064
http://www.biomedrealty.comPrimary Contacts
Luyen Pham
Associate
510-505-6064
Scott Altick
Associate
510-505-6044
Anne Hoffman
Senior Vice President, Development
510 505 6046
Company Profile
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. We acquire, develop, own and operate laboratory and office space. Our properties are designed to effectively support the demanding needs of a wide range of pharmaceutical, biotechnology and research institutions. We currently own or have interests in 85 properties, which comprise 147 buildings with approximately 12.2 million rentable square feet.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
BioSpace
6465 South Greenwood Plaza Blvd.
Centennial, CO, United States, 80111
888.BIOSPACE
http://www.biospace.comPrimary Contacts
Sahar Azarabadi
Director of Sales
415-775-1141
Joe Kroog
Director, Product Management
303-562-0351
June Salvati
Director, Career Fairs
(732-746-2296
Valerie Quintanilla
Senior Manager, Marketing Communications
303-562-0144
Company Profile
BioSpace (www.biospace.com) is the leading online community for life science careers, news and other resources. For more than two decades, BioSpace has helped accelerate recruitment, communication and discovery among business and scientific leaders in the biopharmaceutical market. BioSpace hosts more than 20 biopharmaceutical career events every year across the U.S. and has over 1,500 life science companies looking for talented professionals online. Job Seekers can create a free profile, set up automatic job alerts, post their resume, search & apply to life sciences jobs and subscribe to FREE BioSpace eNewsletters. An onTargetjobs, Inc., company, BioSpace.com powers DeviceSpace.com (www.devicespace.com) as a portal for medical device and diagnostics industries, ClinicaSpace.com (www.clinicaspace.com) for clinical research professionals and BioSpace Collaborative for those in academic and biomedical research (www.biospace.com/collaborative).Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
MediaClinical Development Stage
Phase I
6465 South Greenwood Plaza Blvd.
Centennial, CO, United States, 80111
888.BIOSPACE
http://www.biospace.comPrimary Contacts
Sahar Azarabadi
Director of Sales
415-775-1141
Joe Kroog
Director, Product Management
303-562-0351
June Salvati
Director, Career Fairs
(732-746-2296
Valerie Quintanilla
Senior Manager, Marketing Communications
303-562-0144
Company Profile
BioSpace (www.biospace.com) is the leading online community for life science careers, news and other resources. For more than two decades, BioSpace has helped accelerate recruitment, communication and discovery among business and scientific leaders in the biopharmaceutical market. BioSpace hosts more than 20 biopharmaceutical career events every year across the U.S. and has over 1,500 life science companies looking for talented professionals online. Job Seekers can create a free profile, set up automatic job alerts, post their resume, search & apply to life sciences jobs and subscribe to FREE BioSpace eNewsletters. An onTargetjobs, Inc., company, BioSpace.com powers DeviceSpace.com (www.devicespace.com) as a portal for medical device and diagnostics industries, ClinicaSpace.com (www.clinicaspace.com) for clinical research professionals and BioSpace Collaborative for those in academic and biomedical research (www.biospace.com/collaborative).Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
MediaClinical Development Stage
Phase I
Burr Pilger Mayer, Inc.
2000 University Ave, Suite 201
East Palo Alto, CA, United States, 94303
415-421-5757
http://www.bpmcpa.comPrimary Contacts
Michael Benjamin
Partner
415-288-6294
Company Profile
Burr Pilger Mayer (BPM) is the largest California-based accounting and consulting firm. We’ve been serving the Bay Area’s emerging and mid-cap businesses as well as high net worth individuals for 25 years.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
2000 University Ave, Suite 201
East Palo Alto, CA, United States, 94303
415-421-5757
http://www.bpmcpa.comPrimary Contacts
Michael Benjamin
Partner
415-288-6294
Company Profile
Burr Pilger Mayer (BPM) is the largest California-based accounting and consulting firm. We’ve been serving the Bay Area’s emerging and mid-cap businesses as well as high net worth individuals for 25 years.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Cooley Godward Kronish LLP
United States, http://www.cooley.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
United States, http://www.cooley.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
Corning Axygen
United States, http://www.corning.com/lifesciences/us_canada/en/index.aspxCompany Classification
Associate/Service Providers
United States, http://www.corning.com/lifesciences/us_canada/en/index.aspxCompany Classification
Associate/Service Providers
Deloitte & Touche
555 Mission Street
San Francisco, CA, 94105
415-783-4000
http://www.us.deloitte.comPrimary Contacts
Keith Donnermeyer
Partner, U.S. Life Sciences Industry Leader, Audit & Enterprise Risk Services
415-783-5554
Cathy Coste
Partner, Life Sciences - Enterprise Risk Services
415-783-4357
Matthew Hudes
U.S. Managing Principal, Biotechnology
415-783-6161
Christie Smith, PhD
Principal, West Region Life Science Industry Leader
1-646-785-6711
Michael Vanderklugt
Partner, Life Sciences - Audit Services
415-783-4517
Alfonse Upshaw
Partner, Life Sciences - Audit Services
415-783-6280
Company Profile
Deloitte’s Life Sciences practice brings fresh ideas and groundbreaking concepts to clients and industry leaders alike. Whether it’s market innovations in biotechnology or providing exceptional counsel to some of the world's leading pharmaceutical and medical device companies, Deloitte offers a distinctive menu of professional services delivered in an integrated, collaborative approach that cuts across all segments of the Life Science industry - pharmaceuticals, biotechnology, medical products and technology and medical devices. We work in four key business areas — audit, financial advisory, tax and consulting — but our real strength comes from combining the talents of those groups to address clients’ needs. Deloitte is one of the largest private professional services network in the world with approximately 170,000 professionals in more than 140 countries. In the United States, Deloitte LLP and its subsidiaries have more than 45,000 professionals with a single focus: serving our clients and helping them solve their toughest problems. Our clients demand top value and unbending commitment from us. We demand nothing less of ourselves in working to become their trusted business advisors.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
555 Mission Street
San Francisco, CA, 94105
415-783-4000
http://www.us.deloitte.comPrimary Contacts
Keith Donnermeyer
Partner, U.S. Life Sciences Industry Leader, Audit & Enterprise Risk Services
415-783-5554
Cathy Coste
Partner, Life Sciences - Enterprise Risk Services
415-783-4357
Matthew Hudes
U.S. Managing Principal, Biotechnology
415-783-6161
Christie Smith, PhD
Principal, West Region Life Science Industry Leader
1-646-785-6711
Michael Vanderklugt
Partner, Life Sciences - Audit Services
415-783-4517
Alfonse Upshaw
Partner, Life Sciences - Audit Services
415-783-6280
Company Profile
Deloitte’s Life Sciences practice brings fresh ideas and groundbreaking concepts to clients and industry leaders alike. Whether it’s market innovations in biotechnology or providing exceptional counsel to some of the world's leading pharmaceutical and medical device companies, Deloitte offers a distinctive menu of professional services delivered in an integrated, collaborative approach that cuts across all segments of the Life Science industry - pharmaceuticals, biotechnology, medical products and technology and medical devices. We work in four key business areas — audit, financial advisory, tax and consulting — but our real strength comes from combining the talents of those groups to address clients’ needs. Deloitte is one of the largest private professional services network in the world with approximately 170,000 professionals in more than 140 countries. In the United States, Deloitte LLP and its subsidiaries have more than 45,000 professionals with a single focus: serving our clients and helping them solve their toughest problems. Our clients demand top value and unbending commitment from us. We demand nothing less of ourselves in working to become their trusted business advisors.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
DLA Piper US LLP
555 Mission Street, Suite 2400
San Francisco, CA, United States, 94105
415.836.2530
http://www.dlapiper.comPrimary Contacts
Bruce W. Jenett
Partner
650.833.2321
Lisa Haile
Partner
858.677.1456
Company Profile
DLA Piper has 3,500 lawyers in offices throughout Asia-Pacific, Europe, the Middle East and the United States. In the US alone, we have 1,500 lawyers in more than 20 cities, including top business and technology markets across the country. We represent more clients in a broader range of geographies and practice disciplines than virtually any other law firm in the world. Our client commitment is also our brand – everything matters when it comes to the way we serve and interact with our clients. If it matters to them, it matters to us. DLA Piper was built to serve clients wherever in the world they do business - quickly, efficiently and with genuine knowledge of both local and international considerations. But while markets around the world are internationalizing, this doesn’t mean they are becoming the same. We remain committed, as always, to the local markets that are the building blocks of international business.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
555 Mission Street, Suite 2400
San Francisco, CA, United States, 94105
415.836.2530
http://www.dlapiper.comPrimary Contacts
Bruce W. Jenett
Partner
650.833.2321
Lisa Haile
Partner
858.677.1456
Company Profile
DLA Piper has 3,500 lawyers in offices throughout Asia-Pacific, Europe, the Middle East and the United States. In the US alone, we have 1,500 lawyers in more than 20 cities, including top business and technology markets across the country. We represent more clients in a broader range of geographies and practice disciplines than virtually any other law firm in the world. Our client commitment is also our brand – everything matters when it comes to the way we serve and interact with our clients. If it matters to them, it matters to us. DLA Piper was built to serve clients wherever in the world they do business - quickly, efficiently and with genuine knowledge of both local and international considerations. But while markets around the world are internationalizing, this doesn’t mean they are becoming the same. We remain committed, as always, to the local markets that are the building blocks of international business.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Drinker Biddle
United States, http://www.dbr.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
United States, http://www.dbr.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Elan Pharmaceuticals, Inc.
800 Gateway Blvd
South San Francisco, CA, 94080
(650) 877-7647
http://www.elan.comPrimary Contacts
Kelly Martin
Chief Executive Officer
Company Profile
Elan is a neuroscience-based biotechnology company,Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Central NervousPrimary Technology
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
800 Gateway Blvd
South San Francisco, CA, 94080
(650) 877-7647
http://www.elan.comPrimary Contacts
Kelly Martin
Chief Executive Officer
Company Profile
Elan is a neuroscience-based biotechnology company,Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Central NervousPrimary Technology
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Ernst & Young LLP
United States, http://www.ey.comCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Financial Services
United States, http://www.ey.comCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Financial Services
Fenwick and West, LLP
801 California Street
Mountain View, CA, 94041
650.988.8500
http://fenwick.comPrimary Contacts
Stephen M. Graham
Co-Chair, Life Sciences Group; Partner, Corporate Group
206.389.4520
Michael J. Shuster, Ph.D.
Co-Chair, Life Sciences Group; Partner, Intellectual Property Group
415.875.2413
Gordon K. Davidson
Firm Chairman; Partner, Corporate Group
Lynn H. Pasahow
Partner, Litigation Group
650.335.7225
Robert A. Kahn
Director of Business Development
650.335.7616
Tory B. Duffy
Marketing and Recruiting Coordinator
206.389.4589
Company Profile
Fenwick & West's Life Sciences Industry Group consists of more than 60 attorneys and scientists—including more than 15 with Ph.D.s—who provide a broad mix of core legal services to private companies, public companies, investors and research institutions. Many of our Life Sciences Group attorneys have scientific and research experience prior to their legal careers, and a number have advanced technical degrees in disciplines such as molecular biology, organic chemistry, electrical engineering, and immunology. For more information, visit www.fenwick.com/lifesciences.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
801 California Street
Mountain View, CA, 94041
650.988.8500
http://fenwick.comPrimary Contacts
Stephen M. Graham
Co-Chair, Life Sciences Group; Partner, Corporate Group
206.389.4520
Michael J. Shuster, Ph.D.
Co-Chair, Life Sciences Group; Partner, Intellectual Property Group
415.875.2413
Gordon K. Davidson
Firm Chairman; Partner, Corporate Group
Lynn H. Pasahow
Partner, Litigation Group
650.335.7225
Robert A. Kahn
Director of Business Development
650.335.7616
Tory B. Duffy
Marketing and Recruiting Coordinator
206.389.4589
Company Profile
Fenwick & West's Life Sciences Industry Group consists of more than 60 attorneys and scientists—including more than 15 with Ph.D.s—who provide a broad mix of core legal services to private companies, public companies, investors and research institutions. Many of our Life Sciences Group attorneys have scientific and research experience prior to their legal careers, and a number have advanced technical degrees in disciplines such as molecular biology, organic chemistry, electrical engineering, and immunology. For more information, visit www.fenwick.com/lifesciences.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Genencor International
United States, http://www.genencor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
United States, http://www.genencor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
Genentech
1 DNA Way
South San Francisco, CA, 415-650-2000
http://www.gene.comPrimary Contacts
Ian Clark
CEO
Company Profile
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. In March 2009, Genentech became a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Ophthalmology
Respiratory DisordersPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
1 DNA Way
South San Francisco, CA, 415-650-2000
http://www.gene.comPrimary Contacts
Ian Clark
CEO
Company Profile
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. In March 2009, Genentech became a member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Ophthalmology
Respiratory DisordersPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA, 94404
650 574 3000 or 800
http://www.gilead.comPrimary Contacts
John C. Martin, PhD
Chairman and Chief Executive Officer
John F. Milligan, PhD
President and Chief Operating Officer
Gregg H. Alton
Executive Vice President, Corporate and Medical Affairs
Company Profile
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
333 Lakeside Drive
Foster City, CA, 94404
650 574 3000 or 800
http://www.gilead.comPrimary Contacts
John C. Martin, PhD
Chairman and Chief Executive Officer
John F. Milligan, PhD
President and Chief Operating Officer
Gregg H. Alton
Executive Vice President, Corporate and Medical Affairs
Company Profile
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
King & Spalding LLP
United States, http://www.kslaw.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
United States, http://www.kslaw.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
KPMG
55 Second St, Suite 1400
San Francisco, CA, 94105
415-963-0100
http://wwww.kpmg.comPrimary Contacts
Paulette DeFalco
West Area Life Sciences Leader
415-963-7345
Chris Cimino
Advisory Partner- Life Sciences
415-963-5451
Company Profile
KPMG is a global professional services firm specializing in providing audit, tax and advisory services to small, middle market and global life science companiesCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
55 Second St, Suite 1400
San Francisco, CA, 94105
415-963-0100
http://wwww.kpmg.comPrimary Contacts
Paulette DeFalco
West Area Life Sciences Leader
415-963-7345
Chris Cimino
Advisory Partner- Life Sciences
415-963-5451
Company Profile
KPMG is a global professional services firm specializing in providing audit, tax and advisory services to small, middle market and global life science companiesCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Latham & Watkins
140 Scott Dr.
Menlo Park, CA, 94025
650-328-4600
http://www.lw.comPrimary Contacts
Alan Mendelson
Partner
650.328.4600
Mark Roeder
Partner
650.328.4600
Judith Hasko
Partner
650.328.4600
Chuck Hoyng
Partner
650.328.4600
Cory Cullen
Business Development Manager
650.328.4600
Peter Boyd
Associate
650.328.4600
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
140 Scott Dr.
Menlo Park, CA, 94025
650-328-4600
http://www.lw.comPrimary Contacts
Alan Mendelson
Partner
650.328.4600
Mark Roeder
Partner
650.328.4600
Judith Hasko
Partner
650.328.4600
Chuck Hoyng
Partner
650.328.4600
Cory Cullen
Business Development Manager
650.328.4600
Peter Boyd
Associate
650.328.4600
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Merrill DataSite
United States, http://www.datasite.com/Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
United States, http://www.datasite.com/Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
Morrison & Foerster LLP
United States, http://www.mofo.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
United States, http://www.mofo.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
MPI Research
54943 North Main Street
Mattawan, MI, United States, 49071
+1.269.668.3336
http://www.mpiresearch.comPrimary Contacts
Stephen Frantz
Senior Business Development Director
+1.269.668.3336
William Jefferson
Business Development Manager
+1.269.668.3336
Company Profile
MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, and animal health industries. Scientific knowledge and experience, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. MPI Research has conducted thousands of drug safety, discovery, and bioanalytical and analytical studies in both small and large molecules. The company’s internal structure allows us to respond and adapt rapidly, from making last minute scheduling changes to developing new capabilities as needed. We test a wide and diverse range of compound classes, provide all routes of administration (exception: inhalation) and offer studies with numerous species and models. With ample physical and technical capacity, we can accommodate multiple requirements simultaneously, adjust schedules readily, and produce results quickly. MPI Research Study Directors and Scientists are uniquely accessible on a real-time basis and proactive in keeping you informed as developments unfold, from collaboration on the initial program design through final report. Learn more about how we can exceed your expectations at www.mpiresearch.com.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationClinical Development Stage
PreClinical
54943 North Main Street
Mattawan, MI, United States, 49071
+1.269.668.3336
http://www.mpiresearch.comPrimary Contacts
Stephen Frantz
Senior Business Development Director
+1.269.668.3336
William Jefferson
Business Development Manager
+1.269.668.3336
Company Profile
MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, and animal health industries. Scientific knowledge and experience, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. MPI Research has conducted thousands of drug safety, discovery, and bioanalytical and analytical studies in both small and large molecules. The company’s internal structure allows us to respond and adapt rapidly, from making last minute scheduling changes to developing new capabilities as needed. We test a wide and diverse range of compound classes, provide all routes of administration (exception: inhalation) and offer studies with numerous species and models. With ample physical and technical capacity, we can accommodate multiple requirements simultaneously, adjust schedules readily, and produce results quickly. MPI Research Study Directors and Scientists are uniquely accessible on a real-time basis and proactive in keeping you informed as developments unfold, from collaboration on the initial program design through final report. Learn more about how we can exceed your expectations at www.mpiresearch.com.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationClinical Development Stage
PreClinical
Nektar Therapeutics
http://www.nektar.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.nektar.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Novartis Diagnostics
4560 Horton St.
Emeryville, CA, 94608
http://www.novartis.comPrimary Contacts
Peter Maag
President, Novartis Diagnostics, Emeryville Site Head
Company Profile
Novartis provides healthcare solutions that address the evolving needs of patients and societies. In Emeryville, CA, Novartis has two divisions, Novartis Diagnostics and Novartis Institutes for BioMedical Research (NIBR). Novartis Diagnostics is the established global leader in blood safety, a position built on more than 20 years of scientific excellence, ongoing innovation, and collaboration with our development partners. Worldwide, more of the 93 million units of donated blood are tested with Novartis' blood screening products than any other NAT system. Building on its strong presence in transfusion medicine, Novartis Diagnostics is moving into new diagnostic areas, creating innovative tests to detect, prevent and predict disease and to improve medical outcomes. Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis committed to discovering innovative medicines that treat disease and improve human health. At NIBR Emeryville, the Oncology and Infectious Disease teams cover a broad spectrum of expertise including signal transduction pathways, cell cycle control, pharmacology, biologics research, structural biology and medicinal and computational chemistry.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
4560 Horton St.
Emeryville, CA, 94608
http://www.novartis.comPrimary Contacts
Peter Maag
President, Novartis Diagnostics, Emeryville Site Head
Company Profile
Novartis provides healthcare solutions that address the evolving needs of patients and societies. In Emeryville, CA, Novartis has two divisions, Novartis Diagnostics and Novartis Institutes for BioMedical Research (NIBR). Novartis Diagnostics is the established global leader in blood safety, a position built on more than 20 years of scientific excellence, ongoing innovation, and collaboration with our development partners. Worldwide, more of the 93 million units of donated blood are tested with Novartis' blood screening products than any other NAT system. Building on its strong presence in transfusion medicine, Novartis Diagnostics is moving into new diagnostic areas, creating innovative tests to detect, prevent and predict disease and to improve medical outcomes. Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis committed to discovering innovative medicines that treat disease and improve human health. At NIBR Emeryville, the Oncology and Infectious Disease teams cover a broad spectrum of expertise including signal transduction pathways, cell cycle control, pharmacology, biologics research, structural biology and medicinal and computational chemistry.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Onyx Pharmaceuticals, Inc.
249 East Grand Avenue
South San Francisco, CA, 94080
650.266.0000
http://www.onyx-pharm.com/Primary Contacts
N. Anthony Coles, M.D.
President and CEO
Laura A. Brege
Executive Vice President, Corporate Affairs
Matthew K. Fust
Executive Vice President and Chief Financial Officer
Company Profile
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of the thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
249 East Grand Avenue
South San Francisco, CA, 94080
650.266.0000
http://www.onyx-pharm.com/Primary Contacts
N. Anthony Coles, M.D.
President and CEO
Laura A. Brege
Executive Vice President, Corporate Affairs
Matthew K. Fust
Executive Vice President and Chief Financial Officer
Company Profile
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of the thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Pfizer Inc./Rinat
230 E. Grand Ave.
South San Francisco, CA, 94080
650-615-7300
http://www.pfizer.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
230 E. Grand Ave.
South San Francisco, CA, 94080
650-615-7300
http://www.pfizer.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
PwC
3 Embarcadero Center
San Francisco, CA, 94111
415.498.5000
http://www.pwcglobal.com/Primary Contacts
Lisa Gaston
Geography Marketing Manager
415-498-5389
Peter Claude
Northern California, Pharmaceutical/Life Sciences Sector Leader
415.498.5024
Tracy Lefteroff
National Life Sciences Partner
408.817.4176
John Sichak
Pharmaceutical/Life Sciences Assurance Partner
408.817.3930
Company Profile
PwC firms provide industry-focused assurance, tax and advisory services to enhance value for their clients. More than 161,000 people in 154 countries in firms across the PwC network share their thinking, experience and solutions to develop fresh perspectives and practical advice.Company Classification
Associate/Service Providers
3 Embarcadero Center
San Francisco, CA, 94111
415.498.5000
http://www.pwcglobal.com/Primary Contacts
Lisa Gaston
Geography Marketing Manager
415-498-5389
Peter Claude
Northern California, Pharmaceutical/Life Sciences Sector Leader
415.498.5024
Tracy Lefteroff
National Life Sciences Partner
408.817.4176
John Sichak
Pharmaceutical/Life Sciences Assurance Partner
408.817.3930
Company Profile
PwC firms provide industry-focused assurance, tax and advisory services to enhance value for their clients. More than 161,000 people in 154 countries in firms across the PwC network share their thinking, experience and solutions to develop fresh perspectives and practical advice.Company Classification
Associate/Service Providers
RoseRyan
United States, http://www.roseryan.comCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
United States, http://www.roseryan.comCompany Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Salter Group
1840 Century Park East, Suite 400
Los Angeles, CA, United States, http://www.saltergroup.comPrimary Contacts
Sam Renwick
Managing Director
925-942-0373
Company Profile
Salter Group is a leading financial and strategic advisory firm specializing in providing independent forecasting services, valuations, financial opinions, financial and strategic advisory services and transaction support. Since our formation in 2003, Salter Group has completed over 400 life sciences and health care engagements representing over $10 billion in asset and transaction values. Salter Group cost-effectively offers a unique perspective for the development of forecasts, valuations and advisory services by combining the analytical and modeling rigor of a capital markets constituent with a robust data-intensive primary and secondary research capability that spans 100,000’s of thought leaders, care providers, payors and other experts through our partners. Rather than relying on a significant up-front fee regardless of whether a transaction closes (the model for many consulting firms), we have the flexibility to earn our fees in a different fashion, charging less up front but earning a fee if a transaction is successfully completed. The end result is a cost-effective integrated research and model solution that can help your company be better prepared in your discussions with licensing partners, investors, lenders or acquirers.Organization Type
Financial Services
1840 Century Park East, Suite 400
Los Angeles, CA, United States, http://www.saltergroup.comPrimary Contacts
Sam Renwick
Managing Director
925-942-0373
Company Profile
Salter Group is a leading financial and strategic advisory firm specializing in providing independent forecasting services, valuations, financial opinions, financial and strategic advisory services and transaction support. Since our formation in 2003, Salter Group has completed over 400 life sciences and health care engagements representing over $10 billion in asset and transaction values. Salter Group cost-effectively offers a unique perspective for the development of forecasts, valuations and advisory services by combining the analytical and modeling rigor of a capital markets constituent with a robust data-intensive primary and secondary research capability that spans 100,000’s of thought leaders, care providers, payors and other experts through our partners. Rather than relying on a significant up-front fee regardless of whether a transaction closes (the model for many consulting firms), we have the flexibility to earn our fees in a different fashion, charging less up front but earning a fee if a transaction is successfully completed. The end result is a cost-effective integrated research and model solution that can help your company be better prepared in your discussions with licensing partners, investors, lenders or acquirers.Organization Type
Financial Services
Squire Sanders
275 Battery Street
San Francisco, CA, United States, 94121
415-954-0358
http://www.ssd.comPrimary Contacts
Maureen Bennett
maureen.bennett@squiresaunders.com
Cameron Kerrigan
cameron.kerrigan@squiresanders.com
Rahul Pathak
rahul.pathak@squiresanders.com
Beth Seals
beth.seals@squiresanders.com
Phil Zender
philip.zeder@squiresanders.com
Company Profile
A global legal practice, Squire Sanders combines sound legal counsel with a deep knowledge of our clients’ businesses to resolve their legal challenges. We care about the quality of our services, the success of our clients and the relationships that are forged through those successes. Our lawyers have an in-depth understanding of the life sciences industry, gained through their representation of clients in life sciences and interrelated sectors such as: Bioengineering Biomedical Biotechnology Pharmaceuticals Medical devices We offer a full range of life sciences services: Competition law Consumer protection Intellectual property rights protection International trade Leveraged buyouts Licensing Litigation and arbitration Manufacturing and distribution Marketing practices Mergers, acquisitions and joint ventures Patent and technology licensing Private placements of securities Product liability Public offerings Recapitalization Taxation Technology transfer Venture capital investmentsCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
275 Battery Street
San Francisco, CA, United States, 94121
415-954-0358
http://www.ssd.comPrimary Contacts
Maureen Bennett
maureen.bennett@squiresaunders.com
Cameron Kerrigan
cameron.kerrigan@squiresanders.com
Rahul Pathak
rahul.pathak@squiresanders.com
Beth Seals
beth.seals@squiresanders.com
Phil Zender
philip.zeder@squiresanders.com
Company Profile
A global legal practice, Squire Sanders combines sound legal counsel with a deep knowledge of our clients’ businesses to resolve their legal challenges. We care about the quality of our services, the success of our clients and the relationships that are forged through those successes. Our lawyers have an in-depth understanding of the life sciences industry, gained through their representation of clients in life sciences and interrelated sectors such as: Bioengineering Biomedical Biotechnology Pharmaceuticals Medical devices We offer a full range of life sciences services: Competition law Consumer protection Intellectual property rights protection International trade Leveraged buyouts Licensing Litigation and arbitration Manufacturing and distribution Marketing practices Mergers, acquisitions and joint ventures Patent and technology licensing Private placements of securities Product liability Public offerings Recapitalization Taxation Technology transfer Venture capital investmentsCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
Thermo Fisher Scientific
81 Wyman Street
Waltham, United States, MA
781-622-1000
http://www.thermofisher.comPrimary Contacts
Michael J. Brown
Vice President, Business Development
(508) 963-3168
Andrew Setikas
Strategic Account Director
(707) 547-7223
Company Profile
Thermo Fisher Scientific offers BayBio members access to technology and expertise for every step in bioproduction - from research and development through scale up. With a mission to enable our customers to make the world healthier, cleaner, and safer Thermo Fisher Scientific provides an unmatched breadth and depth of capabilities, including: • Analytical, Environmental and Process instrument solutions enabled by world-class software • Bioprocess production technologies • Financial Services solutions • Clinical Trial Services and Supply Chain Integration • Biological Off-Site Storage and Logistics • Educational programs and technology forums With revenues of more than $11 billion and approximately 37,000 employees, Thermo Fisher Scientific is the world leader in serving science serving customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.Company Classification
Associate/Service ProvidersOrganization Type
BioTool
Consulting Firms
81 Wyman Street
Waltham, United States, MA
781-622-1000
http://www.thermofisher.comPrimary Contacts
Michael J. Brown
Vice President, Business Development
(508) 963-3168
Andrew Setikas
Strategic Account Director
(707) 547-7223
Company Profile
Thermo Fisher Scientific offers BayBio members access to technology and expertise for every step in bioproduction - from research and development through scale up. With a mission to enable our customers to make the world healthier, cleaner, and safer Thermo Fisher Scientific provides an unmatched breadth and depth of capabilities, including: • Analytical, Environmental and Process instrument solutions enabled by world-class software • Bioprocess production technologies • Financial Services solutions • Clinical Trial Services and Supply Chain Integration • Biological Off-Site Storage and Logistics • Educational programs and technology forums With revenues of more than $11 billion and approximately 37,000 employees, Thermo Fisher Scientific is the world leader in serving science serving customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.Company Classification
Associate/Service ProvidersOrganization Type
BioTool
Consulting Firms
VWR International, LLC
3745 Bayshore Blvd
Brisbane, CA, United States, 94005
800-932-5000
http://www.vwr.comPrimary Contacts
Kareem Dossa
Vice President - West
415-570-0740
Joe Pellegrino
Region Manager
415-570-0738
Don Brennan
Region Manager
408-307-0084
Kalei Hampson
Region Manager
707-293-7505
Michael Guerra
Business Development Director
408-888-0021
Kim Brocchini
Region Manager
916-397-7324
Company Profile
VWR International, LLC, headquartered in Radnor, Pennsylvania, is a global laboratory supply and distribution company with worldwide sales in excess of $3.6 billion in 2010. VWR enables the advancement of the world’s most critical research through the distribution of a highly diversified product line to most of the world's top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations. With 150 years of industry experience, VWR offers a well-established distribution network that reaches thousands of specialized labs and facilities spanning the globe. VWR has over 7,000 associates around the world working to streamline the way researchers across North America, Europe, and Asia stock and maintain their labs. In addition, VWR further supports its customers by providing onsite services, storeroom management, product procurement, supply chain systems integration and technical services. For more information on VWR please visit www.vwr.com.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
3745 Bayshore Blvd
Brisbane, CA, United States, 94005
800-932-5000
http://www.vwr.comPrimary Contacts
Kareem Dossa
Vice President - West
415-570-0740
Joe Pellegrino
Region Manager
415-570-0738
Don Brennan
Region Manager
408-307-0084
Kalei Hampson
Region Manager
707-293-7505
Michael Guerra
Business Development Director
408-888-0021
Kim Brocchini
Region Manager
916-397-7324
Company Profile
VWR International, LLC, headquartered in Radnor, Pennsylvania, is a global laboratory supply and distribution company with worldwide sales in excess of $3.6 billion in 2010. VWR enables the advancement of the world’s most critical research through the distribution of a highly diversified product line to most of the world's top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations. With 150 years of industry experience, VWR offers a well-established distribution network that reaches thousands of specialized labs and facilities spanning the globe. VWR has over 7,000 associates around the world working to streamline the way researchers across North America, Europe, and Asia stock and maintain their labs. In addition, VWR further supports its customers by providing onsite services, storeroom management, product procurement, supply chain systems integration and technical services. For more information on VWR please visit www.vwr.com.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Wareham Development
1120 Nye Street, Suite 400
San Rafael, CA, 94901
415-457-4964
http://www.warehamproperties.comPrimary Contacts
Chris Barlow
Partner
415-457-4964
Geoffrey B. Sears
Partner
415-457-4964
James Goddard
Partner
045-457-4964
Judith Wetterer
Communications Director
415-457-4964
Company Profile
Over the years, Wareham Development has earned a stellar reputation as a developer, owner and landlord for companies in the life sciences, film production, and other industries requiring complex technology infrastructures. Investing the up-front capital to meet today’s needs, Wareham Development creates spaces that adapt to tomorrow’s vision. The Wareham approach is to foster mutually beneficial long-term relationships with their tenants. As a privately-held company with a dedicated team of professionals on its staff, Wareham Development prides itself on the ability to be agile and decisive. Their principals are personally involved in every project, crafting creative leases to support business growth and managing buildings to ensure ongoing efficiency. Above all, Wareham Development believes in the future promise of its tenants, whether it’s a start-up sparked by a brilliant idea, or a major corporation building on past successesCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
1120 Nye Street, Suite 400
San Rafael, CA, 94901
415-457-4964
http://www.warehamproperties.comPrimary Contacts
Chris Barlow
Partner
415-457-4964
Geoffrey B. Sears
Partner
415-457-4964
James Goddard
Partner
045-457-4964
Judith Wetterer
Communications Director
415-457-4964
Company Profile
Over the years, Wareham Development has earned a stellar reputation as a developer, owner and landlord for companies in the life sciences, film production, and other industries requiring complex technology infrastructures. Investing the up-front capital to meet today’s needs, Wareham Development creates spaces that adapt to tomorrow’s vision. The Wareham approach is to foster mutually beneficial long-term relationships with their tenants. As a privately-held company with a dedicated team of professionals on its staff, Wareham Development prides itself on the ability to be agile and decisive. Their principals are personally involved in every project, crafting creative leases to support business growth and managing buildings to ensure ongoing efficiency. Above all, Wareham Development believes in the future promise of its tenants, whether it’s a start-up sparked by a brilliant idea, or a major corporation building on past successesCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
Wells Fargo Insurance Services Inc.
959 Skyway Road, Suite 200
San Carlos, CA, United States, 94070
650.413.4200
http://www.wellsfargo.comPrimary Contacts
Peter B. Daly
Senior Vice President
650.413.4213
Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
Insurance
959 Skyway Road, Suite 200
San Carlos, CA, United States, 94070
650.413.4200
http://www.wellsfargo.comPrimary Contacts
Peter B. Daly
Senior Vice President
650.413.4213
Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
Insurance
17th Street Legal, PLLC
1714 n. McCadden Pl. #2404
Los Angeles, CA, United States, 90028
301-520-9950
http://www.17thstreetlegal.comPrimary Contacts
Holly Logue
Founder
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
1714 n. McCadden Pl. #2404
Los Angeles, CA, United States, 90028
301-520-9950
http://www.17thstreetlegal.comPrimary Contacts
Holly Logue
Founder
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
3-V Biosciences, Inc.
1050 Hamilton Court
Menlo Park, CA, United States, 94025
650-561-8690
http://www.3vbio.com/Primary Contacts
Merdad Parsey
Chief Executive Officer
Stephen Brady
Chief Business Officer
Robert McDowell
Vice President Research
Company Profile
The company is initially focused on treating respiratory illnesses, and its strategy is readily applicable to other types of infections. 3-V Biosciences uses small interfering RNA (siRNA) to identify host targets required for successful viral replication. Small molecule inhibitors of these host targets are used to confirm antiviral activity while also assessing potential cell toxicity. Using this integrated approach, the company has discovered a number of targets and related host pathways required for viral infection. The lead program's small molecule inhibitor blocks infection by multiple pathogens without causing toxicity.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Cell Biology
Drug Discovery
PharmacogenomicsClinical Development Stage
PreClinical
1050 Hamilton Court
Menlo Park, CA, United States, 94025
650-561-8690
http://www.3vbio.com/Primary Contacts
Merdad Parsey
Chief Executive Officer
Stephen Brady
Chief Business Officer
Robert McDowell
Vice President Research
Company Profile
The company is initially focused on treating respiratory illnesses, and its strategy is readily applicable to other types of infections. 3-V Biosciences uses small interfering RNA (siRNA) to identify host targets required for successful viral replication. Small molecule inhibitors of these host targets are used to confirm antiviral activity while also assessing potential cell toxicity. Using this integrated approach, the company has discovered a number of targets and related host pathways required for viral infection. The lead program's small molecule inhibitor blocks infection by multiple pathogens without causing toxicity.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Cell Biology
Drug Discovery
PharmacogenomicsClinical Development Stage
PreClinical
5AM Ventures
United States, http://www.5amventures.comCompany Classification
Associate/Service Providers
United States, http://www.5amventures.comCompany Classification
Associate/Service Providers
720 Strategies
United States, http://www.720strategies.com/Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
United States, http://www.720strategies.com/Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
AAT Bioquest, Inc.
923 Thompson Place
Sunnyvale, CA, 94085
4087331055
http://www.aatbio.comPrimary Contacts
Jack Diwu
CEO
Jennifer Liao
VP
Cindy Zhang
VP
Company Profile
AAT Bioquest, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to scientists engaged in life sciences research, diagnostic R&D and drug discovery. We specialize in the area of photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's products enable scientists and biomedical researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest constantly introduces new products, and offers a rapidly expanding list of products that are grouped into several product lines. 1) Our reactive fluorescent and luminescent probes, biotins and tag enzymes are used for labeling small drug molecules and biopolymers, e.g, proteins, nucleic acids and carbohydrates; 2) We develop fluorescent and luminescent probes for detecting proteins, nucleic acids and live cells; 3) We constantly introduce novel fluorescent and luminescent probes for detecting various enzymes, in particular, hydrolytic and redox enzymes; 4) We focus on developing reagents for signal transduction research; and 5) We also offer physiological and neurological probes, e.g., calcium indicators and membrane potential probes. Besides the standard catalog products we also offer custom service to meet your special research needs. Our current services include custom synthesis of colorimetric, fluorescent and luminescent probes, custom development of biochemical, cell-based and diagnostic assays and custom screening of your compound libraries against your defined targets using our validated HTS assays.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolPrimary Technology
Cell Biology
Imaging
Screening
923 Thompson Place
Sunnyvale, CA, 94085
4087331055
http://www.aatbio.comPrimary Contacts
Jack Diwu
CEO
Jennifer Liao
VP
Cindy Zhang
VP
Company Profile
AAT Bioquest, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to scientists engaged in life sciences research, diagnostic R&D and drug discovery. We specialize in the area of photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's products enable scientists and biomedical researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest constantly introduces new products, and offers a rapidly expanding list of products that are grouped into several product lines. 1) Our reactive fluorescent and luminescent probes, biotins and tag enzymes are used for labeling small drug molecules and biopolymers, e.g, proteins, nucleic acids and carbohydrates; 2) We develop fluorescent and luminescent probes for detecting proteins, nucleic acids and live cells; 3) We constantly introduce novel fluorescent and luminescent probes for detecting various enzymes, in particular, hydrolytic and redox enzymes; 4) We focus on developing reagents for signal transduction research; and 5) We also offer physiological and neurological probes, e.g., calcium indicators and membrane potential probes. Besides the standard catalog products we also offer custom service to meet your special research needs. Our current services include custom synthesis of colorimetric, fluorescent and luminescent probes, custom development of biochemical, cell-based and diagnostic assays and custom screening of your compound libraries against your defined targets using our validated HTS assays.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolPrimary Technology
Cell Biology
Imaging
Screening
Abingworth Management Inc.
http://www.abingworth.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
http://www.abingworth.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
ACCELOVANCE, Inc.
2275 Research Blvd., Suite 700
Rockville, MD, 20850
619-446-8501
http://www.accelovance.comPrimary Contacts
Renee Hermer
Associate VP, Business Development
619.446.8501
Garrett D. Smith
VP, Business Development and Marketing
301-802-6275
Company Profile
Winner of the Vie Award for “BEST CRO” in 2009, 2010 and 2011, Accelovance has a proven approach for accelerating clinical development. Our ownership of a full-service CRO, research dedicated sites and strategic patient management solutions create operational efficiencies that enhance productivity, quality and timely delivery of clinical studies. Whether our services are used independently or as a fully outsourced solution, Sponsors benefit from our ability to leverage control at every level of the clinical process. 15-25% cost savings; 25-75% reduction in timelines; Guaranteed Deliverables.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
2275 Research Blvd., Suite 700
Rockville, MD, 20850
619-446-8501
http://www.accelovance.comPrimary Contacts
Renee Hermer
Associate VP, Business Development
619.446.8501
Garrett D. Smith
VP, Business Development and Marketing
301-802-6275
Company Profile
Winner of the Vie Award for “BEST CRO” in 2009, 2010 and 2011, Accelovance has a proven approach for accelerating clinical development. Our ownership of a full-service CRO, research dedicated sites and strategic patient management solutions create operational efficiencies that enhance productivity, quality and timely delivery of clinical studies. Whether our services are used independently or as a fully outsourced solution, Sponsors benefit from our ability to leverage control at every level of the clinical process. 15-25% cost savings; 25-75% reduction in timelines; Guaranteed Deliverables.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Accurus Biosciences
2929 7th St. Suite 120
Berkeley, CA, United States, 94710
650-796-0856
Primary Contacts
Richard Yi Zhang
President and CEO
Company Classification
Associate/Service ProvidersOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Infectious Disease
Metabolic/Endocrinology Disorders
2929 7th St. Suite 120
Berkeley, CA, United States, 94710
650-796-0856
Primary Contacts
Richard Yi Zhang
President and CEO
Company Classification
Associate/Service ProvidersOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Infectious Disease
Metabolic/Endocrinology Disorders
Achaogen
7000 Shoreline Drive Ste 372
South San Francisco, CA, 94080
650.266.1120
http://www.achaogen.comPrimary Contacts
J. Kevin Judice, Ph.D.
Chief Executive Officer & Chief Scientific Officer
Kenneth J. Hillan, M.B. Ch.B.
Chief Medical Officer
John C. Doyle
Chief Operating Officer
Company Profile
Achaogen is a biopharmaceutical company dedicated to discovering and developing life-saving therapies that address the growing, significant unmet need of Gram-negative bacterial resistance.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
7000 Shoreline Drive Ste 372
South San Francisco, CA, 94080
650.266.1120
http://www.achaogen.comPrimary Contacts
J. Kevin Judice, Ph.D.
Chief Executive Officer & Chief Scientific Officer
Kenneth J. Hillan, M.B. Ch.B.
Chief Medical Officer
John C. Doyle
Chief Operating Officer
Company Profile
Achaogen is a biopharmaceutical company dedicated to discovering and developing life-saving therapies that address the growing, significant unmet need of Gram-negative bacterial resistance.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
ACME Bioscience, Inc.
3941 E Bayshore Road
Palo Alto, CA, United States, 94303
(650) 969-8000
http://www.acmeca.comPrimary Contacts
Jason Zhang
President & CEO
ZJ Ni
Cheif Scientific Officer
Jane Wang
Vice President of Business Development
Company Profile
Acme Bioscience is a chemistry based contract research organization with its headquarter in Silicon Valley, and research labs both in Palo Alto and Shanghai Our business areas include: - Medicinal chemistry: lead optimization - Custom synthesis: reference compounds, intermediates, building blocks, by-products, drug metabolites etc. - Process research and development - New product developmentCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Cancer
Infectious DiseasePrimary Technology
Drug Discovery
3941 E Bayshore Road
Palo Alto, CA, United States, 94303
(650) 969-8000
http://www.acmeca.comPrimary Contacts
Jason Zhang
President & CEO
ZJ Ni
Cheif Scientific Officer
Jane Wang
Vice President of Business Development
Company Profile
Acme Bioscience is a chemistry based contract research organization with its headquarter in Silicon Valley, and research labs both in Palo Alto and Shanghai Our business areas include: - Medicinal chemistry: lead optimization - Custom synthesis: reference compounds, intermediates, building blocks, by-products, drug metabolites etc. - Process research and development - New product developmentCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Cancer
Infectious DiseasePrimary Technology
Drug Discovery
ACT Biotech, Inc.
http://www.actbiotech.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.actbiotech.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Actelion Pharmaceuticals US, Inc.
5000 Shoreline Ct. Ste 2000
South San Francisco, CA, United States, 94080
650-808-6536
http://www.actelion.com/Primary Contacts
Jean-Marc Bellamin
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
5000 Shoreline Ct. Ste 2000
South San Francisco, CA, United States, 94080
650-808-6536
http://www.actelion.com/Primary Contacts
Jean-Marc Bellamin
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
ActiveSite Pharmaceuticals, Inc.
1456 Fourth St., Unit C
Berkeley, CA, 94710
510-665-5939
http://www.activesitepharma.comPrimary Contacts
Sukanto Sinha
CEO
Tamie Chilcote
COO
Company Profile
ActiveSite Pharmaceuticals, Inc., is a privately held, preclinical stage pharmaceutical company, located in the San Francisco Bay Area. The company utilizes proprietary lead discovery technology to discover new inhibitors for therapeutic enzyme targets in diseases with unmet medical need.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
1456 Fourth St., Unit C
Berkeley, CA, 94710
510-665-5939
http://www.activesitepharma.comPrimary Contacts
Sukanto Sinha
CEO
Tamie Chilcote
COO
Company Profile
ActiveSite Pharmaceuticals, Inc., is a privately held, preclinical stage pharmaceutical company, located in the San Francisco Bay Area. The company utilizes proprietary lead discovery technology to discover new inhibitors for therapeutic enzyme targets in diseases with unmet medical need.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Adheren
United States, http://www.adheren.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.adheren.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Aduro BioTech
626 Bancroft Way, 3C
Berkeley, CA, 94710-2224
510/848-4400 x101
http://www.adurobiotech.comPrimary Contacts
Stephen Isaacs
Chairman & CEO
Dirk Brockstedt
VP, Research & Developement
Company Profile
Aduro's therapeutic vaccines have already been tested in three Phase 1 clinical safety trials in cancer and infectious disease with a total of 30 patients, and Aduro is currently planning Phase 2A and Phase 1B cancer trials with its lead therapeutic, CRS-207. In addition to building its own proprietary pipeline, Aduro is actively seeking partnerships and contract research agreements to develop new vaccines and to boost the efficacies of other vaccines and treatments. Aduro can engineer a new vaccine strain and have it ready for clinical testing within 12 months.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
VaccineDisease Areas of Focus
Cancer
Infectious DiseaseClinical Development Stage
Phase II
626 Bancroft Way, 3C
Berkeley, CA, 94710-2224
510/848-4400 x101
http://www.adurobiotech.comPrimary Contacts
Stephen Isaacs
Chairman & CEO
Dirk Brockstedt
VP, Research & Developement
Company Profile
Aduro's therapeutic vaccines have already been tested in three Phase 1 clinical safety trials in cancer and infectious disease with a total of 30 patients, and Aduro is currently planning Phase 2A and Phase 1B cancer trials with its lead therapeutic, CRS-207. In addition to building its own proprietary pipeline, Aduro is actively seeking partnerships and contract research agreements to develop new vaccines and to boost the efficacies of other vaccines and treatments. Aduro can engineer a new vaccine strain and have it ready for clinical testing within 12 months.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
VaccineDisease Areas of Focus
Cancer
Infectious DiseaseClinical Development Stage
Phase II
Advansta Inc.
1455 Adams Dr. Suite 1160
Menlo Park, CA, United States, 94025
650-325-1982
http://www.advansta.comPrimary Contacts
Dmitry Bochkariov
President
Sia Ghazvini
Director, Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
BioToolPrimary Technology
Cell Biology
Drug Discovery
Proteomics
1455 Adams Dr. Suite 1160
Menlo Park, CA, United States, 94025
650-325-1982
http://www.advansta.comPrimary Contacts
Dmitry Bochkariov
President
Sia Ghazvini
Director, Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
BioToolPrimary Technology
Cell Biology
Drug Discovery
Proteomics
Advantage Pharma Solutions LLC
11379 Huntington Village Lane
Gold River, CA, United States, 95670
916-806-9377
Company Profile
Consulting company that focuses on Business Development and Supply Chain StrategiesCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
TherapeuticPrimary Technology
Biomanufacturing
Drug DeliveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
11379 Huntington Village Lane
Gold River, CA, United States, 95670
916-806-9377
Company Profile
Consulting company that focuses on Business Development and Supply Chain StrategiesCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
TherapeuticPrimary Technology
Biomanufacturing
Drug DeliveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Advantar Laboratories, Inc.
http://www.advantarlabs.comCompany Classification
Associate/Service Providers
http://www.advantarlabs.comCompany Classification
Associate/Service Providers
Advocates-US LLC
10, S. Third Street, 3rd Floor
San Jose, CA, United States, 95113
001 (408) 3513386
http://www.advocates.ltd.ukPrimary Contacts
Jules Fisher
Managing Director
+44 (0)7885 574 573
Angelina Fisher
Director of Corporate Affairs
+44 (0)7959 671 290
Shona Moyes
Project Development Manager
+44 (0)131 661 6100
Company Profile
Advocates Pharmaceutical & Healthcare is a Contract Development Organisation. Since 2002, we have been committed to creating better opportunities for the development of drug therapies, treatments & investment into global drug development for the biotech, pharmaceutical & healthcare sector. Through our UK, US and Hong Kong operations, our scientists, project managers & technical experts progress compounds from lab bench to 1st in man (translational medicine) & from 1st in man to out-licensing point or commercialisation in the most cost effective & efficient way. By streamlining development programmes to global standards Advocates maximises the value of compounds & products, minimising time to market. This is one of our core strengths & where we add significant value. Discovery & Pre-Clinical Support Identification & lead optimisation Medical Devices Expertise CE marking & manufacturing Project Management & Controls Resource/budget planning Life-cycle management eCTD compliant project & document management system Supplies Management Vendor identification & selection Logistics management & technical assessment Pharmaceutical Development Technical support of formulation development Investigational Medicinal Product formulation & development management Operational CMC Manufacturing support & validation Technology scale-up & transfer Regulatory Preparation & Submission Common Technical Documentation & IMPD preparation Submissions to FDA, EMEA & national agencies Clinical identification/Good Laboratory Practices (cGLP) Quality & technical gap analysis Quality Auditing Good Manufacturing Practices (cGMP) & ISO compliance Qualified Person (QP) assessment Investor Support Technical due diligence & post-investment evaluationCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
10, S. Third Street, 3rd Floor
San Jose, CA, United States, 95113
001 (408) 3513386
http://www.advocates.ltd.ukPrimary Contacts
Jules Fisher
Managing Director
+44 (0)7885 574 573
Angelina Fisher
Director of Corporate Affairs
+44 (0)7959 671 290
Shona Moyes
Project Development Manager
+44 (0)131 661 6100
Company Profile
Advocates Pharmaceutical & Healthcare is a Contract Development Organisation. Since 2002, we have been committed to creating better opportunities for the development of drug therapies, treatments & investment into global drug development for the biotech, pharmaceutical & healthcare sector. Through our UK, US and Hong Kong operations, our scientists, project managers & technical experts progress compounds from lab bench to 1st in man (translational medicine) & from 1st in man to out-licensing point or commercialisation in the most cost effective & efficient way. By streamlining development programmes to global standards Advocates maximises the value of compounds & products, minimising time to market. This is one of our core strengths & where we add significant value. Discovery & Pre-Clinical Support Identification & lead optimisation Medical Devices Expertise CE marking & manufacturing Project Management & Controls Resource/budget planning Life-cycle management eCTD compliant project & document management system Supplies Management Vendor identification & selection Logistics management & technical assessment Pharmaceutical Development Technical support of formulation development Investigational Medicinal Product formulation & development management Operational CMC Manufacturing support & validation Technology scale-up & transfer Regulatory Preparation & Submission Common Technical Documentation & IMPD preparation Submissions to FDA, EMEA & national agencies Clinical identification/Good Laboratory Practices (cGLP) Quality & technical gap analysis Quality Auditing Good Manufacturing Practices (cGMP) & ISO compliance Qualified Person (QP) assessment Investor Support Technical due diligence & post-investment evaluationCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Affymax, Inc.
4001 Miranda Avenue/ 4015 Miranda Avenue
Palo Alto, CA, 94304
(650) 812-8700
http://www.affymax.comPrimary Contacts
Sylvia Wheeler
Vice President, Corporate Communications
Company Profile
Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, peginesatide, recently completed Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit www.affymax.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic DiseasesClinical Development Stage
Phase III
4001 Miranda Avenue/ 4015 Miranda Avenue
Palo Alto, CA, 94304
(650) 812-8700
http://www.affymax.comPrimary Contacts
Sylvia Wheeler
Vice President, Corporate Communications
Company Profile
Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, peginesatide, recently completed Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit www.affymax.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic DiseasesClinical Development Stage
Phase III
Agile Pharmacy Services
61 Airport Blvd, Suite B
South San Francisco, CA, United States, 94080
650-871-2848
http://www.agilepharm.comPrimary Contacts
Brian J. Davis
CEO
Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
61 Airport Blvd, Suite B
South San Francisco, CA, United States, 94080
650-871-2848
http://www.agilepharm.comPrimary Contacts
Brian J. Davis
CEO
Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
Agilent Technologies, Inc.
5301 Stevens Creek Boulevard
Santa Clara, CA, 95051
408-345-8886
http://www.agilent.comPrimary Contacts
Bill Sullivan
President and CEO
Didier Hirsch
SVP and Chief Financial Officer
Nick Roelofs
President, Life Sciences Group
Company Profile
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Drug Discovery
Functional Genetics
Genomics
Imaging
Micro Arrays
Nanotechnology
Proteomics
5301 Stevens Creek Boulevard
Santa Clara, CA, 95051
408-345-8886
http://www.agilent.comPrimary Contacts
Bill Sullivan
President and CEO
Didier Hirsch
SVP and Chief Financial Officer
Nick Roelofs
President, Life Sciences Group
Company Profile
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Drug Discovery
Functional Genetics
Genomics
Imaging
Micro Arrays
Nanotechnology
Proteomics
Alion, Inc.
http://www.alionscience.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.alionscience.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Alios BioPharma, Inc.
260 E. Grand Ave, 2nd Floor
South San Francisco, CA, 94080
650-635-5500
http://www.aliosbiopharma.comPrimary Contacts
Lawrence Blatt, Ph.D.
President & CEO
Leonid Beigelman, Ph.D.
CSO
Company Profile
Alios is a biotechnology company located in South San Francisco, California that is developing novel medicines that treat viral diseases. Alios has two platform technologies: small molecule activators of the RNase-L pathway and novel nucleoside/nucleotide chemistries. These complementary technologies have the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). Alios has a staff of 28 full time employees, of which 22 are scientists, working in a 20,000 square foot facility. Alios management has discovered or led the development of numerous compounds that have reached the clinic for the treatment of chronic hepatitis C including: Infergen, Pegasys, RG7227, R1626, RG7128, and RG7348. We are funded by an experienced group of Venture Capital backers with extensive industry experience including: Novo A/S, Novartis Ventures, Roche Ventures, and SR-One (GlaxoSmithKline ventures).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
260 E. Grand Ave, 2nd Floor
South San Francisco, CA, 94080
650-635-5500
http://www.aliosbiopharma.comPrimary Contacts
Lawrence Blatt, Ph.D.
President & CEO
Leonid Beigelman, Ph.D.
CSO
Company Profile
Alios is a biotechnology company located in South San Francisco, California that is developing novel medicines that treat viral diseases. Alios has two platform technologies: small molecule activators of the RNase-L pathway and novel nucleoside/nucleotide chemistries. These complementary technologies have the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS). Alios has a staff of 28 full time employees, of which 22 are scientists, working in a 20,000 square foot facility. Alios management has discovered or led the development of numerous compounds that have reached the clinic for the treatment of chronic hepatitis C including: Infergen, Pegasys, RG7227, R1626, RG7128, and RG7348. We are funded by an experienced group of Venture Capital backers with extensive industry experience including: Novo A/S, Novartis Ventures, Roche Ventures, and SR-One (GlaxoSmithKline ventures).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Allcells, LLC
http://allcells.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://allcells.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Allopartis
United States, http://www.allopartis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
United States, http://www.allopartis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
Alston & Bird LLP
275 Middlefield Road Suite 150
Menlo Park, CA, 94025
650-838-2000
http://www.alston.comPrimary Contacts
Romi Celli
Partner
650-838-2011
Joe Liebeschuetz
Partner
650-838-2000
Lance Termes
Senior Associate
650-838-2000
Company Profile
With 800 attorneys, Alston & Bird is a leading national AmLaw 100 firm. The firm’s core practice areas are intellectual property, complex litigation, corporate and tax, with national industry focuses in energy and sustainability, health care, financial services and public policy. The firm has built a reputation as one of the country’s best employers, appearing on FORTUNE magazine’s ranking of the “100 Best Companies to Work For” 12 consecutive years, an unprecedented accomplishment among law firms in the United States. The firm has offices in Atlanta, Charlotte, Dallas, Los Angeles, New York, Research Triangle, Silicon Valley, Ventura County and Washington, D.C. Our Silicon Valley office boasts extensive experience in biotechnology. Our Biotechnology Group provides a range of services including patentability, validity, non-infringement, and freedom-to-operate opinions, patent drafting, prosecution, due diligence analysis, development of business strategies, and general client counseling. All of the attorneys in our practice group have Ph.D.’s or master’s degrees representing diverse scientific fields. We service a wide range of corporate and university clients in the areas of molecular/cellular biology, genomics, pharmaceuticals, immunology, medical diagnostics, and agricultural biotechnology. Our corporate clients include leading biotechnology companies, large and mid-size pharmaceutical companies, and various smaller companies with cutting edge technologies.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
275 Middlefield Road Suite 150
Menlo Park, CA, 94025
650-838-2000
http://www.alston.comPrimary Contacts
Romi Celli
Partner
650-838-2011
Joe Liebeschuetz
Partner
650-838-2000
Lance Termes
Senior Associate
650-838-2000
Company Profile
With 800 attorneys, Alston & Bird is a leading national AmLaw 100 firm. The firm’s core practice areas are intellectual property, complex litigation, corporate and tax, with national industry focuses in energy and sustainability, health care, financial services and public policy. The firm has built a reputation as one of the country’s best employers, appearing on FORTUNE magazine’s ranking of the “100 Best Companies to Work For” 12 consecutive years, an unprecedented accomplishment among law firms in the United States. The firm has offices in Atlanta, Charlotte, Dallas, Los Angeles, New York, Research Triangle, Silicon Valley, Ventura County and Washington, D.C. Our Silicon Valley office boasts extensive experience in biotechnology. Our Biotechnology Group provides a range of services including patentability, validity, non-infringement, and freedom-to-operate opinions, patent drafting, prosecution, due diligence analysis, development of business strategies, and general client counseling. All of the attorneys in our practice group have Ph.D.’s or master’s degrees representing diverse scientific fields. We service a wide range of corporate and university clients in the areas of molecular/cellular biology, genomics, pharmaceuticals, immunology, medical diagnostics, and agricultural biotechnology. Our corporate clients include leading biotechnology companies, large and mid-size pharmaceutical companies, and various smaller companies with cutting edge technologies.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Alta Partners Management Corp.
One Embarcadero Center, Suite 3700
San Francisco, CA, United States, 94111
415-362-4022
http://www.altapartners.com/Primary Contacts
Georgianne Compton
Fund Accountant
415-362-4022
Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
One Embarcadero Center, Suite 3700
San Francisco, CA, United States, 94111
415-362-4022
http://www.altapartners.com/Primary Contacts
Georgianne Compton
Fund Accountant
415-362-4022
Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Althea Technologies, Inc.
http://www.altheatech.comCompany Classification
Associate/Service ProvidersOrganization Type
Therapeutic
http://www.altheatech.comCompany Classification
Associate/Service ProvidersOrganization Type
Therapeutic
Altravax, Inc.
552 Del Rey Avenue
Sunnyvale, CA, 94085
(888)-710-9203
http://www.altravax.comPrimary Contacts
Richard Rayl
CEO
Robert Whalen
CSO
Company Profile
Altravax, Inc. is a privately held biopharmaceutical company with headquarters in Fargo, ND and research laboratories in Sunnyvale, CA. Altravax has acquired the rights to MolecularBreeding(TM) directed molecular evolution technology in the area of infectious diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
VaccineDisease Areas of Focus
Infectious DiseasePrimary Technology
Combinatorial Chemistry
Protein EngineeringClinical Development Stage
PreClinical
552 Del Rey Avenue
Sunnyvale, CA, 94085
(888)-710-9203
http://www.altravax.comPrimary Contacts
Richard Rayl
CEO
Robert Whalen
CSO
Company Profile
Altravax, Inc. is a privately held biopharmaceutical company with headquarters in Fargo, ND and research laboratories in Sunnyvale, CA. Altravax has acquired the rights to MolecularBreeding(TM) directed molecular evolution technology in the area of infectious diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
VaccineDisease Areas of Focus
Infectious DiseasePrimary Technology
Combinatorial Chemistry
Protein EngineeringClinical Development Stage
PreClinical
Alvine Pharmaceuticals, Inc.
75 Shoreway Rd., Suite B
San Carlos, CA, 94070
650 632-1645
http://www.alvinepharma.comPrimary Contacts
Abhay Joshi, Ph.D.
President and Chief Executive Officer
Daniel Adelman, M.D.
Sr. VP of Development and Chief Medical Officer
Kirk Essemacher, M.D.
VP of Marketing, Corporate and Strategic Development
Company Profile
Alvine is a clinical stage biopharmaceutical company developing biologics to target autoimmune/inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Digestive SystemPrimary Technology
Drug DiscoveryClinical Development Stage
Phase II
75 Shoreway Rd., Suite B
San Carlos, CA, 94070
650 632-1645
http://www.alvinepharma.comPrimary Contacts
Abhay Joshi, Ph.D.
President and Chief Executive Officer
Daniel Adelman, M.D.
Sr. VP of Development and Chief Medical Officer
Kirk Essemacher, M.D.
VP of Marketing, Corporate and Strategic Development
Company Profile
Alvine is a clinical stage biopharmaceutical company developing biologics to target autoimmune/inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Digestive SystemPrimary Technology
Drug DiscoveryClinical Development Stage
Phase II
Amarantus BioSciences
866 Malcolm Rd
Burlingame, CA, United States, 94010
http://www.amarantus.comPrimary Contacts
Martin Cleary
CEO
Gerald Commissiong
COO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Central Nervous
Metabolic/Endocrinology Disorders
Ophthalmology
866 Malcolm Rd
Burlingame, CA, United States, 94010
http://www.amarantus.comPrimary Contacts
Martin Cleary
CEO
Gerald Commissiong
COO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Central Nervous
Metabolic/Endocrinology Disorders
Ophthalmology
Amunix, Inc.
500 Ellis St
Mountain View, CA, 94043
6504281800
http://www.amunix.comPrimary Contacts
Willem Stemmer
CEO
Volker Schellenberger
VP Research
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory DisordersPrimary Technology
Cell Biology
Protein EngineeringClinical Development Stage
PreClinical
Phase I
500 Ellis St
Mountain View, CA, 94043
6504281800
http://www.amunix.comPrimary Contacts
Willem Stemmer
CEO
Volker Schellenberger
VP Research
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory DisordersPrimary Technology
Cell Biology
Protein EngineeringClinical Development Stage
PreClinical
Phase I
Amyris, Inc.
http://www.amyrisbiotech.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
http://www.amyrisbiotech.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
Anacor Pharmaceuticals
United States, http://www.anacor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.anacor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Anaspec, Inc.
34801 Campus Dr.
Fremont, CA, United States, 94555
510-791-9560
http://www.anaspec.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
34801 Campus Dr.
Fremont, CA, United States, 94555
510-791-9560
http://www.anaspec.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
AP Pharma
123 Saginaw Dr.
Redwood City, CA, United States, 94063
650-366-2626
http://www.appharma.comPrimary Contacts
John Whelan
CEO
Tom Ottoboni
VP Pharmaceutical Development
Sandra Squires
Manager Human Resources
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central Nervous
Digestive System
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Biomanufacturing
Drug Delivery
ScreeningClinical Development Stage
PreClinical
Phase I
Phase III
123 Saginaw Dr.
Redwood City, CA, United States, 94063
650-366-2626
http://www.appharma.comPrimary Contacts
John Whelan
CEO
Tom Ottoboni
VP Pharmaceutical Development
Sandra Squires
Manager Human Resources
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central Nervous
Digestive System
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Biomanufacturing
Drug Delivery
ScreeningClinical Development Stage
PreClinical
Phase I
Phase III
Aperys, Inc.
United States, http://www.aperys.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
United States, http://www.aperys.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Apexigen
United States, http://www.apexigen.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.apexigen.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
ApniCure, Inc.
900 Chesapeake Drive
Redwood City, CA, 94063
650-361-9300
http://www.apnicure.comPrimary Contacts
Matt Vaska
President & CEO
Chris Daniel
EVP, Operations
John Lipman
VP, Marketing
Company Profile
Developing novel therapy for sleep apnea.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Respiratory DisordersClinical Development Stage
Phase I
900 Chesapeake Drive
Redwood City, CA, 94063
650-361-9300
http://www.apnicure.comPrimary Contacts
Matt Vaska
President & CEO
Chris Daniel
EVP, Operations
John Lipman
VP, Marketing
Company Profile
Developing novel therapy for sleep apnea.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Respiratory DisordersClinical Development Stage
Phase I
Applied Biomics, Inc.
23785 Cabot Blvd. Suite 311
Hayward, CA, 94545
510-887-0889
http://www.appliedbiomics.comPrimary Contacts
John Liao
CTO
Hongjin Huang
Vice President
Company Profile
Proteomics Service Proteomics Methods and Reagent DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
CancerPrimary Technology
ProteomicsClinical Development Stage
PreClinical
23785 Cabot Blvd. Suite 311
Hayward, CA, 94545
510-887-0889
http://www.appliedbiomics.comPrimary Contacts
John Liao
CTO
Hongjin Huang
Vice President
Company Profile
Proteomics Service Proteomics Methods and Reagent DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
CancerPrimary Technology
ProteomicsClinical Development Stage
PreClinical
Applied Stemcell, Inc.
http://www.appliedstemcell.comCompany Classification
Associate/Service Providers
http://www.appliedstemcell.comCompany Classification
Associate/Service Providers
APT Pharmaceuticals
700 Airport Blvd
Burlingame, CA, 94010
650-931-1666
http://www.aptbio.comPrimary Contacts
Stephen Dilly,MD.
CEO
Howard V Raff, Ph.D.
COO
Christina Thomson
General Council
Company Profile
Develop drugs to meet unmet medical needs in lung diseasesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DeliveryClinical Development Stage
Phase III
700 Airport Blvd
Burlingame, CA, 94010
650-931-1666
http://www.aptbio.comPrimary Contacts
Stephen Dilly,MD.
CEO
Howard V Raff, Ph.D.
COO
Christina Thomson
General Council
Company Profile
Develop drugs to meet unmet medical needs in lung diseasesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DeliveryClinical Development Stage
Phase III
Aradigm Corporation
United States, http://www.aradigm.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
United States, http://www.aradigm.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Arcadia Biosciences, Inc.
202 Cousteau Place Ste 200
Davis, CA, 95168
(530) 756-7077
http://www.arcadiabio.comPrimary Contacts
Eric Rey
President and CEO
Wendy Neal
VP and Chief Legal Officer
Steve Brandwein
VP Finance
Company Profile
Agricultural products that benefit the environment or human health.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AgricultureDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Dermatology
Womens HealthPrimary Technology
Transgenics
202 Cousteau Place Ste 200
Davis, CA, 95168
(530) 756-7077
http://www.arcadiabio.comPrimary Contacts
Eric Rey
President and CEO
Wendy Neal
VP and Chief Legal Officer
Steve Brandwein
VP Finance
Company Profile
Agricultural products that benefit the environment or human health.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AgricultureDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Dermatology
Womens HealthPrimary Technology
Transgenics
Ardelyx, Inc. (formerly Nteryx, Inc)
34175 ARdenwood Blvd
Fremont, CA, 94555
510 745-1700
http://www.ardelyx.comPrimary Contacts
Michael G. Raab
CEO and Chairman
Dominique Charmot
Chief Scientific Officer
George Jue
Vice President Finance and Operations
Company Profile
Through a radical approach to drug discovery and development, Ardelyx™ has established a pipeline of novel, first-in-class drugs engineered to correct mineral metabolism imbalance and metabolic disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Digestive System
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
GenomicsClinical Development Stage
PreClinical
Phase I
Phase II
34175 ARdenwood Blvd
Fremont, CA, 94555
510 745-1700
http://www.ardelyx.comPrimary Contacts
Michael G. Raab
CEO and Chairman
Dominique Charmot
Chief Scientific Officer
George Jue
Vice President Finance and Operations
Company Profile
Through a radical approach to drug discovery and development, Ardelyx™ has established a pipeline of novel, first-in-class drugs engineered to correct mineral metabolism imbalance and metabolic disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Digestive System
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
GenomicsClinical Development Stage
PreClinical
Phase I
Phase II
Aria Diagnostics
5941 Optical Court, Suite 226
San Jose, CA, United States, 95138
(408) 960-2198
http://www.ariadx.comPrimary Contacts
John Stuelpnagel
Executive Chairman
Ken Song
CEO
Arnold Oliphant
CSO
Company Profile
Molecular diagnostics company focused on prenatal testing.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticPrimary Technology
Bioinformatics
GenomicsClinical Development Stage
PreClinical
5941 Optical Court, Suite 226
San Jose, CA, United States, 95138
(408) 960-2198
http://www.ariadx.comPrimary Contacts
John Stuelpnagel
Executive Chairman
Ken Song
CEO
Arnold Oliphant
CSO
Company Profile
Molecular diagnostics company focused on prenatal testing.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticPrimary Technology
Bioinformatics
GenomicsClinical Development Stage
PreClinical
Arnold & Porter LLP
Three Embarcadero Center, 7th Floor
San Francisco, CA, United States, 94111
415-471-3100
http://www.arnoldporter.comPrimary Contacts
Julia Vax
Partner
415-471-3173
Marty Duvall
Director, Business Development
202-942-6258
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Three Embarcadero Center, 7th Floor
San Francisco, CA, United States, 94111
415-471-3100
http://www.arnoldporter.comPrimary Contacts
Julia Vax
Partner
415-471-3173
Marty Duvall
Director, Business Development
202-942-6258
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Astex Pharmaceuticals
4140 Dublin Blvd, Suite 200
Dublin, CA, United States, 94568
925-560-0100
http://www.astx.comPrimary Contacts
Timothy Enns
Senior Vice President, Corporate Communications and Marketing
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
CancerClinical Development Stage
PreClinical
Phase I
Phase II
Approved
4140 Dublin Blvd, Suite 200
Dublin, CA, United States, 94568
925-560-0100
http://www.astx.comPrimary Contacts
Timothy Enns
Senior Vice President, Corporate Communications and Marketing
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
CancerClinical Development Stage
PreClinical
Phase I
Phase II
Approved
Astraea Therapeutics, LLC
320 Logue Avenue, Suites 142/131
Mountain View, CA, 95070
650-254-0786
http://www.astraeatherapeutics.comPrimary Contacts
Nurulain Zaveri, Ph.D.
President and Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central Nervous
Substance AbusePrimary Technology
Combinatorial Chemistry
Drug Discovery
320 Logue Avenue, Suites 142/131
Mountain View, CA, 95070
650-254-0786
http://www.astraeatherapeutics.comPrimary Contacts
Nurulain Zaveri, Ph.D.
President and Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central Nervous
Substance AbusePrimary Technology
Combinatorial Chemistry
Drug Discovery
Athena Discovery Inc
United States, http://www.athenadiscovery.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.athenadiscovery.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Aurora Algae, Inc.
3325 Investment Blvd
Hayward, CA, 94545
5102665000
http://www.aurorainc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
3325 Investment Blvd
Hayward, CA, 94545
5102665000
http://www.aurorainc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Auxogyn, Inc.
1490 Obrien Dr. Ste A
Menlo Park, CA, United States, 94025
650-931-6732
http://www.auxogyn.comPrimary Contacts
Rob Newman
Vice President, Regulatory Affairs
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
1490 Obrien Dr. Ste A
Menlo Park, CA, United States, 94025
650-931-6732
http://www.auxogyn.comPrimary Contacts
Rob Newman
Vice President, Regulatory Affairs
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
Avalanche Biotechnologies, Inc
665 Third St., Suite 250
San Francisco, CA, United States, 94107
650-924-1324
http://www.avalanchebiotech.comPrimary Contacts
Thomas Chalberg
Founder and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
OphthalmologyPrimary Technology
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
665 Third St., Suite 250
San Francisco, CA, United States, 94107
650-924-1324
http://www.avalanchebiotech.comPrimary Contacts
Thomas Chalberg
Founder and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
OphthalmologyPrimary Technology
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
AvidBiotics Corp.
300 Utah Ave., Suite 150
South San Francisco, CA, 94080
650.873.1141
http://www.avidbiotics.comPrimary Contacts
James L. Knighton
President
David W. Martin
CEO
Company Profile
AvidBiotics is a developer of novel, non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancers. The scaffolds of AvidBiotics' proteins exhibit functional potency, e.g. killing, exceeding that of antibodies. The company's lead program centers on Avidocin proteins, a new class of narrow-spectrum bactericidal agents for use in the treatment or prevention of specific bacterial infections. AvidBiotics is also developing novel Micacide proteins that specifically flag virus-infected or cancerous cells for enhanced destruction by the potent innate immunity system. AvidBiotics focuses on human therapeutic applications of its technologies, both on its own and in partnership with governmental agencies and research institutions, while taking advantage of further near-term collaborative opportunities offered by specific applications of its products and technology platforms in areas such as food safety, cleantech and biodefense.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Infectious DiseasePrimary Technology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
300 Utah Ave., Suite 150
South San Francisco, CA, 94080
650.873.1141
http://www.avidbiotics.comPrimary Contacts
James L. Knighton
President
David W. Martin
CEO
Company Profile
AvidBiotics is a developer of novel, non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancers. The scaffolds of AvidBiotics' proteins exhibit functional potency, e.g. killing, exceeding that of antibodies. The company's lead program centers on Avidocin proteins, a new class of narrow-spectrum bactericidal agents for use in the treatment or prevention of specific bacterial infections. AvidBiotics is also developing novel Micacide proteins that specifically flag virus-infected or cancerous cells for enhanced destruction by the potent innate immunity system. AvidBiotics focuses on human therapeutic applications of its technologies, both on its own and in partnership with governmental agencies and research institutions, while taking advantage of further near-term collaborative opportunities offered by specific applications of its products and technology platforms in areas such as food safety, cleantech and biodefense.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Infectious DiseasePrimary Technology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Avrygen Therapeutics, Inc.
United States, http://www.avrygen.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.avrygen.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Bay Area Biotechnologies
2324 Montpelier Dr. Ste 7
San Jose, CA, 95116
408-694-3573
http://www.bayareabiotechs.com/Primary Contacts
Devin Du
CEO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
2324 Montpelier Dr. Ste 7
San Jose, CA, 95116
408-694-3573
http://www.bayareabiotechs.com/Primary Contacts
Devin Du
CEO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Bay Area Biotechnology Education Consortium
P.O. Box 1824
Morgan Hill, CA, United States, 95038
408.924.4814
http://www.BABEC.orgPrimary Contacts
Katy Korsmeyer
President
408.924.4814
Victoria Walton
Treasurer
408.782.5037
Company Profile
The Bay Area Biotechnology Education Consortium (BABEC) is a regional network of local science education organizations based in the Northern California Bay Area. BABEC is dedicated to increasing student understanding of key concepts in molecular biology and raising student awareness of applications and careers in biotechnology. In the process, BABEC is enabling systemic reform in an important area of science education by helping teachers bring relevant, thought-provoking, hands-on activities into the classroom.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
P.O. Box 1824
Morgan Hill, CA, United States, 95038
408.924.4814
http://www.BABEC.orgPrimary Contacts
Katy Korsmeyer
President
408.924.4814
Victoria Walton
Treasurer
408.782.5037
Company Profile
The Bay Area Biotechnology Education Consortium (BABEC) is a regional network of local science education organizations based in the Northern California Bay Area. BABEC is dedicated to increasing student understanding of key concepts in molecular biology and raising student awareness of applications and careers in biotechnology. In the process, BABEC is enabling systemic reform in an important area of science education by helping teachers bring relevant, thought-provoking, hands-on activities into the classroom.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
BCC Partners
1215 Elder Avenue
Menlo Park, CA, 94025
650-323-1717
http://www.bccpartners.comPrimary Contacts
Karen L Bergman
Partner and Founder
650-323-1717
Michelle Corral
Partner and Founder
415-738-8383
Company Profile
Founded in 2001, BCC Partners, LLC provides outstanding strategic planning and execution of branding, competitive positioning, communications and investor relations services to public and private companies in the life sciences industry. With extensive experience from the corporate, agency, media and advocacy settings, we take a senior-level and hands-on approach to building distinctive positioning and visibility across targeted audiences in alignment with our clients' business objectives and values.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication/Media
1215 Elder Avenue
Menlo Park, CA, 94025
650-323-1717
http://www.bccpartners.comPrimary Contacts
Karen L Bergman
Partner and Founder
650-323-1717
Michelle Corral
Partner and Founder
415-738-8383
Company Profile
Founded in 2001, BCC Partners, LLC provides outstanding strategic planning and execution of branding, competitive positioning, communications and investor relations services to public and private companies in the life sciences industry. With extensive experience from the corporate, agency, media and advocacy settings, we take a senior-level and hands-on approach to building distinctive positioning and visibility across targeted audiences in alignment with our clients' business objectives and values.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication/Media
Bell Biosystems, Inc.
4305 El Camino Real
Palo Alto, CA, United States, 94306
703-343-6477
http://www.bellbiosystems.comPrimary Contacts
Dr. Caleb B. Bell, III
CEO
Daniel Bell
CFO
Dr. Brett Staahl
CSO
Company Profile
Bell Biosystems' caters to researchers, institutions, academia, and private companies that develop stem cell diagnostics, cellular based therapeutics, and regenerative medicines.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory DisordersPrimary Technology
Drug Delivery
Stem Cell ResearchClinical Development Stage
PreClinical
4305 El Camino Real
Palo Alto, CA, United States, 94306
703-343-6477
http://www.bellbiosystems.comPrimary Contacts
Dr. Caleb B. Bell, III
CEO
Daniel Bell
CFO
Dr. Brett Staahl
CSO
Company Profile
Bell Biosystems' caters to researchers, institutions, academia, and private companies that develop stem cell diagnostics, cellular based therapeutics, and regenerative medicines.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory DisordersPrimary Technology
Drug Delivery
Stem Cell ResearchClinical Development Stage
PreClinical
Bench International
120 South Doheny Drive
Beverly Hills, California, United States, 90211
310-854-9900
www.benchinternational.comPrimary Contacts
Denise DeMan
Founder, Chairman & CEO
310-854-9900
Jenny Breselow
Vice President
415-500-5748
Company Profile
We are a global, retained, executive recruiting and consulting firm providing senior talent to life science institutions, exclusively, since 1974. We pride ourselves as being one of the top executive recruitment providers for the Life Science including pharmaceutical, healthcare, biotech and other life sciences fields. Our team is deeply experienced and accomplished within the life sciences and has the content knowledge and expertise to translate and meet our client’s needs and expectations for executive talent. With headquarters in Los Angeles, California, and satellite offices in San Francisco, New York, the United Kingdom and Switzerland, Bench International’s multinational presence makes it one the largest retained executive search firms. The Bench International team comprises more than 30 seasoned executives with over 110 years of combined experience in life sciences recruiting.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Human Resources
Staffing
120 South Doheny Drive
Beverly Hills, California, United States, 90211
310-854-9900
www.benchinternational.comPrimary Contacts
Denise DeMan
Founder, Chairman & CEO
310-854-9900
Jenny Breselow
Vice President
415-500-5748
Company Profile
We are a global, retained, executive recruiting and consulting firm providing senior talent to life science institutions, exclusively, since 1974. We pride ourselves as being one of the top executive recruitment providers for the Life Science including pharmaceutical, healthcare, biotech and other life sciences fields. Our team is deeply experienced and accomplished within the life sciences and has the content knowledge and expertise to translate and meet our client’s needs and expectations for executive talent. With headquarters in Los Angeles, California, and satellite offices in San Francisco, New York, the United Kingdom and Switzerland, Bench International’s multinational presence makes it one the largest retained executive search firms. The Bench International team comprises more than 30 seasoned executives with over 110 years of combined experience in life sciences recruiting.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Human Resources
Staffing
Bend Research Inc.
64550 Research Rd.
Bend, Oregon, United States, 97701
541-382-4100
http://www.bendresearch.comPrimary Contacts
Walter Babcock
President and CEO
541-382-4100
Phoenex Ivers
Business Development Administrator
541-706-8326
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
64550 Research Rd.
Bend, Oregon, United States, 97701
541-382-4100
http://www.bendresearch.comPrimary Contacts
Walter Babcock
President and CEO
541-382-4100
Phoenex Ivers
Business Development Administrator
541-706-8326
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
BetaStem Therapeutics
300 Brannan Street, Suite 407
San Francisco, CA, 94107
415-913-7595
http://betastemtherapy.com/Primary Contacts
Stephen Bartelmez PhD
President, CSO and Founder
Stephen Bartelmez PhD
CSO
Raj Prasad MBA
CFO
Company Profile
OVERVIEW: Patient-derived hematopoietic stem cells represent a proven clinical strategy for treatment of a wide range of important human diseases. BetaStem has developed proprietary methods and reagents to dramatically improve the application and efficacy of activated stem cell products from patient’s blood, bone marrow and cord blood. Applications for these products are broad and include unmet medical needs such as the repair of damaged blood vessels in heart disease, peripheral vascular disease and retinopathy, especially in the diabetic patient. Our stem cell approaches can also dramatically accelerate bone marrow stem cell engraftment in transplantation settings. BetaStem has developed an efficient pre-clinical development strategy that blends leading academic health care centers, substantial manufacturing and clinical outsourcing, with the goal of filing an IND by July 2011, and start a Phase 1 clinical trial by July 2012. PAIN: Therapies for diabetic retinopathy (a major cause of vision loss), coronary infarcts (heart attacks), and diabetic peripheral vascular disease are limited because they do not repair blood vessel endothelium. Our technology regenerates damaged endothelial cells which are a major component of blood vessels. In addition, our approaches can also improve current bone marrow transplantation processes that are used in the treatment of blood cancers. SOLUTION: Activate/enable a patient’s own stem cells to repair damaged vasculature by collecting stem cells from their blood and/or bone marrow, activating stem cells to overnight, and then administering the stem cells back to the patient for repair and regeneration (proliferation).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Cell Biology
Stem Cell ResearchClinical Development Stage
PreClinical
300 Brannan Street, Suite 407
San Francisco, CA, 94107
415-913-7595
http://betastemtherapy.com/Primary Contacts
Stephen Bartelmez PhD
President, CSO and Founder
Stephen Bartelmez PhD
CSO
Raj Prasad MBA
CFO
Company Profile
OVERVIEW: Patient-derived hematopoietic stem cells represent a proven clinical strategy for treatment of a wide range of important human diseases. BetaStem has developed proprietary methods and reagents to dramatically improve the application and efficacy of activated stem cell products from patient’s blood, bone marrow and cord blood. Applications for these products are broad and include unmet medical needs such as the repair of damaged blood vessels in heart disease, peripheral vascular disease and retinopathy, especially in the diabetic patient. Our stem cell approaches can also dramatically accelerate bone marrow stem cell engraftment in transplantation settings. BetaStem has developed an efficient pre-clinical development strategy that blends leading academic health care centers, substantial manufacturing and clinical outsourcing, with the goal of filing an IND by July 2011, and start a Phase 1 clinical trial by July 2012. PAIN: Therapies for diabetic retinopathy (a major cause of vision loss), coronary infarcts (heart attacks), and diabetic peripheral vascular disease are limited because they do not repair blood vessel endothelium. Our technology regenerates damaged endothelial cells which are a major component of blood vessels. In addition, our approaches can also improve current bone marrow transplantation processes that are used in the treatment of blood cancers. SOLUTION: Activate/enable a patient’s own stem cells to repair damaged vasculature by collecting stem cells from their blood and/or bone marrow, activating stem cells to overnight, and then administering the stem cells back to the patient for repair and regeneration (proliferation).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Cell Biology
Stem Cell ResearchClinical Development Stage
PreClinical
Bexel Pharmaceuticals Inc
32980 Alvarado-Niles Road Suite 810
Union City, CA, 94587
510-324-0015
http://www.orchidpharma.comPrimary Contacts
Dr. Prasad S Patala
Corporate Vice President
Aparna Mukherjee
Associate Manager- Scientific Affairs & Business Development
Company Profile
Bexel Pharmaceuticals Inc., an US subsidiary of Orchid Chemicals & Pharmaceuticals Ltd. Orchid Chemicals and Pharmaceuticals Ltd, India (ORCHID group) through its wholly owned subsidiaries, Orchid Research Laboratories Ltd in India, Bexel Pharmaceuticals Inc USA, and affiliate, Diakron Pharmaceuticals Inc in USA is an Integrated Research Company of Global Standing, is committed to the discovery and development of safe and efficacious medicines for global healthcare needs. Ongoing discovery and development programs are in the therapeutic areas of Cancer, Inflammation, Anti-infective, Cardio-Vascular and Metabolic Disorder. The key aspects include NCE/Product pipeline for licensing, flexible approach to collaboration, state-of-the-art research centers and access to the groups' Parent US FDA & MHRA approved Dosage and API facilities.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Cell Biology
Combinatorial Chemistry
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
32980 Alvarado-Niles Road Suite 810
Union City, CA, 94587
510-324-0015
http://www.orchidpharma.comPrimary Contacts
Dr. Prasad S Patala
Corporate Vice President
Aparna Mukherjee
Associate Manager- Scientific Affairs & Business Development
Company Profile
Bexel Pharmaceuticals Inc., an US subsidiary of Orchid Chemicals & Pharmaceuticals Ltd. Orchid Chemicals and Pharmaceuticals Ltd, India (ORCHID group) through its wholly owned subsidiaries, Orchid Research Laboratories Ltd in India, Bexel Pharmaceuticals Inc USA, and affiliate, Diakron Pharmaceuticals Inc in USA is an Integrated Research Company of Global Standing, is committed to the discovery and development of safe and efficacious medicines for global healthcare needs. Ongoing discovery and development programs are in the therapeutic areas of Cancer, Inflammation, Anti-infective, Cardio-Vascular and Metabolic Disorder. The key aspects include NCE/Product pipeline for licensing, flexible approach to collaboration, state-of-the-art research centers and access to the groups' Parent US FDA & MHRA approved Dosage and API facilities.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Cell Biology
Combinatorial Chemistry
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Bio-Link
1855 Folsom Street, Suite 643
San Francisco, CA, United States, 94103
415 487 2470
http://www.bio-link.orgPrimary Contacts
Elaine A. Johnson, PhD
Executive Director
415-487-2472
Lisa Huffman
Office Manager and Events Coordinator
415-487-2471
Company Profile
Bio-Link is the Next Generation Advanced Technological Education (ATE) National Center of Excellence for Biotechnology and Life Sciences. Bio-Link has received major funding from the National Science Foundation to work with community and technical colleges that have programs that prepare the technical workforce for the biotechnology industry. Bio-Link is based at City College of San Francisco and serves to network biotechnology programs across the nation.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
EducationPrimary Technology
Bioinformatics
Biomanufacturing
Stem Cell Research
1855 Folsom Street, Suite 643
San Francisco, CA, United States, 94103
415 487 2470
http://www.bio-link.orgPrimary Contacts
Elaine A. Johnson, PhD
Executive Director
415-487-2472
Lisa Huffman
Office Manager and Events Coordinator
415-487-2471
Company Profile
Bio-Link is the Next Generation Advanced Technological Education (ATE) National Center of Excellence for Biotechnology and Life Sciences. Bio-Link has received major funding from the National Science Foundation to work with community and technical colleges that have programs that prepare the technical workforce for the biotechnology industry. Bio-Link is based at City College of San Francisco and serves to network biotechnology programs across the nation.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
EducationPrimary Technology
Bioinformatics
Biomanufacturing
Stem Cell Research
Bio-Rad Laboratories, Inc.
Alfred Nobel Drive
Hercules, CA, United States, 94547
510 724-7000
http://www.bio-rad.comPrimary Contacts
David Schwartz
Chairman of the Board
Norman Schwartz
President and CEO
Christine Tsingos
Vice President and CFO
Company Profile
Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative products and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,800 employees and serves more than 100,000 research and industry customers worldwide through its global network of operations. Throughout its existence, Bio Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Biomanufacturing
Cell Biology
Drug Discovery
Functional Genetics
Gene/Cell Therapy
Genomics
Imaging
Micro Arrays
Protein Engineering
Proteomics
Screening
Stem Cell Research
Alfred Nobel Drive
Hercules, CA, United States, 94547
510 724-7000
http://www.bio-rad.comPrimary Contacts
David Schwartz
Chairman of the Board
Norman Schwartz
President and CEO
Christine Tsingos
Vice President and CFO
Company Profile
Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative products and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,800 employees and serves more than 100,000 research and industry customers worldwide through its global network of operations. Throughout its existence, Bio Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Biomanufacturing
Cell Biology
Drug Discovery
Functional Genetics
Gene/Cell Therapy
Genomics
Imaging
Micro Arrays
Protein Engineering
Proteomics
Screening
Stem Cell Research
BioCardia
http://www.biocardia.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
http://www.biocardia.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
BioCheck, Inc.
323 Vintage Park Drive
Foster City, CA, 94404
(650) 573-1968
http://www.biocheckinc.comPrimary Contacts
John Chen
CEO/President
Company Profile
BioCheck is a FDA and ISO certified facility specializing in the development, manufacturing and marketing of high-quality ELISA kits. Product line includes tests for tumor markers, cardiac markers, steroids, thyroids, TORCH and infectious diseases. BioCheck also provides contract services such as custom ELISA kit development, reagent manufacturing and antibody purification.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
Infectious Disease
323 Vintage Park Drive
Foster City, CA, 94404
(650) 573-1968
http://www.biocheckinc.comPrimary Contacts
John Chen
CEO/President
Company Profile
BioCheck is a FDA and ISO certified facility specializing in the development, manufacturing and marketing of high-quality ELISA kits. Product line includes tests for tumor markers, cardiac markers, steroids, thyroids, TORCH and infectious diseases. BioCheck also provides contract services such as custom ELISA kit development, reagent manufacturing and antibody purification.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
Infectious Disease
BioCycive
4688 Cuernavaca Circulo
Mountain View, CA, United States, 94040
650-334-2642
http://www.biocycive.comPrimary Contacts
Shalabh Gupta, MD
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerClinical Development Stage
PreClinical
4688 Cuernavaca Circulo
Mountain View, CA, United States, 94040
650-334-2642
http://www.biocycive.comPrimary Contacts
Shalabh Gupta, MD
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Biologics Consulting Group, Inc.
1840 Gateway Drive, Suite 200
San Mateo, CA, 94404
650-378-1303
http://www.bcg-usa.com/index.htmlPrimary Contacts
Ronald A. Marchesani
Head, West Coast Operations
650-387-1303
Jim Kenimer
CEO/President
703-739-5695
Company Profile
Biologics Consulting Group, Inc. (BCG) is an international consulting firm whose consultants provide national and international regulatory and product development advice on the development and commercial production of biological, drug, and device products. Our staff consists of experts in regulatory affairs, product manufacturing and testing, pharmacology/toxicology, facility inspections, statistics, program management, and clinical trial design and evaluation. Many of our consultants are former CBER, CDER, and CDRH reviewers, certified FDA inspectors, and senior scientists from the biotechnology industry. Because of our familiarity with FDA expectations we have an excellent reputation at the Agency for filing high-quality, easily reviewable applicationsCompany Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Central Nervous
Dental
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
OphthalmologyPrimary Technology
Biomanufacturing
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
1840 Gateway Drive, Suite 200
San Mateo, CA, 94404
650-378-1303
http://www.bcg-usa.com/index.htmlPrimary Contacts
Ronald A. Marchesani
Head, West Coast Operations
650-387-1303
Jim Kenimer
CEO/President
703-739-5695
Company Profile
Biologics Consulting Group, Inc. (BCG) is an international consulting firm whose consultants provide national and international regulatory and product development advice on the development and commercial production of biological, drug, and device products. Our staff consists of experts in regulatory affairs, product manufacturing and testing, pharmacology/toxicology, facility inspections, statistics, program management, and clinical trial design and evaluation. Many of our consultants are former CBER, CDER, and CDRH reviewers, certified FDA inspectors, and senior scientists from the biotechnology industry. Because of our familiarity with FDA expectations we have an excellent reputation at the Agency for filing high-quality, easily reviewable applicationsCompany Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Central Nervous
Dental
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
OphthalmologyPrimary Technology
Biomanufacturing
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
BioMarin Pharmaceutical, Inc.
105 Digital Drive
Novato, CA, 94949
415-506-6700
http://www.bmrn.comPrimary Contacts
Jean-Jacques Bienaimè
Chief Executive Officer
Stephen Aselage
Executive Vice President, Business Operations
Henry J. Fuchs, M.D.
Executive Vice President and Chief Medical Officer
Company Profile
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four marketed products and multiple clinical and pre-clinical product candidates. Marketed products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (currently approved in the EU only) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Genetic Diseases
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersPrimary Technology
Bioinformatics
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
105 Digital Drive
Novato, CA, 94949
415-506-6700
http://www.bmrn.comPrimary Contacts
Jean-Jacques Bienaimè
Chief Executive Officer
Stephen Aselage
Executive Vice President, Business Operations
Henry J. Fuchs, M.D.
Executive Vice President and Chief Medical Officer
Company Profile
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four marketed products and multiple clinical and pre-clinical product candidates. Marketed products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (currently approved in the EU only) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Genetic Diseases
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersPrimary Technology
Bioinformatics
Biomanufacturing
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Bioneer Inc.
1000 Atlantic Avenue
Alameda, CA, United States, 94501
(877) 264-4300
http://us.bioneer.com/Primary Contacts
Myeong Hee Kim
President
Vincent R. Prezioso, Ph.D.
Vice President of Sales and Marketing
Kira Reinhart
Director of Sales, North America
Company Profile
Bioneer Corporation is Korea's leading biotech company. Bioneer was the first Korean biotechnology company when it was established in 1992. The company has developed state of art molecular biology products and technologies including oligonucleotides, thermostable polymerases, and instruments of gene manipulation (automatic nucleic acid extractor, thermal cycler, real-time QPCR instruments and DNA sequencer). From its inception, Bioneer has invested in the integration of recombinant DNA technology, fermentation, biochemistry and nucleic acid chemistry in addition to mechanics, photonics and electronics. The company is positioned to fully-integrate its capability to develop next generation technologies in the post-genome era through the invention of new biochemistry and instruments. Bioneer now runs two production and research facilities in Korea which are a total of 226,000 square feet. Equipped with proprietary 384 synthesizers, these facilities contain a full production line for oligonucleotide and siRNA synthesis. In addition to DNA manufacturing, Bioneer processes recombinant proteins which are fermented and purified on proprietary purification systems. After a successful Initial Public Offering a few years ago, Bioneer Corporation launched Bioneer Inc., a wholly owned subsidiary. The American subsidiary is located in a 22,000 square foot production and distribution facility in Alameda, CA, the heart of the San Francisco Bay Area. The company is devoted to providing state of art solutions to the global community of life science researchers in academia, biotech and pharmaceutical companies. We have expertise in a wide range of areas. Our products include: - DNA amplification products - DNA purification products - RNA purification products - Phosphoramidites for DNA/RNA synthesis - Gene Synthesis services - Enzymes such as DNA polymerases and reverse transcriptase - DNA ladders and DNA markers - Oligonucleotide synthesis products - PCR master mixes - ExiPrep, automated Nucleic acid purification - ExiSpin, Combination Vortex/CentrifugeCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Infectious Disease
Respiratory DisordersPrimary Technology
Drug Delivery
Functional Genetics
GenomicsClinical Development Stage
PreClinical
1000 Atlantic Avenue
Alameda, CA, United States, 94501
(877) 264-4300
http://us.bioneer.com/Primary Contacts
Myeong Hee Kim
President
Vincent R. Prezioso, Ph.D.
Vice President of Sales and Marketing
Kira Reinhart
Director of Sales, North America
Company Profile
Bioneer Corporation is Korea's leading biotech company. Bioneer was the first Korean biotechnology company when it was established in 1992. The company has developed state of art molecular biology products and technologies including oligonucleotides, thermostable polymerases, and instruments of gene manipulation (automatic nucleic acid extractor, thermal cycler, real-time QPCR instruments and DNA sequencer). From its inception, Bioneer has invested in the integration of recombinant DNA technology, fermentation, biochemistry and nucleic acid chemistry in addition to mechanics, photonics and electronics. The company is positioned to fully-integrate its capability to develop next generation technologies in the post-genome era through the invention of new biochemistry and instruments. Bioneer now runs two production and research facilities in Korea which are a total of 226,000 square feet. Equipped with proprietary 384 synthesizers, these facilities contain a full production line for oligonucleotide and siRNA synthesis. In addition to DNA manufacturing, Bioneer processes recombinant proteins which are fermented and purified on proprietary purification systems. After a successful Initial Public Offering a few years ago, Bioneer Corporation launched Bioneer Inc., a wholly owned subsidiary. The American subsidiary is located in a 22,000 square foot production and distribution facility in Alameda, CA, the heart of the San Francisco Bay Area. The company is devoted to providing state of art solutions to the global community of life science researchers in academia, biotech and pharmaceutical companies. We have expertise in a wide range of areas. Our products include: - DNA amplification products - DNA purification products - RNA purification products - Phosphoramidites for DNA/RNA synthesis - Gene Synthesis services - Enzymes such as DNA polymerases and reverse transcriptase - DNA ladders and DNA markers - Oligonucleotide synthesis products - PCR master mixes - ExiPrep, automated Nucleic acid purification - ExiSpin, Combination Vortex/CentrifugeCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Infectious Disease
Respiratory DisordersPrimary Technology
Drug Delivery
Functional Genetics
GenomicsClinical Development Stage
PreClinical
Bionovo, Inc.
5858 Horton St., Ste 400
Emeryville, CA, United States, 94608
510-601-2000
http://www.bionovo.comPrimary Contacts
Isaac Cohen
President & CEO
Tom Chesterman
Senior Vice President and Chief Financial Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
5858 Horton St., Ste 400
Emeryville, CA, United States, 94608
510-601-2000
http://www.bionovo.comPrimary Contacts
Isaac Cohen
President & CEO
Tom Chesterman
Senior Vice President and Chief Financial Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Biosearch Technologies, Inc.
81 Digital Drive
Novato, CA, 94949
415-883-8400
http://www.biosearchtech.comCompany Profile
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications. In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009025), and as such, its contract manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostic, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Genomics
81 Digital Drive
Novato, CA, 94949
415-883-8400
http://www.biosearchtech.comCompany Profile
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications. In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009025), and as such, its contract manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostic, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Genomics
BioStorage Technologies, Inc.
2910 Fortune Circle West, Suite E
Indianapolis, IN, 46241
1 866 697 2675
http://www.biostorage.comPrimary Contacts
Jessette Novero
Business Development Manager (Pacific Northwest)
650-731-3116
Nick Garside
Sr. Business Development Manager
317-332-5942
Company Profile
After years of working in pharmaceutical and biological development, the principals of BioStorage Technologies recognized the need to bring the science of development to sample storage and management. Because the industry had not yet developed the standards of Good Storage Practices, BioStorage Technologies took the rigorous scientific processes used in development and applied them to sample storage. With facilities custom-designed for cold chain management, BioStorage Technologies has definitively brought science to sample storage and protection.Company Classification
Associate/Service Providers
2910 Fortune Circle West, Suite E
Indianapolis, IN, 46241
1 866 697 2675
http://www.biostorage.comPrimary Contacts
Jessette Novero
Business Development Manager (Pacific Northwest)
650-731-3116
Nick Garside
Sr. Business Development Manager
317-332-5942
Company Profile
After years of working in pharmaceutical and biological development, the principals of BioStorage Technologies recognized the need to bring the science of development to sample storage and management. Because the industry had not yet developed the standards of Good Storage Practices, BioStorage Technologies took the rigorous scientific processes used in development and applied them to sample storage. With facilities custom-designed for cold chain management, BioStorage Technologies has definitively brought science to sample storage and protection.Company Classification
Associate/Service Providers
BioSurplus
10805 Vista Sorrento Parkway, Suite 200
San Diego, CA, 92121
858-550-0800
http://www.biosurplus.com/Primary Contacts
Jackie Konstanturos
Chief Marketing Officer
858-550-0800
Kathy Scott
CFO
858-550-0800
Company Profile
Reseller of used and demo laboratory equipmentCompany Classification
Associate/Service Providers
10805 Vista Sorrento Parkway, Suite 200
San Diego, CA, 92121
858-550-0800
http://www.biosurplus.com/Primary Contacts
Jackie Konstanturos
Chief Marketing Officer
858-550-0800
Kathy Scott
CFO
858-550-0800
Company Profile
Reseller of used and demo laboratory equipmentCompany Classification
Associate/Service Providers
Biotech Primer
United States, http://www.biotechprimerinc.comCompany Classification
Associate/Service ProvidersOrganization Type
Education
United States, http://www.biotechprimerinc.comCompany Classification
Associate/Service ProvidersOrganization Type
Education
BioTime, Inc.
United States, http://www.biotimeinc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
United States, http://www.biotimeinc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
Bioxiness Pharmaceuticals, Inc.
750 Alfred Nobel Drive Suite 106
Hercules, CA, United States, 94547
(510)724-1548
http://www.bioxiness.comPrimary Contacts
Mansour Bassiri, PhD.
Chairman & CEO
Reza Ilkhani, MBA
CFO
Clint H. Severson
Sr. Board Member
Company Profile
Bioxiness Pharmaceuticals is a pre-clinical stage company, developing a novel class of antimicrobial compounds for the treatment of severe bacterial infections. These drugs are small molecules engineered for enhanced bacteria uptake as well as inhibiting previously underexplored bacterial targets (as new mode of action). Bioxiness’ compounds have the potential to be used as systemic antimicrobial drugs in multiple clinical areas.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Consulting Firms
TherapeuticDisease Areas of Focus
Cancer
Dermatology
Digestive System
Infectious Disease
Kidneys & Genito-Urinary System
Ophthalmology
Respiratory Disorders
Womens HealthPrimary Technology
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
750 Alfred Nobel Drive Suite 106
Hercules, CA, United States, 94547
(510)724-1548
http://www.bioxiness.comPrimary Contacts
Mansour Bassiri, PhD.
Chairman & CEO
Reza Ilkhani, MBA
CFO
Clint H. Severson
Sr. Board Member
Company Profile
Bioxiness Pharmaceuticals is a pre-clinical stage company, developing a novel class of antimicrobial compounds for the treatment of severe bacterial infections. These drugs are small molecules engineered for enhanced bacteria uptake as well as inhibiting previously underexplored bacterial targets (as new mode of action). Bioxiness’ compounds have the potential to be used as systemic antimicrobial drugs in multiple clinical areas.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Consulting Firms
TherapeuticDisease Areas of Focus
Cancer
Dermatology
Digestive System
Infectious Disease
Kidneys & Genito-Urinary System
Ophthalmology
Respiratory Disorders
Womens HealthPrimary Technology
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
Bloomberg Government
1101 K Street NW, Suite 500
Washington, DC, 20005
1-877-498-3587
http://www.bloomberg.comPrimary Contacts
Sean Bogdany
Sales
202-507-3729
Carolyn Spiro
Sales Programs
202-416-3203
Company Profile
Bloomberg Government is an online resource for professionals who need to understand the business implications of government actions so they can work quickly, decisively and effectively. This comprehensive, subscription-based, online tool collects best-in-class data, provides high-end analysis and analytic tools, and delivers deep, reliable, timely and unbiased reporting from a team of more than 2,300 journalists and multimedia specialists worldwide.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication/Media
1101 K Street NW, Suite 500
Washington, DC, 20005
1-877-498-3587
http://www.bloomberg.comPrimary Contacts
Sean Bogdany
Sales
202-507-3729
Carolyn Spiro
Sales Programs
202-416-3203
Company Profile
Bloomberg Government is an online resource for professionals who need to understand the business implications of government actions so they can work quickly, decisively and effectively. This comprehensive, subscription-based, online tool collects best-in-class data, provides high-end analysis and analytic tools, and delivers deep, reliable, timely and unbiased reporting from a team of more than 2,300 journalists and multimedia specialists worldwide.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication/Media
BN ImmunoTherapeutics Inc.
http://www.bavarian-nordic.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.bavarian-nordic.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Booz & Company
101 California Street, Suite 3300
San Francisco, CA, United States, 94107
415-421-1900
www.booz.comCompany Profile
Booz & Company is a leading global management consulting firm, helping the world's top businesses, governments, and other institutions. Booz & Company works closely with clients to create and deliver essential advantage. We bring foresight and knowledge, deep functional expertise, and a practical approach to build capabilities and deliver real impact.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
101 California Street, Suite 3300
San Francisco, CA, United States, 94107
415-421-1900
www.booz.comCompany Profile
Booz & Company is a leading global management consulting firm, helping the world's top businesses, governments, and other institutions. Booz & Company works closely with clients to create and deliver essential advantage. We bring foresight and knowledge, deep functional expertise, and a practical approach to build capabilities and deliver real impact.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Borson Law Group PC
1078 Carol Lane, Suite 200
Lafayette, CA, 94549-4760
925-310-2060
http://www.borsonlaw.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
1078 Carol Lane, Suite 200
Lafayette, CA, 94549-4760
925-310-2060
http://www.borsonlaw.comCompany Classification
Associate/Service ProvidersOrganization Type
Law Firms
Brains On-Line, LLC
7000 Shoreline Court Suite 275
South San Francisco, CA, United States, 94080
650-873-2026
http://www.brainsonline.orgPrimary Contacts
Thomas Cremers
CEO
Arash Rassoulpour
Director
Marieke van der Hart
Director Bioanalytical Sciences
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
7000 Shoreline Court Suite 275
South San Francisco, CA, United States, 94080
650-873-2026
http://www.brainsonline.orgPrimary Contacts
Thomas Cremers
CEO
Arash Rassoulpour
Director
Marieke van der Hart
Director Bioanalytical Sciences
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Bridgehead International
2155A Union St
San Francisco, CA, United States, 94123
415 529 1202
www.bridgehead.comPrimary Contacts
Sasha Richardson
Vice President
415 529 1202
Company Profile
Bridgehead International is a leading strategic life sciences consultancy, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain. Our mission is to work with commercial organizations, government agencies and the investment community to ensure that: • Life science organizations have the funding, structure and strategic focus to deliver high levels of innovation and financial return • Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need With over 55 consultants and 60 associates in Europe, The Americas and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modeling and intellectual property skills and experience. Bridgehead is globally recognized and renowned for its expertise in: • Technical and commercial evaluation • Due diligence and Experts’ Reports • Forecasting and valuation • Market access • Pricing and reimbursement strategy • Health economics and health technology assessment.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
2155A Union St
San Francisco, CA, United States, 94123
415 529 1202
www.bridgehead.comPrimary Contacts
Sasha Richardson
Vice President
415 529 1202
Company Profile
Bridgehead International is a leading strategic life sciences consultancy, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain. Our mission is to work with commercial organizations, government agencies and the investment community to ensure that: • Life science organizations have the funding, structure and strategic focus to deliver high levels of innovation and financial return • Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need With over 55 consultants and 60 associates in Europe, The Americas and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modeling and intellectual property skills and experience. Bridgehead is globally recognized and renowned for its expertise in: • Technical and commercial evaluation • Due diligence and Experts’ Reports • Forecasting and valuation • Market access • Pricing and reimbursement strategy • Health economics and health technology assessment.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Brinson Patrick Securities Corporation
4370 La Jolla Village Drive; Suite 400
San Diego, CA, 92122
858-453-2906
http://www.brinsonpatrick.comPrimary Contacts
Jack J Florio
Senior Vice President
858-453-2906
Company Profile
Brinson Patrick Securities Corporation has honed its expertise through well over a decade of cost-effectively raising equity capital for issuers seeking increased control and flexibility over the capital raising process. With experience across industries and a focus on life science and real-estate related businesses, Brinson Patrick is a proven boutique investment bank that works exclusively with issuers to raise equity capital with little or no impact on stock price. Brinson Patrick Securities Corporation is an investment banking boutique serving the equity capital raising needs of publicly traded companies, from small cap to Fortune 500. For over a decade, Brinson Patrick has worked closely with its clients to cost-effectively raise capital with little or no impact on stock price. Leveraging our DOCS® (Dynamic Offering of Common Stock) financing facility, we have worked with companies of various sizes and stages of growth to raise capital when and how they need it. We are a broker-dealer, registered with FINRA and the SEC. If your publicly traded company seeks increased flexibility and control in the capital raising process, you should get to know Brinson Patrick. Unp UNPARALLED CONTROL - PROVEN EXPERTISE - UNIQUE APPROACHCompany Classification
Associate/Service ProvidersOrganization Type
Investment Bank
4370 La Jolla Village Drive; Suite 400
San Diego, CA, 92122
858-453-2906
http://www.brinsonpatrick.comPrimary Contacts
Jack J Florio
Senior Vice President
858-453-2906
Company Profile
Brinson Patrick Securities Corporation has honed its expertise through well over a decade of cost-effectively raising equity capital for issuers seeking increased control and flexibility over the capital raising process. With experience across industries and a focus on life science and real-estate related businesses, Brinson Patrick is a proven boutique investment bank that works exclusively with issuers to raise equity capital with little or no impact on stock price. Brinson Patrick Securities Corporation is an investment banking boutique serving the equity capital raising needs of publicly traded companies, from small cap to Fortune 500. For over a decade, Brinson Patrick has worked closely with its clients to cost-effectively raise capital with little or no impact on stock price. Leveraging our DOCS® (Dynamic Offering of Common Stock) financing facility, we have worked with companies of various sizes and stages of growth to raise capital when and how they need it. We are a broker-dealer, registered with FINRA and the SEC. If your publicly traded company seeks increased flexibility and control in the capital raising process, you should get to know Brinson Patrick. Unp UNPARALLED CONTROL - PROVEN EXPERTISE - UNIQUE APPROACHCompany Classification
Associate/Service ProvidersOrganization Type
Investment Bank
Bristol-Myers Squibb Company
521 Cottonwood Drive
Milpitas, CA, United States, 95035
408-545-2700
http://www.bms.comPrimary Contacts
Lamberto Andreotti
CEO
Carlo de Notaristefani
President
Elliott Sigal
Executive Vice President, Chief Scientific Officer and President, R&D
Company Profile
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
521 Cottonwood Drive
Milpitas, CA, United States, 95035
408-545-2700
http://www.bms.comPrimary Contacts
Lamberto Andreotti
CEO
Carlo de Notaristefani
President
Elliott Sigal
Executive Vice President, Chief Scientific Officer and President, R&D
Company Profile
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Buck Institute for Age Research
8001 Redwood Blvd.
Novato, CA, United States, 94945
415.209.2000
http://www.buckinstitute.org/Primary Contacts
Remy Gross, III
Director, Technology Transfer
4154933639
Company Profile
The Buck Institute is a non-profit institute dedicated to the study of aging and age-related disease. The institute has 18 faculty members focused on the biology of aging, such as mitochondrial dysfunction and molecular pathways of aging, and age-related disease, such as neurodegeneration, cancer, cardiovascular and metabolic disease.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research InstituteDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
8001 Redwood Blvd.
Novato, CA, United States, 94945
415.209.2000
http://www.buckinstitute.org/Primary Contacts
Remy Gross, III
Director, Technology Transfer
4154933639
Company Profile
The Buck Institute is a non-profit institute dedicated to the study of aging and age-related disease. The institute has 18 faculty members focused on the biology of aging, such as mitochondrial dysfunction and molecular pathways of aging, and age-related disease, such as neurodegeneration, cancer, cardiovascular and metabolic disease.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research InstituteDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
Burrill & Company
One Embarcadero Center, Suite 2700
San Francisco, CA, United States, 94111
415 591 5400
http://www.burrillandco.comPrimary Contacts
G. Steven Burrill
CEO
415 591 5404
Roger Wyse
Managing Director
415 591 5416
Ann Hanham
Managing Director
415 591 5429
Bryant Fong
Managing Director
415 591 5412
John Hamer
Managing Director
415 591 5432
Company Profile
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the Life Sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking and media. This unique combination of resources and capabilities enables us to provide Life Sciences companies with capital, management expertise, industry insight, market intelligence and analysis through its investments, conferences and publications. Headquartered in San Francisco, Burrill & Company oversees a global network of offices throughout the United States, Latin America, Europe and Asia.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
One Embarcadero Center, Suite 2700
San Francisco, CA, United States, 94111
415 591 5400
http://www.burrillandco.comPrimary Contacts
G. Steven Burrill
CEO
415 591 5404
Roger Wyse
Managing Director
415 591 5416
Ann Hanham
Managing Director
415 591 5429
Bryant Fong
Managing Director
415 591 5412
John Hamer
Managing Director
415 591 5432
Company Profile
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the Life Sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking and media. This unique combination of resources and capabilities enables us to provide Life Sciences companies with capital, management expertise, industry insight, market intelligence and analysis through its investments, conferences and publications. Headquartered in San Francisco, Burrill & Company oversees a global network of offices throughout the United States, Latin America, Europe and Asia.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Business Wire
United States, http://www.businesswire.comCompany Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
United States, http://www.businesswire.comCompany Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
C S Bio Company, Inc.
http://www.csbio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://www.csbio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Cal Poly San Luis Obispo
United States, http://www.calpoly.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.calpoly.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Calera Corporation
14600 Winchester Boulevard
Los Gatos, CA, 95032
408 340 4600
http://www.calera.comPrimary Contacts
Will Roach
CEO
Bob Kelly
CFO
Jon Sobel
CLO
Company Profile
CO2 sequestration through technologies which such as biological capture through enzymes such as carbonic anhydraseCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Nanotechnology
14600 Winchester Boulevard
Los Gatos, CA, 95032
408 340 4600
http://www.calera.comPrimary Contacts
Will Roach
CEO
Bob Kelly
CFO
Jon Sobel
CLO
Company Profile
CO2 sequestration through technologies which such as biological capture through enzymes such as carbonic anhydraseCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Nanotechnology
California Community College Biological Technologies Initiative
http://www.cccbiotech.org
http://www.cccbiotech.org
California Healthcare Institute
United States, http://www.chi.org/Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
United States, http://www.chi.org/Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
California Institute for Regenerative Medicine
210 King St.
San Francisco, CA, United States, 94107
(415) 396-9100
http://www.cirm.ca.gov/Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
210 King St.
San Francisco, CA, United States, 94107
(415) 396-9100
http://www.cirm.ca.gov/Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
Calithera Biosciences
341 Oyster Point Blvd.
South San Francisco, CA, 94080
650 870-1000
http://www.calithera.comPrimary Contacts
Susan Molineaux
Founder, Chief Executive Officer
Mark Bennett
EVP, Research
Eric Sjogren
EVP, Discovery
Company Profile
The primary mission of Calithera Biosciences is to develop novel therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Cell Biology
Combinatorial Chemistry
Drug DiscoveryClinical Development Stage
PreClinical
341 Oyster Point Blvd.
South San Francisco, CA, 94080
650 870-1000
http://www.calithera.comPrimary Contacts
Susan Molineaux
Founder, Chief Executive Officer
Mark Bennett
EVP, Research
Eric Sjogren
EVP, Discovery
Company Profile
The primary mission of Calithera Biosciences is to develop novel therapeutic approaches to the treatment of cancer by using small molecules to activate, rather than inhibit, enzymesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Cell Biology
Combinatorial Chemistry
Drug DiscoveryClinical Development Stage
PreClinical
Caltherix Inc.
United States, http://www.caltherix.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.caltherix.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Cambridge BioPartners
United States, http://www.cambridgebiopartners.comCompany Classification
Associate/Service ProvidersOrganization Type
Human Resources/Staffing
United States, http://www.cambridgebiopartners.comCompany Classification
Associate/Service ProvidersOrganization Type
Human Resources/Staffing
Cambrios Technologies Corp.
930 East Arques Avenue
Sunnyvale, CA, 94087
408-738-7400
http://www.cambrios.comPrimary Contacts
Dr. Michael Knapp
President & CEO
Company Profile
Cambrios is a materials company that develops proprietary, competitive products using nanotechnology. Cambrios implements its novel technology to simplify manufacturing processes, improve end-product performance and identify ways to satisfy unmet industry needs.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Imaging
Nanotechnology
930 East Arques Avenue
Sunnyvale, CA, 94087
408-738-7400
http://www.cambrios.comPrimary Contacts
Dr. Michael Knapp
President & CEO
Company Profile
Cambrios is a materials company that develops proprietary, competitive products using nanotechnology. Cambrios implements its novel technology to simplify manufacturing processes, improve end-product performance and identify ways to satisfy unmet industry needs.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Imaging
Nanotechnology
Caprion Proteomics US LLC
1455 Adams Dr. Suite 2126
Menlo Park, CA, United States, 94025
650-618-9858
http://www.caprion.comPrimary Contacts
Sushmita Mimi Roy
Senior Director and Site Head
Martin LeBlanc
CEO
Daniel Chelsky
CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Central Nervous
Infectious Disease
Womens HealthPrimary Technology
Bioinformatics
Proteomics
1455 Adams Dr. Suite 2126
Menlo Park, CA, United States, 94025
650-618-9858
http://www.caprion.comPrimary Contacts
Sushmita Mimi Roy
Senior Director and Site Head
Martin LeBlanc
CEO
Daniel Chelsky
CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Central Nervous
Infectious Disease
Womens HealthPrimary Technology
Bioinformatics
Proteomics
Carbylan Biosurgery
3181 Porter Drive
Palo Alto, CA, 94304
650-855-6777
http://www.carbylan.comPrimary Contacts
George Daniloff
President & CEO
Gordon Saul
CBO
David Gravett
VP, R & D
Company Profile
Medical Device DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Musculoskeletal DisordersPrimary Technology
Combinatorial Chemistry
Drug DeliveryClinical Development Stage
PreClinical
3181 Porter Drive
Palo Alto, CA, 94304
650-855-6777
http://www.carbylan.comPrimary Contacts
George Daniloff
President & CEO
Gordon Saul
CBO
David Gravett
VP, R & D
Company Profile
Medical Device DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Musculoskeletal DisordersPrimary Technology
Combinatorial Chemistry
Drug DeliveryClinical Development Stage
PreClinical
CardioDx, Inc.
United States, http://www.cardiodx.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.cardiodx.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Carmenta Bioscience
800 High St.
Palo Alto, CA, United States, 94301
650-308-8544
http://www.carmentabio.comPrimary Contacts
Matthew Cooper
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Womens HealthPrimary Technology
Bioinformatics
ScreeningClinical Development Stage
PreClinical
800 High St.
Palo Alto, CA, United States, 94301
650-308-8544
http://www.carmentabio.comPrimary Contacts
Matthew Cooper
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Womens HealthPrimary Technology
Bioinformatics
ScreeningClinical Development Stage
PreClinical
Carmot Therapeutics, Inc.
409 Illinois Street
San Francisco, CA, United States, 94158
http://www.carmot.usPrimary Contacts
Daniel Erlanson
President
Stig Hansen
CEO
Company Profile
Carmot will discover breakthrough therapeutics for major human diseases by applying its proprietary technology, Chemotype Evolution, to rapidly identify drugs with superior properties through evolutionary screening paradigms.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
409 Illinois Street
San Francisco, CA, United States, 94158
http://www.carmot.usPrimary Contacts
Daniel Erlanson
President
Stig Hansen
CEO
Company Profile
Carmot will discover breakthrough therapeutics for major human diseases by applying its proprietary technology, Chemotype Evolution, to rapidly identify drugs with superior properties through evolutionary screening paradigms.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Catalyst Biosciences, Inc.
http://www.catbio.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.catbio.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Cato Research
601 Gateway Drive, Suite 1010
South San Francisco, CA, United States, 94080
650-588-8256
http://www.catobioventures.com/Primary Contacts
Jo Cato
Managing Director
Randy Lane
Associate Managing Director
Company Profile
Cato BioVentures is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepeneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of sucessful product development programs. Through strategic CRO service agreements with Cato Research, we have invested our CRO Service Capital™ in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity. If strategic outsourcing for development and regulatory and clinical support is a core component of a company's business plan, then our investment model can make a positive difference in the company's overall success.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
601 Gateway Drive, Suite 1010
South San Francisco, CA, United States, 94080
650-588-8256
http://www.catobioventures.com/Primary Contacts
Jo Cato
Managing Director
Randy Lane
Associate Managing Director
Company Profile
Cato BioVentures is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization (CRO). For over 20 years, Cato BioVentures and Cato Research have partnered with entrepeneurs, academic institutions, and a broad base of biotech and pharmaceutical companies to advance a robust portfolio of sucessful product development programs. Through strategic CRO service agreements with Cato Research, we have invested our CRO Service Capital™ in innovative therapeutics, medical devices and stem cell technologies that improve Pharma's Research and Development productivity. If strategic outsourcing for development and regulatory and clinical support is a core component of a company's business plan, then our investment model can make a positive difference in the company's overall success.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
CBS5
United States, http://sanfrancisco.cbslocal.com/Company Classification
Associate/Service Providers
United States, http://sanfrancisco.cbslocal.com/Company Classification
Associate/Service Providers
Celera
1401 Harbor Bay Parkway
Alameda, CA, 94502
510 749 4200
http://www.celera.comPrimary Contacts
Kathy Ordonez
President, Celera & SVP, Discovery and Development
Mike Zoccoli
VP and General Manager, Products Group
Michael Mercer
VP and General Manager, Berkeley HeartLab
Company Profile
Personalizing Disease Management can improve the length and quality of life, while reducing the cost of managing your health. We're developing tests and services that identify a person's inherent risk for a disease and may also characterize its biological basis, aiding selection among treatment options and monitoring treatment effectiveness.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory Disorders
1401 Harbor Bay Parkway
Alameda, CA, 94502
510 749 4200
http://www.celera.comPrimary Contacts
Kathy Ordonez
President, Celera & SVP, Discovery and Development
Mike Zoccoli
VP and General Manager, Products Group
Michael Mercer
VP and General Manager, Berkeley HeartLab
Company Profile
Personalizing Disease Management can improve the length and quality of life, while reducing the cost of managing your health. We're developing tests and services that identify a person's inherent risk for a disease and may also characterize its biological basis, aiding selection among treatment options and monitoring treatment effectiveness.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Celgene Corporation
86 Morris Avenue
Summit, NJ, United States, 7901
908-673-9000
http://www.celgene.comPrimary Contacts
Robert J. Hugin
Chief Executive Officer
Jacqualyn Fouse
Chief Financial Officer
Perry Karsen
Chief Operations Officer
Company Profile
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
CancerPrimary Technology
Drug Discovery
Nanotechnology
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
86 Morris Avenue
Summit, NJ, United States, 7901
908-673-9000
http://www.celgene.comPrimary Contacts
Robert J. Hugin
Chief Executive Officer
Jacqualyn Fouse
Chief Financial Officer
Perry Karsen
Chief Operations Officer
Company Profile
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
CancerPrimary Technology
Drug Discovery
Nanotechnology
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Cellecta, Inc.
320 Logue Ave
Mountain View, CA, United States, 94043
650-938-3910
http://www.cellecta.comPrimary Contacts
Paul Diehl
Director of Marketing and Business Development
650-938-4050
Karim Hyder
Director of Operations
650-938-3912
Company Profile
Cellecta provides HT RNAi-based genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA libraries, shRNA library screening and analysis by HT sequencing, and stable reporter, overexpression, or knockdown cell lines.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Genetic DiseasesPrimary Technology
Bioinformatics
Cell Biology
Drug Delivery
Functional Genetics
Genomics
ScreeningClinical Development Stage
PreClinical
320 Logue Ave
Mountain View, CA, United States, 94043
650-938-3910
http://www.cellecta.comPrimary Contacts
Paul Diehl
Director of Marketing and Business Development
650-938-4050
Karim Hyder
Director of Operations
650-938-3912
Company Profile
Cellecta provides HT RNAi-based genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA libraries, shRNA library screening and analysis by HT sequencing, and stable reporter, overexpression, or knockdown cell lines.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Genetic DiseasesPrimary Technology
Bioinformatics
Cell Biology
Drug Delivery
Functional Genetics
Genomics
ScreeningClinical Development Stage
PreClinical
Cellerant Therapeutics
http://www.cellerant.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.cellerant.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
CellSight Technologies, Inc.
165 Berry Avenue, Suite 350
San Francisco, CA, United States, 94107
650-799-1589
http://www.CellSightTech.comPrimary Contacts
Aruna Gambhir
CEO
Sam Quezada
COO
Shahriar Yaghoubi
CSO
Company Profile
In-vivo imaging of cell kineticsCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic DiseasesPrimary Technology
ImagingClinical Development Stage
PreClinical
Phase I
165 Berry Avenue, Suite 350
San Francisco, CA, United States, 94107
650-799-1589
http://www.CellSightTech.comPrimary Contacts
Aruna Gambhir
CEO
Sam Quezada
COO
Shahriar Yaghoubi
CSO
Company Profile
In-vivo imaging of cell kineticsCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic DiseasesPrimary Technology
ImagingClinical Development Stage
PreClinical
Phase I
Centella Therapeutics, Inc.
3120 Hansen Way
Palo Alto, CA, United States, 94304
650 251 5543
http://www.centellatx.comPrimary Contacts
Thorsten Melcher
President & CEO
Jim Mervis
Chief Business Officer
Company Profile
Centella Therapeutics develops treatments for human cancer by combining spatially targeted external-beam radiation therapy with molecular targeted therapeutics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Drug Discovery
ImagingClinical Development Stage
PreClinical
Phase I
Phase II
3120 Hansen Way
Palo Alto, CA, United States, 94304
650 251 5543
http://www.centellatx.comPrimary Contacts
Thorsten Melcher
President & CEO
Jim Mervis
Chief Business Officer
Company Profile
Centella Therapeutics develops treatments for human cancer by combining spatially targeted external-beam radiation therapy with molecular targeted therapeutics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Drug Discovery
ImagingClinical Development Stage
PreClinical
Phase I
Phase II
Centerline Medical LLC
2684 Middlefield Road, Unit H
Redwood City, CA, 94063
650-363-8400
Primary Contacts
Ronald G. Williams
Owner
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Dental
Dermatology
Digestive System
OphthalmologyClinical Development Stage
PreClinical
2684 Middlefield Road, Unit H
Redwood City, CA, 94063
650-363-8400
Primary Contacts
Ronald G. Williams
Owner
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Dental
Dermatology
Digestive System
OphthalmologyClinical Development Stage
PreClinical
Cepheid
904 Caribbean Drive
Sunnyvale, CA, 94089
http://www.cepheid.comPrimary Contacts
Humberto Reyes
EVP & COO
Company Profile
BioTechnologyCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseaseClinical Development Stage
Approved
904 Caribbean Drive
Sunnyvale, CA, 94089
http://www.cepheid.comPrimary Contacts
Humberto Reyes
EVP & COO
Company Profile
BioTechnologyCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseaseClinical Development Stage
Approved
Cerexa
2100 Franklin St. Ste 900
Oakland, CA, United States, 94612-3055
510-285-9200
http://www.cerexa.com/Primary Contacts
Paul Grint, M.D.
President
Dan Puckett
Executive Director, Operations
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseaseClinical Development Stage
Phase I
Phase II
Phase III
Approved
2100 Franklin St. Ste 900
Oakland, CA, United States, 94612-3055
510-285-9200
http://www.cerexa.com/Primary Contacts
Paul Grint, M.D.
President
Dan Puckett
Executive Director, Operations
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseaseClinical Development Stage
Phase I
Phase II
Phase III
Approved
Cerus Corporation
2550 Stanwell Drive
Concord, CA, United States, 94520
925.288.6000
http://www.cerus.comPrimary Contacts
William Greenman
President a& CEO
Kevin Green
Chief Accounting Officer
Howard Ervin
Chief Legal Officer
Company Profile
Cerus is a biomedical products company focused on commercializing the INTERCEPT Blood System, to enhance blood safety. The INTERCEPT system is designged to inactivate blood-borne pathogens in donated blood components intended for transfusion. We are a global organization, currently marketing and selling the INTERCEPT system for both platelets and plasma in a number of countries in Europe, CIS, the Middle East and selected countries in other regions around the world using our direct sales force or through distributors.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Blood & Lymphatic DiseasesClinical Development Stage
Phase I
Phase III
Approved
2550 Stanwell Drive
Concord, CA, United States, 94520
925.288.6000
http://www.cerus.comPrimary Contacts
William Greenman
President a& CEO
Kevin Green
Chief Accounting Officer
Howard Ervin
Chief Legal Officer
Company Profile
Cerus is a biomedical products company focused on commercializing the INTERCEPT Blood System, to enhance blood safety. The INTERCEPT system is designged to inactivate blood-borne pathogens in donated blood components intended for transfusion. We are a global organization, currently marketing and selling the INTERCEPT system for both platelets and plasma in a number of countries in Europe, CIS, the Middle East and selected countries in other regions around the world using our direct sales force or through distributors.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Blood & Lymphatic DiseasesClinical Development Stage
Phase I
Phase III
Approved
Charisela Technologies, Inc
1600 Adams Drive, Suite 124
Menlo Park, CA, United States, 94025
650 328 1750
http://www.charisela.comPrimary Contacts
Richard Preston
CEO
Bob Daneilzadeh
CTO
Dan Curtis
VP Mfg
Company Profile
Company makes bead based assays for all flow cytometers. Company's area of expertise is assays for high concentration analytes. New platform is faster, simpler, and more accurate than competitionCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
1600 Adams Drive, Suite 124
Menlo Park, CA, United States, 94025
650 328 1750
http://www.charisela.comPrimary Contacts
Richard Preston
CEO
Bob Daneilzadeh
CTO
Dan Curtis
VP Mfg
Company Profile
Company makes bead based assays for all flow cytometers. Company's area of expertise is assays for high concentration analytes. New platform is faster, simpler, and more accurate than competitionCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
AnalyticsDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
Chemical Research Consultants
88 Elm Ave.
Larkspur, CA, 94939
415-680-8266
Primary Contacts
Christian Apfel
Founder
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
88 Elm Ave.
Larkspur, CA, 94939
415-680-8266
Primary Contacts
Christian Apfel
Founder
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
ChemoCentryx, Inc
850 Maude Ave.
Mountain View, CA, United States, 949043
650-210-2900
http://www.chemocentryx.comPrimary Contacts
Thomas Schall
President and CEO
Susan Kanaya
Senior Vice President and Chief Financial Officer
Juan Jaen
Senior Vice President, Drug Discover and CSO
Markus Cappel
Chief Business Officer and Treasurer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Digestive System
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
850 Maude Ave.
Mountain View, CA, United States, 949043
650-210-2900
http://www.chemocentryx.comPrimary Contacts
Thomas Schall
President and CEO
Susan Kanaya
Senior Vice President and Chief Financial Officer
Juan Jaen
Senior Vice President, Drug Discover and CSO
Markus Cappel
Chief Business Officer and Treasurer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Digestive System
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Children's Hospital Research Institute Oakland
5700 Martin Luther King Jr. Way
Oakland, CA, United States, 94609
(510) 428-3885
http://www.chori.orgPrimary Contacts
Kathleen Hogue Gonzalez
VP Research Administration
(510) 450-7602
Suzanne Haendel, JD, CLP
Technology Transfer Director
(510) 428-3885, ext 5103
Company Profile
CHORI is the internationally renowned biomedical research institute of Children's Hospital and Research Center at Oakland. With world-class scientists and research centers known both nationally and internationally in multiple fields, CHORI is 5th in the nation for National Institutes of Health pediatric research funding. Bridging basic science and clinical research in the treatment and prevention of human disease, CHORI is a leader in translational research, providing cures for blood diseases, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions. Striving to provide the highest standard of excellence and innovation, CHORI brings together a multidisciplinary collaborative of distinguished investigators in six different Centers of Research: The Center for Cancer Research, The Center for Genetics, The Center for Immunobiology & Vaccine Development, The Center for Nutrition & Metabolism, The Center for Prevention of Obesity, Cardiovascular Disease & Diabetes, and The Center for Sickle Cell Disease & Thalassemia. Within these major areas of focus, CHORI pushes the frontiers of science – and of excellence – beyond their borders.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
5700 Martin Luther King Jr. Way
Oakland, CA, United States, 94609
(510) 428-3885
http://www.chori.orgPrimary Contacts
Kathleen Hogue Gonzalez
VP Research Administration
(510) 450-7602
Suzanne Haendel, JD, CLP
Technology Transfer Director
(510) 428-3885, ext 5103
Company Profile
CHORI is the internationally renowned biomedical research institute of Children's Hospital and Research Center at Oakland. With world-class scientists and research centers known both nationally and internationally in multiple fields, CHORI is 5th in the nation for National Institutes of Health pediatric research funding. Bridging basic science and clinical research in the treatment and prevention of human disease, CHORI is a leader in translational research, providing cures for blood diseases, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions. Striving to provide the highest standard of excellence and innovation, CHORI brings together a multidisciplinary collaborative of distinguished investigators in six different Centers of Research: The Center for Cancer Research, The Center for Genetics, The Center for Immunobiology & Vaccine Development, The Center for Nutrition & Metabolism, The Center for Prevention of Obesity, Cardiovascular Disease & Diabetes, and The Center for Sickle Cell Disease & Thalassemia. Within these major areas of focus, CHORI pushes the frontiers of science – and of excellence – beyond their borders.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
Circuit Therapeutics, Inc
1430 O'Brien Dr. Suite F
Menlo Park, CA, United States, 94025
650-324-9400
Primary Contacts
Karoly Nikolich
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
Kidneys & Genito-Urinary SystemPrimary Technology
Drug Discovery
Gene/Cell Therapy
NanotechnologyClinical Development Stage
PreClinical
1430 O'Brien Dr. Suite F
Menlo Park, CA, United States, 94025
650-324-9400
Primary Contacts
Karoly Nikolich
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
Kidneys & Genito-Urinary SystemPrimary Technology
Drug Discovery
Gene/Cell Therapy
NanotechnologyClinical Development Stage
PreClinical
City of Berkeley
United States, http://www.ci.berkeley.ca.usCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
United States, http://www.ci.berkeley.ca.usCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
City of Emeryville
1333 Park Avenue
Emeryville, CA, United States, 94706
510 596-4355
http://www.emeryville.orgCompany Profile
City GovernmentCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
1333 Park Avenue
Emeryville, CA, United States, 94706
510 596-4355
http://www.emeryville.orgCompany Profile
City GovernmentCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
City of South San Francisco
400 Grand Avenue
South San Francisco, CA, United States, 94080
650-877-8500
http://www.ssf.netPrimary Contacts
Marty Van Duyn
Assistant City Manager
650-877-8500
Company Profile
We are a local government and home to approximately 70 bioscience companies.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
400 Grand Avenue
South San Francisco, CA, United States, 94080
650-877-8500
http://www.ssf.netPrimary Contacts
Marty Van Duyn
Assistant City Manager
650-877-8500
Company Profile
We are a local government and home to approximately 70 bioscience companies.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
Clarkston Consulting
1007 Slater Road, Suite 400
Durham, NC, 27703
1-800-652-4274
http://www.clarkstonconsulting.comPrimary Contacts
Tony Stlois
Client Sales Executive
650-400-1656
Company Profile
Clarkston Consulting is a different kind of management and technology consulting firm. We deliver a unique experience for market leaders within the Consumer Products and Life Sciences industries. Considering professionalism, expertise, and value as prerequisites, we take service a step further through our unyielding commitment to the success of people as individuals, both our clients and our employees. By combining integrity, adaptability, and a whatever-it-takes attitude, we have achieved an extremely high rate of referral and repeat business and a 7-year average client satisfaction rate of 97%. Founded in 1991, Clarkston continues to strengthen our industry depth working with senior executives in the world’s foremost companies managing the best of brands. As the market shifts in both life sciences and consumer products from bottom-line cost cutting to driving top-line growth, we are helping our clients focus on every aspect of their business from innovation and new product development to manufacturing and supply chain execution and out to the field working to maximize customer relationships and pricing strategies.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
1007 Slater Road, Suite 400
Durham, NC, 27703
1-800-652-4274
http://www.clarkstonconsulting.comPrimary Contacts
Tony Stlois
Client Sales Executive
650-400-1656
Company Profile
Clarkston Consulting is a different kind of management and technology consulting firm. We deliver a unique experience for market leaders within the Consumer Products and Life Sciences industries. Considering professionalism, expertise, and value as prerequisites, we take service a step further through our unyielding commitment to the success of people as individuals, both our clients and our employees. By combining integrity, adaptability, and a whatever-it-takes attitude, we have achieved an extremely high rate of referral and repeat business and a 7-year average client satisfaction rate of 97%. Founded in 1991, Clarkston continues to strengthen our industry depth working with senior executives in the world’s foremost companies managing the best of brands. As the market shifts in both life sciences and consumer products from bottom-line cost cutting to driving top-line growth, we are helping our clients focus on every aspect of their business from innovation and new product development to manufacturing and supply chain execution and out to the field working to maximize customer relationships and pricing strategies.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Cleave Biosciences
866 Malcolm Rd #100
Burlingame, CA, United States, 94010
650-443-3000
Primary Contacts
Laura Shawver, PhD
CEO
Mark Rolfe
VP and CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerClinical Development Stage
PreClinical
866 Malcolm Rd #100
Burlingame, CA, United States, 94010
650-443-3000
Primary Contacts
Laura Shawver, PhD
CEO
Mark Rolfe
VP and CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Clinigen, Ltd.
1007 Slater Road, Suite 400
Burton-on-Trent, Great Britain, DE14 2WW
+44 (0) 1283 494 326
http://www.clinigen.co.ukPrimary Contacts
Mark Corbett
Global Strategic Planning Director
+44 (0) 1283 494326
Peter George
CEO
+44 (0) 1283 494326
David Bryant
Global Business Development Director
+44 (0) 1283 494326
Company Profile
Clinigen focuses solely on the consultancy, management and implementation of Named Patient and Early Access solutions. Clinigen offers Pharma/Biotech companies a fully outsourced solution in providing Global Early Access/Named Patient Programs across late stage clinical development, pre- launch, launch and product withdrawal sections of the pharmaceutical life cycle, supporting patient and physician access to investigational products in countries where they are not approved or available. Clinigen’s Named Patient and Early Access solutions under the leadership of a dedicated Project Manager encompass all elements from consultancy and set up of the solution, Handling Requests for Access, Regulatory Requirements, Invoicing / Credit Management, Storage, Logistics, Data Capture and Report Generation. These services are underpinned by Clinigen’s in house Regulatory, Pharmacovigilance, Medical, Logistics and Quality expertise. Alongside the implementation of a Global Early Access / Named Patient Solutions, Clinigen can also support market development activities in Europe for those companies without a European presence. This includes, Global Launch Planning, Stakeholder Mapping, KOL Engagement Activities, Pricing and Reimbursement Negotiations, Registration Planning, Market Access Activities and Commercialisation Support. Our client base is diverse with organisations ranging from Global Pharma to mid-sized Pharma/biotechnology companies with limited EU commercial presence through to start up, single asset organisations.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
1007 Slater Road, Suite 400
Burton-on-Trent, Great Britain, DE14 2WW
+44 (0) 1283 494 326
http://www.clinigen.co.ukPrimary Contacts
Mark Corbett
Global Strategic Planning Director
+44 (0) 1283 494326
Peter George
CEO
+44 (0) 1283 494326
David Bryant
Global Business Development Director
+44 (0) 1283 494326
Company Profile
Clinigen focuses solely on the consultancy, management and implementation of Named Patient and Early Access solutions. Clinigen offers Pharma/Biotech companies a fully outsourced solution in providing Global Early Access/Named Patient Programs across late stage clinical development, pre- launch, launch and product withdrawal sections of the pharmaceutical life cycle, supporting patient and physician access to investigational products in countries where they are not approved or available. Clinigen’s Named Patient and Early Access solutions under the leadership of a dedicated Project Manager encompass all elements from consultancy and set up of the solution, Handling Requests for Access, Regulatory Requirements, Invoicing / Credit Management, Storage, Logistics, Data Capture and Report Generation. These services are underpinned by Clinigen’s in house Regulatory, Pharmacovigilance, Medical, Logistics and Quality expertise. Alongside the implementation of a Global Early Access / Named Patient Solutions, Clinigen can also support market development activities in Europe for those companies without a European presence. This includes, Global Launch Planning, Stakeholder Mapping, KOL Engagement Activities, Pricing and Reimbursement Negotiations, Registration Planning, Market Access Activities and Commercialisation Support. Our client base is diverse with organisations ranging from Global Pharma to mid-sized Pharma/biotechnology companies with limited EU commercial presence through to start up, single asset organisations.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Clovis Oncology, Inc
1700 Owens Street
San Franciso, CA, United States, 94158
415.409.5440
http://www.clovisoncology.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Phase I
Phase II
1700 Owens Street
San Franciso, CA, United States, 94158
415.409.5440
http://www.clovisoncology.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Phase I
Phase II
CogENT Therapeutics
156 Holly Ct.
Mountain view, CA, United States, 94061
650-450-4956
http://www.cogent-tx.comPrimary Contacts
Scott Sershen
Principal
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
PreClinical
156 Holly Ct.
Mountain view, CA, United States, 94061
650-450-4956
http://www.cogent-tx.comPrimary Contacts
Scott Sershen
Principal
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
PreClinical
Compensia
12340 El Camino Real Ste 400
San Diego, CA, 92130-3079
858-755-8675
http://remedycomp.com/Primary Contacts
Ken Wechlser
Principal
858-755-8675
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
12340 El Camino Real Ste 400
San Diego, CA, 92130-3079
858-755-8675
http://remedycomp.com/Primary Contacts
Ken Wechlser
Principal
858-755-8675
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Complete Genomics, Inc.
http://completegenomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
http://completegenomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Compliance Implementation Services
1400 N Providence Rd Ste 3005
Media, PA, 19063
484-445-7200
http://www.cis-partners.com/Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
1400 N Providence Rd Ste 3005
Media, PA, 19063
484-445-7200
http://www.cis-partners.com/Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Compugen, Inc.
260 East Grand Ave.
South San Francisco, CA, United States, 94080
415-373-0556
www.cgen.comPrimary Contacts
Dr. Mary Haak-Frendscho
Executive Chairman Board of Directors
Company Profile
Compugen, Inc. is biotech start-up company focused on the development of oncology and immunology monoclonal antibody (mAb) drug candidates. Based in South San Francisco, Compugen Inc is a wholly owned subsidiary of Compugen Ltd.; working to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company into promising mAb drug candidates for licensing and partnering.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Cell Biology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
260 East Grand Ave.
South San Francisco, CA, United States, 94080
415-373-0556
www.cgen.comPrimary Contacts
Dr. Mary Haak-Frendscho
Executive Chairman Board of Directors
Company Profile
Compugen, Inc. is biotech start-up company focused on the development of oncology and immunology monoclonal antibody (mAb) drug candidates. Based in South San Francisco, Compugen Inc is a wholly owned subsidiary of Compugen Ltd.; working to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company into promising mAb drug candidates for licensing and partnering.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Cell Biology
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Conceptus, Inc.
331 E. Evelyn Avenue
Mountain View, ca, 94041
650.962.4000
http://www.conceptus.comPrimary Contacts
Mark Sieczkarek
CEO
Gregory Lichtwardt
EVP, CFO
Julie A. Brooks
EVP, General Counsel, Chief Compliance Officer and Secretary
Company Profile
Medical device company in Women's healhcare providing the most effective form of permanent birth control with no cutting, no hormones, no general anesthesia, that takes 9 minutes in the doctor's office.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
Approved
331 E. Evelyn Avenue
Mountain View, ca, 94041
650.962.4000
http://www.conceptus.comPrimary Contacts
Mark Sieczkarek
CEO
Gregory Lichtwardt
EVP, CFO
Julie A. Brooks
EVP, General Counsel, Chief Compliance Officer and Secretary
Company Profile
Medical device company in Women's healhcare providing the most effective form of permanent birth control with no cutting, no hormones, no general anesthesia, that takes 9 minutes in the doctor's office.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
Approved
Consulate General of Canada
580 California St. Fl 14
San Francisco, CA, United States, 94104-1000
415-834-3180
http://www.sanfrancisco.gc.caCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
Government Agencies
580 California St. Fl 14
San Francisco, CA, United States, 94104-1000
415-834-3180
http://www.sanfrancisco.gc.caCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
Government Agencies
Consulate General of the Netherlands
1 Montgomery Street, Suite 3100
San Francisco, CA, United States, 94104
4152912080
http://www.sanfrancisco.the-netherlands.org/Primary Contacts
Marc Nellen
Science and Technology Officer
4152912082
Lisette Gieling
Area director
4152061
Jaap Veerman
Head economic department
4152912092
Kamillia Kotlewska
Area Assistent
4152912063
Company Profile
The Consulate General of the Netherlands in San Francisco is the oficial government organizations that represents the Netherlands in the West Coast of the United States.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
1 Montgomery Street, Suite 3100
San Francisco, CA, United States, 94104
4152912080
http://www.sanfrancisco.the-netherlands.org/Primary Contacts
Marc Nellen
Science and Technology Officer
4152912082
Lisette Gieling
Area director
4152061
Jaap Veerman
Head economic department
4152912092
Kamillia Kotlewska
Area Assistent
4152912063
Company Profile
The Consulate General of the Netherlands in San Francisco is the oficial government organizations that represents the Netherlands in the West Coast of the United States.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
Cor Innovations
813 Heinz Ave.
Berkeley, CA, United States, 94710
510-809-2512
Primary Contacts
Karen Havenstrite
CSO
Bilal Shafi
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
PreClinical
813 Heinz Ave.
Berkeley, CA, United States, 94710
510-809-2512
Primary Contacts
Karen Havenstrite
CSO
Bilal Shafi
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
PreClinical
Corcept Therapeutics
149 Commonwealth Drive
Menlo Park, CA, 94025
650-327-3270
http://www.corcept.comPrimary Contacts
Joseph Belanoff, MD
CEO
Robert Roe, MD
President
Caroline Loewy
CFO
Company Profile
Corcept Therapeutics Incorporated (NASDAQ: CORT), is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Phase II
Phase III
149 Commonwealth Drive
Menlo Park, CA, 94025
650-327-3270
http://www.corcept.comPrimary Contacts
Joseph Belanoff, MD
CEO
Robert Roe, MD
President
Caroline Loewy
CFO
Company Profile
Corcept Therapeutics Incorporated (NASDAQ: CORT), is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Phase II
Phase III
Cornish & Carey Commercial
5980 Horton Street, Suite 100
Emeryville, California, United States, 94608
5109236202
http://www.ccareynkf.comPrimary Contacts
Bill Nork
5109236202
Company Profile
Cornish & Carey Commercial Newmark, Knight Frank is Northern California's largest full service commercial real estate company. C&C's Life Sciences specialty group specializes in helping companies in the life sciences and other science fields with their real estate needs.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
5980 Horton Street, Suite 100
Emeryville, California, United States, 94608
5109236202
http://www.ccareynkf.comPrimary Contacts
Bill Nork
5109236202
Company Profile
Cornish & Carey Commercial Newmark, Knight Frank is Northern California's largest full service commercial real estate company. C&C's Life Sciences specialty group specializes in helping companies in the life sciences and other science fields with their real estate needs.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
Covington & Burling
One Front Street
San Francisco, CA, 94111
415 591 6000
http://www.cov.comPrimary Contacts
Bruce Deming
Partner
Ken Ebanks
Partner
Emily Leonard
Partner
Jim Snipes
Partner
Amy Toro
Partner
Company Profile
Covington’s Life Sciences Industry Group integrates the firm’s extensive transactional, regulatory and intellectual property experience to meet the specialized needs of life sciences companies. The lawyers in this group have substantial cross-disciplinary experience in these practice areas, as well as significant international experience in the major pharmaceutical markets, including practice experience in the European Union and Japan. This multi-disciplinary and multi-jurisdictional approach enables us to quickly assimilate our clients’ regulatory, intellectual property and commercial goals, identify potential issues and, as appropriate, develop creative and novel approaches to maximize value for our clients. When problems arise, we are able to help clients respond quickly to achieve efficient and cost-effective solutions.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
One Front Street
San Francisco, CA, 94111
415 591 6000
http://www.cov.comPrimary Contacts
Bruce Deming
Partner
Ken Ebanks
Partner
Emily Leonard
Partner
Jim Snipes
Partner
Amy Toro
Partner
Company Profile
Covington’s Life Sciences Industry Group integrates the firm’s extensive transactional, regulatory and intellectual property experience to meet the specialized needs of life sciences companies. The lawyers in this group have substantial cross-disciplinary experience in these practice areas, as well as significant international experience in the major pharmaceutical markets, including practice experience in the European Union and Japan. This multi-disciplinary and multi-jurisdictional approach enables us to quickly assimilate our clients’ regulatory, intellectual property and commercial goals, identify potential issues and, as appropriate, develop creative and novel approaches to maximize value for our clients. When problems arise, we are able to help clients respond quickly to achieve efficient and cost-effective solutions.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
CPMC Research Institute (Sutter West Bay Hospitals)
475 Brannan St. Ste 220
San Francisco, CA, United States, 94107
415-600-1600
http://www.cpmc.orgPrimary Contacts
Michael C. Rowbotham, MD
Scientific Director Research Institute
Maryam Khotani
General Counsel
Lynne Day
Director Research Operations
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Substance AbusePrimary Technology
Bioinformatics
Cell Biology
Gene/Cell Therapy
Micro Arrays
Screening
475 Brannan St. Ste 220
San Francisco, CA, United States, 94107
415-600-1600
http://www.cpmc.orgPrimary Contacts
Michael C. Rowbotham, MD
Scientific Director Research Institute
Maryam Khotani
General Counsel
Lynne Day
Director Research Operations
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Substance AbusePrimary Technology
Bioinformatics
Cell Biology
Gene/Cell Therapy
Micro Arrays
Screening
Crescendo Bioscience, Inc.
341 Oyster Point Blvd.
South San Francisco, CA, United States, 94080
650.351.1603
http://www.crescendobio.comPrimary Contacts
WILLIAM A. HAGSTROM
CHIEF EXECUTIVE OFFICER AND PRESIDENT
WILLIAM R. SALISBURY
CHIEF FINANCIAL OFFICER
TED SNELGROVE
CHIEF COMMERCIAL OFFICER
Company Profile
Crescendo Bioscience™ is a molecular diagnostics laboratory focused on rheumatology. Crescendo is developing quantitative, objective, biology-based tests to provide rheumatologists with deeper clinical insights to help enable more effective management of patients with autoimmune and inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & InflammatoryPrimary Technology
Bioinformatics
Micro Arrays
Proteomics
341 Oyster Point Blvd.
South San Francisco, CA, United States, 94080
650.351.1603
http://www.crescendobio.comPrimary Contacts
WILLIAM A. HAGSTROM
CHIEF EXECUTIVE OFFICER AND PRESIDENT
WILLIAM R. SALISBURY
CHIEF FINANCIAL OFFICER
TED SNELGROVE
CHIEF COMMERCIAL OFFICER
Company Profile
Crescendo Bioscience™ is a molecular diagnostics laboratory focused on rheumatology. Crescendo is developing quantitative, objective, biology-based tests to provide rheumatologists with deeper clinical insights to help enable more effective management of patients with autoimmune and inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & InflammatoryPrimary Technology
Bioinformatics
Micro Arrays
Proteomics
Cryospec, Inc.
156 West Harris Avenue
South San Francisco, CA, 94080
650-871-2190
http://www.cryospec.comPrimary Contacts
Douglas F. Wells
President, C.E.O.
650-871-2190
Amy Love
Account Executive
650-871-2190
Suzanne Bell
Account Executive
510-438-6734
Jamie Wells
Account Executive
650-871-2190
Katina Nelson
Client Service Manager - So. S.F.
650-871-2190
Christina Rodriguez
Client Service Manager - Fremont
650-871-2190
Company Profile
Cryospec, Inc. is an independently owned and operated company focused on servicing many specialty applications as well as the following related industries: - Life Sciences: Biotechnology, Pharmaceuticals, Stem Cells and Bio Fuels - Semiconductors: Electronics, Nanotechnology and Photovoltaic. Cryospec is strategically located in South San Francisco and Fremont to effectively service the greater Bay Area. Cryospec provides superior gas delivery service and technical application design and support for a full range of application. We supply a full line of gas and liquid related products and systems from the smallest fittings to large bulk systems. Let us demonstrate why Cryospec should be your gas supplier. WWW.CRYOSPEC.COM. Proud Member of BAYBIO's BUSINESS SOLUTIONS PROGRAMCompany Classification
Associate/Service Providers
156 West Harris Avenue
South San Francisco, CA, 94080
650-871-2190
http://www.cryospec.comPrimary Contacts
Douglas F. Wells
President, C.E.O.
650-871-2190
Amy Love
Account Executive
650-871-2190
Suzanne Bell
Account Executive
510-438-6734
Jamie Wells
Account Executive
650-871-2190
Katina Nelson
Client Service Manager - So. S.F.
650-871-2190
Christina Rodriguez
Client Service Manager - Fremont
650-871-2190
Company Profile
Cryospec, Inc. is an independently owned and operated company focused on servicing many specialty applications as well as the following related industries: - Life Sciences: Biotechnology, Pharmaceuticals, Stem Cells and Bio Fuels - Semiconductors: Electronics, Nanotechnology and Photovoltaic. Cryospec is strategically located in South San Francisco and Fremont to effectively service the greater Bay Area. Cryospec provides superior gas delivery service and technical application design and support for a full range of application. We supply a full line of gas and liquid related products and systems from the smallest fittings to large bulk systems. Let us demonstrate why Cryospec should be your gas supplier. WWW.CRYOSPEC.COM. Proud Member of BAYBIO's BUSINESS SOLUTIONS PROGRAMCompany Classification
Associate/Service Providers
Crystal Bioscience Inc
5980 Horton Street Suite 405
Emeryville, CA, 94608
510 250 7800
http://www.crystalbio.bizPrimary Contacts
Robert J Etches, PhD, DSc
President and CEO
Bill Harriman PhD
Chief Science Officer
Marie-Cecile van de Lavoir, DVM, PhD
Chief Operating Officer
Company Profile
Crystal Bioscience uses its proprietary GEM screening technology to identify unique antibodies against elusive therapeutic targets.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Animal-made Pharmaceuticals
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
5980 Horton Street Suite 405
Emeryville, CA, 94608
510 250 7800
http://www.crystalbio.bizPrimary Contacts
Robert J Etches, PhD, DSc
President and CEO
Bill Harriman PhD
Chief Science Officer
Marie-Cecile van de Lavoir, DVM, PhD
Chief Operating Officer
Company Profile
Crystal Bioscience uses its proprietary GEM screening technology to identify unique antibodies against elusive therapeutic targets.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Animal-made Pharmaceuticals
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
CSU East Bay
United States, http://www.csuhayward.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.csuhayward.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
CSU Program for Education and Research in Biotechnology (CSUBERB)
SDSU, 5500 Campanile Drive
San Diego, CA, 92182-1011
619-594-2822
http://www.calstate.edu/csuperb/Primary Contacts
Susan Baxter, PhD
Executive Director, CSUPERB
619-594-2822
James Schmitt
Budget Analyst, CSUPERB
619-594-5299
Terri Swartz
Dean, Business and Economics; CSU East Bay
510-885-3291
Michael Groziak
Professor of Chemistry, CSU East Bay
510-885-3407
Lanny Griffin
Professor & Chair of Biomedical Engineering, Cal Poly San Luis Obispo
805-756-2575
Michael Goldman
Professor & Chair, Dept. of Biology, San Francisco State
415-338-7671
Company Profile
CSUPERB's mission is to develop a professional biotechnology workforce by mobilizing and supporting collaborative California State University (CSU) student and faculty research, innovating educational practices, and responding to and anticipating the needs of the life science industry.Company Classification
Associate/Service ProvidersOrganization Type
Education
SDSU, 5500 Campanile Drive
San Diego, CA, 92182-1011
619-594-2822
http://www.calstate.edu/csuperb/Primary Contacts
Susan Baxter, PhD
Executive Director, CSUPERB
619-594-2822
James Schmitt
Budget Analyst, CSUPERB
619-594-5299
Terri Swartz
Dean, Business and Economics; CSU East Bay
510-885-3291
Michael Groziak
Professor of Chemistry, CSU East Bay
510-885-3407
Lanny Griffin
Professor & Chair of Biomedical Engineering, Cal Poly San Luis Obispo
805-756-2575
Michael Goldman
Professor & Chair, Dept. of Biology, San Francisco State
415-338-7671
Company Profile
CSUPERB's mission is to develop a professional biotechnology workforce by mobilizing and supporting collaborative California State University (CSU) student and faculty research, innovating educational practices, and responding to and anticipating the needs of the life science industry.Company Classification
Associate/Service ProvidersOrganization Type
Education
Cureline, Inc.
290 Utah Ave, Ste 300
South San Francisco, CA, United States, 94080
650-875-6400
http://www.cureline.comPrimary Contacts
Olga Potapova
CEO
Kathleen Talmadge
VP Finance
Irina Zautseva
VP Business Development
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
290 Utah Ave, Ste 300
South San Francisco, CA, United States, 94080
650-875-6400
http://www.cureline.comPrimary Contacts
Olga Potapova
CEO
Kathleen Talmadge
VP Finance
Irina Zautseva
VP Business Development
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Cytel Inc.
United States, http://www.cytel.com/Home/
United States, http://www.cytel.com/Home/
Cytokinetics, Inc.
http://www.cytokinetics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.cytokinetics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
CytomX Therapeutics, Inc.
650 Gateway Blvd., Suite 125
South San Francisco, CA, 94080-7014
650.515.3185
http://www.cytomx.comPrimary Contacts
Nancy Stagliano, PhD
CEO
Sean McCarthy, DPhil
CBO
Mark Rolfe, PhD
CSO
Company Profile
CytomX Therapeutics, Inc. is an early stage, privately-funded biotechnology company developing Probodies�, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets, as well as enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Drug Delivery
Protein EngineeringClinical Development Stage
PreClinical
650 Gateway Blvd., Suite 125
South San Francisco, CA, 94080-7014
650.515.3185
http://www.cytomx.comPrimary Contacts
Nancy Stagliano, PhD
CEO
Sean McCarthy, DPhil
CBO
Mark Rolfe, PhD
CSO
Company Profile
CytomX Therapeutics, Inc. is an early stage, privately-funded biotechnology company developing Probodies�, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets, as well as enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Drug Delivery
Protein EngineeringClinical Development Stage
PreClinical
Dance Pharmaceuticals
2 Mint Plaza, Suite 804
San Francisco, CA, United States, 94103
415-369-9415
http://www.dancepharma.comPrimary Contacts
Mei-chang Kuo
Vice President of Pharmaceutics
John Patton
President and CEO
Ryan Patton
Engineer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
Medical DevicesDisease Areas of Focus
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
PreClinical
2 Mint Plaza, Suite 804
San Francisco, CA, United States, 94103
415-369-9415
http://www.dancepharma.comPrimary Contacts
Mei-chang Kuo
Vice President of Pharmaceutics
John Patton
President and CEO
Ryan Patton
Engineer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
Medical DevicesDisease Areas of Focus
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
PreClinical
DataSafe, Inc.
574 Eccles Avenue
South San Francisco, CA, 94080
650-875-3800
http://www.datasafe.comPrimary Contacts
Karen Lynch
Director of Sales
650-201-6386
Preety Sohal
Marketing Manager
650-875-3800
Company Profile
Off-site storage of business records Storage and rotation of backup tapes Secure Destruction (shredding) Online backup and disaster recovery Document ImagingCompany Classification
Associate/Service Providers
574 Eccles Avenue
South San Francisco, CA, 94080
650-875-3800
http://www.datasafe.comPrimary Contacts
Karen Lynch
Director of Sales
650-201-6386
Preety Sohal
Marketing Manager
650-875-3800
Company Profile
Off-site storage of business records Storage and rotation of backup tapes Secure Destruction (shredding) Online backup and disaster recovery Document ImagingCompany Classification
Associate/Service Providers
DBA-NSF LLC
101 Federal St. #101
Boston, MA, 02110-1817
617-342-3618
http://www.nsf-dba.com/Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
101 Federal St. #101
Boston, MA, 02110-1817
617-342-3618
http://www.nsf-dba.com/Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Delpor
United States, http://www.delpor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.delpor.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
DepoMed, Inc.
1360 O'Brien Dr.
Menlo Park, CA, United States, 94025
650-462-5900
http://www.depomed.comPrimary Contacts
Kevin Weber
VP, Marketing
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Central Nervous
Musculoskeletal DisordersPrimary Technology
Drug Delivery
1360 O'Brien Dr.
Menlo Park, CA, United States, 94025
650-462-5900
http://www.depomed.comPrimary Contacts
Kevin Weber
VP, Marketing
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Central Nervous
Musculoskeletal DisordersPrimary Technology
Drug Delivery
DiaCarta
3535 Breakwater Ave.
Hayward, CA, United States, 94545
510-314-8858
http://www.diacarta.com/Primary Contacts
Aiguo Zhang
President and Founder
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
3535 Breakwater Ave.
Hayward, CA, United States, 94545
510-314-8858
http://www.diacarta.com/Primary Contacts
Aiguo Zhang
President and Founder
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
diaDexus, Inc.
United States, http://www.diadexus.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.diadexus.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Dickstein Shapiro LLP
1825 Eye St. NW
Washington, DC, 20006
202-420-2200
http://www.dicksteinshapiro.comPrimary Contacts
Deborah Fishman
Partner
650-632-4209
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
1825 Eye St. NW
Washington, DC, 20006
202-420-2200
http://www.dicksteinshapiro.comPrimary Contacts
Deborah Fishman
Partner
650-632-4209
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Direct Flow Medical, Inc.
451 Aviation Blvd
Santa Rosa, CA, 95403
707-576-0420
http://www.directflowmedical.com/Primary Contacts
Bernard Lyons
CEO
Gordon Bishop
VP, Founder
David Elizondo
Chief Development Officer
Company Profile
Medical Device DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
PreClinical
451 Aviation Blvd
Santa Rosa, CA, 95403
707-576-0420
http://www.directflowmedical.com/Primary Contacts
Bernard Lyons
CEO
Gordon Bishop
VP, Founder
David Elizondo
Chief Development Officer
Company Profile
Medical Device DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
PreClinical
DURECT Corporation
http://www.durect.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.durect.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Elegrity, Inc.
160 Pine Street, Suite 720
San Francisco, CA, United States, 94111
415-821-0900
http://www.elegrity.comPrimary Contacts
Tina Gregory
Manager, Business Operations
415-821-0900
Joy Spicer
President/CEO
415-821-0900
Company Profile
We help organizations optimize their business and IT performance by carefully listening to customer needs and objectives, advising how technology could be leveraged to address those needs, and then designing, delivering and supporting the resulting solutions. After implementation, our team acts as a trusted advisor to our customers, helping them evolve and align their technology investments with their shifting business needs in dynamic environments. Our diverse product and services offering ensures our customers ‘right-fitted’ solutions to their unique business challenges: Business Analysis and Business Process Re-engineering SharePoint Workflow Solution Development SharePoint Security to ensure effective, but secure collaboration with your external vendors. SharePoint Business Systems Integration Business Process Automation (including Law Business Management System, a legal-specific business process management system) Web Application Solution Architecture and Development Server Virtualization Desktop Virtualization Windows 7 Upgrade / Deployment Windows 7 / Direct Access Cloud Computing Architecture and Implementation ServicesCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
160 Pine Street, Suite 720
San Francisco, CA, United States, 94111
415-821-0900
http://www.elegrity.comPrimary Contacts
Tina Gregory
Manager, Business Operations
415-821-0900
Joy Spicer
President/CEO
415-821-0900
Company Profile
We help organizations optimize their business and IT performance by carefully listening to customer needs and objectives, advising how technology could be leveraged to address those needs, and then designing, delivering and supporting the resulting solutions. After implementation, our team acts as a trusted advisor to our customers, helping them evolve and align their technology investments with their shifting business needs in dynamic environments. Our diverse product and services offering ensures our customers ‘right-fitted’ solutions to their unique business challenges: Business Analysis and Business Process Re-engineering SharePoint Workflow Solution Development SharePoint Security to ensure effective, but secure collaboration with your external vendors. SharePoint Business Systems Integration Business Process Automation (including Law Business Management System, a legal-specific business process management system) Web Application Solution Architecture and Development Server Virtualization Desktop Virtualization Windows 7 Upgrade / Deployment Windows 7 / Direct Access Cloud Computing Architecture and Implementation ServicesCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
Elim Biopharmaceuticals Inc.
25495 Whitesell St.
Hayward, CA, 94545-3618
510-783-1112
http://ElimBiopharm.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
25495 Whitesell St.
Hayward, CA, 94545-3618
510-783-1112
http://ElimBiopharm.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
EndoOrthopaedics, Inc.
450 Sutter Street, Suite 910
San Francisco, CA, United States, 94108
415-362-8880
http://www.endoorthopaedics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
450 Sutter Street, Suite 910
San Francisco, CA, United States, 94108
415-362-8880
http://www.endoorthopaedics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Engine Room
2225 E. Bayshore Rd. Ste 200
Palo Atlo, CA, United States, 94303
650-388-9298
http://www.engine-room.comPrimary Contacts
Michael Rose
CEO
858-455-5447 (103)
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
2225 E. Bayshore Rd. Ste 200
Palo Atlo, CA, United States, 94303
650-388-9298
http://www.engine-room.comPrimary Contacts
Michael Rose
CEO
858-455-5447 (103)
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Envirotainer
1101 Court Street
Alameda, CA, 94501
510 522 6041
http://www.envirotainer.com/Primary Contacts
Douglas Wettergren
Healthcare Sales Manager
415 336 0066
Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Muscu
1101 Court Street
Alameda, CA, 94501
510 522 6041
http://www.envirotainer.com/Primary Contacts
Douglas Wettergren
Healthcare Sales Manager
415 336 0066
Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Muscu
Epitomics, Inc.
United States, http://www.epitomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.epitomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Eric P. Mirabel, JD, LLM
3783 Darcus
Houston, TX, United States, 77005
281-772-3794
http://www.emirabel.comPrimary Contacts
Eric P. Mirabel
JD, LLM
281-772-3794
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
3783 Darcus
Houston, TX, United States, 77005
281-772-3794
http://www.emirabel.comPrimary Contacts
Eric P. Mirabel
JD, LLM
281-772-3794
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Ernest Gallo Clinic & Research Center
5858 Horton St, Ste 200
Emeryville, CA, United States, 94608
520-985-3100
http://www.egcrc.orgPrimary Contacts
William Sawyers
Chief Administration Officer
510-985-3104
Nancy Green
Director of Administration
510-985-3109
Susan Allinsmith
Director of Operations
510-985-3120
Amber Shomo
Controller
510-985-3856
Asha John
Procurement Manager
510-985-3118
Rowena Alfonzo
Human Resources
510-985-3864
Company Profile
The Ernest Gallo Clinic and Research Center (Gallo Center) is one of the world's preeminent academic centers for the study of the biological basis of alcohol and substance abuse. Gallo Center research has a remarkable track record of innovative and important discoveries of the molecular, cellular, and neuronal mechanisms that underlie alcoholism and substance abuse and their co-morbidities.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
5858 Horton St, Ste 200
Emeryville, CA, United States, 94608
520-985-3100
http://www.egcrc.orgPrimary Contacts
William Sawyers
Chief Administration Officer
510-985-3104
Nancy Green
Director of Administration
510-985-3109
Susan Allinsmith
Director of Operations
510-985-3120
Amber Shomo
Controller
510-985-3856
Asha John
Procurement Manager
510-985-3118
Rowena Alfonzo
Human Resources
510-985-3864
Company Profile
The Ernest Gallo Clinic and Research Center (Gallo Center) is one of the world's preeminent academic centers for the study of the biological basis of alcohol and substance abuse. Gallo Center research has a remarkable track record of innovative and important discoveries of the molecular, cellular, and neuronal mechanisms that underlie alcoholism and substance abuse and their co-morbidities.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
Essrig Taylor Construction
United States, http://www.etcusa.netCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
United States, http://www.etcusa.netCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
EUDAX SrI
Via Frank, 38
Pavia, Italy, 27100
+390382175650
http://www.eudax.comPrimary Contacts
Giancarlo Bolognesi
+3903821750653
Giusepe Dastoli
President
+3903821750651
Company Classification
Associate/Service ProvidersOrganization Type
Business Development
Consulting Firms
Contract Research Organization
Via Frank, 38
Pavia, Italy, 27100
+390382175650
http://www.eudax.comPrimary Contacts
Giancarlo Bolognesi
+3903821750653
Giusepe Dastoli
President
+3903821750651
Company Classification
Associate/Service ProvidersOrganization Type
Business Development
Consulting Firms
Contract Research Organization
Eureka Genomics Corporation
750 Alfred Nobel Drive
Hercules, CA, 94547
510 964 0461
http://www.eurekagenomics.comPrimary Contacts
Didier G. Perez
Co-founder COO & CFO
Heather Koshinsky, PhD
Co-founder CSO
Yuriy Fofanov, PhD
C0-founder CTO
Company Profile
The exceptional efficiency of the Eureka Genomics' software, based on proprietary databases, novel algorithms and data structures, and its ability to manipulate huge amounts of genomic data opens a unique opportunity to perform sophisticated analysis of a large number of genomic sequences (animals, plants, insects and thousands of bacteria and viruses) in conjunction with the data produced by Next Generation Sequencing technology. This unique ability allows us to identify unknown and emerging microorganisms (virus, bacteria and fungi) potentially associated with causes of cancers and infectious diseases affecting humans, animals and the environment. Eureka Genomics is developing screening tests and co-developing therapeutics and vaccines based on the identification of these unknown microorganisms.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Womens HealthPrimary Technology
Bioinformatics
Functional Genetics
Genomics
750 Alfred Nobel Drive
Hercules, CA, 94547
510 964 0461
http://www.eurekagenomics.comPrimary Contacts
Didier G. Perez
Co-founder COO & CFO
Heather Koshinsky, PhD
Co-founder CSO
Yuriy Fofanov, PhD
C0-founder CTO
Company Profile
The exceptional efficiency of the Eureka Genomics' software, based on proprietary databases, novel algorithms and data structures, and its ability to manipulate huge amounts of genomic data opens a unique opportunity to perform sophisticated analysis of a large number of genomic sequences (animals, plants, insects and thousands of bacteria and viruses) in conjunction with the data produced by Next Generation Sequencing technology. This unique ability allows us to identify unknown and emerging microorganisms (virus, bacteria and fungi) potentially associated with causes of cancers and infectious diseases affecting humans, animals and the environment. Eureka Genomics is developing screening tests and co-developing therapeutics and vaccines based on the identification of these unknown microorganisms.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Womens HealthPrimary Technology
Bioinformatics
Functional Genetics
Genomics
EvolveMol
1442A #444 Walnut St.
Berkeley, CA, United States, 94709
415-894-2783
http://www.evolvemol.comPrimary Contacts
Zachary Apte
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Drug DevelopmentPrimary Technology
Biocatalysis
Biomanufacturing
Cell Biology
Drug Discovery
Microfluidics
ScreeningClinical Development Stage
PreClinical
1442A #444 Walnut St.
Berkeley, CA, United States, 94709
415-894-2783
http://www.evolvemol.comPrimary Contacts
Zachary Apte
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Drug DevelopmentPrimary Technology
Biocatalysis
Biomanufacturing
Cell Biology
Drug Discovery
Microfluidics
ScreeningClinical Development Stage
PreClinical
Exelixis, Inc.
United States, http://www.exelixis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
United States, http://www.exelixis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
ExThera Medical Corporation
813 Heinz Ave.
Berkeley, CA, United States, 94710
510-809-2500
http://www.extheramedical.comPrimary Contacts
Robert Ward
CEO
Kathleen White
VP and COO
George Pitarra
CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Infectious DiseasePrimary Technology
Animal-made Pharmaceuticals
MicrofluidicsClinical Development Stage
PreClinical
813 Heinz Ave.
Berkeley, CA, United States, 94710
510-809-2500
http://www.extheramedical.comPrimary Contacts
Robert Ward
CEO
Kathleen White
VP and COO
George Pitarra
CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Infectious DiseasePrimary Technology
Animal-made Pharmaceuticals
MicrofluidicsClinical Development Stage
PreClinical
FibroGen
409 Illinois Street
San Francisco, CA, 94158
415-978-1200
http://www.fibrogen.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
409 Illinois Street
San Francisco, CA, 94158
415-978-1200
http://www.fibrogen.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco, CA, 94080
415-365-5600
http://www.fiveprime.comPrimary Contacts
Julia P. Gregory
President and CEO
Lewis T.
Executive Chairman and Founder
Marc L. Belsky
Vice President, Finance
Company Profile
Five Prime Therapeutics, Inc. is a clinical stage biotechnology company discovering and developing protein and antibody therapeutics using its biologics discovery platform.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersPrimary Technology
Bioinformatics
Drug Discovery
ProteomicsClinical Development Stage
Phase II
Two Corporate Drive
South San Francisco, CA, 94080
415-365-5600
http://www.fiveprime.comPrimary Contacts
Julia P. Gregory
President and CEO
Lewis T.
Executive Chairman and Founder
Marc L. Belsky
Vice President, Finance
Company Profile
Five Prime Therapeutics, Inc. is a clinical stage biotechnology company discovering and developing protein and antibody therapeutics using its biologics discovery platform.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersPrimary Technology
Bioinformatics
Drug Discovery
ProteomicsClinical Development Stage
Phase II
Flad Architects
United States, http://www.flad.comCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
United States, http://www.flad.comCompany Classification
Associate/Service ProvidersOrganization Type
Real Estate
FLG Partners, LLC
228 Hamilton Ave., 3rd Fl.
Palo Alto, CA, United States, 94301
650-224-9204
http://www.flgpartners.comPrimary Contacts
Jeffrey Kuhn
Managing Partner
415-990-5774
Company Profile
FLG Partners is the leading and most experienced CFO consulting and board advisory firm in Northern California.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
228 Hamilton Ave., 3rd Fl.
Palo Alto, CA, United States, 94301
650-224-9204
http://www.flgpartners.comPrimary Contacts
Jeffrey Kuhn
Managing Partner
415-990-5774
Company Profile
FLG Partners is the leading and most experienced CFO consulting and board advisory firm in Northern California.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Foley & Lardner LLP
975 Page Mill Road
Palo Alto, CA, United States, 94304
650.856.3700
http://www.foley.comPrimary Contacts
Antoinette Konski
Partner
650.251.1129
Meg Ryan
Marketing Project Manager
312-832-5778
Company Profile
With offices strategically located in San Francisco and Palo Alto, Foley's legal practice in the critical areas of pharmaceutical and biotechnology is well established in the market. With a deep-bench of life sciences attorneys from IP, IP litigation, corporate and regulatory and compliance services Foley is able to serve the diverse needs of enterprises looking to meet the challenges of a competitive, dynamic life sciences marketplace.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
975 Page Mill Road
Palo Alto, CA, United States, 94304
650.856.3700
http://www.foley.comPrimary Contacts
Antoinette Konski
Partner
650.251.1129
Meg Ryan
Marketing Project Manager
312-832-5778
Company Profile
With offices strategically located in San Francisco and Palo Alto, Foley's legal practice in the critical areas of pharmaceutical and biotechnology is well established in the market. With a deep-bench of life sciences attorneys from IP, IP litigation, corporate and regulatory and compliance services Foley is able to serve the diverse needs of enterprises looking to meet the challenges of a competitive, dynamic life sciences marketplace.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
ForteBio, Inc.
http://www.fortebio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://www.fortebio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Fujifilm Diosynth Biotechnologies
101 J. Morris Commons Lane
Morrisville, NC, United States, 27560
919-337-4400
http://www.fujifilmdiosynth.comPrimary Contacts
Matthew Beauleu
Director, Commercial Development
919-602-6777
Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
101 J. Morris Commons Lane
Morrisville, NC, United States, 27560
919-337-4400
http://www.fujifilmdiosynth.comPrimary Contacts
Matthew Beauleu
Director, Commercial Development
919-602-6777
Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
G-Tech, Inc.
39055 Hastings St. 207-A
Fremont, CA, United States, 94555
510-301-1283
Primary Contacts
Uday Devanaboyina
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
39055 Hastings St. 207-A
Fremont, CA, United States, 94555
510-301-1283
Primary Contacts
Uday Devanaboyina
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
Gamma Therapeutics, Inc.
http://www.gamma-therapeutics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.gamma-therapeutics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
GE Healthcare Life Sciences
800 Centennial Ave.
Piscataway, NJ, United States, 08854
732-457-8000
http://www.gelifesciences.comPrimary Contacts
Bob Moore
National Director of Service Sales
262-893-3883
Company Profile
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE Healthcare’s Life Sciences products and services support breakthroughs in drug discovery, biopharmaceutical manufacturing and the latest in cellular technologies, so scientists around the world discover new ways to predict, diagnose and treat disease earlier. GE’s “Smart Asset Management Services” is a modular, scalable service that enables consolidation of multi-vendor service support for lab assets, provides insights into asset utilization, and process optimization. Lab Optimization Solutions support customers in the drive to asset management optimization by providing tools and analytics that enable smart decision-making: from service model optimization, to CAPEX reduction via intelligent utilization. Life Cycle Asset Management goes beyond conventional maintenance for all lab equipment, regardless of manufacturer, by providing total cost of ownership per asset, powerful metrics and analytics and accurate evaluation of service spend and service levels. GE and Partner Solutions. Our goal is to make our customers’ businesses thrive and grow. By leveraging our wealth of experience company wide, business acumen, technical expertise and best practices gleaned from the broad spectrum of GE industries and other collaborations, we provide a solid foundation on which to build a dynamic, long-term relationship.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
800 Centennial Ave.
Piscataway, NJ, United States, 08854
732-457-8000
http://www.gelifesciences.comPrimary Contacts
Bob Moore
National Director of Service Sales
262-893-3883
Company Profile
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE Healthcare’s Life Sciences products and services support breakthroughs in drug discovery, biopharmaceutical manufacturing and the latest in cellular technologies, so scientists around the world discover new ways to predict, diagnose and treat disease earlier. GE’s “Smart Asset Management Services” is a modular, scalable service that enables consolidation of multi-vendor service support for lab assets, provides insights into asset utilization, and process optimization. Lab Optimization Solutions support customers in the drive to asset management optimization by providing tools and analytics that enable smart decision-making: from service model optimization, to CAPEX reduction via intelligent utilization. Life Cycle Asset Management goes beyond conventional maintenance for all lab equipment, regardless of manufacturer, by providing total cost of ownership per asset, powerful metrics and analytics and accurate evaluation of service spend and service levels. GE and Partner Solutions. Our goal is to make our customers’ businesses thrive and grow. By leveraging our wealth of experience company wide, business acumen, technical expertise and best practices gleaned from the broad spectrum of GE industries and other collaborations, we provide a solid foundation on which to build a dynamic, long-term relationship.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Gemmus Pharma, Inc.
409 Illinois Street
San Francisco, CA, United States, 94158
(415) 978-2151
http://www.gemmuspharma.comPrimary Contacts
Agustin de la Calle
Vice President Business Development
Daryl Faulds
CEO
William Guilford
President
Company Profile
Gemmus Pharma addresses the critical need to develop novel therapies to treat influenza infections. Gemmus is developing its lead candidate GP1001 for the treatment of patients with moderate to acute and potentially life-threatening influenza. This orally available product has shown very convincing efficacy data in mouse lethal influenza models where it has proven to save lives and even extend the short critical therapeutic window of standard of care anti-virals. GP1001 modulates hypercytokinemia in animal models by restraining pro-inflammatory cytokine levels, including IF-gamma, which is directly responsible for the miserable effects of flu in patients. This opens up potential large markets by improving quality of life and earlier rejoining the workforce for even moderate flu patients.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Infectious Disease
Kidneys & Genito-Urinary System
Respiratory DisordersClinical Development Stage
PreClinical
Phase I
409 Illinois Street
San Francisco, CA, United States, 94158
(415) 978-2151
http://www.gemmuspharma.comPrimary Contacts
Agustin de la Calle
Vice President Business Development
Daryl Faulds
CEO
William Guilford
President
Company Profile
Gemmus Pharma addresses the critical need to develop novel therapies to treat influenza infections. Gemmus is developing its lead candidate GP1001 for the treatment of patients with moderate to acute and potentially life-threatening influenza. This orally available product has shown very convincing efficacy data in mouse lethal influenza models where it has proven to save lives and even extend the short critical therapeutic window of standard of care anti-virals. GP1001 modulates hypercytokinemia in animal models by restraining pro-inflammatory cytokine levels, including IF-gamma, which is directly responsible for the miserable effects of flu in patients. This opens up potential large markets by improving quality of life and earlier rejoining the workforce for even moderate flu patients.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Infectious Disease
Kidneys & Genito-Urinary System
Respiratory DisordersClinical Development Stage
PreClinical
Phase I
Genemed Biotechnologies, Inc.
United States, http://www.genemed.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.genemed.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
GENEWIZ
115 Corporate Blvd.
South Plainfield, NJ, United States, 07080
1-877-436-3949
http://www.genewiz.comPrimary Contacts
Deborah Ferstl
Sr. Sales Executive
1-510-303-9209
Company Profile
GENEWIZ is a CRO that is focused on DNA-based services. Common services we provide are Gene Synthesis, DNA(Sanger)Sequencing,High Throughput Sequecing, Bioinformatics, Regulatory Services, Mutagenesis, Molecular Cloning, DNA prepartations, SNP analysis and detection, Fragment Analysis, Mutation Analysis and more. Please go to our website at www.genewiz.com for more information.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
115 Corporate Blvd.
South Plainfield, NJ, United States, 07080
1-877-436-3949
http://www.genewiz.comPrimary Contacts
Deborah Ferstl
Sr. Sales Executive
1-510-303-9209
Company Profile
GENEWIZ is a CRO that is focused on DNA-based services. Common services we provide are Gene Synthesis, DNA(Sanger)Sequencing,High Throughput Sequecing, Bioinformatics, Regulatory Services, Mutagenesis, Molecular Cloning, DNA prepartations, SNP analysis and detection, Fragment Analysis, Mutation Analysis and more. Please go to our website at www.genewiz.com for more information.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA, 94063
650-556-9300
http://www.genomichealth.com/Primary Contacts
Kim Popovits
President and CEO
Randy Scott
Executive Chairman
Brad Cole
COO
Company Profile
Genomic Health (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. The company was founded in 2000 and is located in Redwood City, California.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Genomics
301 Penobscot Drive
Redwood City, CA, 94063
650-556-9300
http://www.genomichealth.com/Primary Contacts
Kim Popovits
President and CEO
Randy Scott
Executive Chairman
Brad Cole
COO
Company Profile
Genomic Health (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. The company was founded in 2000 and is located in Redwood City, California.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Genomics
GenturaDx
24590 Clawiter Road
Hayward, CA, United States, 94612
http://wwwgenturadx.comPrimary Contacts
Mark Bagnall
CEO
Jesus Ching, Ph.D.
CSO
Deborah Wright
VP, Operations
Company Profile
Development stage molecular diagnostics company developing fully automated and fully integrated system for the small to mid-sized hospital. Initial focus will be assays for infectious diseases including STDs, respiratory diseases and hospital acquired infections.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious Disease
Womens HealthPrimary Technology
Screening
24590 Clawiter Road
Hayward, CA, United States, 94612
http://wwwgenturadx.comPrimary Contacts
Mark Bagnall
CEO
Jesus Ching, Ph.D.
CSO
Deborah Wright
VP, Operations
Company Profile
Development stage molecular diagnostics company developing fully automated and fully integrated system for the small to mid-sized hospital. Initial focus will be assays for infectious diseases including STDs, respiratory diseases and hospital acquired infections.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious Disease
Womens HealthPrimary Technology
Screening
GGA Software Services
One Mifflin Place
Cambridge, MA, 02138
617-491-5100
http://www.ggasoftware.comPrimary Contacts
James Martin
Director of Market Development
617-491-5100 x224
Company Profile
GGA Software Services is a leading provider of outsourced scientific informatics services to the life sciences industry. Headquartered in Cambridge, Massachusetts, with a best-of-class development center in St. Petersburg, Russia, GGA offers broad capabilities in scientific software engineering, algorithm development, and knowledge management. Global pharmaceutical, scientific instrumentation, and medical device corporations as well as early-stage life science companies rely on GGA to provide ongoing scientific informatics services, including support, maintenance, and QA services, to enhance their internal resources. Since 1994, GGA has successfully served as an extended workbench for its clients, allowing them to both achieve their critical objectives and maximize their informatics budget.Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
One Mifflin Place
Cambridge, MA, 02138
617-491-5100
http://www.ggasoftware.comPrimary Contacts
James Martin
Director of Market Development
617-491-5100 x224
Company Profile
GGA Software Services is a leading provider of outsourced scientific informatics services to the life sciences industry. Headquartered in Cambridge, Massachusetts, with a best-of-class development center in St. Petersburg, Russia, GGA offers broad capabilities in scientific software engineering, algorithm development, and knowledge management. Global pharmaceutical, scientific instrumentation, and medical device corporations as well as early-stage life science companies rely on GGA to provide ongoing scientific informatics services, including support, maintenance, and QA services, to enhance their internal resources. Since 1994, GGA has successfully served as an extended workbench for its clients, allowing them to both achieve their critical objectives and maximize their informatics budget.Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
GlaxoSmithKline
1017 L Street, Suite 182
Sacramento, CA, 95814
916 443 6885
http://www.gsk.comPrimary Contacts
Jack Bailey
Senior Vice President, Public,Private, Institution Customers
John DelGiorno
Vice President, State and Federal Government Relations
Jack Graham
Director, State Government Affairs
Company Profile
BioPharmaceutical Manufacturer, Research and DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
PharmacogenomicsClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
1017 L Street, Suite 182
Sacramento, CA, 95814
916 443 6885
http://www.gsk.comPrimary Contacts
Jack Bailey
Senior Vice President, Public,Private, Institution Customers
John DelGiorno
Vice President, State and Federal Government Relations
Jack Graham
Director, State Government Affairs
Company Profile
BioPharmaceutical Manufacturer, Research and DevelopmentCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
PharmacogenomicsClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Glialogix, Inc.
38 Bayo Vista
Larkspur, CA, United States, 94939
650-766-1629
http://www.glialogix.comPrimary Contacts
Mark Moore
President and CEO
Thadd Reeder
CSO
Alan Mendelson
Corporate Counsel
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousPrimary Technology
Computational Chemistry
Drug Delivery
ScreeningClinical Development Stage
PreClinical
38 Bayo Vista
Larkspur, CA, United States, 94939
650-766-1629
http://www.glialogix.comPrimary Contacts
Mark Moore
President and CEO
Thadd Reeder
CSO
Alan Mendelson
Corporate Counsel
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousPrimary Technology
Computational Chemistry
Drug Delivery
ScreeningClinical Development Stage
PreClinical
Global Submit
United States, http://www.globalsubmit.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
United States, http://www.globalsubmit.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Glytrix
1535 Chestnut St.
San Francisco, CA, United States, 94123
415-379-0711
http://www.glytrix.comPrimary Contacts
John Paderi
Founder, Principal Biomedical Engineer
Dennis Goldberg
President and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cardiovascular & Circulatory Disorders
DermatologyClinical Development Stage
PreClinical
1535 Chestnut St.
San Francisco, CA, United States, 94123
415-379-0711
http://www.glytrix.comPrimary Contacts
John Paderi
Founder, Principal Biomedical Engineer
Dennis Goldberg
President and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cardiovascular & Circulatory Disorders
DermatologyClinical Development Stage
PreClinical
Greater Phoenix Economic Council
2 N. Central Ave., Ste. 2500
Phoenix, AZ, United States, 85004
602.256.7700
http://www.gpec.orgPrimary Contacts
Chris Camacho
Executive Vice President, Business Development
602.256.7744
Company Profile
The Greater Phoenix Economic Council (GPEC) provides complimentary site-selection services, regional data and analysis and helps foster partnerships between companies entering the market and key leaders/businesses in Greater Phoenix. GPEC was founded in 1989 and is currently supported by Maricopa County, 20 cities and towns and more than 140 private-sector businesses. Home to a dynamic and growing bioscience community, Greater Phoenix is anchored by leaders such as the Mayo Clinic, Barrow Neurological Institute and Cancer Treatment Centers of America. The region has an appetite for collaboration, demonstrated by ventures like the Phoenix Biomedical Campus, Healthcare Transformation Institute and Arizona Biomedical Collaboration. Unprecedented partnerships with world-class talent at Arizona State University, Translational Genomics Research Institute (TGen), Sun Health Research Institute and dozens others help accelerate the development of new bioscience and personalized medicine solutions. Bioscience companies in Greater Phoenix enjoy valuable public-private partnerships and innovative business accelerators in a supportive, growing community.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
2 N. Central Ave., Ste. 2500
Phoenix, AZ, United States, 85004
602.256.7700
http://www.gpec.orgPrimary Contacts
Chris Camacho
Executive Vice President, Business Development
602.256.7744
Company Profile
The Greater Phoenix Economic Council (GPEC) provides complimentary site-selection services, regional data and analysis and helps foster partnerships between companies entering the market and key leaders/businesses in Greater Phoenix. GPEC was founded in 1989 and is currently supported by Maricopa County, 20 cities and towns and more than 140 private-sector businesses. Home to a dynamic and growing bioscience community, Greater Phoenix is anchored by leaders such as the Mayo Clinic, Barrow Neurological Institute and Cancer Treatment Centers of America. The region has an appetite for collaboration, demonstrated by ventures like the Phoenix Biomedical Campus, Healthcare Transformation Institute and Arizona Biomedical Collaboration. Unprecedented partnerships with world-class talent at Arizona State University, Translational Genomics Research Institute (TGen), Sun Health Research Institute and dozens others help accelerate the development of new bioscience and personalized medicine solutions. Bioscience companies in Greater Phoenix enjoy valuable public-private partnerships and innovative business accelerators in a supportive, growing community.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
Ground Zero Pharmaceuticals, Inc.
http://www.groundzerous.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Therapeutic
http://www.groundzerous.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Therapeutic
Halcyon Molecular, Inc.
http://www.halcyonmolecular.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://www.halcyonmolecular.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Harley Ellis Deveraux
360 17th St. Suite 210
Oakland, CA, United States, 94556
510-268-3800
http://www.harleyellisdeveraux.comPrimary Contacts
Lee Vanderkerchove
Science and Technology Studio Leader
510-268-3801
360 17th St. Suite 210
Oakland, CA, United States, 94556
510-268-3800
http://www.harleyellisdeveraux.comPrimary Contacts
Lee Vanderkerchove
Science and Technology Studio Leader
510-268-3801
HCP Life Science Estates
400 Oyster Point Boulevard, Suite 409
South San Francisco, CA, 94110
650-875-1002
http://www.hcpi.comPrimary Contacts
Jon Bergschneider
Senior Vice President
650-875-1002
Company Profile
Real estate provider for the life sciences industry.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
400 Oyster Point Boulevard, Suite 409
South San Francisco, CA, 94110
650-875-1002
http://www.hcpi.comPrimary Contacts
Jon Bergschneider
Senior Vice President
650-875-1002
Company Profile
Real estate provider for the life sciences industry.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
Health Advances, LLC
201 Mission St. Suite 500
San Francisco, CA, 94109
415-834-0800
http://www.healthadvances.com/Primary Contacts
Kimberly Howland
Vice President
415-834-0800
Vivek Mittal
Manager
415-834-0800
Company Profile
Founded in 1992, Health Advances is a leading healthcare strategy firm advising clients in the biopharma, diagnostic, device, and healthcare services sectors, as well as investors and non-profit organizations. Operating at the intersection of science, technology, and business strategy, Health Advances provides clients with innovative solutions based on deep industry insight, analytical rigor, and an objective perspective. Healthcare executives rely on our professionals to help them make confident decisions involving the greatest challenges in the commercialization of medical technologies and services throughout the world.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
201 Mission St. Suite 500
San Francisco, CA, 94109
415-834-0800
http://www.healthadvances.com/Primary Contacts
Kimberly Howland
Vice President
415-834-0800
Vivek Mittal
Manager
415-834-0800
Company Profile
Founded in 1992, Health Advances is a leading healthcare strategy firm advising clients in the biopharma, diagnostic, device, and healthcare services sectors, as well as investors and non-profit organizations. Operating at the intersection of science, technology, and business strategy, Health Advances provides clients with innovative solutions based on deep industry insight, analytical rigor, and an objective perspective. Healthcare executives rely on our professionals to help them make confident decisions involving the greatest challenges in the commercialization of medical technologies and services throughout the world.Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Henlius Biopharmaceuticals, Inc.
48860 Milmont Drive Ste 107C
Fremont, CA, 94538
510-445-0305
http://www.henliusbio.comPrimary Contacts
Scott Liu
CEO
Weidong Jiang
VP
Paul Liu
VP
Company Profile
Henlix Biopharmaceuticals is a joint venture company formed by Henlius Biotech Co. Ltd (a China based biotech company) and Shanghai Fosun Pharma. The company focuses on development and commercilaization of mAb-based therapeutics using state-of-the-art technologies. Pursuing higher standard of quality is always our first priority in our business strategy. We work relentlessly, at any tie and under any condition, for the Research & Development of products with the highest qualities.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerClinical Development Stage
PreClinical
48860 Milmont Drive Ste 107C
Fremont, CA, 94538
510-445-0305
http://www.henliusbio.comPrimary Contacts
Scott Liu
CEO
Weidong Jiang
VP
Paul Liu
VP
Company Profile
Henlix Biopharmaceuticals is a joint venture company formed by Henlius Biotech Co. Ltd (a China based biotech company) and Shanghai Fosun Pharma. The company focuses on development and commercilaization of mAb-based therapeutics using state-of-the-art technologies. Pursuing higher standard of quality is always our first priority in our business strategy. We work relentlessly, at any tie and under any condition, for the Research & Development of products with the highest qualities.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Herrera & Company
P.O. Box 7127
Stockton, CA, United States, 95267
209-478-9317
http://www.herreracompany.comPrimary Contacts
Phillip R. Herrera
Managing Partner
209-482-7740
Company Profile
Founded in 1986, Herrera & Company is a full-service, workforce grant development and administration consulting firm. We have over 20 years of experience in the acquisition and management of over $100 million in State of California, Employment Training Panel (ETP) funding. The agency has paid out over $1 billion in training funds since its inception with over 600,000 California workers trained. 50,400 California businesses have been served and many of our clients participating have been Fortune 500 corporations located in San Francisco Bay Area including Abbott Diabetes Care, Abbott Vascular, Abbott Medical, Agilent, Boston Scientific, Applied Materials, National Semiconductor, and many more. Because the ETP program is unique and can become complex, the importance of having a well-written application and a robust ETP project management/reporting structure cannot be over emphasized. Herrera & Company has a long history of successful ETP consulting with large high technology and bio science firms. Our fees are performance based and paid after ETP funds have been earned.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Cardiovascular & Circulatory DisordersPrimary Technology
BiomanufacturingClinical Development Stage
Approved
P.O. Box 7127
Stockton, CA, United States, 95267
209-478-9317
http://www.herreracompany.comPrimary Contacts
Phillip R. Herrera
Managing Partner
209-482-7740
Company Profile
Founded in 1986, Herrera & Company is a full-service, workforce grant development and administration consulting firm. We have over 20 years of experience in the acquisition and management of over $100 million in State of California, Employment Training Panel (ETP) funding. The agency has paid out over $1 billion in training funds since its inception with over 600,000 California workers trained. 50,400 California businesses have been served and many of our clients participating have been Fortune 500 corporations located in San Francisco Bay Area including Abbott Diabetes Care, Abbott Vascular, Abbott Medical, Agilent, Boston Scientific, Applied Materials, National Semiconductor, and many more. Because the ETP program is unique and can become complex, the importance of having a well-written application and a robust ETP project management/reporting structure cannot be over emphasized. Herrera & Company has a long history of successful ETP consulting with large high technology and bio science firms. Our fees are performance based and paid after ETP funds have been earned.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Cardiovascular & Circulatory DisordersPrimary Technology
BiomanufacturingClinical Development Stage
Approved
Hogan Lovells US LLP
4 Embarcadero Center, 22nd Floor
San Francisco, CA, 94111
415.374.2300
http://www.hoganlovells.comPrimary Contacts
Justin Portaz
Marketing Manager
310-785-4671
Laura Berezin
Partner
650-463-4000
Company Profile
In a world where both business risks and opportunities are continuously evolving, Hogan Lovells is a global legal practice that sees the whole picture and is dedicated and equipped to help clients across the spectrum of their critical business and legal issues. With 2,500 lawyers in more than 40 global offices, Hogan Lovells has an established presence in the fastest growing regions of the world, including Asia, Latin America, and the Middle East. With a network of more than 350 life sciences lawyers and specialists worldwide, we serve our clients at every stage of their products' life cycle, including discovery, research and development; intellectual property protection; regulatory approval; commercialization; antitrust, product liability; litigation; and corporate transactions. Our cross-disciplinary approach, the deep bench of talent we have in virtually every discipline, and our knowledge of and contacts with U.S., European, and Asian government agencies enable us to help clients operate or expand globally and achieve their long-term business objectives. Wherever and whenever you need advice, we are able to support you with dedicated and experienced life sciences lawyers.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
4 Embarcadero Center, 22nd Floor
San Francisco, CA, 94111
415.374.2300
http://www.hoganlovells.comPrimary Contacts
Justin Portaz
Marketing Manager
310-785-4671
Laura Berezin
Partner
650-463-4000
Company Profile
In a world where both business risks and opportunities are continuously evolving, Hogan Lovells is a global legal practice that sees the whole picture and is dedicated and equipped to help clients across the spectrum of their critical business and legal issues. With 2,500 lawyers in more than 40 global offices, Hogan Lovells has an established presence in the fastest growing regions of the world, including Asia, Latin America, and the Middle East. With a network of more than 350 life sciences lawyers and specialists worldwide, we serve our clients at every stage of their products' life cycle, including discovery, research and development; intellectual property protection; regulatory approval; commercialization; antitrust, product liability; litigation; and corporate transactions. Our cross-disciplinary approach, the deep bench of talent we have in virtually every discipline, and our knowledge of and contacts with U.S., European, and Asian government agencies enable us to help clients operate or expand globally and achieve their long-term business objectives. Wherever and whenever you need advice, we are able to support you with dedicated and experienced life sciences lawyers.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Honeywell Burdick & Jackson
101 Columbia Rd
Morristown, NJ, 07962
973-455-2000
http://www.honeywell.com/burdickandjacksonPrimary Contacts
Jeremy Diringer
Marketing Manager
973-455-2528
Company Classification
Associate/Service Providers
101 Columbia Rd
Morristown, NJ, 07962
973-455-2000
http://www.honeywell.com/burdickandjacksonPrimary Contacts
Jeremy Diringer
Marketing Manager
973-455-2528
Company Classification
Associate/Service Providers
Horizon Biopharm (HB)
5941 Optical Court
San Jose, CA, United States, 95138
408-260-5337
http://www.horizonbiopharm.comPrimary Contacts
Grace Xu
Director
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerClinical Development Stage
PreClinical
5941 Optical Court
San Jose, CA, United States, 95138
408-260-5337
http://www.horizonbiopharm.comPrimary Contacts
Grace Xu
Director
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerClinical Development Stage
PreClinical
Hotspur Technologies, Inc.
880 Maude Ave., Ste. A
Mountain View, CA, 94043
650-969-3150
http://www.hotspur-inc.comPrimary Contacts
Gwen Watanabe
President & CEO
Will Martin
Director of Sales & Marketing
Jeff Krolik
Technology Co-Founder
Company Profile
Hotspur Technologies is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company is committed to being responsive to the needs of medical professionals and patients, as well as, leading the industry with lean innovation and delivering high quality value-added products to the marketplace. Hotspur's products are based on unique and groundbreaking technology that opens blood vessels more efficiently and less invasively.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
Approved
880 Maude Ave., Ste. A
Mountain View, CA, 94043
650-969-3150
http://www.hotspur-inc.comPrimary Contacts
Gwen Watanabe
President & CEO
Will Martin
Director of Sales & Marketing
Jeff Krolik
Technology Co-Founder
Company Profile
Hotspur Technologies is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company is committed to being responsive to the needs of medical professionals and patients, as well as, leading the industry with lean innovation and delivering high quality value-added products to the marketplace. Hotspur's products are based on unique and groundbreaking technology that opens blood vessels more efficiently and less invasively.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Cardiovascular & Circulatory DisordersClinical Development Stage
Approved
Hull Associates LLC
100 Ledgewood Place, Suite 204
Rockland, MA, United States, 02370
781-982-2600
http://www.hullassociates.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
100 Ledgewood Place, Suite 204
Rockland, MA, United States, 02370
781-982-2600
http://www.hullassociates.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Humboldt State University
United States, http://www.humboldt.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.humboldt.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Huntingdon Life Sciences
PO Box 2360, Mettlers Road
East Millstone, NJ, 08875
732-873-2550
http://www.huntingdon.comPrimary Contacts
Taylor Norwitt
Director Business Development
732-640-7827
Company Profile
Huntingdon Life Sciences, one of the world’s largest contract research organizations, provides a comprehensive range of safety testing for the pharmaceutical, biopharmaceutical, industrial chemical, agrochemical, food & veterinary industries. With testing facilities in both the USA and the UK our 1600 highly qualified staff offers all aspects of pre-clinical research. Our services include general toxicology, respiratory safety assessment, infusion toxicology, metabolism, pharmacokinetics, pharmacology, reproductive toxicology, and genetic toxicology across a wide range of species. Support services include immunoassay, mass spectrometry, experimental biology, formulation chemistry, pathology, clinical pathology and regulatory affairs. Our business is to help our customers develop and bring to market safe and effective new compounds. Our role is to work closely with our customers to help fulfil the regulatory requirements. Our commitment is the welfare of our animals and to provide the highest standards of integrity. We are proud to be working for a better future.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Genetic Diseases
Respiratory DisordersPrimary Technology
Cell Biology
Screening
TransgenicsClinical Development Stage
PreClinical
PO Box 2360, Mettlers Road
East Millstone, NJ, 08875
732-873-2550
http://www.huntingdon.comPrimary Contacts
Taylor Norwitt
Director Business Development
732-640-7827
Company Profile
Huntingdon Life Sciences, one of the world’s largest contract research organizations, provides a comprehensive range of safety testing for the pharmaceutical, biopharmaceutical, industrial chemical, agrochemical, food & veterinary industries. With testing facilities in both the USA and the UK our 1600 highly qualified staff offers all aspects of pre-clinical research. Our services include general toxicology, respiratory safety assessment, infusion toxicology, metabolism, pharmacokinetics, pharmacology, reproductive toxicology, and genetic toxicology across a wide range of species. Support services include immunoassay, mass spectrometry, experimental biology, formulation chemistry, pathology, clinical pathology and regulatory affairs. Our business is to help our customers develop and bring to market safe and effective new compounds. Our role is to work closely with our customers to help fulfil the regulatory requirements. Our commitment is the welfare of our animals and to provide the highest standards of integrity. We are proud to be working for a better future.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Genetic Diseases
Respiratory DisordersPrimary Technology
Cell Biology
Screening
TransgenicsClinical Development Stage
PreClinical
ICE Consulting, Inc.
United States, http://www.iceconsultinginc.comCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
United States, http://www.iceconsultinginc.comCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
IGeneX
http://www.igenex.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.igenex.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Igenica, Inc.
863 Mitten Road Suite 102
Burlingame, CA, 94010
650-231-4320
http://www.igenica-inc.comPrimary Contacts
Mike Rothe
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformaticsDisease Areas of Focus
CancerClinical Development Stage
PreClinical
863 Mitten Road Suite 102
Burlingame, CA, 94010
650-231-4320
http://www.igenica-inc.comPrimary Contacts
Mike Rothe
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformaticsDisease Areas of Focus
CancerClinical Development Stage
PreClinical
INC Research
23268 NE 16th Pl
Sammamish, WA, United States, 98074
425-836-8421
http://www.incresearch.comPrimary Contacts
Mike Blume
Senior Director, Business Development
(425)836-8421
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
23268 NE 16th Pl
Sammamish, WA, United States, 98074
425-836-8421
http://www.incresearch.comPrimary Contacts
Mike Blume
Senior Director, Business Development
(425)836-8421
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Incline Therapeutics Inc.
900 Saginaw Dr. Suite 200
Redwood City, CA, 94063
650-241-6800
http://www.inclinethera.comPrimary Contacts
Alan Levy
CEO
Dave Socks
President & CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentPrimary Technology
Drug DeliveryClinical Development Stage
Phase III
900 Saginaw Dr. Suite 200
Redwood City, CA, 94063
650-241-6800
http://www.inclinethera.comPrimary Contacts
Alan Levy
CEO
Dave Socks
President & CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentPrimary Technology
Drug DeliveryClinical Development Stage
Phase III
Independent Advisors Group, Inc.
United States, Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
United States, Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Innovation Center Denmark
200 Page Mill Road
San Francisco, CA, United States, 94306-2022
+1 650 543 3188
http://www.innovationcenterdenmark.comPrimary Contacts
Jacob Nedergaard
Investment manager
+1 415-699-5469
Company Profile
The mission of Innovation Center Denmark is to build bridges between companies, research institutions and capital in Denmark and Silicon Valley within the Life Science space. To accelerate the entry of Danish companies into Silicon Valley, promote US investments in Denmark, facilitate research cooperation and provide inspiration to help drive innovation in Denmark.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
200 Page Mill Road
San Francisco, CA, United States, 94306-2022
+1 650 543 3188
http://www.innovationcenterdenmark.comPrimary Contacts
Jacob Nedergaard
Investment manager
+1 415-699-5469
Company Profile
The mission of Innovation Center Denmark is to build bridges between companies, research institutions and capital in Denmark and Silicon Valley within the Life Science space. To accelerate the entry of Danish companies into Silicon Valley, promote US investments in Denmark, facilitate research cooperation and provide inspiration to help drive innovation in Denmark.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
InSite Vision, Inc.
965 Atlantic Ave.
Alameda, CA, United States, 94501
510-865-8800
http://www.insitevision.comCompany Profile
InSite Vision develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Our goal is to provide patients and physicians with improved treatment options that help preserve and improve vision worldwide. Based on our DuraSite® drug delivery technology, we are creating alternative ocular anti-infective therapies, such as AzaSite Plus™ and AzaSite Xtra™ with the potential to provide significant advantages currently not available with conventional treatment options.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
OphthalmologyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
965 Atlantic Ave.
Alameda, CA, United States, 94501
510-865-8800
http://www.insitevision.comCompany Profile
InSite Vision develops novel ophthalmic products designed to treat a growing range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Our goal is to provide patients and physicians with improved treatment options that help preserve and improve vision worldwide. Based on our DuraSite® drug delivery technology, we are creating alternative ocular anti-infective therapies, such as AzaSite Plus™ and AzaSite Xtra™ with the potential to provide significant advantages currently not available with conventional treatment options.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
OphthalmologyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Integrated Plasmonics
United States, http://integratedplasmonics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://integratedplasmonics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Integrated Project Management Company
400 Oyster Point Vlvd, Suite 405
South San Francisco, CA, 94583
(650) 244-9981
http://www.ipmcinc.comPrimary Contacts
Harry Georgiades
Director, Regional Operations
(650)244-9981
Mally Arad
Manager, Planning and Execution
(650) 244-9981
Kim Pham
Manager, Planning and Execution
(650) 244-9981
Dick Piehl
Manager, Planning and Execution
(650) 244-9981
Dorene Lynch
Business Development Executive
(630) 789-8600
Mike McLeod
VP, Operatiosn
(630) 789-8600
Company Profile
Integrated Project Management Company, Inc. (IPM) is a project management consulting firm specializing in the life sciences industry. Working with companies ranging from global pharmaceutical manufacturers to biotechnology start-ups and medical technology companies, IPM leads teams on-site to integrate the discipline of project management into any business and deliver results. Areas of expertise include product development, alliance management, business process improvement, technology transfer, and regulatory/quality compliance. With regional offices in San Francisco, Chicago, St. Louis, and Boston, IPM provides consulting expertise to clients everywhere. For further information, visit www.ipmcinc.com or call 650-244-9981.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/EndocrinolClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
400 Oyster Point Vlvd, Suite 405
South San Francisco, CA, 94583
(650) 244-9981
http://www.ipmcinc.comPrimary Contacts
Harry Georgiades
Director, Regional Operations
(650)244-9981
Mally Arad
Manager, Planning and Execution
(650) 244-9981
Kim Pham
Manager, Planning and Execution
(650) 244-9981
Dick Piehl
Manager, Planning and Execution
(650) 244-9981
Dorene Lynch
Business Development Executive
(630) 789-8600
Mike McLeod
VP, Operatiosn
(630) 789-8600
Company Profile
Integrated Project Management Company, Inc. (IPM) is a project management consulting firm specializing in the life sciences industry. Working with companies ranging from global pharmaceutical manufacturers to biotechnology start-ups and medical technology companies, IPM leads teams on-site to integrate the discipline of project management into any business and deliver results. Areas of expertise include product development, alliance management, business process improvement, technology transfer, and regulatory/quality compliance. With regional offices in San Francisco, Chicago, St. Louis, and Boston, IPM provides consulting expertise to clients everywhere. For further information, visit www.ipmcinc.com or call 650-244-9981.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/EndocrinolClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Integrium,LLC
14351 Myford Road
Tustin, CA, United States, 92780
(619)295-8321
http://www.integrium.comPrimary Contacts
Laura M. Robinson, MBA
Director, Business Development - West Coast
(619) 295-8321
Company Profile
Integrium, LLC is a full-service clinical research organization (CRO) focused on the therapeutic areas of cardiovascular disease, metabolic disease, wound healing, and dermatology. The Integrium team understands biotech companies’ need for reliable, accurate data to make informed decisions, reach inflection points, and make go-no go decisions on development compounds. We conduct Phase 1/PK studies, and help many companies move from IND creation to topline results in as few as 90 days. Integrium conducts Phase I/PK studies: • First-in-Human Studies • Pharmacokinetics / Pharmacodynamics • Single /Multiple Ascending Dose • Dose Ranging • Maximum Tolerated Dose • Bioavailability / Bioequivalence Integrium accelerated Phase I studies feature: • Expert Study Design and Protocol Writing • Rapid Enrollment • Fully-Equipped 50-Bed Clinical Research Unit with: o Extensive Subject Database o ECG, ABPM, Holter Monitoring o Thorough QT/QTc, Telemetry o PK/PD Medical Monitoring Data Management and Biostatistics Clinical Study ReportsCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug Development
Medical Devices
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Dermatology
Metabolic/Endocrinology DisordersClinical Development Stage
Phase I
Phase II
Phase III
Approved
14351 Myford Road
Tustin, CA, United States, 92780
(619)295-8321
http://www.integrium.comPrimary Contacts
Laura M. Robinson, MBA
Director, Business Development - West Coast
(619) 295-8321
Company Profile
Integrium, LLC is a full-service clinical research organization (CRO) focused on the therapeutic areas of cardiovascular disease, metabolic disease, wound healing, and dermatology. The Integrium team understands biotech companies’ need for reliable, accurate data to make informed decisions, reach inflection points, and make go-no go decisions on development compounds. We conduct Phase 1/PK studies, and help many companies move from IND creation to topline results in as few as 90 days. Integrium conducts Phase I/PK studies: • First-in-Human Studies • Pharmacokinetics / Pharmacodynamics • Single /Multiple Ascending Dose • Dose Ranging • Maximum Tolerated Dose • Bioavailability / Bioequivalence Integrium accelerated Phase I studies feature: • Expert Study Design and Protocol Writing • Rapid Enrollment • Fully-Equipped 50-Bed Clinical Research Unit with: o Extensive Subject Database o ECG, ABPM, Holter Monitoring o Thorough QT/QTc, Telemetry o PK/PD Medical Monitoring Data Management and Biostatistics Clinical Study ReportsCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug Development
Medical Devices
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Dermatology
Metabolic/Endocrinology DisordersClinical Development Stage
Phase I
Phase II
Phase III
Approved
InterMune, Inc.
3280 Bayshore Boulevard
Brisbane, CA, 94005
415-466-2200
http://www.intermune.comPrimary Contacts
Daniel G. Welch
Chairman, CEO & President
John Hodgman
SVP, Finance & CFO
Robin Steele
SVP, General Counsel & Corporate Secretary
Company Profile
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
Phase III
3280 Bayshore Boulevard
Brisbane, CA, 94005
415-466-2200
http://www.intermune.comPrimary Contacts
Daniel G. Welch
Chairman, CEO & President
John Hodgman
SVP, Finance & CFO
Robin Steele
SVP, General Counsel & Corporate Secretary
Company Profile
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
Phase III
International Center for Regulatory Sciences
School of Pharmacy, USC, 1540 Alcazar St. CHP 140
Los Angeles, CA, United States, 90089-9014
323-442-3521
http://regcenter.usc.eduPrimary Contacts
Frances Richmond Ph.D
Director
323-442-3531
Michael Jamieson DRSc.
Asociate Director
323-442-1276
Kim Horwood MS
Program Specilialist
323-442-1975
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
School of Pharmacy, USC, 1540 Alcazar St. CHP 140
Los Angeles, CA, United States, 90089-9014
323-442-3521
http://regcenter.usc.eduPrimary Contacts
Frances Richmond Ph.D
Director
323-442-3531
Michael Jamieson DRSc.
Asociate Director
323-442-1276
Kim Horwood MS
Program Specilialist
323-442-1975
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
IonArmour
1700 Owens St, Suite 240
San Francisco, CA, 94158
415.796.6445
http://www.ionarmour.comPrimary Contacts
Alexander Mittal
CEO
Arjun Srinivas
COO
Michael Young
Director of Technology Development
Company Profile
IonArmour combines breakthrough materials technology with natural antimicrobial ingredients to provide surfaces with safe, built-in, antimicrobial weaponry to defend them against microbes and fouling. Surfaces enhanced with IonArmour inhibit bacteria, fungus, mold and other microbes more effectively than other antimicrobial enhancements.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Infectious DiseasePrimary Technology
Nanotechnology
1700 Owens St, Suite 240
San Francisco, CA, 94158
415.796.6445
http://www.ionarmour.comPrimary Contacts
Alexander Mittal
CEO
Arjun Srinivas
COO
Michael Young
Director of Technology Development
Company Profile
IonArmour combines breakthrough materials technology with natural antimicrobial ingredients to provide surfaces with safe, built-in, antimicrobial weaponry to defend them against microbes and fouling. Surfaces enhanced with IonArmour inhibit bacteria, fungus, mold and other microbes more effectively than other antimicrobial enhancements.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Infectious DiseasePrimary Technology
Nanotechnology
iPierian, Inc.
http://izumibio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://izumibio.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Ironshore
United States, http://www.ironshore.comCompany Classification
Associate/Service ProvidersOrganization Type
Insurance
United States, http://www.ironshore.comCompany Classification
Associate/Service ProvidersOrganization Type
Insurance
Jackson Laboratory - West
4910 Raley Blvd
Sacramento, CA, 95838
916-469-2603
http://www.jax.orgPrimary Contacts
Sr. Site Director
916-469-2556
Margaret Bundy
Finance Generalist
916-469-2609
Company Profile
The Jackson Laboratory—West, located in California, opened its doors several years ago and for nearly a decade now has supported the West Coast research community with a local supply of many popular JAX® Mice strains as well as mouse breeding and in vivo research services. To keep pace with the explosive growth in biomedical research on the West Coast we opened a much expanded facility in Sacramento, CA in early 2009. This new, state-of-the-art facility provides increased production of an expanded selection of JAX® Mice strains. The facility also provides additional space for significantly expanded colony management and drug efficacy testing and phenotyping services, and more extensive in vivo services offerings, including cancer and stem cell research. The facility is fully AAALAC accredited and OLAW assured.Company Classification
Associate/Service ProvidersOrganization Type
Non‐Profit Organizations
4910 Raley Blvd
Sacramento, CA, 95838
916-469-2603
http://www.jax.orgPrimary Contacts
Sr. Site Director
916-469-2556
Margaret Bundy
Finance Generalist
916-469-2609
Company Profile
The Jackson Laboratory—West, located in California, opened its doors several years ago and for nearly a decade now has supported the West Coast research community with a local supply of many popular JAX® Mice strains as well as mouse breeding and in vivo research services. To keep pace with the explosive growth in biomedical research on the West Coast we opened a much expanded facility in Sacramento, CA in early 2009. This new, state-of-the-art facility provides increased production of an expanded selection of JAX® Mice strains. The facility also provides additional space for significantly expanded colony management and drug efficacy testing and phenotyping services, and more extensive in vivo services offerings, including cancer and stem cell research. The facility is fully AAALAC accredited and OLAW assured.Company Classification
Associate/Service ProvidersOrganization Type
Non‐Profit Organizations
Jazz Pharmaceuticals
http://www.jazzpharmaceuticals.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.jazzpharmaceuticals.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Jennerex Biotherapeutics
http://www.jennerex.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.jennerex.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
JMP Securities LLC
600 Montgomery St
San Francisco, CA, 94111
415-835-8900
http://jmpsecurities.comPrimary Contacts
Robert F. Carey
Managing Director
415-835-8901
Company Profile
Growth equity focused investment bank.Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
600 Montgomery St
San Francisco, CA, 94111
415-835-8900
http://jmpsecurities.comPrimary Contacts
Robert F. Carey
Managing Director
415-835-8901
Company Profile
Growth equity focused investment bank.Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
Johnson & Johnson
United States, http://ww.jnj.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Drug Development
Medical Devices
Therapeutic
United States, http://ww.jnj.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Drug Development
Medical Devices
Therapeutic
KAI Pharmaceuticals, Inc
270 Littlefield Avenue
South San Francisco, CA, 94080
650-244-1100
http://www.kaipharmaceuticals.comPrimary Contacts
Steven P. James
President and Chief Executive Officer
Gregory Bell, M.D.
Senior Vice President, Development and Chief Medical Officer
Randolph M. Johnson, Ph.D.
Vice President of Research and Chief of Technology Development
Company Profile
KAI Pharmaceuticals is a biology-based product-driven biopharmaceutical company developing a new class of therapeutics targeting protein kinase C (PKC), an important and validated family of kinases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Kidneys & Genito-Urinary SystemPrimary Technology
Cell Biology
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
270 Littlefield Avenue
South San Francisco, CA, 94080
650-244-1100
http://www.kaipharmaceuticals.comPrimary Contacts
Steven P. James
President and Chief Executive Officer
Gregory Bell, M.D.
Senior Vice President, Development and Chief Medical Officer
Randolph M. Johnson, Ph.D.
Vice President of Research and Chief of Technology Development
Company Profile
KAI Pharmaceuticals is a biology-based product-driven biopharmaceutical company developing a new class of therapeutics targeting protein kinase C (PKC), an important and validated family of kinases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Kidneys & Genito-Urinary SystemPrimary Technology
Cell Biology
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
KaloBios Pharmaceuticals, Inc.
260 East Grand Avenue
South San Francisco, CA, United States, 94080
(650) 243-3100
http://www.kalobios.comPrimary Contacts
David Pritchard
President & CEO
Jonathan Leff, M.D.
Chief Medical Officer
Geoffrey Yarranton, Ph.D.
EVP, R&D and Chief Scientific Officer
Company Profile
KaloBios Pharmaceuticals, Inc., a private company based in South San Francisco, California, is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies (mAb) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, KaloBios is conducting three clinical development programs in leukemias, infectious diseases, and autoimmune diseases. Within each of these programs, KaloBios focuses primarily on patient-targeted drug indications where a diagnostic is typically used to prescreen patients to determine those most likely to respond to a given treatment. KB001, an anti-PcrV mAb, is targeted against Pseudomonas aeruginosa in mechanically ventilated and cystic fibrosis patients. KB003, an anti-GM-CSF mAb, is under evaluation for treatment of inflammatory diseases such as rheumatoid arthritis and asthma. KB004, an anti-EphA3 mAb, is being developed initially for hematological malignancies. KaloBios plans to partner its programs while retaining rights to patient-targeted orphan indications in the United States. In 2010, KaloBios partnered KB001 to Sanofi Pasteur for the development and commercialization of the drug worldwide, while remaining responsible for developing KB001 in cystic fibrosis. KaloBios generates its antibodies using proprietary technology, including the company�s Humaneering� technology, an antibody engineering approach for the creation of optimized drug candidates. The Humaneered� antibody is designed to have little or no immunogenicity. KaloBios then adds further features to enhance the antibody's therapeutic performance. KaloBios has raised over $80 million in four rounds of venture funding since the company�s founding in 2001. Major shareholders include MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, 5 AM Ventures, Bio 1 Capital, Mitsubishi UFJ Capital, Genzyme Ventures, Baxter International, Inc., and Development Bank of Japan.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Infectious Disease
Musculoskeletal Disorders
Respiratory DisordersClinical Development Stage
PreClinical
Phase I
Phase II
260 East Grand Avenue
South San Francisco, CA, United States, 94080
(650) 243-3100
http://www.kalobios.comPrimary Contacts
David Pritchard
President & CEO
Jonathan Leff, M.D.
Chief Medical Officer
Geoffrey Yarranton, Ph.D.
EVP, R&D and Chief Scientific Officer
Company Profile
KaloBios Pharmaceuticals, Inc., a private company based in South San Francisco, California, is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies (mAb) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, KaloBios is conducting three clinical development programs in leukemias, infectious diseases, and autoimmune diseases. Within each of these programs, KaloBios focuses primarily on patient-targeted drug indications where a diagnostic is typically used to prescreen patients to determine those most likely to respond to a given treatment. KB001, an anti-PcrV mAb, is targeted against Pseudomonas aeruginosa in mechanically ventilated and cystic fibrosis patients. KB003, an anti-GM-CSF mAb, is under evaluation for treatment of inflammatory diseases such as rheumatoid arthritis and asthma. KB004, an anti-EphA3 mAb, is being developed initially for hematological malignancies. KaloBios plans to partner its programs while retaining rights to patient-targeted orphan indications in the United States. In 2010, KaloBios partnered KB001 to Sanofi Pasteur for the development and commercialization of the drug worldwide, while remaining responsible for developing KB001 in cystic fibrosis. KaloBios generates its antibodies using proprietary technology, including the company�s Humaneering� technology, an antibody engineering approach for the creation of optimized drug candidates. The Humaneered� antibody is designed to have little or no immunogenicity. KaloBios then adds further features to enhance the antibody's therapeutic performance. KaloBios has raised over $80 million in four rounds of venture funding since the company�s founding in 2001. Major shareholders include MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, 5 AM Ventures, Bio 1 Capital, Mitsubishi UFJ Capital, Genzyme Ventures, Baxter International, Inc., and Development Bank of Japan.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Infectious Disease
Musculoskeletal Disorders
Respiratory DisordersClinical Development Stage
PreClinical
Phase I
Phase II
Kanion USA, Inc.
3916 Trust Way
Hayward, CA, 94545
510-781-0700
http://www.kanionusa.comPrimary Contacts
Wang Shen
President and CEO
Company Profile
Tiny start up doing caner researchCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
3916 Trust Way
Hayward, CA, 94545
510-781-0700
http://www.kanionusa.comPrimary Contacts
Wang Shen
President and CEO
Company Profile
Tiny start up doing caner researchCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Kaplan IP Law
PO Box 66744
Scotts Valley, CA, United States, 95067
831-440-7282
http://www.kaplan-iplaw.comPrimary Contacts
Jonathan M. Kaplan
Principal
831-440-7282
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
PO Box 66744
Scotts Valley, CA, United States, 95067
831-440-7282
http://www.kaplan-iplaw.comPrimary Contacts
Jonathan M. Kaplan
Principal
831-440-7282
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Kateeva, Inc. (formerly TJet Technologies)
United States, http://tjettechnologies.com/index.htmlCompany Classification
Associate/Service Providers
United States, http://tjettechnologies.com/index.htmlCompany Classification
Associate/Service Providers
KBA Docusys Inc
32950 Alvarado Niles Rd. #505
Union City, CA, 94587
510-214-4040
http://www.kbadocusys.comPrimary Contacts
Jim Leaf
VP Sales
650-376-9340
Todd Moody
President
510-214-4040
Todd Court
CFO
510-214-4040
Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
32950 Alvarado Niles Rd. #505
Union City, CA, 94587
510-214-4040
http://www.kbadocusys.comPrimary Contacts
Jim Leaf
VP Sales
650-376-9340
Todd Moody
President
510-214-4040
Todd Court
CFO
510-214-4040
Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
KDH Systems
United States, http://www.kdhsystems.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
United States, http://www.kdhsystems.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Kerilyn A. Sappington
2370 Fountain Crest Ln. #27
Thousand Oaks, CA, United States, 91362
818-212-5419
http://kerilyn.translatorscafe.comPrimary Contacts
Kerilyn Sappington
Chinese/English Translator
818-212-5419
Company Classification
Associate/Service Providers
2370 Fountain Crest Ln. #27
Thousand Oaks, CA, United States, 91362
818-212-5419
http://kerilyn.translatorscafe.comPrimary Contacts
Kerilyn Sappington
Chinese/English Translator
818-212-5419
Company Classification
Associate/Service Providers
Kidder Mathews
United States, http://www.gvakm.com/Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
United States, http://www.gvakm.com/Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
KineMed Inc.
5980 Horton St. Suite 470
Emeryville, CA, United States, 94608
510.655.6525
http://www.kinemed.comPrimary Contacts
David Fineman
Presiden t& CEO, Co-Founder
Marc K. Hellerstein M.D., Ph.D
Co-Founder and Chairman of the Scientific Advisory Board
Alexander Glass Ph.D.
Chief Operating Officer
Company Profile
For almost a decade KineMed had assisted major pharmaceutical and biotechnology clients to discover, advance, and validate novel compounds more effectively. Since its founding in 2001, KineMed has serviced more than 25 of the world's top pharmaceutical companies and leading biotechnology companies, as well as the NIH, and medical research foundations. KineMed provides unique insights into the dynamics of complex biochemical networks within cells. Our "Network Dynamics" platform reveals the underlying biological pathways of disease initiation and progression, enabling our clients to create therapeutics to reverse them. The Kinemed platform works by detecting subtle changes using stable isotopes and ultra-sensitive mass spectrometry to measure the flux of labeled biomarkers in vivo. We work at all stages of the pipeline and undertake projects both large and small for clients to discover, develop and validate drugs in development. These range from projects to develop and validate biomarkers that are predictive of clinical outcome, to major investigative studies of disease progression, mode of action and therapeutic efficacy. KineMed's ability to detect causal rather than consequential pathways of disease enable its clients to focus on therapeutic strategies which address fundamental rather than symptomatic biology -- a powerful approach for developing future blockbusters. KineMed�s platform technology has been applied across a range of therapeutic areas including cancer, cardiovascular disease, metabolic syndrome, and diseases of the nervous system. The majority of KineMed�s biomarkers can be translated from preclinical animal studies to clinical trials, accelerating development. Our own pipeline of promising candidates, to which KineMed's innovations have been applied, are available for out-licensing or co-development.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
5980 Horton St. Suite 470
Emeryville, CA, United States, 94608
510.655.6525
http://www.kinemed.comPrimary Contacts
David Fineman
Presiden t& CEO, Co-Founder
Marc K. Hellerstein M.D., Ph.D
Co-Founder and Chairman of the Scientific Advisory Board
Alexander Glass Ph.D.
Chief Operating Officer
Company Profile
For almost a decade KineMed had assisted major pharmaceutical and biotechnology clients to discover, advance, and validate novel compounds more effectively. Since its founding in 2001, KineMed has serviced more than 25 of the world's top pharmaceutical companies and leading biotechnology companies, as well as the NIH, and medical research foundations. KineMed provides unique insights into the dynamics of complex biochemical networks within cells. Our "Network Dynamics" platform reveals the underlying biological pathways of disease initiation and progression, enabling our clients to create therapeutics to reverse them. The Kinemed platform works by detecting subtle changes using stable isotopes and ultra-sensitive mass spectrometry to measure the flux of labeled biomarkers in vivo. We work at all stages of the pipeline and undertake projects both large and small for clients to discover, develop and validate drugs in development. These range from projects to develop and validate biomarkers that are predictive of clinical outcome, to major investigative studies of disease progression, mode of action and therapeutic efficacy. KineMed's ability to detect causal rather than consequential pathways of disease enable its clients to focus on therapeutic strategies which address fundamental rather than symptomatic biology -- a powerful approach for developing future blockbusters. KineMed�s platform technology has been applied across a range of therapeutic areas including cancer, cardiovascular disease, metabolic syndrome, and diseases of the nervous system. The majority of KineMed�s biomarkers can be translated from preclinical animal studies to clinical trials, accelerating development. Our own pipeline of promising candidates, to which KineMed's innovations have been applied, are available for out-licensing or co-development.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
Kinestral Technologies
1455 Adams Ct. Ste 1190
Menlo Park, CA, United States, 94025
650-327-1032
Primary Contacts
Oxana Munn
Research Associate
Company Classification
Bioscience/R&D/Non-Profit conducting R&D
1455 Adams Ct. Ste 1190
Menlo Park, CA, United States, 94025
650-327-1032
Primary Contacts
Oxana Munn
Research Associate
Company Classification
Bioscience/R&D/Non-Profit conducting R&D
Kleiner Perkins Caufield & Byers
2750 Sand Hill Rd.
Menlo Park, CA, 94025
650-233-2750
http://www.kpcb.com/Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
2750 Sand Hill Rd.
Menlo Park, CA, 94025
650-233-2750
http://www.kpcb.com/Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Knobbe, Martens, Olson & Bear, LLP
333 Bush Street, 21st Floor
San Francisco, CA, United States, 94104
415-954-4114
http://kmob.comPrimary Contacts
Eli Loots
Partner
415-954-4114
Corey Cooper
Business Development
949-721-7679
Company Profile
Knobbe Martens Olson & Bear LLP, currently the third largest IP firm nationwide, is a law firm practicing exclusively in the area of intellectual property law including patents, trademarks, copyrights, trade secrets, rights of publicity, client counseling, due diligence, and related litigation and licensing. At present, the firm is composed of more than 275 lawyers and scientists, with over 100 working in Cleantech and Biotech, and 95 of whom hold advanced degrees in various technologies. This combination of law and technology makes Knobbe Martens uniquely qualified to represent a diverse array of clients in a broad spectrum of intellectual property matters, and internationally recognized across a vast spectrum of clean technologies and life science areas.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
333 Bush Street, 21st Floor
San Francisco, CA, United States, 94104
415-954-4114
http://kmob.comPrimary Contacts
Eli Loots
Partner
415-954-4114
Corey Cooper
Business Development
949-721-7679
Company Profile
Knobbe Martens Olson & Bear LLP, currently the third largest IP firm nationwide, is a law firm practicing exclusively in the area of intellectual property law including patents, trademarks, copyrights, trade secrets, rights of publicity, client counseling, due diligence, and related litigation and licensing. At present, the firm is composed of more than 275 lawyers and scientists, with over 100 working in Cleantech and Biotech, and 95 of whom hold advanced degrees in various technologies. This combination of law and technology makes Knobbe Martens uniquely qualified to represent a diverse array of clients in a broad spectrum of intellectual property matters, and internationally recognized across a vast spectrum of clean technologies and life science areas.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Knome, Inc.
25 1st St. Ste 107
Cambridge, MA, United States, 02141
617-715-1000
http://www.knome.com/Primary Contacts
Jorge Conde
CEO
Geoffrey Routh
Account Manager
Ari Kiiriki
VP of Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
25 1st St. Ste 107
Cambridge, MA, United States, 02141
617-715-1000
http://www.knome.com/Primary Contacts
Jorge Conde
CEO
Geoffrey Routh
Account Manager
Ari Kiiriki
VP of Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Kromite, LLC
United States, http://www.kromite.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
United States, http://www.kromite.comCompany Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Lab Support
United States, http://www.labsupport.comCompany Classification
Associate/Service ProvidersOrganization Type
Human Resources
Staffing
United States, http://www.labsupport.comCompany Classification
Associate/Service ProvidersOrganization Type
Human Resources
Staffing
LAP IQ
18921 Portola Dr. Ste B
Salinas, CA, United States, 93908
831-758-4412
http://www.lapiq.comPrimary Contacts
Mike Klein, MD, FACS
Founder and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
18921 Portola Dr. Ste B
Salinas, CA, United States, 93908
831-758-4412
http://www.lapiq.comPrimary Contacts
Mike Klein, MD, FACS
Founder and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
Lazard
4 Embarcadero Center, Suite 650
San Francisco, CA, United States, 94111
415-623-5000
http://www.lazard.comPrimary Contacts
David N. Low Jr.
Managing Director
415-623-5077
Andrew Dickinson
Managing Director
415-623-5019
Company Profile
Investment BankCompany Classification
Associate/Service ProvidersOrganization Type
Investment Bank
4 Embarcadero Center, Suite 650
San Francisco, CA, United States, 94111
415-623-5000
http://www.lazard.comPrimary Contacts
David N. Low Jr.
Managing Director
415-623-5077
Andrew Dickinson
Managing Director
415-623-5019
Company Profile
Investment BankCompany Classification
Associate/Service ProvidersOrganization Type
Investment Bank
Lin-Zhi International Inc.
670 Almanor Avenue
Sunnyvale, CA, 94085
408-732-3856
http://lin-zhi.comPrimary Contacts
Marie Lin
President, CEO
Justin Lin
VP Marketing
Bernice Lin
VP Operations
Company Profile
clinical diagnostics manufacturerCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticPrimary Technology
BiomanufacturingClinical Development Stage
Approved
670 Almanor Avenue
Sunnyvale, CA, 94085
408-732-3856
http://lin-zhi.comPrimary Contacts
Marie Lin
President, CEO
Justin Lin
VP Marketing
Bernice Lin
VP Operations
Company Profile
clinical diagnostics manufacturerCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticPrimary Technology
BiomanufacturingClinical Development Stage
Approved
List Biological Laboratories, Inc.
http://www.listlabs.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://www.listlabs.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
LiveLeaf Bioscience
1200 Industrial Rd, Suite 9B
San Carlos, CA, United States, 94070
650-274-3888
http://www.liveleaf.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Digestive SystemPrimary Technology
Plant-made Pharmaceuticals
1200 Industrial Rd, Suite 9B
San Carlos, CA, United States, 94070
650-274-3888
http://www.liveleaf.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Digestive SystemPrimary Technology
Plant-made Pharmaceuticals
LS9, Inc.
http://www.ls9.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
http://www.ls9.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
Industrial Biotechnology
Luxembourg Trade and Investment Office
1 Sansome Street Suite 830
San Francisco, CA, United States, 94104
415-788-0816
http://www.investinluxembourg.usPrimary Contacts
Dr. Philippe Lamesch
Life Sciences Advisor
650-576-9015
Georges Schmit
Consul General of Luxembourg
Company Profile
In 2008 the Luxembourg Government launched its Biotechnology program, whose main priorities were to set up local centers of scientific excellence and to diversify the Luxembourg economic fabric by promoting research activities, particularly in the areas of molecular diagnostics and personalized medicine. The centerpiece of the overall project is the new ‘Integrated Biobank of Luxembourg’ (IBBL) which opened its doors in 2010 and is specializing in the collection, distribution, and analysis of blood & tissue and the storage of the underlying clinical data for research purposes with an initial focus on cancers (lung/colon/breast), type II diabetes, and neurodegenerative diseases. Luxembourg has also established a center of excellence in systems biology, the ‘Luxembourg Center for Systems Biomedicine’ (LCSB). One of the main missions of the Luxembourg’s Trade and Investment office in San Francisco is to introduce Luxembourg’s health sciences and biotechnology efforts to US companies and research institutes, promote Luxembourg as a prime business location for biotech in Europe and foster scientific collaborations between American and Luxembourg researchers.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
1 Sansome Street Suite 830
San Francisco, CA, United States, 94104
415-788-0816
http://www.investinluxembourg.usPrimary Contacts
Dr. Philippe Lamesch
Life Sciences Advisor
650-576-9015
Georges Schmit
Consul General of Luxembourg
Company Profile
In 2008 the Luxembourg Government launched its Biotechnology program, whose main priorities were to set up local centers of scientific excellence and to diversify the Luxembourg economic fabric by promoting research activities, particularly in the areas of molecular diagnostics and personalized medicine. The centerpiece of the overall project is the new ‘Integrated Biobank of Luxembourg’ (IBBL) which opened its doors in 2010 and is specializing in the collection, distribution, and analysis of blood & tissue and the storage of the underlying clinical data for research purposes with an initial focus on cancers (lung/colon/breast), type II diabetes, and neurodegenerative diseases. Luxembourg has also established a center of excellence in systems biology, the ‘Luxembourg Center for Systems Biomedicine’ (LCSB). One of the main missions of the Luxembourg’s Trade and Investment office in San Francisco is to introduce Luxembourg’s health sciences and biotechnology efforts to US companies and research institutes, promote Luxembourg as a prime business location for biotech in Europe and foster scientific collaborations between American and Luxembourg researchers.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Government Agencies
Lypro Biosciences, Inc.
QB3 Incubator, 1700 4th Street, Byers Hall
San Francisco, CA, United States, 94158
510 748-9500
http://www.lyprobio.comPrimary Contacts
Michelle Stecklein Call
CEO
Robert O. Ryan, Ph.D.
Chief Science Officer, Co-Founder
Michael N. Oda, Ph.D.
Chief Development Officer, Co-Founder
Company Profile
Lypro Biosciences is a specialty biopharmaceutical company whose proprietary drug delivery technology increases the bioavailability of hydrophobic drugs and facilitates drug targeting to specific receptor(s). We have looked to the body's natural mechanism for transporting insoluble compounds to develop our novel delivery ideas. Lypro�s technology is based on targetable, self-assembling, nanometer-scale bioparticles, termed�NanoDisks�. Incorporating hydrophobic bioactive agents into the stable and water-soluble NanoDisks holds the promise of increased efficacy, lower doses, and reduced incidence and severity of side effects compared to current formulations. Lypro has programs underway in oncology, infectious diseases, neurobiology, imaging and siRNA delivery.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Infectious DiseasePrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
PreClinical
QB3 Incubator, 1700 4th Street, Byers Hall
San Francisco, CA, United States, 94158
510 748-9500
http://www.lyprobio.comPrimary Contacts
Michelle Stecklein Call
CEO
Robert O. Ryan, Ph.D.
Chief Science Officer, Co-Founder
Michael N. Oda, Ph.D.
Chief Development Officer, Co-Founder
Company Profile
Lypro Biosciences is a specialty biopharmaceutical company whose proprietary drug delivery technology increases the bioavailability of hydrophobic drugs and facilitates drug targeting to specific receptor(s). We have looked to the body's natural mechanism for transporting insoluble compounds to develop our novel delivery ideas. Lypro�s technology is based on targetable, self-assembling, nanometer-scale bioparticles, termed�NanoDisks�. Incorporating hydrophobic bioactive agents into the stable and water-soluble NanoDisks holds the promise of increased efficacy, lower doses, and reduced incidence and severity of side effects compared to current formulations. Lypro has programs underway in oncology, infectious diseases, neurobiology, imaging and siRNA delivery.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Infectious DiseasePrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
PreClinical
MabVax Therapeutics, Inc.
http://www.mabvax.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.mabvax.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
MacDougall Biomedical Communications, Inc.
Belmot, MA, United States, 94002
650-339-7533
http://www.macbiocom.comPrimary Contacts
Christine Labaree
Senior Vice President
650-339-7533
Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
Belmot, MA, United States, 94002
650-339-7533
http://www.macbiocom.comPrimary Contacts
Christine Labaree
Senior Vice President
650-339-7533
Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
MandalMed, Inc.
665 3rd Street, Suite 250
San Francisco, CA, 94107
http://www.mandalmed.comPrimary Contacts
Constance M. John, Ph.D.
President & CEO
Company Profile
MandalMed is a biotechnology company focused in two areas. We are developing therapeutic agents that act to modulate galectins, which are human carbohydrate binding proteins. The lead product in this area is galectin-3C, a truncated proprietary form of galectin-3, that acts to inhibit angiogenesis, invasion, and metastasis of cancer. The second area is based on proprietary proliferative human Sertoli cells that have applications in cell therapy and in spermatogenesis for some types of male infertility.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central NervousPrimary Technology
Cell Biology
Gene/Cell TherapyClinical Development Stage
PreClinical
665 3rd Street, Suite 250
San Francisco, CA, 94107
http://www.mandalmed.comPrimary Contacts
Constance M. John, Ph.D.
President & CEO
Company Profile
MandalMed is a biotechnology company focused in two areas. We are developing therapeutic agents that act to modulate galectins, which are human carbohydrate binding proteins. The lead product in this area is galectin-3C, a truncated proprietary form of galectin-3, that acts to inhibit angiogenesis, invasion, and metastasis of cancer. The second area is based on proprietary proliferative human Sertoli cells that have applications in cell therapy and in spermatogenesis for some types of male infertility.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central NervousPrimary Technology
Cell Biology
Gene/Cell TherapyClinical Development Stage
PreClinical
MAP Pharmaceuticals, Inc.
2400 Bayshore Pkwy
Mountain View, CA, 94043
650-386-3100
http://www.mappharma.comPrimary Contacts
Timothy Nelson
CEO
Chris Chai
CFO
Thomas Armer
CSO
Company Profile
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX™ inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug Delivery
Drug Discovery
NanotechnologyClinical Development Stage
Phase III
2400 Bayshore Pkwy
Mountain View, CA, 94043
650-386-3100
http://www.mappharma.comPrimary Contacts
Timothy Nelson
CEO
Chris Chai
CFO
Thomas Armer
CSO
Company Profile
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX™ inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug Delivery
Drug Discovery
NanotechnologyClinical Development Stage
Phase III
Marin Biologic Laboratories, Inc.
378 Bel Marin Keys Blvd
Novato, CA, United States, 94949
(415)883-8000
http://www.marinbio.com/Company Profile
Marin Biologic Laboratories, Inc. is a leading contract laboratory that provides collaborative and custom research, testing and manufacturing services (GMP/GLP optional) for the biotechnology, pharmaceutical, cosmetic, diagnostic and agricultural industries. We are housed in our new, custom-designed laboratory, located in beautiful Marin County, California, between the Golden Gate Bridge and bucolic and iconic Napa and Sonoma wine growing regions. For 16 years we have served clients ranging from the largest pharmaceutical companies, to midsize bio-techs, to virtual companies with no laboratories for whom we are their scientists. Our commitment is to deliver exceptional custom service to our commercial and academic clients at the very best rates. To achieve this, we have: Assembled a creative team of scientists experienced in the diversified technologies of cell biology, immunology, biochemistry, microbiology, molecular biology, and neurobiology •Created a culture that strives for the best communication with our clients and reaches across disciplines to provide you with comprehensive solutions •Perfected scientific systems and best practices that are both efficient and effective, saving your budget while achieving your project goals •Invested in a custom-designed laboratory that allows us to better control and execute on client projects to meet and exceed your task and process goals at a competitive price We combine and integrate our talents to provide a comprehensive solution for your unique projects. Since many of our scientific staff has significant research and development experience, we can provide innovative and practical approaches to your complex projects in a timely manner. For those projects that require a more focused approach, we also provide expertise in each individual field.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
378 Bel Marin Keys Blvd
Novato, CA, United States, 94949
(415)883-8000
http://www.marinbio.com/Company Profile
Marin Biologic Laboratories, Inc. is a leading contract laboratory that provides collaborative and custom research, testing and manufacturing services (GMP/GLP optional) for the biotechnology, pharmaceutical, cosmetic, diagnostic and agricultural industries. We are housed in our new, custom-designed laboratory, located in beautiful Marin County, California, between the Golden Gate Bridge and bucolic and iconic Napa and Sonoma wine growing regions. For 16 years we have served clients ranging from the largest pharmaceutical companies, to midsize bio-techs, to virtual companies with no laboratories for whom we are their scientists. Our commitment is to deliver exceptional custom service to our commercial and academic clients at the very best rates. To achieve this, we have: Assembled a creative team of scientists experienced in the diversified technologies of cell biology, immunology, biochemistry, microbiology, molecular biology, and neurobiology •Created a culture that strives for the best communication with our clients and reaches across disciplines to provide you with comprehensive solutions •Perfected scientific systems and best practices that are both efficient and effective, saving your budget while achieving your project goals •Invested in a custom-designed laboratory that allows us to better control and execute on client projects to meet and exceed your task and process goals at a competitive price We combine and integrate our talents to provide a comprehensive solution for your unique projects. Since many of our scientific staff has significant research and development experience, we can provide innovative and practical approaches to your complex projects in a timely manner. For those projects that require a more focused approach, we also provide expertise in each individual field.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Marken, LTD
840 Dubuque Ave
South San Francisco, CA, 94080
650 266 9950
http://www.marken.comPrimary Contacts
Tim Blofeld
General manager San Francisco
650 266 9950
Dan Bell
Operations Manager
650 266 9950
Company Profile
Global bio/pharma and clinical trial logistics specialist, including temperature and time critical shipments, international strategic CT planning, global depot network, kit building, customs and other governmental organization assistance, door to door fully inclusive service.Company Classification
Associate/Service Providers
840 Dubuque Ave
South San Francisco, CA, 94080
650 266 9950
http://www.marken.comPrimary Contacts
Tim Blofeld
General manager San Francisco
650 266 9950
Dan Bell
Operations Manager
650 266 9950
Company Profile
Global bio/pharma and clinical trial logistics specialist, including temperature and time critical shipments, international strategic CT planning, global depot network, kit building, customs and other governmental organization assistance, door to door fully inclusive service.Company Classification
Associate/Service Providers
Maxygen, Inc.
515 Galveston Dr.
Redwood city, CA, United States, 94063
650-298-5300
http://www.maxygen.comPrimary Contacts
Jim Sulat
CEO
Keith Lenden
VP, Business Development
Michael Byrnes
Controller
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Academic
Major Research Institute
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
515 Galveston Dr.
Redwood city, CA, United States, 94063
650-298-5300
http://www.maxygen.comPrimary Contacts
Jim Sulat
CEO
Keith Lenden
VP, Business Development
Michael Byrnes
Controller
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Academic
Major Research Institute
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Medical Marketing Economics (MME)
1200 Jefferson Ave., Suite 200
Oxford, MS, United States, 38655
662-282-0502x309
http://www.m2econ.comPrimary Contacts
Sam Wichairud
Director
662-281-0502 x309
Kevin Petterson
Vice President and Partner
662-281-0502
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
1200 Jefferson Ave., Suite 200
Oxford, MS, United States, 38655
662-282-0502x309
http://www.m2econ.comPrimary Contacts
Sam Wichairud
Director
662-281-0502 x309
Kevin Petterson
Vice President and Partner
662-281-0502
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Medicus Biosciences
409 Illinois Street
San Francisco, CA, United States, 94158
415-978-2180
Primary Contacts
Dan Nathanson
CEO
Syed Askari
Co-founder CTO
George Horng
Co-founder CMO
Company Profile
Controlled Drug DeliveryCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase I
409 Illinois Street
San Francisco, CA, United States, 94158
415-978-2180
Primary Contacts
Dan Nathanson
CEO
Syed Askari
Co-founder CTO
George Horng
Co-founder CMO
Company Profile
Controlled Drug DeliveryCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase I
MedImmune
Mountain View, CA, United States, (650)603-2000
http://www.medimmune.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Mountain View, CA, United States, (650)603-2000
http://www.medimmune.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Medivation, Inc
201 Spear Street, 3rd Floor
San Francisco, CA, 94105
415-543-3470
http://www.medivation.com/Primary Contacts
David Hung, M.D.
President and Chief Executive Officer, Director
C. Patrick Machado, J.D.
Chief Business Officer, Chief Financial Officer
Lynn Seely, M.D.
Chief Medical Officer
Company Profile
Medivation blends a unique business model with an expert team to bring promising medical technologies from the lab bench to the patient bedside. Our current clinical development programs address large markets with significant unmet medical needs. Medivation was founded by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical, biotechnology and medical device industries. We founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Through our extensive network of contacts with top-flight scientists and research institutions, we acquire early-development stage pharmaceuticals and medical devices that have promising clinical, intellectual property and commercial prospects. Using the extensive development experience and expertise of our core team, supplemented by expert consultants in relevant functions, we identify and execute the strategic pathway that will allow the most rapid, efficient and effective development. Our business strategy is straightforward: ?Build a portfolio of four to six product candidates that have the potential to be in clinical development within 12 to 18 months after acquisition; ?Develop those product candidates as rapidly and efficiently as possible; and ?Consider partnering or selling successful programs to large pharmaceutical, biotechnology or medical device companies for late-stage clinical studies and commercialization or, depending on the indication, conduct those activities internally. Our current clinical development programs address large markets with significant unmet medical needs. These include: ?MDV3100 for early-stage and advanced prostate cancer ?Dimebon for Alzheimer's diseaseCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central NervousPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
Phase II
Phase III
201 Spear Street, 3rd Floor
San Francisco, CA, 94105
415-543-3470
http://www.medivation.com/Primary Contacts
David Hung, M.D.
President and Chief Executive Officer, Director
C. Patrick Machado, J.D.
Chief Business Officer, Chief Financial Officer
Lynn Seely, M.D.
Chief Medical Officer
Company Profile
Medivation blends a unique business model with an expert team to bring promising medical technologies from the lab bench to the patient bedside. Our current clinical development programs address large markets with significant unmet medical needs. Medivation was founded by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical, biotechnology and medical device industries. We founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Through our extensive network of contacts with top-flight scientists and research institutions, we acquire early-development stage pharmaceuticals and medical devices that have promising clinical, intellectual property and commercial prospects. Using the extensive development experience and expertise of our core team, supplemented by expert consultants in relevant functions, we identify and execute the strategic pathway that will allow the most rapid, efficient and effective development. Our business strategy is straightforward: ?Build a portfolio of four to six product candidates that have the potential to be in clinical development within 12 to 18 months after acquisition; ?Develop those product candidates as rapidly and efficiently as possible; and ?Consider partnering or selling successful programs to large pharmaceutical, biotechnology or medical device companies for late-stage clinical studies and commercialization or, depending on the indication, conduct those activities internally. Our current clinical development programs address large markets with significant unmet medical needs. These include: ?MDV3100 for early-stage and advanced prostate cancer ?Dimebon for Alzheimer's diseaseCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central NervousPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
Phase II
Phase III
Mendel Biotechnology, Inc.
3935 Point Eden Way
Hayward, CA, United States, 94545
510-264-0280
http://www.mendelbio.comPrimary Contacts
Neal Gutterson
President and CEO
Rasto Ivanic
Senior Director, Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Agriculture
3935 Point Eden Way
Hayward, CA, United States, 94545
510-264-0280
http://www.mendelbio.comPrimary Contacts
Neal Gutterson
President and CEO
Rasto Ivanic
Senior Director, Business Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Agriculture
Merck & Co., Inc.
One Merck Dr.
Whitehouse Station, NJ, 8889
908-423-1000
http://www.merck.comPrimary Contacts
Dick Clark
Chairman, Merck & Co., Inc.
Kenneth Frazier
President and CEO, Merck & Co., Inc.
Leslie A. Brun
Chairman and CEO, Sarr Group, LLC
Company Profile
Merck & Co., Inc., Whitehouse Station, NJ, USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
One Merck Dr.
Whitehouse Station, NJ, 8889
908-423-1000
http://www.merck.comPrimary Contacts
Dick Clark
Chairman, Merck & Co., Inc.
Kenneth Frazier
President and CEO, Merck & Co., Inc.
Leslie A. Brun
Chairman and CEO, Sarr Group, LLC
Company Profile
Merck & Co., Inc., Whitehouse Station, NJ, USA, is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Cardiovascular & Circulatory Disorders
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Drug Delivery
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Metabolex, Inc.
3876 Bay Center Place
Hayward, CA, 94545
510-293-8800
http://www.metabolex.comPrimary Contacts
Harold Van Wart
President and CEO
Donald Hill
CFO
Charles McWherter
SVP, Research & Preclinical Development
Company Profile
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Our deep understanding of the biology of these diseases has enabled us to build a robust pipeline of proprietary product candidates. The Company’s strategy is to discover and develop promising therapies for metabolic diseases to address significant unmet medical needs in large markets, developing them through proof-of-concept studies and then collaborating with companies through late-stage clinical trials and commercialization to maximize the value of our compounds.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Metabolic/Endocrinology DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
3876 Bay Center Place
Hayward, CA, 94545
510-293-8800
http://www.metabolex.comPrimary Contacts
Harold Van Wart
President and CEO
Donald Hill
CFO
Charles McWherter
SVP, Research & Preclinical Development
Company Profile
Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Our deep understanding of the biology of these diseases has enabled us to build a robust pipeline of proprietary product candidates. The Company’s strategy is to discover and develop promising therapies for metabolic diseases to address significant unmet medical needs in large markets, developing them through proof-of-concept studies and then collaborating with companies through late-stage clinical trials and commercialization to maximize the value of our compounds.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Metabolic/Endocrinology DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Molecular Sciences Institute, The
2168 Shattuck Avenue
Berkeley, CA, United States, 94704
510 647-0690
http://www.molsci.orgPrimary Contacts
Orna Resnekov
Director
(510) 981-8711
Rebecca Stiewig
Accounting Manager
510 981-8741
Company Profile
Research at the Molecular Sciences Institute enables the quantitative prediction of the behaviors of biological systems. MSI emphasizes the creation of tools and techniques for generating biological information, the development of computational and analytical frameworks for integrating this data, and the design and engineering of biological systems. The goal of Institute scientists is to significantly advance our understanding of how living systems function and evolve, and their work will have positive effects on human health, the bioeconomy and agriculture.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
2168 Shattuck Avenue
Berkeley, CA, United States, 94704
510 647-0690
http://www.molsci.orgPrimary Contacts
Orna Resnekov
Director
(510) 981-8711
Rebecca Stiewig
Accounting Manager
510 981-8741
Company Profile
Research at the Molecular Sciences Institute enables the quantitative prediction of the behaviors of biological systems. MSI emphasizes the creation of tools and techniques for generating biological information, the development of computational and analytical frameworks for integrating this data, and the design and engineering of biological systems. The goal of Institute scientists is to significantly advance our understanding of how living systems function and evolve, and their work will have positive effects on human health, the bioeconomy and agriculture.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
Moximed, Inc.
26460 Corporate Avenue, Suite 100
Hayward, CA, United States, 94545
510-887-3300
http://www.moximed.comPrimary Contacts
Kevin Sidow
President
Anton Clifford
Vice President Research & Development
John Ordway
Director of Operations
Company Profile
Moximed is an OrthopedicMedical Device Manufacturer Dedicated to Improving the Standard of Care for Patients with Osteoarthritis.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Musculoskeletal DisordersClinical Development Stage
PreClinical
Approved
26460 Corporate Avenue, Suite 100
Hayward, CA, United States, 94545
510-887-3300
http://www.moximed.comPrimary Contacts
Kevin Sidow
President
Anton Clifford
Vice President Research & Development
John Ordway
Director of Operations
Company Profile
Moximed is an OrthopedicMedical Device Manufacturer Dedicated to Improving the Standard of Care for Patients with Osteoarthritis.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Musculoskeletal DisordersClinical Development Stage
PreClinical
Approved
Multispan Inc.
26219 Eden Landing Road
Hayward, CA, United States, 94545
510 887 0817
http://www.multispaninc.comCompany Profile
Multispan Inc. is a San Francisco Bay Area-based company focusing exclusively on drug discovery research targeting GPCRs. Multispan has developed proprietary HEx technology for GPCR expression and antibody generation and created the industry's largest collection of human GPCR clones and highly characterized GPCR-expressing stable cell lines compatible for multiple HST applications such as cAMP assay, calcium assay and Multispan's proprietary internalization assay. Multispan has established successful collaborations in compound screening and profiling, antibody development, cell line and assay development with a wide range of leading pharmaceutical and biotech companies globally.Company Classification
Associate/Service ProvidersDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
OphthalmologyPrimary Technology
Cell Biology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
26219 Eden Landing Road
Hayward, CA, United States, 94545
510 887 0817
http://www.multispaninc.comCompany Profile
Multispan Inc. is a San Francisco Bay Area-based company focusing exclusively on drug discovery research targeting GPCRs. Multispan has developed proprietary HEx technology for GPCR expression and antibody generation and created the industry's largest collection of human GPCR clones and highly characterized GPCR-expressing stable cell lines compatible for multiple HST applications such as cAMP assay, calcium assay and Multispan's proprietary internalization assay. Multispan has established successful collaborations in compound screening and profiling, antibody development, cell line and assay development with a wide range of leading pharmaceutical and biotech companies globally.Company Classification
Associate/Service ProvidersDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
OphthalmologyPrimary Technology
Cell Biology
Drug Discovery
ScreeningClinical Development Stage
PreClinical
Murgitroyd and Company
71 Stevenson St. Ste 400
San Francisco, CA, United States, 415-819-8849
http://www.murgitroyd.comPrimary Contacts
Dylan Gittleman
Client Liason Western US Regional Manager
415-819-8849
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
71 Stevenson St. Ste 400
San Francisco, CA, United States, 415-819-8849
http://www.murgitroyd.comPrimary Contacts
Dylan Gittleman
Client Liason Western US Regional Manager
415-819-8849
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Myelin Repair Translational Medicine Center
525 Del Rey Ave. Suite B
Sunnyvale, CA, United States, 94085
650-922-6924
http://www.myelinrepair.orgPrimary Contacts
Jason Dugas
Senior Staff Scientist
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Central NervousPrimary Technology
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
525 Del Rey Ave. Suite B
Sunnyvale, CA, United States, 94085
650-922-6924
http://www.myelinrepair.orgPrimary Contacts
Jason Dugas
Senior Staff Scientist
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Central NervousPrimary Technology
Cell Biology
Drug DiscoveryClinical Development Stage
PreClinical
MyeloRx LLC
741 Railroad Ave
Vallejo, CA, 94692
650 759 3595
http://www.myelorx.comPrimary Contacts
John H. Musser
CEO
Neil R. Ackerman
VP, Bus. Dev.
John Fidler
VP, R&D
Company Profile
MyeloRx LLC is a California-based biotechnology company that develops drugs for oncology and immune-based diseases based on the natural product, triptolide. Triptolide is derived from a plant that has been used classically for autoimmune diseases. It has been shown to be effective clinically in acute leukemias as well in prevention of renal transplant rejection. The company has exclusively licensed four patents, which cover a series of triptolide analogues and prodrugs. MRx102 is the lead compound in the series; it is being developed initially for acute myeloid leukemia (AML). It is a prodrug of triptolide, and is rapidly and completely converted to the parent.. Mechanistically triptolide binds to human XPB, a subunit of the transcription factor THllH thereby affecting a number of cell signaling pathways as well as nuclear excision repair. It has shown a high level of effectiveness in killing blast cells removed from AML patients as well as leukemic cell lines. The company received a Fast Track NCI SBIR contract for approximately $2M which is being used to fund the development of MRx102. The company plans to enter clinical trials in 2012.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
CancerPrimary Technology
Cell Biology
Drug Discovery
Plant-made PharmaceuticalsClinical Development Stage
PreClinical
741 Railroad Ave
Vallejo, CA, 94692
650 759 3595
http://www.myelorx.comPrimary Contacts
John H. Musser
CEO
Neil R. Ackerman
VP, Bus. Dev.
John Fidler
VP, R&D
Company Profile
MyeloRx LLC is a California-based biotechnology company that develops drugs for oncology and immune-based diseases based on the natural product, triptolide. Triptolide is derived from a plant that has been used classically for autoimmune diseases. It has been shown to be effective clinically in acute leukemias as well in prevention of renal transplant rejection. The company has exclusively licensed four patents, which cover a series of triptolide analogues and prodrugs. MRx102 is the lead compound in the series; it is being developed initially for acute myeloid leukemia (AML). It is a prodrug of triptolide, and is rapidly and completely converted to the parent.. Mechanistically triptolide binds to human XPB, a subunit of the transcription factor THllH thereby affecting a number of cell signaling pathways as well as nuclear excision repair. It has shown a high level of effectiveness in killing blast cells removed from AML patients as well as leukemic cell lines. The company received a Fast Track NCI SBIR contract for approximately $2M which is being used to fund the development of MRx102. The company plans to enter clinical trials in 2012.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
CancerPrimary Technology
Cell Biology
Drug Discovery
Plant-made PharmaceuticalsClinical Development Stage
PreClinical
Nano Precision Medical, Inc.
United States, http://www.nanoprecisionmedical.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
United States, http://www.nanoprecisionmedical.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
NanoNerve, Inc.
United States, http://www.nanonerve.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
United States, http://www.nanonerve.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
Napo Pharmaceuticals, Inc.
http://www.napopharma.com/index.htmlCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.napopharma.com/index.htmlCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Natera, Inc.
2686 Middlefield Road, Suite D
Redwood City, CA, United States, 94063
650-249-9090
http://http://www.natera.comPrimary Contacts
MATTHEW RABINOWITZ, PHD
CHIEF EXECUTIVE OFFICER
JONATHAN SHEENA, M.ENG
CHIEF TECHNOLOGY OFFICER
GEORGE GEMELOS, PHD
DIRECTOR OF RESEARCH
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Genetic DiseasesPrimary Technology
Bioinformatics
2686 Middlefield Road, Suite D
Redwood City, CA, United States, 94063
650-249-9090
http://http://www.natera.comPrimary Contacts
MATTHEW RABINOWITZ, PHD
CHIEF EXECUTIVE OFFICER
JONATHAN SHEENA, M.ENG
CHIEF TECHNOLOGY OFFICER
GEORGE GEMELOS, PHD
DIRECTOR OF RESEARCH
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Genetic DiseasesPrimary Technology
Bioinformatics
NDA Group
1369 De Soto Avenue
Burlingame, CA, United States, 94010
(650) 302-5560
http://www.ndareg.comPrimary Contacts
Agustin de la Calle, Ph.D.
Vice President Business Development, USA
(650) 302-5560
Company Profile
The NDA Group represents the most successful development expertise for European product development. We are particularly experienced when it comes to bringing products to their fullest commercial potential in a convincingly short time frame and certainly at the highest success rate. We have an unmatched success record in EU product approvals where we regularly work on over one third of approved products. You can even utilize us as the most experienced “second opinion” when developing products for the European markets and the means to likely raise significantly your shareholder’s value. This is because we have working for us exclusively many of the former leaders of the EMA who have developed today's guidelines and thus we have the best connections to the EMA, which vastly improves the dialog, the speed and success rate. We also work for 90% of the top pharmaceutical companies, where often many hundreds of dedicated regulatory affairs professionals are part of the drug development process and where they appreciate our up-to-date and unmatched expertise. I am sure you will be pleased with NDA’s services, since we are proud to have a 98% customer retention rate. The remaining 2% of companies were acquired.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
1369 De Soto Avenue
Burlingame, CA, United States, 94010
(650) 302-5560
http://www.ndareg.comPrimary Contacts
Agustin de la Calle, Ph.D.
Vice President Business Development, USA
(650) 302-5560
Company Profile
The NDA Group represents the most successful development expertise for European product development. We are particularly experienced when it comes to bringing products to their fullest commercial potential in a convincingly short time frame and certainly at the highest success rate. We have an unmatched success record in EU product approvals where we regularly work on over one third of approved products. You can even utilize us as the most experienced “second opinion” when developing products for the European markets and the means to likely raise significantly your shareholder’s value. This is because we have working for us exclusively many of the former leaders of the EMA who have developed today's guidelines and thus we have the best connections to the EMA, which vastly improves the dialog, the speed and success rate. We also work for 90% of the top pharmaceutical companies, where often many hundreds of dedicated regulatory affairs professionals are part of the drug development process and where they appreciate our up-to-date and unmatched expertise. I am sure you will be pleased with NDA’s services, since we are proud to have a 98% customer retention rate. The remaining 2% of companies were acquired.Company Classification
Associate/Service ProvidersOrganization Type
Consulting FirmsDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dental
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
NEOX USA, LLC
12100 Wilshire Blvd, Suite 1275
Lose Angeles, CA, United States, 90025
323-354-9169
http://www.neoxcro.comPrimary Contacts
Matt Delaney
Managing Director
512-922-2839
Pavel Marek, M.D.
CEO
+420-737-550-445
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
12100 Wilshire Blvd, Suite 1275
Lose Angeles, CA, United States, 90025
323-354-9169
http://www.neoxcro.comPrimary Contacts
Matt Delaney
Managing Director
512-922-2839
Pavel Marek, M.D.
CEO
+420-737-550-445
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Neuraltus Pharmaceuticals, Inc.
2483 E. Bayshore Road, Ste 212
Palo Alto, CA, 94303
650-424-1600
http://www.neuraltus.comPrimary Contacts
Andrew Gengos
President & CEO
Ari Azhir, PhD
Chief Operating Officer & Founder
Company Profile
Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig�s disease), Parkinson�s disease and dyskinesias associated with the treatment of Parkinson�s disease, Alzheimer�s disease, and multiple sclerosis, as well as lysosomal storage disorders such as Fabry�s disease and Gaucher�s disease. Each of Neuraltus� clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company�s target disease indications.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
Phase II
2483 E. Bayshore Road, Ste 212
Palo Alto, CA, 94303
650-424-1600
http://www.neuraltus.comPrimary Contacts
Andrew Gengos
President & CEO
Ari Azhir, PhD
Chief Operating Officer & Founder
Company Profile
Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig�s disease), Parkinson�s disease and dyskinesias associated with the treatment of Parkinson�s disease, Alzheimer�s disease, and multiple sclerosis, as well as lysosomal storage disorders such as Fabry�s disease and Gaucher�s disease. Each of Neuraltus� clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company�s target disease indications.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
Phase II
NeurogeseX, Inc
2215 Bridgepointe Parkway, Suite 200
San Mateo, CA, United States, 94404
650-358-3300
http://www.neurogesx.comPrimary Contacts
Anthony DiTonno
President and CEO
Stephen Ghiglieri
EVP, COO and CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousPrimary Technology
Drug DeliveryClinical Development Stage
Phase II
Approved
2215 Bridgepointe Parkway, Suite 200
San Mateo, CA, United States, 94404
650-358-3300
http://www.neurogesx.comPrimary Contacts
Anthony DiTonno
President and CEO
Stephen Ghiglieri
EVP, COO and CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousPrimary Technology
Drug DeliveryClinical Development Stage
Phase II
Approved
New Biology Ventures
2350 Taylor Street, Suite 3
San Francisco, CA, 94133
415 447 6003
http://www.newbiologyventures.com/homePrimary Contacts
Douglas A. Hamilton
Partner
415 447 6003
Company Profile
New Biology Ventures is an early stage life-science focused venture capital incubator/accelerator. We provide consulting services and capital to innovative start-up companies focused on the development and commercialization of biotechnology research tools, medical devices and therapeutics.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
2350 Taylor Street, Suite 3
San Francisco, CA, 94133
415 447 6003
http://www.newbiologyventures.com/homePrimary Contacts
Douglas A. Hamilton
Partner
415 447 6003
Company Profile
New Biology Ventures is an early stage life-science focused venture capital incubator/accelerator. We provide consulting services and capital to innovative start-up companies focused on the development and commercialization of biotechnology research tools, medical devices and therapeutics.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
NEW RENAISSANCE COMMERCIAL
1825 s. grant street #240
san mateo, California, United States, 94402
6502121111
www.newrenaissanceinstitute.comPrimary Contacts
Lisa Negele
CEO -- NRC
Company Profile
NRC is the business development arm of New Renaissance Institute, a privately-held interdisciplinary R&D firm that focuses on developing innovative technologies. Areas of interest include chemistry, biochemistry, RLoC, nanoelectronics, advanced touch interface & gestures, data sonification & green technologies. Strong emphasis is placed on establishing solid IP protection and NRI has over 130 issued and pending patents, with several dozen more in active preparation. Business strategies employed by NRC include licensing deals, JVs, collaborations, spin-outs, patent asset sales and more. The elected strategy is driven by the nature of the technological innovation, the competitive landscape, the overall market opportunity, timing and other such considerations. NRI has been the recipient of a number of National Science Foundation SBIR grants and actively pursues funding opportunities from a number of federal agencies.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
1825 s. grant street #240
san mateo, California, United States, 94402
6502121111
www.newrenaissanceinstitute.comPrimary Contacts
Lisa Negele
CEO -- NRC
Company Profile
NRC is the business development arm of New Renaissance Institute, a privately-held interdisciplinary R&D firm that focuses on developing innovative technologies. Areas of interest include chemistry, biochemistry, RLoC, nanoelectronics, advanced touch interface & gestures, data sonification & green technologies. Strong emphasis is placed on establishing solid IP protection and NRI has over 130 issued and pending patents, with several dozen more in active preparation. Business strategies employed by NRC include licensing deals, JVs, collaborations, spin-outs, patent asset sales and more. The elected strategy is driven by the nature of the technological innovation, the competitive landscape, the overall market opportunity, timing and other such considerations. NRI has been the recipient of a number of National Science Foundation SBIR grants and actively pursues funding opportunities from a number of federal agencies.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology DisordersPrimary Technology
Bioinformatics
Drug Delivery
Drug DiscoveryClinical Development Stage
PreClinical
Northern California Institute for Research & Education
United States, http://www.ncire.orgCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
United States, http://www.ncire.orgCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Research Institute
NovaBay Pharmaceuticals, Inc.
5980 Horton Street, Suite 550
Emeryville, CA, 94608
510-899-8800
http://www.novabaypharma.comPrimary Contacts
Ramin (
Chairman and Chief Executive Officer
Thomas J. Paulson
Chief Financial Officer
Behzad (
Senior Vice President and Chief Alliance Officer
Company Profile
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Dermatology
Infectious Disease
Kidneys & Genito-Urinary System
OphthalmologyClinical Development Stage
PreClinical
Phase I
Phase II
5980 Horton Street, Suite 550
Emeryville, CA, 94608
510-899-8800
http://www.novabaypharma.comPrimary Contacts
Ramin (
Chairman and Chief Executive Officer
Thomas J. Paulson
Chief Financial Officer
Behzad (
Senior Vice President and Chief Alliance Officer
Company Profile
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Dermatology
Infectious Disease
Kidneys & Genito-Urinary System
OphthalmologyClinical Development Stage
PreClinical
Phase I
Phase II
Novella Clinical
4309 Emperor Blvd, Suite 400
Durham, NC, 27703
(866) 303-4966
http://www.novellaclinical.comPrimary Contacts
Paul Steinberg
Director, Business Development & Client ServicesDirector, Business Development & Client Services
310-455-1781
Richard Staub
CEO
(866) 303-4966 x2107
Jessica Cunningham
Director of Marketing
(919) 972-2175
Nick Dyer
EVP Business Development
(866) 303-4966
Robert King
COO
(866) 303-4966
Company Profile
Novella Clinical, Inc. is a full service contract research organization headquartered in Research Triangle Park, N.C. For more than a decade, Novella has served as an active partner to the oncology, biopharma and medical device industries. As the first global eCRO, Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
4309 Emperor Blvd, Suite 400
Durham, NC, 27703
(866) 303-4966
http://www.novellaclinical.comPrimary Contacts
Paul Steinberg
Director, Business Development & Client ServicesDirector, Business Development & Client Services
310-455-1781
Richard Staub
CEO
(866) 303-4966 x2107
Jessica Cunningham
Director of Marketing
(919) 972-2175
Nick Dyer
EVP Business Development
(866) 303-4966
Robert King
COO
(866) 303-4966
Company Profile
Novella Clinical, Inc. is a full service contract research organization headquartered in Research Triangle Park, N.C. For more than a decade, Novella has served as an active partner to the oncology, biopharma and medical device industries. As the first global eCRO, Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Novici Biotech LLC
3333 Vaca Valley Parkway, Suite 400
Vacaville, CA, 95688
707-446-5502
http://www.novicibiotech.comPrimary Contacts
Hal S. Padgett
General Manager and Chief Scientific Officer
Robert L. Erwin
Chairman
Company Profile
Novici Biotech LLC is a private biotechnology company offering proprietary synthetic biology tools and directed evolution capabilities to advance the product-focused goals of our clients in the pharmaceutical, agricultural, and industrial fields. Novici’s patented GRAMMR® technology for high-resolution genetic reassortment is at the heart of our ability to enhance gene functionality at both the nucleotide and protein level. Novici is focused on bringing to market these unique synthetic biology technologies, including the means to empirically optimize the codon usage structure of any gene to endow it with optimal expression yield, protein folding integrity, and cell type compatibility, and to optimize protein structure and function for commercial use.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolPrimary Technology
Biocatalysis
Protein Engineering
3333 Vaca Valley Parkway, Suite 400
Vacaville, CA, 95688
707-446-5502
http://www.novicibiotech.comPrimary Contacts
Hal S. Padgett
General Manager and Chief Scientific Officer
Robert L. Erwin
Chairman
Company Profile
Novici Biotech LLC is a private biotechnology company offering proprietary synthetic biology tools and directed evolution capabilities to advance the product-focused goals of our clients in the pharmaceutical, agricultural, and industrial fields. Novici’s patented GRAMMR® technology for high-resolution genetic reassortment is at the heart of our ability to enhance gene functionality at both the nucleotide and protein level. Novici is focused on bringing to market these unique synthetic biology technologies, including the means to empirically optimize the codon usage structure of any gene to endow it with optimal expression yield, protein folding integrity, and cell type compatibility, and to optimize protein structure and function for commercial use.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolPrimary Technology
Biocatalysis
Protein Engineering
Novo Nordisk Inc
100 College Road West
Princeton, NJ, United States, 8540
(609) 987-5800
http://www.novonordisk-us.comPrimary Contacts
Jerzy Gruhn
President, Novo Nordisk Inc.
Company Profile
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 31,400 employees in 74 countries and markets its products in 179 countries.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Digestive System
Metabolic/Endocrinology Disorders
Womens HealthPrimary Technology
Drug Delivery
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
100 College Road West
Princeton, NJ, United States, 8540
(609) 987-5800
http://www.novonordisk-us.comPrimary Contacts
Jerzy Gruhn
President, Novo Nordisk Inc.
Company Profile
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 31,400 employees in 74 countries and markets its products in 179 countries.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Digestive System
Metabolic/Endocrinology Disorders
Womens HealthPrimary Technology
Drug Delivery
Drug Discovery
Protein EngineeringClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Novo Ventures (U.S.)
1700 Owens St. Suite 540
San Francisco, CA, 94158-0002
4155524154
http://www.novo.dkPrimary Contacts
Nicole Zilveti
Office Administration Manager
4155524154
Jack Nielsen
Partner
4155524154
Company Profile
Novo Ventures Novo A/S is an active and independent company in its support of biotech ventures. The aspiration is to bring together the best of both worlds: industry insight and network from our pharma/biotech inheritance combined with a venture capital mindset that focuses on results and value creation. Novo A/S' portfolio of investments in life science has grown considerably since the company's start. Novo has invested in more than 60 portfolio companies. There is considerable diversity in the portfolio across technologies, products and financial stages. Furthermore, the portfolio is international, currently with more than half the invested capital in North American companies and the rest in Denmark and Europe.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
1700 Owens St. Suite 540
San Francisco, CA, 94158-0002
4155524154
http://www.novo.dkPrimary Contacts
Nicole Zilveti
Office Administration Manager
4155524154
Jack Nielsen
Partner
4155524154
Company Profile
Novo Ventures Novo A/S is an active and independent company in its support of biotech ventures. The aspiration is to bring together the best of both worlds: industry insight and network from our pharma/biotech inheritance combined with a venture capital mindset that focuses on results and value creation. Novo A/S' portfolio of investments in life science has grown considerably since the company's start. Novo has invested in more than 60 portfolio companies. There is considerable diversity in the portfolio across technologies, products and financial stages. Furthermore, the portfolio is international, currently with more than half the invested capital in North American companies and the rest in Denmark and Europe.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Novozymes
1445 Drew Avenue
Davis, CA, 95618
530.757.8100
http://www.novozymes.comPrimary Contacts
Claus Crone Fuglsang
Managing Director, Novozymes Inc.
Alan Berry
Director, Microbial Physiology and HTS
Randy Berka
Director
Company Profile
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Novozymes’ natural solutions enhance and promote everything, from removing trans fats in food to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces. Our 5,000+ employees working in research, production, and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen A/S. Read more at www.novozymes.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
1445 Drew Avenue
Davis, CA, 95618
530.757.8100
http://www.novozymes.comPrimary Contacts
Claus Crone Fuglsang
Managing Director, Novozymes Inc.
Alan Berry
Director, Microbial Physiology and HTS
Randy Berka
Director
Company Profile
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Novozymes’ natural solutions enhance and promote everything, from removing trans fats in food to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature’s potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces. Our 5,000+ employees working in research, production, and sales around the world are committed to shaping business today and our world tomorrow. Novozymes is quoted on NASDAQ OMX Copenhagen A/S. Read more at www.novozymes.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
NuMedii, Inc.
United States, http://numedii.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
United States, http://numedii.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
Numerate, Inc.
1150 Bayhill Dr, Suite 203
San Bruno, CA, 94066
650-472-0632
http://www.numerate.comPrimary Contacts
Guido Lanza
CEO
Nigel Duffy
CTO
John H. Griffin
CSO
Company Profile
Numerate’s in silico drug design technology makes the drug design process more efficient and less unpredictable. Our novel approach to chemical design reduces the timelines, costs, and attrition rates of traditional drug discovery. Our technology combines advances in computer science and statistics with medicinal chemistry, enabling us to predict potential causes of drug success and failure at design-time, and to identify the best compounds based on these predictionsCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious DiseaseClinical Development Stage
PreClinical
1150 Bayhill Dr, Suite 203
San Bruno, CA, 94066
650-472-0632
http://www.numerate.comPrimary Contacts
Guido Lanza
CEO
Nigel Duffy
CTO
John H. Griffin
CSO
Company Profile
Numerate’s in silico drug design technology makes the drug design process more efficient and less unpredictable. Our novel approach to chemical design reduces the timelines, costs, and attrition rates of traditional drug discovery. Our technology combines advances in computer science and statistics with medicinal chemistry, enabling us to predict potential causes of drug success and failure at design-time, and to identify the best compounds based on these predictionsCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Infectious DiseaseClinical Development Stage
PreClinical
Nurix, Inc.
1700 Owens St. Suite 240
San Francisco, CA, United States, 94158
650-918-8818
Primary Contacts
Luis Bayol
Interim CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
1700 Owens St. Suite 240
San Francisco, CA, United States, 94158
650-918-8818
Primary Contacts
Luis Bayol
Interim CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
NUTEK Corporation
http://www.nutekcorp.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
http://www.nutekcorp.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Nvigen, Inc
265 Sobrante Way, Suite H
Sunnyvale, CA, United States, 94086
408-830-9988
http://www.nvigen.comPrimary Contacts
Aihua Fu
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Industrial BiotechnologyDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central NervousPrimary Technology
Drug Delivery
Imaging
NanotechnologyClinical Development Stage
PreClinical
265 Sobrante Way, Suite H
Sunnyvale, CA, United States, 94086
408-830-9988
http://www.nvigen.comPrimary Contacts
Aihua Fu
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Industrial BiotechnologyDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central NervousPrimary Technology
Drug Delivery
Imaging
NanotechnologyClinical Development Stage
PreClinical
Ocular Dynamics, LLC
6231 Mojave Dr.
San Jose, CA, United States, 95120
559-709-7137
Primary Contacts
Victor McCray
CEO
Karen Havenstrite
Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Corporate Communication
Media
Medical DevicesDisease Areas of Focus
OphthalmologyClinical Development Stage
PreClinical
6231 Mojave Dr.
San Jose, CA, United States, 95120
559-709-7137
Primary Contacts
Victor McCray
CEO
Karen Havenstrite
Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Corporate Communication
Media
Medical DevicesDisease Areas of Focus
OphthalmologyClinical Development Stage
PreClinical
Oculus Innovative Sciences
1129 N. McDowell Blvd.
Petaluma, CA, United States, 94954
707-283-0550
http://www.oculusis.comPrimary Contacts
Hoji Alimi
Chairman and CEO
Robert Miller
CFO
Jim Schutz
COO, VP Corporate Development, General Counsel
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Dermatology
Infectious Disease
Metabolic/Endocrinology Disorders
Respiratory DisordersPrimary Technology
Biomanufacturing
Computational Chemistry
Drug Delivery
PharmacogenomicsClinical Development Stage
PreClinical
Phase II
Approved
1129 N. McDowell Blvd.
Petaluma, CA, United States, 94954
707-283-0550
http://www.oculusis.comPrimary Contacts
Hoji Alimi
Chairman and CEO
Robert Miller
CFO
Jim Schutz
COO, VP Corporate Development, General Counsel
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Dermatology
Infectious Disease
Metabolic/Endocrinology Disorders
Respiratory DisordersPrimary Technology
Biomanufacturing
Computational Chemistry
Drug Delivery
PharmacogenomicsClinical Development Stage
PreClinical
Phase II
Approved
Ohlone College
United States, http://www.ohlone.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.ohlone.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Olema Pharmaceuticals, Inc.
United States, http://www.olemapharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.olemapharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Oligasis, LLC
http://www.oligasis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
http://www.oligasis.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Omniox Inc.
1700 4th street, QB3 218C-219 UCSF MC2522
San Francisco, CA, United States, 94158
415-255-5590
http://www.omnioxinc.comPrimary Contacts
Stephen Cary
CEO
Company Profile
Omniox is a biotechnology company commercializing a revolutionary and proprietary oxygen delivery technology for a broad range of clinical indications in cancer, surgical and cardiovascular markets.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic Diseases
CancerClinical Development Stage
PreClinical
1700 4th street, QB3 218C-219 UCSF MC2522
San Francisco, CA, United States, 94158
415-255-5590
http://www.omnioxinc.comPrimary Contacts
Stephen Cary
CEO
Company Profile
Omniox is a biotechnology company commercializing a revolutionary and proprietary oxygen delivery technology for a broad range of clinical indications in cancer, surgical and cardiovascular markets.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Blood & Lymphatic Diseases
CancerClinical Development Stage
PreClinical
OncoHealth Corporation
2381 Zanker Rd. Ste 150
San Jose, CA, United States, 95313
650-241-8099
http://www.oncohealthcorp.com/Primary Contacts
Winnie Han
Executive Chairman & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
2381 Zanker Rd. Ste 150
San Jose, CA, United States, 95313
650-241-8099
http://www.oncohealthcorp.com/Primary Contacts
Winnie Han
Executive Chairman & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cancer
OncoMed Pharmaceuticals, Inc.
800 Chesapeake Drive
Redwood City, CA, 94063
650-995-8200
http://www.oncomed.comPrimary Contacts
Paul J. Hastings
President & CEO
John A. Lewicki, Ph.D.
Executive Vice President and Chief Scientific Officer
William D. Waddill
Senior Vice President and Chief Financial Officer
Company Profile
OncoMed Pharmaceuticals was founded in August 2004, by Drs. Michael F. Clarke and Max Wicha who led the discovery of cancer stem cells, in solid tumors. The cancer stem cell hypothesis suggests that tumors are composed of heterogeneous cell types and that cancer growth and metastasis are driven by a sub-population of cells within the tumor. The tumorigenic cells have been termed cancer stem cells because they exhibit certain properties similar to normal stem cells in adults that replenish tissues, such as the skin and the lining of the intestinal tract. These properties include: self-renewal, the capacity to differentiate into bulk tumor cells and the ability to proliferate extensively. Self-renewal is a unique property of stem cells and is defined as the ability to proliferate while maintaining an undifferentiated, multipotent state. Importantly, cancer stem cells differ from normal stem cells because they have accumulated oncogenic mutations that result in the loss of normal limitations on growth. These differences can be exploited to develop therapies that selectively target tumor initiating cells and not normal stem cells. Our founders invented techniques to identify the subset of cells within a tumor that have stem cell like properties. Injection of very small numbers of these cells into mice has led to the development of tumors that have the surface markers and microscopic appearance of the original human cancer. Subsequent experiments have shown that the tumor initiating cells are more resistant to standard chemotherapy agents and radiotherapy. This raises the possibility that some current treatments may succeed at initially decreasing the size of a cancer, but leave behind an increased proportion of the most malignant cells. The ability to isolate and monitor tumor initiating cells using specific surface markers and flow cytometry has allowed OncoMed to carefully evaluate the importance of specific targets associated with key biologic pathways implicated in both stem cell biology and cancer. Antibodies against these targets have been developed and tested within xenograft models derived from freshly resected human cancers. We believe these models are more representative of the effects of these treatments in cancer patients than traditional models using cancer cell lines which may no longer accurately reflect the properties of the original tumor. Using these approaches, OncoMed has a portfolio of active antibodies that target biologic pathways critical for survival of tumor initiating cells. OncoMed�s first antibody targeting the pathways critical to cancer stem cells has now entered clinical trials. Details of the initial Phase I study, which is now recruiting patients, may be found at ClinicalTrials.gov. Multiple additional promising therapeutic candidates that target other critical pathways are also being developed OncoMed Pharmaceuticals has attracted significant funding from a prominent group of investors, that include, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures and Bay Partners.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Discovery
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
800 Chesapeake Drive
Redwood City, CA, 94063
650-995-8200
http://www.oncomed.comPrimary Contacts
Paul J. Hastings
President & CEO
John A. Lewicki, Ph.D.
Executive Vice President and Chief Scientific Officer
William D. Waddill
Senior Vice President and Chief Financial Officer
Company Profile
OncoMed Pharmaceuticals was founded in August 2004, by Drs. Michael F. Clarke and Max Wicha who led the discovery of cancer stem cells, in solid tumors. The cancer stem cell hypothesis suggests that tumors are composed of heterogeneous cell types and that cancer growth and metastasis are driven by a sub-population of cells within the tumor. The tumorigenic cells have been termed cancer stem cells because they exhibit certain properties similar to normal stem cells in adults that replenish tissues, such as the skin and the lining of the intestinal tract. These properties include: self-renewal, the capacity to differentiate into bulk tumor cells and the ability to proliferate extensively. Self-renewal is a unique property of stem cells and is defined as the ability to proliferate while maintaining an undifferentiated, multipotent state. Importantly, cancer stem cells differ from normal stem cells because they have accumulated oncogenic mutations that result in the loss of normal limitations on growth. These differences can be exploited to develop therapies that selectively target tumor initiating cells and not normal stem cells. Our founders invented techniques to identify the subset of cells within a tumor that have stem cell like properties. Injection of very small numbers of these cells into mice has led to the development of tumors that have the surface markers and microscopic appearance of the original human cancer. Subsequent experiments have shown that the tumor initiating cells are more resistant to standard chemotherapy agents and radiotherapy. This raises the possibility that some current treatments may succeed at initially decreasing the size of a cancer, but leave behind an increased proportion of the most malignant cells. The ability to isolate and monitor tumor initiating cells using specific surface markers and flow cytometry has allowed OncoMed to carefully evaluate the importance of specific targets associated with key biologic pathways implicated in both stem cell biology and cancer. Antibodies against these targets have been developed and tested within xenograft models derived from freshly resected human cancers. We believe these models are more representative of the effects of these treatments in cancer patients than traditional models using cancer cell lines which may no longer accurately reflect the properties of the original tumor. Using these approaches, OncoMed has a portfolio of active antibodies that target biologic pathways critical for survival of tumor initiating cells. OncoMed�s first antibody targeting the pathways critical to cancer stem cells has now entered clinical trials. Details of the initial Phase I study, which is now recruiting patients, may be found at ClinicalTrials.gov. Multiple additional promising therapeutic candidates that target other critical pathways are also being developed OncoMed Pharmaceuticals has attracted significant funding from a prominent group of investors, that include, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures and Bay Partners.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Discovery
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
OncoSynergy, Inc.
2429 Vallejo St. Apt. 9
San Francisco, CA, United States, 94123
617-755-9156
http://wwwoncosynergy.comPrimary Contacts
Shawn Carbonell
CEO
Bob Dunkle
COO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Cell BiologyClinical Development Stage
PreClinical
2429 Vallejo St. Apt. 9
San Francisco, CA, United States, 94123
617-755-9156
http://wwwoncosynergy.comPrimary Contacts
Shawn Carbonell
CEO
Bob Dunkle
COO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Cell BiologyClinical Development Stage
PreClinical
OptiMedica Corporation
3100 Coronado Drive
Santa Clara, CA, 95054
408-850-8600
http://www.optimedica.comPrimary Contacts
Mark J. Forchette
President & CEO
Mark A. Murray
CFO & Vice President of Finance
Robert Eno
Vice President of Global Marketing & International Sales
Company Profile
OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care. Since its founding, OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalys™ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Ophthalmology
3100 Coronado Drive
Santa Clara, CA, 95054
408-850-8600
http://www.optimedica.comPrimary Contacts
Mark J. Forchette
President & CEO
Mark A. Murray
CFO & Vice President of Finance
Robert Eno
Vice President of Global Marketing & International Sales
Company Profile
OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care. Since its founding, OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalys™ Precision Laser System, with very promising results reported across these measures. While the Catalys Precision Laser System is not currently for sale in the United States, OptiMedica expects to launch the system in U.S. and international markets in 2011.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Ophthalmology
Oracle Health Sciences
77 4th Ave
Waltham, MA, United States, 02451
(781)902-4683
http://www.oracle.com/Primary Contacts
Amy Dall
Senior Marketing Manager
781-902-4683
Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
77 4th Ave
Waltham, MA, United States, 02451
(781)902-4683
http://www.oracle.com/Primary Contacts
Amy Dall
Senior Marketing Manager
781-902-4683
Company Classification
Associate/Service ProvidersOrganization Type
Information Technology
OUM & Co. (Odenberg, Ullakko, Muranishi & Co. LLP)
465 California Street, Suite 700
San Francisco, CA, United States, 94104
(415) 434-3744
http://www.oumcpa.comPrimary Contacts
Paul R. Ainslie
Assurance Partner
(415) 350-8521
Brad Weisert
Tax Partner
(415) 796-6640
Gani Laguisma
Assurance Partner
(415) 796-6550
Clara Fong
Assurance Partner
(415) 796-6560
Doug Pallotta
Assurance Partner
(415) 796-6570
Scott Miller
Assurance Partner
(415) 796-6540
Company Profile
OUM is one of the leading accounting firms in California, with offices in San Francisco and the San Diego area. We have more than 70 professionals, including several experienced partners, managers, and staff from Big 4 firms. We have a life sciences group that is dedicating to serving public and private companies in sectors such as biotechnology, specialty pharma, and medical devices. Our firm is an independent member of the BDO Seidman Alliance. Through this affiliation, we’re able to offer our clients the resources of a large international firm, while still providing personalized partner attention. We are also registered with the Public Company Accounting Oversight Board (PCAOB), and a member of the American Institute of Certified Public Accountants’ (AICPA) Center for Audit Quality, the Private Companies Practice Section, and the Tax Section. Our public and non-public assurance practices are reviewed every three years, by the PCAOB and by AICPA peer reviewers, respectively.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
465 California Street, Suite 700
San Francisco, CA, United States, 94104
(415) 434-3744
http://www.oumcpa.comPrimary Contacts
Paul R. Ainslie
Assurance Partner
(415) 350-8521
Brad Weisert
Tax Partner
(415) 796-6640
Gani Laguisma
Assurance Partner
(415) 796-6550
Clara Fong
Assurance Partner
(415) 796-6560
Doug Pallotta
Assurance Partner
(415) 796-6570
Scott Miller
Assurance Partner
(415) 796-6540
Company Profile
OUM is one of the leading accounting firms in California, with offices in San Francisco and the San Diego area. We have more than 70 professionals, including several experienced partners, managers, and staff from Big 4 firms. We have a life sciences group that is dedicating to serving public and private companies in sectors such as biotechnology, specialty pharma, and medical devices. Our firm is an independent member of the BDO Seidman Alliance. Through this affiliation, we’re able to offer our clients the resources of a large international firm, while still providing personalized partner attention. We are also registered with the Public Company Accounting Oversight Board (PCAOB), and a member of the American Institute of Certified Public Accountants’ (AICPA) Center for Audit Quality, the Private Companies Practice Section, and the Tax Section. Our public and non-public assurance practices are reviewed every three years, by the PCAOB and by AICPA peer reviewers, respectively.Company Classification
Associate/Service ProvidersOrganization Type
Accounting Firms
Oxford Finance Corporation
133 North Fairfax Street
Alexandria, VA, United States, 22314
(703)519-4900
http://www.oxfordfinance.comPrimary Contacts
Shelly Davis
Director of Marketing
(703)519-6013
Chris Herr
Managing Director
(858)204-7990 (cell); (858)750-2560 (land)
Company Profile
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Illinois, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
133 North Fairfax Street
Alexandria, VA, United States, 22314
(703)519-4900
http://www.oxfordfinance.comPrimary Contacts
Shelly Davis
Director of Marketing
(703)519-6013
Chris Herr
Managing Director
(858)204-7990 (cell); (858)750-2560 (land)
Company Profile
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Illinois, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.Company Classification
Associate/Service ProvidersOrganization Type
Financial Services
Pacific Pharmaceuticals Services
4850 Joule St. Suite A-8
Reno, NV, United States, 89502
775-453-6408
http://www.pacificpharmaservices.comPrimary Contacts
Scott Chadwick
President
650-787-7695
Company Classification
Associate/Service Providers
4850 Joule St. Suite A-8
Reno, NV, United States, 89502
775-453-6408
http://www.pacificpharmaservices.comPrimary Contacts
Scott Chadwick
President
650-787-7695
Company Classification
Associate/Service Providers
Pan-Pacific Biopharma, Inc.
One Market Plaza, Spear Tower Suite 3579
San Francisco, CA, 94105
415-293-8478
Primary Contacts
Senping Cheng
Vice President
Jingren Xu
President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
Medical DevicesDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemPrimary Technology
Combinatorial Chemistry
Drug Delivery
Drug Discovery
ImagingClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
One Market Plaza, Spear Tower Suite 3579
San Francisco, CA, 94105
415-293-8478
Primary Contacts
Senping Cheng
Vice President
Jingren Xu
President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
Medical DevicesDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemPrimary Technology
Combinatorial Chemistry
Drug Delivery
Drug Discovery
ImagingClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Panomics / Affymetrix
3420 Central Expy
Santa Clara, CA, United States, 95051
408-731-5767
http://www.panomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
3420 Central Expy
Santa Clara, CA, United States, 95051
408-731-5767
http://www.panomics.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Parallel Synthesis Technologies, Inc.
3054 Lawrence Expwy
Santa Clara, CA, 95051
408-749-8318
http://www.parallel-synthesis.comPrimary Contacts
Robert Haushalter
President, Founder
Srini Vetcha
Director - Engineering
Brian Baxter
Director - Physical Sciences
Company Profile
A biotech company with core competencies in many areas such as silicon micromachining, optical encoding, optics, molecular biology, and chemistry. We are currently working on a platform for multiplexing molecular diagnostics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseasePrimary Technology
Genomics
Imaging
Micro Arrays
3054 Lawrence Expwy
Santa Clara, CA, 95051
408-749-8318
http://www.parallel-synthesis.comPrimary Contacts
Robert Haushalter
President, Founder
Srini Vetcha
Director - Engineering
Brian Baxter
Director - Physical Sciences
Company Profile
A biotech company with core competencies in many areas such as silicon micromachining, optical encoding, optics, molecular biology, and chemistry. We are currently working on a platform for multiplexing molecular diagnostics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseasePrimary Technology
Genomics
Imaging
Micro Arrays
Pathway Therapeutics, Inc.
http://www.pathwaytx.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.pathwaytx.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Pathwork Diagnostics, Inc.
595 Penobscot Dr
Redwood City, CA, 94063
650-366-1003
http://www.pathworkdx.comPrimary Contacts
Deborah J. Neff
President & CEO
Fletcher Payne
CFO
Dave Craford
Chief Commercial Officer
Company Profile
The Pathwork® Tissue of Origin Test is an innovation in molecular diagnostics. Cleared by the FDA in 2010, this gene expression–based test uses a tumor's own genomic information to aid in identifying challenging tumors, including metastatic, poorly differentiated and undifferentiated tumors, The test provides objective clinical information previously unavailable to physicians for tissue of origin identification. The Tissue of Origin Test is part of a growing family of products that includes lab service tests for formalin-fixed, paraffin-embedded (FFPE) specimens.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
Micro ArraysClinical Development Stage
Approved
595 Penobscot Dr
Redwood City, CA, 94063
650-366-1003
http://www.pathworkdx.comPrimary Contacts
Deborah J. Neff
President & CEO
Fletcher Payne
CFO
Dave Craford
Chief Commercial Officer
Company Profile
The Pathwork® Tissue of Origin Test is an innovation in molecular diagnostics. Cleared by the FDA in 2010, this gene expression–based test uses a tumor's own genomic information to aid in identifying challenging tumors, including metastatic, poorly differentiated and undifferentiated tumors, The test provides objective clinical information previously unavailable to physicians for tissue of origin identification. The Tissue of Origin Test is part of a growing family of products that includes lab service tests for formalin-fixed, paraffin-embedded (FFPE) specimens.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
Micro ArraysClinical Development Stage
Approved
PCUT BioPartners, Inc.
PO Box 4845
San Jose, CA, United States, 95150
415-637-4774
http://www.pcut.orgPrimary Contacts
Jess Rabourn
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Central Nervous
Genetic DiseasesPrimary Technology
Drug Discovery
Gene/Cell Therapy
Protein EngineeringClinical Development Stage
Phase III
PO Box 4845
San Jose, CA, United States, 95150
415-637-4774
http://www.pcut.orgPrimary Contacts
Jess Rabourn
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Central Nervous
Genetic DiseasesPrimary Technology
Drug Discovery
Gene/Cell Therapy
Protein EngineeringClinical Development Stage
Phase III
Pearl Therapeutics
200 Saginaw Drive
Redwood City,, CA, 94063
650 305 2600
http://www.PearlTherapeutics.comPrimary Contacts
Charles J Bramlage
Pres & CEO
Colin Reisner
EVP Clinical
Sarvajna Dwivedi
EVP R&D
Company Profile
Developing therapies for COPD and AsthmaCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase II
200 Saginaw Drive
Redwood City,, CA, 94063
650 305 2600
http://www.PearlTherapeutics.comPrimary Contacts
Charles J Bramlage
Pres & CEO
Colin Reisner
EVP Clinical
Sarvajna Dwivedi
EVP R&D
Company Profile
Developing therapies for COPD and AsthmaCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Respiratory DisordersPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase II
Percipio Biosciences, Inc.
1499 Rollins Road
Burlingame, CA, 94010
800-547-3686
http://www.percipiobio.comPrimary Contacts
Robert Brooke
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersPrimary Technology
Biocatalysis
Biomanufacturing
Imaging
1499 Rollins Road
Burlingame, CA, 94010
800-547-3686
http://www.percipiobio.comPrimary Contacts
Robert Brooke
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersPrimary Technology
Biocatalysis
Biomanufacturing
Imaging
Personalis, Inc.
530 Lytton Ave., 2nd Floor
Palo Alto, CA, United States, 94301
650-617-3402
http://www.personalis.comPrimary Contacts
John West
CEO
Carol Tillis
VP, Finance and Administration
Elaine Sousa
HR/Office Manager
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
530 Lytton Ave., 2nd Floor
Palo Alto, CA, United States, 94301
650-617-3402
http://www.personalis.comPrimary Contacts
John West
CEO
Carol Tillis
VP, Finance and Administration
Elaine Sousa
HR/Office Manager
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
PharmacoFore, Inc.
http://www.pharmacofore.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
http://www.pharmacofore.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Pharmatek Laboratories, Inc
7330 Carroll Road, Suite 200
San Diego, CA, United States, 92121
(858) 805-6383
http://www.pharmatek.comPrimary Contacts
Ryan Lane
Marketing Associate
(858) 805-6383
Tim Scott
President
(858) 805-6383
Jeff Bibbs, Ph.D.
CEO/CSO
(858) 805-6383
Sandy Valone
Director of Business Development
(858) 805-6383
Company Profile
Pharmatek is a contract development and manufacturing organization (CDMO) that has supported drug development efforts since 1999. We offer drug development services from compound selection through Phase II manufacturing. We’ve built our reputation on our strength in analytical development and formulation work, and over the years have expanded our operations to include 6 suites for GMP manufacturing, including an 18,000 ft2 facility dedicated to highly-potent and cytotoxic drug development needs. Many contract research organizations say they are client focused, few deliver. We believe that to truly serve our clients well, we must listen to our clients, empathize with their unique situations and adapt our various systems to better meet their needs. Pharmatek's unique client-centric approach to drug development brings quality people, quality science and quality systems to every project. Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development organization supporting the pharmaceutical and biotechnology industries with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and highly-potent & cytotoxic development and manufacturing. To learn more about Pharmatek and the services we provide, visit www.Pharmatek.com or call (858) 805-6383.Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
Contract Research OrganizationClinical Development Stage
PreClinical
Phase I
Phase II
7330 Carroll Road, Suite 200
San Diego, CA, United States, 92121
(858) 805-6383
http://www.pharmatek.comPrimary Contacts
Ryan Lane
Marketing Associate
(858) 805-6383
Tim Scott
President
(858) 805-6383
Jeff Bibbs, Ph.D.
CEO/CSO
(858) 805-6383
Sandy Valone
Director of Business Development
(858) 805-6383
Company Profile
Pharmatek is a contract development and manufacturing organization (CDMO) that has supported drug development efforts since 1999. We offer drug development services from compound selection through Phase II manufacturing. We’ve built our reputation on our strength in analytical development and formulation work, and over the years have expanded our operations to include 6 suites for GMP manufacturing, including an 18,000 ft2 facility dedicated to highly-potent and cytotoxic drug development needs. Many contract research organizations say they are client focused, few deliver. We believe that to truly serve our clients well, we must listen to our clients, empathize with their unique situations and adapt our various systems to better meet their needs. Pharmatek's unique client-centric approach to drug development brings quality people, quality science and quality systems to every project. Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development organization supporting the pharmaceutical and biotechnology industries with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and highly-potent & cytotoxic development and manufacturing. To learn more about Pharmatek and the services we provide, visit www.Pharmatek.com or call (858) 805-6383.Company Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
Contract Research OrganizationClinical Development Stage
PreClinical
Phase I
Phase II
PhotoSwitch Biosciences, Inc.
1600 Adams Dr. Suite 105
Menlo Park, CA, United States, 94025
650-773-2942
http://www.photoswitchbio.comPrimary Contacts
Andrew Blatz
Chief Scientific Officer
Jonathan Ross
Chief Financial Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
1600 Adams Dr. Suite 105
Menlo Park, CA, United States, 94025
650-773-2942
http://www.photoswitchbio.comPrimary Contacts
Andrew Blatz
Chief Scientific Officer
Jonathan Ross
Chief Financial Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioTool
Piramal Healthcare
United States, http://www.piramalpharmasolutions.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
United States, http://www.piramalpharmasolutions.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
Pivot Bio, Inc.
2082 Fell St.
San Francisco, CA, United States, 94117
415-987-4408
http://www.pivotbio.comPrimary Contacts
Karsten Temme
CEO
Alvin Tamsi
CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Agriculture
Industrial Biotechnology
2082 Fell St.
San Francisco, CA, United States, 94117
415-987-4408
http://www.pivotbio.comPrimary Contacts
Karsten Temme
CEO
Alvin Tamsi
CSO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Agriculture
Industrial Biotechnology
PlenSat, Inc.
1942 Embarcadero
Oakland, CA, United States, 94606
5105343255
http://www.plensat.comPrimary Contacts
Fred Voss
President/CEO
Bernhard Sterling
CTO
Company Profile
PlenSat is an early stage biomedical device startup pursuing its patented technology for the treatment of obesity. PlenSat Digestible Balloons are a unique approach to potentially achieving the benefits of Bariatric therapy to treat obesity without invasive techniques such as surgery, laparoscopy or endoscopy. Digestible Balloons promise the simplicity of pharmaceutical dosage with the weight loss profile of Bariatric therapy.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
1942 Embarcadero
Oakland, CA, United States, 94606
5105343255
http://www.plensat.comPrimary Contacts
Fred Voss
President/CEO
Bernhard Sterling
CTO
Company Profile
PlenSat is an early stage biomedical device startup pursuing its patented technology for the treatment of obesity. PlenSat Digestible Balloons are a unique approach to potentially achieving the benefits of Bariatric therapy to treat obesity without invasive techniques such as surgery, laparoscopy or endoscopy. Digestible Balloons promise the simplicity of pharmaceutical dosage with the weight loss profile of Bariatric therapy.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemClinical Development Stage
PreClinical
PolyRemedy, Inc.
2637 Marin Way Suite #100
Mountain View, CA, 94043
1-866-609-3515
http://www.polyremedy.comPrimary Contacts
Mark Carbeau
President and CEO
Diane Cooper, PhD
Medical Director and Chief of Clinical Affairs
Cameron McKennett
Chief Business Officer
Company Profile
PolyRemedy combines healthcare information technology with personalized therapeutics to solve the real-world problems that impact chronic wound healing outcomes. The Personalized Woundcare System (PWS) offers a new way to deliver wound care to patients in the in-home setting. For the first time, clinicians can connect to a single solution for streamlined assessment data capture and dressing selection; home delivery of personalized dressings; and clear, real-time feedback reports. Uniting these components into a single, IT-enabled services solution empowers clinicians to manage the healing process while reducing the costs of care.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Bioinformatics
NanotechnologyClinical Development Stage
Approved
2637 Marin Way Suite #100
Mountain View, CA, 94043
1-866-609-3515
http://www.polyremedy.comPrimary Contacts
Mark Carbeau
President and CEO
Diane Cooper, PhD
Medical Director and Chief of Clinical Affairs
Cameron McKennett
Chief Business Officer
Company Profile
PolyRemedy combines healthcare information technology with personalized therapeutics to solve the real-world problems that impact chronic wound healing outcomes. The Personalized Woundcare System (PWS) offers a new way to deliver wound care to patients in the in-home setting. For the first time, clinicians can connect to a single solution for streamlined assessment data capture and dressing selection; home delivery of personalized dressings; and clear, real-time feedback reports. Uniting these components into a single, IT-enabled services solution empowers clinicians to manage the healing process while reducing the costs of care.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Bioinformatics
NanotechnologyClinical Development Stage
Approved
Poniard Pharmaceuticals, Inc
750 Battery Street Suite 330
San Francisco, CA, 94111
650 583-3774
http://www.poniard.comPrimary Contacts
Ronald A. Martell
CEO
Dr. Michael Perry
President and CMO
Dr. Cheni Kwok
SVP Corporate Development
Company Profile
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Delivery
750 Battery Street Suite 330
San Francisco, CA, 94111
650 583-3774
http://www.poniard.comPrimary Contacts
Ronald A. Martell
CEO
Dr. Michael Perry
President and CMO
Dr. Cheni Kwok
SVP Corporate Development
Company Profile
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Delivery
Portola Pharmaceuticals, Inc.
http://www.portola.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&D
http://www.portola.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&D
Presidio Pharmaceuticals, Inc.
1700 Owens Street, Suite 585
San Francisco, CA, 94158
4156557560
http://www.presidiopharma.com/Primary Contacts
Omar K. Haffar
President & CEO
Leo Redmond
CFO
Company Profile
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio has raised over $54 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, New Leaf Venture Partners, Nexus Medical Partners, Emerge Capital, and Sagamore Bioventures LLC.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
1700 Owens Street, Suite 585
San Francisco, CA, 94158
4156557560
http://www.presidiopharma.com/Primary Contacts
Omar K. Haffar
President & CEO
Leo Redmond
CFO
Company Profile
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio has raised over $54 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, New Leaf Venture Partners, Nexus Medical Partners, Emerge Capital, and Sagamore Bioventures LLC.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
Principia BioPharma, Inc.
United States, Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
PRMA Consulting
Centaur House, Ancells Road
Fleet, United States, GU51 2UJ
+44 (0) 1252 786284
http://www.prmaconsulting.comPrimary Contacts
Mark Larkin
Partner
mlarkin@prmaconsulting.com
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Centaur House, Ancells Road
Fleet, United States, GU51 2UJ
+44 (0) 1252 786284
http://www.prmaconsulting.comPrimary Contacts
Mark Larkin
Partner
mlarkin@prmaconsulting.com
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
PrognosDx Health Inc
530 University Ave, Box 203
Palo Alto, CA, United States, 94301
650-566-5068
http://www.prognosDx.comPrimary Contacts
Kamran Tahamtanzadeh
CEO
Carl T. Yamashiro, Ph.D.
Acting CSO
Daniel W. Hunt
Acting SVP, Corporate Development
Babak N. Alizadeh, Ph.D.
COO & EVP Strategic Alliances
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Drug Development
TherapeuticDisease Areas of Focus
Cancer
530 University Ave, Box 203
Palo Alto, CA, United States, 94301
650-566-5068
http://www.prognosDx.comPrimary Contacts
Kamran Tahamtanzadeh
CEO
Carl T. Yamashiro, Ph.D.
Acting CSO
Daniel W. Hunt
Acting SVP, Corporate Development
Babak N. Alizadeh, Ph.D.
COO & EVP Strategic Alliances
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Drug Development
TherapeuticDisease Areas of Focus
Cancer
Project Management Advisors, Inc.
400 Oyster Point Blvd, Suite 336
South San Francisco, CA, United States, 94080
650-491-8800
http://www.pmainc.comPrimary Contacts
Bernard Baker
Vice President
650-491-8808
Robert Holyoake
Vice President
650-491-8810
Company Profile
Project Management Advisors is a professional consulting firm that provides Development Management, Project Management and Investor Representation services for public and private sector clients. PMA brings professional expertise and a personal commitment to achieve your project goals. Your needs, values and aspirations drive everything we do. With insight into your challenges and a passion for finding solutions, we go to great lengths to realize your vision. We get it. Your vision. Your values. Results.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
400 Oyster Point Blvd, Suite 336
South San Francisco, CA, United States, 94080
650-491-8800
http://www.pmainc.comPrimary Contacts
Bernard Baker
Vice President
650-491-8808
Robert Holyoake
Vice President
650-491-8810
Company Profile
Project Management Advisors is a professional consulting firm that provides Development Management, Project Management and Investor Representation services for public and private sector clients. PMA brings professional expertise and a personal commitment to achieve your project goals. Your needs, values and aspirations drive everything we do. With insight into your challenges and a passion for finding solutions, we go to great lengths to realize your vision. We get it. Your vision. Your values. Results.Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
Prolynx, LLC
26138 Research Road
Hayward, CA, United States, 94545
http://www.prolynxllc.comPrimary Contacts
Daniel V. Santi, M.D., Ph.D.
Founder & President
Gary Ashley, Ph.D.
Founder & CSO
Peg Horn, J.D.
COO
Company Profile
Technology company with unique linker technology for releasable macromolecular-drug conjugates whereby the active drug is released from the macromolecule at a pre-programmed rate.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Dermatology
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
26138 Research Road
Hayward, CA, United States, 94545
http://www.prolynxllc.comPrimary Contacts
Daniel V. Santi, M.D., Ph.D.
Founder & President
Gary Ashley, Ph.D.
Founder & CSO
Peg Horn, J.D.
COO
Company Profile
Technology company with unique linker technology for releasable macromolecular-drug conjugates whereby the active drug is released from the macromolecule at a pre-programmed rate.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioToolDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Dermatology
Metabolic/Endocrinology Disorders
OphthalmologyPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Protagonist Therapeutics
1455 Adams Dr.
Menlo Park, CA, United States, 94025
650-587-5070
http://www.protagonist-inc.comPrimary Contacts
Dinesh Patel
President & CEO
Ashok Bhandari
Director of Chemistry
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
Autoimmune & Inflammatory
CancerClinical Development Stage
PreClinical
1455 Adams Dr.
Menlo Park, CA, United States, 94025
650-587-5070
http://www.protagonist-inc.comPrimary Contacts
Dinesh Patel
President & CEO
Ashok Bhandari
Director of Chemistry
Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
Autoimmune & Inflammatory
CancerClinical Development Stage
PreClinical
ProteoSource LLC
800 West El Camino Road, Suite 180
Mountain View, CA, United States, 94040
650-384-0623
http://www.proteosource.comPrimary Contacts
Stephen Pollitt
President
650-384-0623
Company Profile
ProteoSource is a group of protein pharmaceutical professionals with over 60 years of combined experience producing proteins for the pharmaceutical industry. We help companies in the biopharmaceutical and medical device and diagnostics industries produce custom proteins, and allow virtual companies to access protein production expertise while holding down fixed costs associated with full time staff. We help clients outsource production to established contract manufacturing organizations while maintaining their freedom to choose their vendor. We do this by choosing the best candidate expression host(s), designing an expression system, working with partners to scale up fermentation and develop a purification process, and procure bids from competing vendors for cGMP manufacturing. We also help diagnostic and medical device manufacturers access custom made proteins without hiring process development staff or becoming dependant on a single contract manufacturer.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationPrimary Technology
BiomanufacturingClinical Development Stage
PreClinical
Phase I
800 West El Camino Road, Suite 180
Mountain View, CA, United States, 94040
650-384-0623
http://www.proteosource.comPrimary Contacts
Stephen Pollitt
President
650-384-0623
Company Profile
ProteoSource is a group of protein pharmaceutical professionals with over 60 years of combined experience producing proteins for the pharmaceutical industry. We help companies in the biopharmaceutical and medical device and diagnostics industries produce custom proteins, and allow virtual companies to access protein production expertise while holding down fixed costs associated with full time staff. We help clients outsource production to established contract manufacturing organizations while maintaining their freedom to choose their vendor. We do this by choosing the best candidate expression host(s), designing an expression system, working with partners to scale up fermentation and develop a purification process, and procure bids from competing vendors for cGMP manufacturing. We also help diagnostic and medical device manufacturers access custom made proteins without hiring process development staff or becoming dependant on a single contract manufacturer.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationPrimary Technology
BiomanufacturingClinical Development Stage
PreClinical
Phase I
Proteus Biomedical, Inc.
United States, http://www.proteusbiomed.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.proteusbiomed.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
PuraCath Medical
564 Market St. Ste 424
San Francisco, CA, United States, 94104
415-305-4134
http://www.puracath.comPrimary Contacts
Julia Rasoovy
CEO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
564 Market St. Ste 424
San Francisco, CA, United States, 94104
415-305-4134
http://www.puracath.comPrimary Contacts
Julia Rasoovy
CEO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
QuakeHOLD! Industrial, Inc.
1150 Simpson Way
Escondido, CA, United States, 92029
7604661060
http://www.quakeholdindustrial.comPrimary Contacts
Dean Reese
President
7604661060 x: 106
Tom Rundberg
Vice President Sales
6268528800
Dennis Johnson
National Sales Manager
8055511446
Company Profile
QuakeHOLD! Industrial is the leader in Non-Structural Seismic Mitigation. We have over 50 years of combined experience in seismic mitigation including laboratory fastening, clean room fastening, data center seismic mitigation, and office equipment safety fastening. Our innovative countertop fasteners, floor fasteners, and laboratory restraints protect employees from seismic risks within the workplace. QuakeHOLD! Industrial also educates your employees about earthquake safety fastening and the need to have a Grab 'n Go Survival Kit. QuakeHOLD! Industrial was formed by joining together industry leaders from Q-Safety, Thumblock and QuakeHOLD. This alliance has brought together the very best in earthquake fastening and an unparalleled team of professionals. With over 50 years combined experience, we now offer the widest selection of state-of-the-art earthquake fastening products, services and custom-built seismic restraints. We provide these services for any type of business, industry, hospital, lab, school, military, data center and collocation facility. Statistics show that 65% of the damage and injury from severe earthquakes are predictable and preventable. You can ensure the safety of your employees and property, ensure business continuity, and reduce your liability by calling us today to arrange for a site survey.Company Classification
Associate/Service ProvidersPrimary Technology
Imaging
1150 Simpson Way
Escondido, CA, United States, 92029
7604661060
http://www.quakeholdindustrial.comPrimary Contacts
Dean Reese
President
7604661060 x: 106
Tom Rundberg
Vice President Sales
6268528800
Dennis Johnson
National Sales Manager
8055511446
Company Profile
QuakeHOLD! Industrial is the leader in Non-Structural Seismic Mitigation. We have over 50 years of combined experience in seismic mitigation including laboratory fastening, clean room fastening, data center seismic mitigation, and office equipment safety fastening. Our innovative countertop fasteners, floor fasteners, and laboratory restraints protect employees from seismic risks within the workplace. QuakeHOLD! Industrial also educates your employees about earthquake safety fastening and the need to have a Grab 'n Go Survival Kit. QuakeHOLD! Industrial was formed by joining together industry leaders from Q-Safety, Thumblock and QuakeHOLD. This alliance has brought together the very best in earthquake fastening and an unparalleled team of professionals. With over 50 years combined experience, we now offer the widest selection of state-of-the-art earthquake fastening products, services and custom-built seismic restraints. We provide these services for any type of business, industry, hospital, lab, school, military, data center and collocation facility. Statistics show that 65% of the damage and injury from severe earthquakes are predictable and preventable. You can ensure the safety of your employees and property, ensure business continuity, and reduce your liability by calling us today to arrange for a site survey.Company Classification
Associate/Service ProvidersPrimary Technology
Imaging
QuantaLife, Inc.
7068 Koll Center Parkway, Ste. 401
Pleasanton, CA, 94566
925-474-8600
http://www.quantalife.comPrimary Contacts
Bill Colston
CEO
Isaac Bright
VP, Corporate Development
Paul Kidman
VP, Finance
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
7068 Koll Center Parkway, Ste. 401
Pleasanton, CA, 94566
925-474-8600
http://www.quantalife.comPrimary Contacts
Bill Colston
CEO
Isaac Bright
VP, Corporate Development
Paul Kidman
VP, Finance
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
QuantiCell Pharma Inc.
1500 Owens St. Suite 600
San Francisco, CA, United States, 94158
650-521-2170
Primary Contacts
Robert Cho
Director of Biology
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Cell Biology
Drug Discovery
MicrofluidicsClinical Development Stage
PreClinical
1500 Owens St. Suite 600
San Francisco, CA, United States, 94158
650-521-2170
Primary Contacts
Robert Cho
Director of Biology
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Cell Biology
Drug Discovery
MicrofluidicsClinical Development Stage
PreClinical
Raptor Therapeutics
United States, http://www.raptorpharma.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.raptorpharma.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
RC Biotechnologies, Inc
725 San Aleso Ave. Suite 3
Sunnyvale, CA, United States, 94085
650-740-5803
Primary Contacts
Jeff Fang
General Manager
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Cell BiologyClinical Development Stage
PreClinical
725 San Aleso Ave. Suite 3
Sunnyvale, CA, United States, 94085
650-740-5803
Primary Contacts
Jeff Fang
General Manager
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
CancerPrimary Technology
Cell BiologyClinical Development Stage
PreClinical
Redwood Bioscience Inc.
United States, http://www.redwoodbioscience.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.redwoodbioscience.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Rennovia, Inc.
1080 Hamilton Avenue
Menlo Park, CA, 94025
650-804-7400
http://www.rennovia.comPrimary Contacts
Robert Wedinger
CEO
Thomas Boussie
Founder, Vice President
Vince Murphy
Founder, Vice President
Company Profile
Rennovia is dedicated to developing commercially viable routes for the conversion of carbohydrate-based feedstocks to bulk and commodity chemicals that are currently derived from petroleum.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Combinatorial Chemistry
Screening
1080 Hamilton Avenue
Menlo Park, CA, 94025
650-804-7400
http://www.rennovia.comPrimary Contacts
Robert Wedinger
CEO
Thomas Boussie
Founder, Vice President
Vince Murphy
Founder, Vice President
Company Profile
Rennovia is dedicated to developing commercially viable routes for the conversion of carbohydrate-based feedstocks to bulk and commodity chemicals that are currently derived from petroleum.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial BiotechnologyPrimary Technology
Combinatorial Chemistry
Screening
Reset Therapeutics, Inc.
849 Mitten Rd. Suite 102
Burlingame, CA, United States, 94010
650-552-9911
Primary Contacts
Ross Bersot
President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Central Nervous
Metabolic/Endocrinology Disorders
Respiratory DisordersClinical Development Stage
PreClinical
849 Mitten Rd. Suite 102
Burlingame, CA, United States, 94010
650-552-9911
Primary Contacts
Ross Bersot
President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cardiovascular & Circulatory Disorders
Central Nervous
Metabolic/Endocrinology Disorders
Respiratory DisordersClinical Development Stage
PreClinical
RetirementDNA
United States, http://www.RetirementDNA.comCompany Classification
Associate/Service Providers
United States, http://www.RetirementDNA.comCompany Classification
Associate/Service Providers
Revance Therapeutics, Inc.
7555 Gateway Blvd
Newark, CA, United States, 94560
510-742-3400
http://www.revance.com/Primary Contacts
Dan Browne
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Dermatology
Metabolic/Endocrinology DisordersPrimary Technology
Biomanufacturing
Drug Delivery
Drug DiscoveryClinical Development Stage
Phase II
7555 Gateway Blvd
Newark, CA, United States, 94560
510-742-3400
http://www.revance.com/Primary Contacts
Dan Browne
President & CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug Development
TherapeuticDisease Areas of Focus
Dermatology
Metabolic/Endocrinology DisordersPrimary Technology
Biomanufacturing
Drug Delivery
Drug DiscoveryClinical Development Stage
Phase II
Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA, 94080
650-624-1100
http://www.rigel.comPrimary Contacts
James M. Gower
Chairman and CEO
Donald G. Payan, MD
EVP and President of Discovery and Research
Raul Rodriguez
President and COO
Company Profile
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Musculoskeletal Disorders
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
Phase III
1180 Veterans Boulevard
South San Francisco, CA, 94080
650-624-1100
http://www.rigel.comPrimary Contacts
James M. Gower
Chairman and CEO
Donald G. Payan, MD
EVP and President of Discovery and Research
Raul Rodriguez
President and COO
Company Profile
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Musculoskeletal Disorders
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
Phase I
Phase III
S.E.A. Medical Systems, Inc.
3350 Scott Blvd., Bldg. 33
Santa Clara, CA, 95054
408-987-0673
http://www.seamedical.comPrimary Contacts
Michael J. Weickert
Chairman, President and CEO
James W. Bennett
COO
Leo Matsiev
CTO
Company Profile
S.E.A. Medical Systems, Inc. is a private medical device company pioneering smart solutions for safe manufacture, preparation, delivery and disposal of IV and other liquid medications. The product systems instantly detect drug, concentration and diluent using disposable sensors. Smart IV instantaneously reports drug and concentration in IVs alerting healthcare providers to errors. IV Check confirms IVs made in the hospital pharmacy and requires no FDA approval. IV Check also helps check diversion of scheduled drugs by allowing pharmacies to confirm whether leftover narcotics have been replaced with other fluids. Auto IV automates IV delivery and removes many of the sources of error present with current smart pumps. IV Waste systems automate documentation and segregation of EPA regulated pharmaceutical waste streams and document disposal of scheduled drugs like narcotics for DEA compliance. The company's products address major concerns in the healthcare industry, as drug regimen mistakes occur frequently with severe consequences, including many fatalities each year.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Drug Delivery
3350 Scott Blvd., Bldg. 33
Santa Clara, CA, 95054
408-987-0673
http://www.seamedical.comPrimary Contacts
Michael J. Weickert
Chairman, President and CEO
James W. Bennett
COO
Leo Matsiev
CTO
Company Profile
S.E.A. Medical Systems, Inc. is a private medical device company pioneering smart solutions for safe manufacture, preparation, delivery and disposal of IV and other liquid medications. The product systems instantly detect drug, concentration and diluent using disposable sensors. Smart IV instantaneously reports drug and concentration in IVs alerting healthcare providers to errors. IV Check confirms IVs made in the hospital pharmacy and requires no FDA approval. IV Check also helps check diversion of scheduled drugs by allowing pharmacies to confirm whether leftover narcotics have been replaced with other fluids. Auto IV automates IV delivery and removes many of the sources of error present with current smart pumps. IV Waste systems automate documentation and segregation of EPA regulated pharmaceutical waste streams and document disposal of scheduled drugs like narcotics for DEA compliance. The company's products address major concerns in the healthcare industry, as drug regimen mistakes occur frequently with severe consequences, including many fatalities each year.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesPrimary Technology
Drug Delivery
Saltigo (LANXESS Corp.)
United States, http://www.saltigo.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
United States, http://www.saltigo.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Manufacturing
San Diego State University
http://www.csuchico.edu/csuperb
http://www.csuchico.edu/csuperb
San Francisco Business Times
United States, http://www.sanfranciscobusinesstimes.com/discountCompany Classification
Associate/Service Providers
United States, http://www.sanfranciscobusinesstimes.com/discountCompany Classification
Associate/Service Providers
San Francisco State University
United States, http://www.sfsu.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.sfsu.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
San Jose State University
United States, http://www.sjsu.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.sjsu.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Sangamo BioSciences, Inc.
501 Canal Blvd.
Richmond, CA, 94804
510-970-6000
http://www.sangamo.comPrimary Contacts
Edward Lanphier
President & CEO
Ward Wolff
Chief Finacial Officer
Philip Gregory, D. Phil.
Chief Scientific Officer
Company Profile
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
501 Canal Blvd.
Richmond, CA, 94804
510-970-6000
http://www.sangamo.comPrimary Contacts
Edward Lanphier
President & CEO
Ward Wolff
Chief Finacial Officer
Philip Gregory, D. Phil.
Chief Scientific Officer
Company Profile
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Cancer
Central Nervous
Genetic Diseases
Infectious Disease
Metabolic/Endocrinology DisordersPrimary Technology
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Sanofi-Aventis
400 Oyster Point Boulevard, suite 200
South San Francisco, CA, 94080
650 615 7039
http://www.sanofi.comPrimary Contacts
Chris Viebacher
CEO
Elias Zerhouni
VP Executive Research
Jacques Delort
VP Head Partnering and Innovation
Company Profile
Local Partner West Coast: Remi Brouard VP External Innovation (Reporting to J Delort) Classification is impossible in the next paragraph 4 (Vaccine yes, drug devlp yes, therapeutic yes, Industrial Biotech yes ....)Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
Phase II
Phase III
Approved
400 Oyster Point Boulevard, suite 200
South San Francisco, CA, 94080
650 615 7039
http://www.sanofi.comPrimary Contacts
Chris Viebacher
CEO
Elias Zerhouni
VP Executive Research
Jacques Delort
VP Head Partnering and Innovation
Company Profile
Local Partner West Coast: Remi Brouard VP External Innovation (Reporting to J Delort) Classification is impossible in the next paragraph 4 (Vaccine yes, drug devlp yes, therapeutic yes, Industrial Biotech yes ....)Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Musculoskeletal DisordersClinical Development Stage
PreClinical
Phase II
Phase III
Approved
Sanovas, Inc.
85 Liberty Ship Way Ste 110-B
Sausalito, CA, United States, 94965
415-729-9391
http://www.sanovas.comPrimary Contacts
Larry Gerrans
President and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
85 Liberty Ship Way Ste 110-B
Sausalito, CA, United States, 94965
415-729-9391
http://www.sanovas.comPrimary Contacts
Larry Gerrans
President and CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
SARcode Bioscience
1000 Marina Blvd, Suite 250
Brisbane, CA, United States, 94005
650-416-7560
http://www.sarcode.comPrimary Contacts
Quinton C. Oswald
President & CEO
Todd A. Creech
CFO & VP, Business Development
Charles P. Semba, MD, FACR, FACC
CMO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
OphthalmologyClinical Development Stage
Phase III
1000 Marina Blvd, Suite 250
Brisbane, CA, United States, 94005
650-416-7560
http://www.sarcode.comPrimary Contacts
Quinton C. Oswald
President & CEO
Todd A. Creech
CFO & VP, Business Development
Charles P. Semba, MD, FACR, FACC
CMO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
OphthalmologyClinical Development Stage
Phase III
Schwegman, Lundberg & Woessner
United States, http://www.slwip.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
United States, http://www.slwip.com/Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
SciClone Pharmaceuticals, Inc.
950 Tower Lane Suite 900
Foster City, CA, United States, 94404
6503583456
http://www.sciclone.comPrimary Contacts
Friedhelm Blobel PhD
President and CEO
Gary Titus
Sr VP and CFO
Israel Rios MD
Senior Vice President, Medical Affairs and CMO
Company Profile
SciClone is a revenue-generating, profitable China-centric specialty pharmaceutical company with a substantial business and a product portfolio of novel therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central Nervous
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
Phase II
Approved
950 Tower Lane Suite 900
Foster City, CA, United States, 94404
6503583456
http://www.sciclone.comPrimary Contacts
Friedhelm Blobel PhD
President and CEO
Gary Titus
Sr VP and CFO
Israel Rios MD
Senior Vice President, Medical Affairs and CMO
Company Profile
SciClone is a revenue-generating, profitable China-centric specialty pharmaceutical company with a substantial business and a product portfolio of novel therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Cancer
Central Nervous
Infectious DiseasePrimary Technology
Drug DiscoveryClinical Development Stage
Phase II
Approved
Science Futures, Inc.
United States, http://www.sciencefuturesinc.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
United States, http://www.sciencefuturesinc.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Scottish Development International
2570 North First Street
San Jose, CA, 95131
408-436-5520
http://www.scottishdevelopmentinternational.comPrimary Contacts
Larry Reynolds
Vice President. Life Sciences
408-964-5818
Justine Kelly
Assistant Vice President
408-964-5821
Company Profile
Scottish Development International is a government funded organisation with a dedicated life sciences team which provides access to key Scottish product and service companies, together with research and clinical expertise from Scottish Universities and Research Institutes working in a number of areas including: - Basic and Clinical Research in therapeutic areas including Cardiovascular Disease & Metabolism, Neuroscience, Inflammation, Oncology and Womens Health - Bioinformatics - Contract Research [CRO's] - Drug Discovery & Development - Medical Technologies including Diagnostics & Wound Healing - Regenerative Medicine & Stem Cells - Translational MedicineCompany Classification
Associate/Service ProvidersOrganization Type
Government AgenciesDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Metabolic/Endocrinology Disorders
Womens HealthPrimary Technology
Drug Delivery
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
2570 North First Street
San Jose, CA, 95131
408-436-5520
http://www.scottishdevelopmentinternational.comPrimary Contacts
Larry Reynolds
Vice President. Life Sciences
408-964-5818
Justine Kelly
Assistant Vice President
408-964-5821
Company Profile
Scottish Development International is a government funded organisation with a dedicated life sciences team which provides access to key Scottish product and service companies, together with research and clinical expertise from Scottish Universities and Research Institutes working in a number of areas including: - Basic and Clinical Research in therapeutic areas including Cardiovascular Disease & Metabolism, Neuroscience, Inflammation, Oncology and Womens Health - Bioinformatics - Contract Research [CRO's] - Drug Discovery & Development - Medical Technologies including Diagnostics & Wound Healing - Regenerative Medicine & Stem Cells - Translational MedicineCompany Classification
Associate/Service ProvidersOrganization Type
Government AgenciesDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Metabolic/Endocrinology Disorders
Womens HealthPrimary Technology
Drug Delivery
Stem Cell ResearchClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
SeaChange Pharmaceuticals
1700 4th Street, Byers Hall, Ste. 214
San Francisco, CA, United States, 94158-2330
415-937-1732
http://www.seachangepharma.comPrimary Contacts
Nicole Norton
Operations Manager
Michael Keiser, Ph.D.
COO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
1700 4th Street, Byers Hall, Ste. 214
San Francisco, CA, United States, 94158-2330
415-937-1732
http://www.seachangepharma.comPrimary Contacts
Nicole Norton
Operations Manager
Michael Keiser, Ph.D.
COO & President
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
SENS Foundation
United States, http://www.sens.orgCompany Classification
Education, Research Institution, Government Agency, other Non-Profit
United States, http://www.sens.orgCompany Classification
Education, Research Institution, Government Agency, other Non-Profit
Sensorin
863 A Mitten Rd.
Burlingame, CA, United States, 94010
650-552-9324
http://www.sensorin.comPrimary Contacts
Carrie Kahn, Ph.D.
CEO & President
Joan Caldwell
VP, Operations
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
863 A Mitten Rd.
Burlingame, CA, United States, 94010
650-552-9324
http://www.sensorin.comPrimary Contacts
Carrie Kahn, Ph.D.
CEO & President
Joan Caldwell
VP, Operations
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Analytics
Sentrx Safety Solutions
Overlook at Great Notch, 150 Clove Road, 2nd Floor
Little Falls, New Jersey, United States, 07424
973-812-7575
http://www.sentrx.comPrimary Contacts
Linda R. Bernstein, Pharm.D.
Director Commercial Solutions
973-356-2033
Company Profile
Sentrx (www.sentrx.com) has more than 15 years of experience in pharmacovigilance, handling both clinical compounds and commercialized products. Our seasoned drug and device safety experts can partner with you to create a customized program that enables your company to comply with reporting requirements of the FDA, EMA, partners and other world-wide regulatory authorities. Our therapeutic expertise covers a full range of prescription drugs, biotechnology agents, over the counter products, herbals, and medical devices. Our services include: • Safety database management/hosting. Sentrx is an Oracle Gold Partner and the largest hosting provider for the Oracle Argus Drug Safety Database and Argus Electronic Submission Module in North America. • Adverse event management. Our highly qualified healthcare professionals provide data collection, processing, investigation and interpretation of adverse events reported from all sources, including clinical investigators, healthcare providers, sales representatives and patients. • Medical affairs. The Sentrx Call Center handles product complaints, medical inquiries, REMS programs, product returns and more. • Pharmacovigilance consulting and audits. We can help you write SOPs and Working Practices to use in NDAs and do an assessment of your current drug safety processes. We also can assist you in the design and documentation of safety related programs such as REMS or RMP. • Drug safety training. Sentrx University is available to train your pharmacovigilance staff in the latest drug safety processes and skill sets to meet regulatory standards.Company Classification
Associate/Service Providers
Overlook at Great Notch, 150 Clove Road, 2nd Floor
Little Falls, New Jersey, United States, 07424
973-812-7575
http://www.sentrx.comPrimary Contacts
Linda R. Bernstein, Pharm.D.
Director Commercial Solutions
973-356-2033
Company Profile
Sentrx (www.sentrx.com) has more than 15 years of experience in pharmacovigilance, handling both clinical compounds and commercialized products. Our seasoned drug and device safety experts can partner with you to create a customized program that enables your company to comply with reporting requirements of the FDA, EMA, partners and other world-wide regulatory authorities. Our therapeutic expertise covers a full range of prescription drugs, biotechnology agents, over the counter products, herbals, and medical devices. Our services include: • Safety database management/hosting. Sentrx is an Oracle Gold Partner and the largest hosting provider for the Oracle Argus Drug Safety Database and Argus Electronic Submission Module in North America. • Adverse event management. Our highly qualified healthcare professionals provide data collection, processing, investigation and interpretation of adverse events reported from all sources, including clinical investigators, healthcare providers, sales representatives and patients. • Medical affairs. The Sentrx Call Center handles product complaints, medical inquiries, REMS programs, product returns and more. • Pharmacovigilance consulting and audits. We can help you write SOPs and Working Practices to use in NDAs and do an assessment of your current drug safety processes. We also can assist you in the design and documentation of safety related programs such as REMS or RMP. • Drug safety training. Sentrx University is available to train your pharmacovigilance staff in the latest drug safety processes and skill sets to meet regulatory standards.Company Classification
Associate/Service Providers
Sequetech Corporation
United States, http://www.sequetech.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
United States, http://www.sequetech.comCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
ShareVault
United States, http://www.sharevault.com/solutions/life_sciences.htm/?source=BayBioCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
United States, http://www.sharevault.com/solutions/life_sciences.htm/?source=BayBioCompany Classification
Associate/Service ProvidersOrganization Type
Information Technology
Silicon BioDevices
United States, http://www.siliconbiodevices.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
United States, http://www.siliconbiodevices.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical Devices
Silver Creek Pharmaceuticals, Inc.
United States, http://www.silvercreekpharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
United States, http://www.silvercreekpharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
Singulex, Inc.
1650 Harbor Bay Parkway, Suite 200
Alameda, CA, 94502-3012
510 995-9004
Primary Contacts
Howard Czapla
Controller
Company Profile
Clia Operation and Pharma Medical Equipment Sales.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
1650 Harbor Bay Parkway, Suite 200
Alameda, CA, 94502-3012
510 995-9004
Primary Contacts
Howard Czapla
Controller
Company Profile
Clia Operation and Pharma Medical Equipment Sales.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Sirius Genomics Inc
603 - 1125 Howe St
Vancouver, BC, V6Z 2K8
604-484-7195
http://www.siriusgenomics.comPrimary Contacts
Chris Wagner
President and CEO
Kamran Alam
Senior Director, Business Development
Alexandra Mancini
Senior Vice President, Clinical & Regulatory Affairs
Company Profile
Sirius Genomics is a private biotechnology company, based in Vancouver, British Columbia that develops companion diagnostics (CDx) for acute medical conditions. The Company's focus is on developing companion diagnostics for therapeutics, leading to better patient outcomes through personalized medicine. Currently, therapeutics follow a one-size-fits-all pattern. However, the inherent genetic differences between individuals can lead to low efficacy or adverse side effects for a drug, which can limit its clinical utility. Sirius addresses this problem by developing companion diagnostics which identify patient populations that will benefit the most from pharmaceutical therapeutics, enabling patients to get the right medication, doctors to more effectively treat the critically ill and, drug companies to fully realize the market potential for their therapeutics. By correlating patient genetics and other markers with clinical outcomes, Sirius� CDx products aim to enable more effective drug treatment.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Infectious DiseasePrimary Technology
Bioinformatics
Genomics
PharmacogenomicsClinical Development Stage
Phase III
603 - 1125 Howe St
Vancouver, BC, V6Z 2K8
604-484-7195
http://www.siriusgenomics.comPrimary Contacts
Chris Wagner
President and CEO
Kamran Alam
Senior Director, Business Development
Alexandra Mancini
Senior Vice President, Clinical & Regulatory Affairs
Company Profile
Sirius Genomics is a private biotechnology company, based in Vancouver, British Columbia that develops companion diagnostics (CDx) for acute medical conditions. The Company's focus is on developing companion diagnostics for therapeutics, leading to better patient outcomes through personalized medicine. Currently, therapeutics follow a one-size-fits-all pattern. However, the inherent genetic differences between individuals can lead to low efficacy or adverse side effects for a drug, which can limit its clinical utility. Sirius addresses this problem by developing companion diagnostics which identify patient populations that will benefit the most from pharmaceutical therapeutics, enabling patients to get the right medication, doctors to more effectively treat the critically ill and, drug companies to fully realize the market potential for their therapeutics. By correlating patient genetics and other markers with clinical outcomes, Sirius� CDx products aim to enable more effective drug treatment.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Infectious DiseasePrimary Technology
Bioinformatics
Genomics
PharmacogenomicsClinical Development Stage
Phase III
SiteOne Therapeutics
600 Castle Hill Road
Redwood City, CA, United States, 94061
650-368-6983
Primary Contacts
George Miljanich, PhD
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Central Nervous
Dermatology
Genetic DiseasesPrimary Technology
Drug Delivery
Drug Discovery
ImagingClinical Development Stage
PreClinical
600 Castle Hill Road
Redwood City, CA, United States, 94061
650-368-6983
Primary Contacts
George Miljanich, PhD
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Central Nervous
Dermatology
Genetic DiseasesPrimary Technology
Drug Delivery
Drug Discovery
ImagingClinical Development Stage
PreClinical
Slingshot Biosciences
2430 5th St. Suite D
Berkeley, CA, United States, 94710
646-450-7332
http://www.slingshotbio.comPrimary Contacts
Jeffrey Kim
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
BioTool
Industrial BiotechnologyDisease Areas of Focus
Infectious DiseasePrimary Technology
Biocatalysis
Biomanufacturing
2430 5th St. Suite D
Berkeley, CA, United States, 94710
646-450-7332
http://www.slingshotbio.comPrimary Contacts
Jeffrey Kim
CEO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuels
BioTool
Industrial BiotechnologyDisease Areas of Focus
Infectious DiseasePrimary Technology
Biocatalysis
Biomanufacturing
Solazyme, Inc.
225 Gateway Blvd
South San Francisco, CA, 94080
650-780-4777
http://www.solazyme.comPrimary Contacts
Jonathan Wolfson
Chief Executive Officer
Harrison Dillon
President and Chief Technology Officer
Tyler Painter
Chief Financial Officer
Company Profile
We have pioneered an industrial biotechnology platform that harnesses the prolific oil-producing ability of microalgae. We use standard industrial fermentation equipment to efficiently scale and accelerate the microalgae's natural oil production time to just a few days. Our platform is feedstock flexible and can utilize a wide variety of plant-based sugars, such as sugarcane-based sucrose, corn-based dextrose, and sugar from other biomass sources including cellulosics. By growing our proprietary microalgae in the absence of light using fermentation tanks to convert photosynthetic plant sugars into oil, we are in effect utilizing "indirect photosynthesis."Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuelsPrimary Technology
Aquaculture
Biocatalysis
Biomanufacturing
225 Gateway Blvd
South San Francisco, CA, 94080
650-780-4777
http://www.solazyme.comPrimary Contacts
Jonathan Wolfson
Chief Executive Officer
Harrison Dillon
President and Chief Technology Officer
Tyler Painter
Chief Financial Officer
Company Profile
We have pioneered an industrial biotechnology platform that harnesses the prolific oil-producing ability of microalgae. We use standard industrial fermentation equipment to efficiently scale and accelerate the microalgae's natural oil production time to just a few days. Our platform is feedstock flexible and can utilize a wide variety of plant-based sugars, such as sugarcane-based sucrose, corn-based dextrose, and sugar from other biomass sources including cellulosics. By growing our proprietary microalgae in the absence of light using fermentation tanks to convert photosynthetic plant sugars into oil, we are in effect utilizing "indirect photosynthesis."Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioFuelsPrimary Technology
Aquaculture
Biocatalysis
Biomanufacturing
Sonoma State University
United States, http://www.sonoma.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
United States, http://www.sonoma.eduCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Sorbus Advisors LLC
1515 Grant Ave. Ste 320
Novato, CA, United States, 94945
415-898-1098
http://www.sorbusadvisors.comPrimary Contacts
Max Fonarev
President
415-898-1098
Company Classification
Associate/Service Providers
1515 Grant Ave. Ste 320
Novato, CA, United States, 94945
415-898-1098
http://www.sorbusadvisors.comPrimary Contacts
Max Fonarev
President
415-898-1098
Company Classification
Associate/Service Providers
Spinal Kinetics
595 N. Pastoria Ave
Sunnyvale, CA, 95135
408-636-2500
http://www.spinalkinetics.comPrimary Contacts
Darcy Coleman
Manager, Materials and Customer Service
John Tran
VP, Finance
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
Approved
595 N. Pastoria Ave
Sunnyvale, CA, 95135
408-636-2500
http://www.spinalkinetics.comPrimary Contacts
Darcy Coleman
Manager, Materials and Customer Service
John Tran
VP, Finance
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesClinical Development Stage
Approved
SR One, Ltd.
161 Washington Street, Suite 500
Conshohocken, PA, 19428
(610) 567-1000
http://www.srone.comPrimary Contacts
Simeon George
Partner
Simeon.J.George@gsk.com
Karen N. Engel
Finance Manager
(610) 567-1000
Company Profile
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and Europe. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Our current portfolio includes approximately 25 private and public companies and since our founding in 1985, we have invested over $600MM in the biotech space. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
161 Washington Street, Suite 500
Conshohocken, PA, 19428
(610) 567-1000
http://www.srone.comPrimary Contacts
Simeon George
Partner
Simeon.J.George@gsk.com
Karen N. Engel
Finance Manager
(610) 567-1000
Company Profile
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and Europe. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Our current portfolio includes approximately 25 private and public companies and since our founding in 1985, we have invested over $600MM in the biotech space. Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.Company Classification
Associate/Service ProvidersOrganization Type
Venture Capital
SRI International Bioscience
333 Ravenswood Avenue
Menlo Park, CA, United States, 94025
Toll-Free: 866.451.5
http://www.sri.com/biosciencesPrimary Contacts
Janice Schindler-Horvat
Director, Marketing
(650) 859-5516
Company Profile
SRI International’s Biosciences Division partners with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important biomedical problems. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all the resources necessary to take R&D programs from ""idea to IND®""— from initial discovery to investigational new drug applications to start human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the interfaces of science and medicine to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Therapeutic
333 Ravenswood Avenue
Menlo Park, CA, United States, 94025
Toll-Free: 866.451.5
http://www.sri.com/biosciencesPrimary Contacts
Janice Schindler-Horvat
Director, Marketing
(650) 859-5516
Company Profile
SRI International’s Biosciences Division partners with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important biomedical problems. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all the resources necessary to take R&D programs from ""idea to IND®""— from initial discovery to investigational new drug applications to start human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the interfaces of science and medicine to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Therapeutic
Stanford University
School of Medicine - 300 Pasteur Dr., Grant S:005
Stanford, CA, United States, 64305
650.723.2035
http://www.med.stanford.eduPrimary Contacts
Michael A. Alvarez
Director
650.723.2035
Company Profile
Comprehensive Global Research UniversityCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemPrimary Technology
Bioinformatics
Cell Biology
Combinatorial Chemistry
Computational Chemistry
Drug Delivery
Functional Genetics
Gene/Cell Therapy
Genomics
Imaging
Micro Arrays
Microfluidics
Nanotechnology
Pharmacogenomics
Plant-made Pharmaceuticals
Proteomics
Screening
School of Medicine - 300 Pasteur Dr., Grant S:005
Stanford, CA, United States, 64305
650.723.2035
http://www.med.stanford.eduPrimary Contacts
Michael A. Alvarez
Director
650.723.2035
Company Profile
Comprehensive Global Research UniversityCompany Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Non-Profit Research InstituteDisease Areas of Focus
Autoimmune & Inflammatory
Blood & Lymphatic Diseases
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Dermatology
Digestive System
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary SystemPrimary Technology
Bioinformatics
Cell Biology
Combinatorial Chemistry
Computational Chemistry
Drug Delivery
Functional Genetics
Gene/Cell Therapy
Genomics
Imaging
Micro Arrays
Microfluidics
Nanotechnology
Pharmacogenomics
Plant-made Pharmaceuticals
Proteomics
Screening
Stanislaus Economic Develpoment and Workforce Alliance
1010 10th St. Suite 1400
Modesto, CA, United States, 95354
209-567-4985
http://wwwstanalliance.comPrimary Contacts
Bill Bassitt
CEO
209-567-4992
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
1010 10th St. Suite 1400
Modesto, CA, United States, 95354
209-567-4985
http://wwwstanalliance.comPrimary Contacts
Bill Bassitt
CEO
209-567-4992
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Non-Profit Organizations
Stem CentRx, LLC
571 Eccles Avenue
South San Francisco, CA, 94080
650-491-0120
http://www.stemcentrx.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
Drug Discovery
Stem Cell ResearchClinical Development Stage
PreClinical
571 Eccles Avenue
South San Francisco, CA, 94080
650-491-0120
http://www.stemcentrx.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
Drug Discovery
Stem Cell ResearchClinical Development Stage
PreClinical
StemCells, Inc.
3155 Porter Dr
Palo Alto, CA, United States, 94304
650 475 3100
http://www.stemcellsinc.comPrimary Contacts
Martin McGlynn
President and CEO
Rodney Young
Chief Financial Officer
Ann Tsukamoto
Executive Vice President, Research & Development
Company Profile
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
OphthalmologyPrimary Technology
Cell Biology
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
Phase I
3155 Porter Dr
Palo Alto, CA, United States, 94304
650 475 3100
http://www.stemcellsinc.comPrimary Contacts
Martin McGlynn
President and CEO
Rodney Young
Chief Financial Officer
Ann Tsukamoto
Executive Vice President, Research & Development
Company Profile
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central Nervous
OphthalmologyPrimary Technology
Cell Biology
Gene/Cell Therapy
Stem Cell ResearchClinical Development Stage
Phase I
Stockbridge Real Estate
Four Embarcadero Center, #3300
San Francisco, CA, United States, 94111
415-658-3300
http://www.sbfund.comPrimary Contacts
Stephen Pilch
Managing Director
415-658-3335
Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
Four Embarcadero Center, #3300
San Francisco, CA, United States, 94111
415-658-3300
http://www.sbfund.comPrimary Contacts
Stephen Pilch
Managing Director
415-658-3335
Company Classification
Associate/Service ProvidersOrganization Type
Real Estate
SuiteAmerica
4970 Windplay Dr., Ste c-1
El Dorado Hills, CA, 95762
9163639700
http://www.suiteamerica.comPrimary Contacts
Taylor Williams
National Corporate Business Manager
5107727440
Robin Masten
President
9163639700
Laura Gregersen
Corporate Business Manager
4082613656
Company Classification
Associate/Service Providers
4970 Windplay Dr., Ste c-1
El Dorado Hills, CA, 95762
9163639700
http://www.suiteamerica.comPrimary Contacts
Taylor Williams
National Corporate Business Manager
5107727440
Robin Masten
President
9163639700
Laura Gregersen
Corporate Business Manager
4082613656
Company Classification
Associate/Service Providers
Sunesis Pharmaceuticals, Inc.
395 Oyster Point Blvd, Suite 400
South San Francisco, CA, 94080
650.266.3500
http://www.sunesis.comPrimary Contacts
Daniel N. Swisher, Jr.
Chief Executive Officer and President
Eric H. Bjerkholt
Senior Vice President, Corporate Development and Finance, Chief Financial Officer
Steven B. Ketchum Ph.D
Senior Vice President, Research and Development
Company Profile
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Delivery
Drug DiscoveryClinical Development Stage
Phase III
395 Oyster Point Blvd, Suite 400
South San Francisco, CA, 94080
650.266.3500
http://www.sunesis.comPrimary Contacts
Daniel N. Swisher, Jr.
Chief Executive Officer and President
Eric H. Bjerkholt
Senior Vice President, Corporate Development and Finance, Chief Financial Officer
Steven B. Ketchum Ph.D
Senior Vice President, Research and Development
Company Profile
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
CancerPrimary Technology
Drug Delivery
Drug DiscoveryClinical Development Stage
Phase III
Sunovion Pharmaceuticals, Inc.
84 Waterford Drive
Marlborough, MA, 1752
508-481-6700
http://www.sunovion.comPrimary Contacts
April Grant
Director, State Government Affairs
Company Profile
In October 2009, Sepracor Inc., a U.S. pharmaceutical company with a focus in CNS and Respiratory therapies, was acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP), a top ten, stock exchange-listed pharmaceutical company based in Osaka, Japan. The move strengthened DSP's North American based drug development pipeline and commercial capabilities. And brought together extensive expertise in two main treatment categories—disorders of the central nervous system (CNS) and respiratory diseases. In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
Approved
84 Waterford Drive
Marlborough, MA, 1752
508-481-6700
http://www.sunovion.comPrimary Contacts
April Grant
Director, State Government Affairs
Company Profile
In October 2009, Sepracor Inc., a U.S. pharmaceutical company with a focus in CNS and Respiratory therapies, was acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP), a top ten, stock exchange-listed pharmaceutical company based in Osaka, Japan. The move strengthened DSP's North American based drug development pipeline and commercial capabilities. And brought together extensive expertise in two main treatment categories—disorders of the central nervous system (CNS) and respiratory diseases. In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
Approved
Sutro Biopharma, Inc.
310 Utah Avenue, Suite 150
South San Francisco, CA, 94080
650-392-8412
http://www.sutrobio.comPrimary Contacts
William J. Newell
CEO
Trevor J. Hallam, Ph.D.
Chief Scientific Officer
Lesley Stolz, Ph.D.
VP, Busines Development
Company Profile
Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates including protein therapeutics that cannot be produced using conventional methods.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticPrimary Technology
Protein EngineeringClinical Development Stage
PreClinical
310 Utah Avenue, Suite 150
South San Francisco, CA, 94080
650-392-8412
http://www.sutrobio.comPrimary Contacts
William J. Newell
CEO
Trevor J. Hallam, Ph.D.
Chief Scientific Officer
Lesley Stolz, Ph.D.
VP, Busines Development
Company Profile
Sutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates including protein therapeutics that cannot be produced using conventional methods.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticPrimary Technology
Protein EngineeringClinical Development Stage
PreClinical
Syapse, Inc.
United States, http://www.syapse.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Information TechnologyPrimary Technology
Bioinformatics
United States, http://www.syapse.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Information TechnologyPrimary Technology
Bioinformatics
Synarc
7707 Gateway Blvd. 3rd Floor
Newark, CA, United States, 94560
415-817-8900
http://www.synarc.comPrimary Contacts
Sahar Waziri
Business Solutions Architects/Sales Support
415-817-7949
Aaron Timm
CEO
415-817-8996
Ralph Reyes
CFO & VP Operations
415-817-8980
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationPrimary Technology
Imaging
7707 Gateway Blvd. 3rd Floor
Newark, CA, United States, 94560
415-817-8900
http://www.synarc.comPrimary Contacts
Sahar Waziri
Business Solutions Architects/Sales Support
415-817-7949
Aaron Timm
CEO
415-817-8996
Ralph Reyes
CFO & VP Operations
415-817-8980
Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationPrimary Technology
Imaging
Synergenics, LLC
1700 Owens Street Suite 515
San Francisco, CA, 94158
415-554-8170
http://www.synergenics.net/Primary Contacts
William J Rutter
Founder
Company Profile
Synergenics, LLC Operates a consortium of commonly-owned but independent biotech companies offering an innovative and cost-effective approach to start-ups in the life sciences industry. Synergenics provides member companies with financial support, shared laboratory facilities and experienced management and administrative services, creating true economies of scale. In addition, the Synergenics concept provides an open and collaborative environment among member companies that allows a free exchange of ideas and technology, while protecting each company�s defined proprietary domains.Company Classification
Associate/Service ProvidersOrganization Type
Drug Development
Investment Bank
1700 Owens Street Suite 515
San Francisco, CA, 94158
415-554-8170
http://www.synergenics.net/Primary Contacts
William J Rutter
Founder
Company Profile
Synergenics, LLC Operates a consortium of commonly-owned but independent biotech companies offering an innovative and cost-effective approach to start-ups in the life sciences industry. Synergenics provides member companies with financial support, shared laboratory facilities and experienced management and administrative services, creating true economies of scale. In addition, the Synergenics concept provides an open and collaborative environment among member companies that allows a free exchange of ideas and technology, while protecting each company�s defined proprietary domains.Company Classification
Associate/Service ProvidersOrganization Type
Drug Development
Investment Bank
Takeda San Francisco, Inc.
285 E Grand Ave
South San Francisco, CA, 94080
650-745-9332
http://www.takedasf.comPrimary Contacts
Mary Haak- Frendscho
President and CSO
Gregory Landes
VP Discovery, Ab Research and Preclinical Development
Michael Buckley
VP Process Sciences
Company Profile
R&D Division of Takeda Pharmaceuticals, focusing on Therapeutic Antibody ResearchCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
285 E Grand Ave
South San Francisco, CA, 94080
650-745-9332
http://www.takedasf.comPrimary Contacts
Mary Haak- Frendscho
President and CSO
Gregory Landes
VP Discovery, Ab Research and Preclinical Development
Michael Buckley
VP Process Sciences
Company Profile
R&D Division of Takeda Pharmaceuticals, focusing on Therapeutic Antibody ResearchCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Metabolic/Endocrinology DisordersPrimary Technology
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
Talon Therapeutics, Inc.
2207 BridgePoint Parkway, Suite 250
San Mateo, CA., 94404
650-588-6404
http://www.talontx.comPrimary Contacts
Steven R. Deitcher, MD
President & Chief Executive Officer
Craig W. Carlson
Senior Vice President, Chief Financial Officer
Gerry L. Messerschmidt, MD, FACP
Vice President, Clinical Research
Company Profile
Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employeesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
DermatologyPrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
Phase I
Phase II
2207 BridgePoint Parkway, Suite 250
San Mateo, CA., 94404
650-588-6404
http://www.talontx.comPrimary Contacts
Steven R. Deitcher, MD
President & Chief Executive Officer
Craig W. Carlson
Senior Vice President, Chief Financial Officer
Gerry L. Messerschmidt, MD, FACP
Vice President, Clinical Research
Company Profile
Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employeesCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Blood & Lymphatic Diseases
Cancer
DermatologyPrimary Technology
Drug Delivery
NanotechnologyClinical Development Stage
Phase I
Phase II
Tandem Sciences, Inc.
1455 Adams Drive, Suite 1017.
Menlo Park, CA, 94025
1-408-307-7731
http://www.tandemsciences.com/Primary Contacts
Kumar Paulvannan
President & CEO
Company Profile
Tandems Sciences is a recently founded custom synthesis and contract research company to provide tools for the early drug discovery process in the biotech and pharmaceutical industry. We have expertise in the area of organic, medicinal, combinatrorial and heterocyclic chemistry. We are committed to providing high quality products and services to our customers in timely fashion. We are also working with well established off-shore contract research organizations to provide efficient and cost-effective chemistry solutions for all stages of small molecule drug discovery. All research is carried out under strict confidentiallity and products are delivered with full analytical data. Services: Custom Synthesis Contract ResearchCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug DevelopmentPrimary Technology
Drug Discovery
1455 Adams Drive, Suite 1017.
Menlo Park, CA, 94025
1-408-307-7731
http://www.tandemsciences.com/Primary Contacts
Kumar Paulvannan
President & CEO
Company Profile
Tandems Sciences is a recently founded custom synthesis and contract research company to provide tools for the early drug discovery process in the biotech and pharmaceutical industry. We have expertise in the area of organic, medicinal, combinatrorial and heterocyclic chemistry. We are committed to providing high quality products and services to our customers in timely fashion. We are also working with well established off-shore contract research organizations to provide efficient and cost-effective chemistry solutions for all stages of small molecule drug discovery. All research is carried out under strict confidentiallity and products are delivered with full analytical data. Services: Custom Synthesis Contract ResearchCompany Classification
Associate/Service ProvidersOrganization Type
Contract Research Organization
Drug DevelopmentPrimary Technology
Drug Discovery
TaoMedix, Inc.
1151 Harbor Bay Parkway, Ste. 101
Alameda, CA, United States, 94502
510-697-1101
Primary Contacts
Lorelie H. Villarete, Ph.D.
CEO & Co-Founder
M.D. Minor, JD., MBA
General Counsel and Co-Founder
Company Profile
TaoMedix is a biopharmaceutical company focused on the development of therapeutics to accelerate wound healing and enhance tissue repair and regeneration of acute and chronic wounds.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
DermatologyPrimary Technology
Cell Biology
Protein EngineeringClinical Development Stage
PreClinical
1151 Harbor Bay Parkway, Ste. 101
Alameda, CA, United States, 94502
510-697-1101
Primary Contacts
Lorelie H. Villarete, Ph.D.
CEO & Co-Founder
M.D. Minor, JD., MBA
General Counsel and Co-Founder
Company Profile
TaoMedix is a biopharmaceutical company focused on the development of therapeutics to accelerate wound healing and enhance tissue repair and regeneration of acute and chronic wounds.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
DermatologyPrimary Technology
Cell Biology
Protein EngineeringClinical Development Stage
PreClinical
Target Discovery, Inc.
4030 Fabian Way
Palo Alto, CA, 94303
650-812-8100
http://www.targetdiscovery.comPrimary Contacts
Jeffrey N. Peterson
CEO
Dr. Luke V. Schneider
CSO
Dr. David C. Bomberger
Director of Manufacturing
Company Profile
Target Discovery is a Personalized Medicine Diagnostics (PMDx) company. We have developed the proteomics tools required to address the "missing link" in finding and leveraging biomarkers of high utility. We discover, validate, and utilize specific post-translational modification states of proteins (isoforms), where primary biochemical pathway control is modulated, to improve clinical diagnosis, management of disease, patient health outcomes, and overall healthcare economics. We are initially focused on important treatment guidance decisions in cancer. However, our Isonostics(TM) technologies offer disruptive potential across the full spectrum of clinical diagnostics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
ProteomicsClinical Development Stage
PreClinical
Phase I
4030 Fabian Way
Palo Alto, CA, 94303
650-812-8100
http://www.targetdiscovery.comPrimary Contacts
Jeffrey N. Peterson
CEO
Dr. Luke V. Schneider
CSO
Dr. David C. Bomberger
Director of Manufacturing
Company Profile
Target Discovery is a Personalized Medicine Diagnostics (PMDx) company. We have developed the proteomics tools required to address the "missing link" in finding and leveraging biomarkers of high utility. We discover, validate, and utilize specific post-translational modification states of proteins (isoforms), where primary biochemical pathway control is modulated, to improve clinical diagnosis, management of disease, patient health outcomes, and overall healthcare economics. We are initially focused on important treatment guidance decisions in cancer. However, our Isonostics(TM) technologies offer disruptive potential across the full spectrum of clinical diagnostics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
ProteomicsClinical Development Stage
PreClinical
Phase I
Targeted Therapeutics Consulting, Inc.
301 Ashton Ln.
Mill Valley, CA, United States, 94941
877-882-1124
http://www.targettherapeutics.comPrimary Contacts
John R. Hedlund
President & CEO
808-352-3132
John Zorn
CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Consulting Firms
Information Technology
301 Ashton Ln.
Mill Valley, CA, United States, 94941
877-882-1124
http://www.targettherapeutics.comPrimary Contacts
John R. Hedlund
President & CEO
808-352-3132
John Zorn
CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
BioInformatics
Consulting Firms
Information Technology
Technology Vision Group
United States, http://www.techvision.comCompany Classification
Associate/Service Providers
United States, http://www.techvision.comCompany Classification
Associate/Service Providers
Teikoku Pharma USA, Inc.
1718 Ringwood Avenue
San Jose, CA, 95131
(408) 501-1800
http://www.teikokuusa.comPrimary Contacts
Atsumu Matsushita
CFO
Paul Mori
Executive VP and COO
Tetsuto Nagata
Executive VP & CSO
Company Profile
Pharmaceutical Research and manufacturingCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Contract Research OrganizationPrimary Technology
Drug Delivery
1718 Ringwood Avenue
San Jose, CA, 95131
(408) 501-1800
http://www.teikokuusa.comPrimary Contacts
Atsumu Matsushita
CFO
Paul Mori
Executive VP and COO
Tetsuto Nagata
Executive VP & CSO
Company Profile
Pharmaceutical Research and manufacturingCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Contract Manufacturing
Contract Research OrganizationPrimary Technology
Drug Delivery
Telik, Inc.
700 Hansen Way
Palo Alto, CA, 94304
(650)-845-7700
http://www.telik.comPrimary Contacts
Michael M. Wick, M.D., Ph.D.
Chairman, Chief Executive Officer, and President
Wendy K. Wee
Vice President Finance and Controller
Steven R. Schow, Ph.D.
Vice President, Research and Development
Company Profile
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel small-molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA, which is in Phase 2 clinical development for myelodysplastic syndrome and severe chronic idiopathic neutropenia. TELINTRA is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA, is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology TRAP, which enables the rapid and efficient discovery of small-molecule drug candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Computational ChemistryClinical Development Stage
Phase II
700 Hansen Way
Palo Alto, CA, 94304
(650)-845-7700
http://www.telik.comPrimary Contacts
Michael M. Wick, M.D., Ph.D.
Chairman, Chief Executive Officer, and President
Wendy K. Wee
Vice President Finance and Controller
Steven R. Schow, Ph.D.
Vice President, Research and Development
Company Profile
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel small-molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA, which is in Phase 2 clinical development for myelodysplastic syndrome and severe chronic idiopathic neutropenia. TELINTRA is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA, is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology TRAP, which enables the rapid and efficient discovery of small-molecule drug candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
CancerPrimary Technology
Computational ChemistryClinical Development Stage
Phase II
Telome Health, Inc.
United States, http://www.telomehealth.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
United States, http://www.telomehealth.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Diagnostic
Tethys Bioscience, Inc.
Emeryville, CA, 94608
510-420-6700
http://www.tethysbio.com/index.htmlPrimary Contacts
Mickey Urdea
CEO
Randy Strahan
President & COO
Mohan Iyer
CFO
Company Profile
Tethys creates and commercializes innovative, biomarker-based blood tests that enable healthcare providers to accurately predict imminent disease risk, facilitate targeted intervention and preempt the onset of chronic cardiometabolic conditions. Tethys’ PreDx™ Diabetes Risk Score (PreDx DRS) was developed utilizing proprietary biomarker and algorithm technologies to stratify patients based on disease propensity and accurately identify those at highest risk of developing type 2 diabetes within five years, thus enabling early interventions clinically proven to prevent or slow progression. Tethys’ breakthrough PreDx platform can improve health outcomes, save lives and reduce the devastating economic impact that debilitating, preventable diseases have on individuals and societyCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersClinical Development Stage
Approved
Emeryville, CA, 94608
510-420-6700
http://www.tethysbio.com/index.htmlPrimary Contacts
Mickey Urdea
CEO
Randy Strahan
President & COO
Mohan Iyer
CFO
Company Profile
Tethys creates and commercializes innovative, biomarker-based blood tests that enable healthcare providers to accurately predict imminent disease risk, facilitate targeted intervention and preempt the onset of chronic cardiometabolic conditions. Tethys’ PreDx™ Diabetes Risk Score (PreDx DRS) was developed utilizing proprietary biomarker and algorithm technologies to stratify patients based on disease propensity and accurately identify those at highest risk of developing type 2 diabetes within five years, thus enabling early interventions clinically proven to prevent or slow progression. Tethys’ breakthrough PreDx platform can improve health outcomes, save lives and reduce the devastating economic impact that debilitating, preventable diseases have on individuals and societyCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Cardiovascular & Circulatory Disorders
Metabolic/Endocrinology DisordersClinical Development Stage
Approved
Thallo Bioscience Advisors, LLC
580 California Street, Suite 1200
San Francisco, CA, United States, 94104
415-310-5777
http://www.thallobiosciences.comPrimary Contacts
Joanna Schulman
Managing Partner
415-310-5777
Company Profile
Thallo Bioscience Advisors, LLC is a financial and strategic advisory firm serving clients in the global life sciences industry. Our clients range from early stage start-ups to multinational enterprises. At Thallo our goal is to maximize the value of a company by developing individually tailored business and financial solutions to address corporate growth needs. By leveraging our extensive network of investors, key company decision makers and industry thought leaders we are able to facilitate and expedite transactions on behalf of clients. Our advisory services include: •Strategic Advisory •Corporate Partnering and Licensing •Mergers and Acquisition Advisory •Asset Acquisition and Divestiture •Corporate Positioning and Competitive Intelligence •Valuation Analysis •Corporate Formation and Structuring •Capital FinancingCompany Classification
Associate/Service ProvidersOrganization Type
Business Development
580 California Street, Suite 1200
San Francisco, CA, United States, 94104
415-310-5777
http://www.thallobiosciences.comPrimary Contacts
Joanna Schulman
Managing Partner
415-310-5777
Company Profile
Thallo Bioscience Advisors, LLC is a financial and strategic advisory firm serving clients in the global life sciences industry. Our clients range from early stage start-ups to multinational enterprises. At Thallo our goal is to maximize the value of a company by developing individually tailored business and financial solutions to address corporate growth needs. By leveraging our extensive network of investors, key company decision makers and industry thought leaders we are able to facilitate and expedite transactions on behalf of clients. Our advisory services include: •Strategic Advisory •Corporate Partnering and Licensing •Mergers and Acquisition Advisory •Asset Acquisition and Divestiture •Corporate Positioning and Competitive Intelligence •Valuation Analysis •Corporate Formation and Structuring •Capital FinancingCompany Classification
Associate/Service ProvidersOrganization Type
Business Development
The Column Group
United States, http://www.thecolumngroup.netCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
United States, http://www.thecolumngroup.netCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Theravance, Inc.
901 Gateway
South San Francisco, CA, 94010
650-808-6000
http://www.theravance.comPrimary Contacts
Rick E Winningham
CEO and Chairman of the Board
Mike Aguiar
Senior Vice President and Chief Financial Officer
Mathai Mammen
Senior Vice President Research and Early Clinical Development
Company Profile
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. We are focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Our key programs include: RELOVAIR, LAMA/LABA (719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta 2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PMA) program. By leveraging our proprietary insight of multivalency to drug discovery, we are pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central Nervous
Infectious Disease
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
901 Gateway
South San Francisco, CA, 94010
650-808-6000
http://www.theravance.comPrimary Contacts
Rick E Winningham
CEO and Chairman of the Board
Mike Aguiar
Senior Vice President and Chief Financial Officer
Mathai Mammen
Senior Vice President Research and Early Clinical Development
Company Profile
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. We are focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Our key programs include: RELOVAIR, LAMA/LABA (719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta 2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PMA) program. By leveraging our proprietary insight of multivalency to drug discovery, we are pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central Nervous
Infectious Disease
Respiratory DisordersPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Approved
Tobira Therapeutics
400 Oyster Point Blvd. Suite 525
South San Francisco, CA, United States, 94080
650-741-6625
http://www.tobiratherapeutics.comPrimary Contacts
Andrew Hindman
President and CEO
Kathleen McGowan
Vice President, Finance
Eric Lefebvre
CMO
Antoun Nabhan
VP, Corporate Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Infectious DiseaseClinical Development Stage
Phase II
400 Oyster Point Blvd. Suite 525
South San Francisco, CA, United States, 94080
650-741-6625
http://www.tobiratherapeutics.comPrimary Contacts
Andrew Hindman
President and CEO
Kathleen McGowan
Vice President, Finance
Eric Lefebvre
CMO
Antoun Nabhan
VP, Corporate Development
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Autoimmune & Inflammatory
Infectious DiseaseClinical Development Stage
Phase II
Topica Pharmaceuticals, Inc.
435 Tasso Street, Suite 325
Palo Alto, CA, 94301
650-473-3811
http://www.topicapharma.comPrimary Contacts
Greg Vontz
President and Chief Executive Officer
Joe Golemme
Chief Financial Officer
Mark Davis
Vice President of Clinical Development
Company Profile
TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-Pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of onychomycosis (fungal infections of the nail).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
DermatologyClinical Development Stage
Phase II
435 Tasso Street, Suite 325
Palo Alto, CA, 94301
650-473-3811
http://www.topicapharma.comPrimary Contacts
Greg Vontz
President and Chief Executive Officer
Joe Golemme
Chief Financial Officer
Mark Davis
Vice President of Clinical Development
Company Profile
TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-Pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of onychomycosis (fungal infections of the nail).Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
DermatologyClinical Development Stage
Phase II
Touro University California
1310 Club Drive
Vallejo, CA, United States, 94592
707-638-5002
http://www.tu.eduPrimary Contacts
Dr. Marilyn Hopkins
Provost and Chief Operating Officer
707-638-5276
Reed Goertler
Chief Financial Officer
707-638-5259
Dr. Katherine Knapp
Dean, College of Pharmacy
707-638-5221
Company Profile
Touro University California is an independent institution of higher and professional education. Together with Touro University Nevada, it constitutes the Western Division of the Touro system, comprised of 28 undergraduate and graduate degree granting institutions world-wide. Touro has long been interested in medical education. In 1983, Touro established the Center for Biomedical Education, a cooperative program leading to an M.D. from the Technion-Israel Institute of Technology, Israel's premier school of applied sciences. Success in this and related programs led Touro to establish a College of Osteopathic Medicine in the San Francisco Bay Area in 1997. The campus was moved to Mare Island, California in 1999, and became the founding college of Touro University California. Touro University California is now composed of four colleges: • College of Osteopathic Medicine - Granting the Doctor of Osteopathic Medicine (D.O.) degree. • College of Health Sciences - Founded 2003 and granting the Master of Science in Physician Assistant Studies (MSPAS) and Master of Public Health (MPH) degrees. • College of Education - Founded 2004 and providing special education teacher credentials. • College of Pharmacy - Founded 2005 and granting the Doctor of Pharmacy (Pharm.D.) degree. All four programs are fully accredited.Company Classification
Associate/Service ProvidersOrganization Type
Education
1310 Club Drive
Vallejo, CA, United States, 94592
707-638-5002
http://www.tu.eduPrimary Contacts
Dr. Marilyn Hopkins
Provost and Chief Operating Officer
707-638-5276
Reed Goertler
Chief Financial Officer
707-638-5259
Dr. Katherine Knapp
Dean, College of Pharmacy
707-638-5221
Company Profile
Touro University California is an independent institution of higher and professional education. Together with Touro University Nevada, it constitutes the Western Division of the Touro system, comprised of 28 undergraduate and graduate degree granting institutions world-wide. Touro has long been interested in medical education. In 1983, Touro established the Center for Biomedical Education, a cooperative program leading to an M.D. from the Technion-Israel Institute of Technology, Israel's premier school of applied sciences. Success in this and related programs led Touro to establish a College of Osteopathic Medicine in the San Francisco Bay Area in 1997. The campus was moved to Mare Island, California in 1999, and became the founding college of Touro University California. Touro University California is now composed of four colleges: • College of Osteopathic Medicine - Granting the Doctor of Osteopathic Medicine (D.O.) degree. • College of Health Sciences - Founded 2003 and granting the Master of Science in Physician Assistant Studies (MSPAS) and Master of Public Health (MPH) degrees. • College of Education - Founded 2004 and providing special education teacher credentials. • College of Pharmacy - Founded 2005 and granting the Doctor of Pharmacy (Pharm.D.) degree. All four programs are fully accredited.Company Classification
Associate/Service ProvidersOrganization Type
Education
Transcept Pharmaceuticals, Inc.
1003 W. Cutting Blvd., Suite 110
Point Richmond, CA, 94804
510.215.3500
http://www.transcept.comPrimary Contacts
Glenn A. Oclassen
President & Chief Executive Officer
Thomas P. soloway
Senior Vice President & Chief Financial Officer
Nikhilesh N. Singh, PhD
Senior Vice President, Founder, & Chief Scientific Officer
Company Profile
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
1003 W. Cutting Blvd., Suite 110
Point Richmond, CA, 94804
510.215.3500
http://www.transcept.comPrimary Contacts
Glenn A. Oclassen
President & Chief Executive Officer
Thomas P. soloway
Senior Vice President & Chief Financial Officer
Nikhilesh N. Singh, PhD
Senior Vice President, Founder, & Chief Scientific Officer
Company Profile
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
Trigemina, Inc.
1036 Country Club Dr. Ste 200
Moraga, CA, United States, 94556
925-377-0664
http://www.trigemina.comPrimary Contacts
Charles C. Yeomens
President & CEO
Brian Frenzel
Consultant and CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousClinical Development Stage
Phase I
1036 Country Club Dr. Ste 200
Moraga, CA, United States, 94556
925-377-0664
http://www.trigemina.comPrimary Contacts
Charles C. Yeomens
President & CEO
Brian Frenzel
Consultant and CFO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Central NervousClinical Development Stage
Phase I
Tunitas Therapeutics, Inc.
409 Illinois Street
San Francisco, CA, United States, 94158
650-887-4747
http://www.tunitastherapeutics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
409 Illinois Street
San Francisco, CA, United States, 94158
650-887-4747
http://www.tunitastherapeutics.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
U.S. Venture Partners
United States, http://www.usvp.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
United States, http://www.usvp.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
U.S. WorldMeds, LLC
United States, Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
UBIFRANCE
88 Kearny street, suite 700
San Francisco, CA, United States, 94108
415-568-4570
http://www.ubifrance.com/us/Primary Contacts
Benoit Colinot
DIRECTOR - Biotech & Medical Device Team
415-568-4566
Delphine Ortega
Biotech trade advisor
415-568-4581
Company Profile
Ubifrance is the French agency in charge of facilitating partnerships and collaborations between French and foreign companies. We work with more than 800 foreign and 100 French companies each year, ranging from large Pharma companies to start-ups and academic institutions.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Business Development
Government AgenciesDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Respiratory DisordersPrimary Technology
Drug Delivery
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
88 Kearny street, suite 700
San Francisco, CA, United States, 94108
415-568-4570
http://www.ubifrance.com/us/Primary Contacts
Benoit Colinot
DIRECTOR - Biotech & Medical Device Team
415-568-4566
Delphine Ortega
Biotech trade advisor
415-568-4581
Company Profile
Ubifrance is the French agency in charge of facilitating partnerships and collaborations between French and foreign companies. We work with more than 800 foreign and 100 French companies each year, ranging from large Pharma companies to start-ups and academic institutions.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Business Development
Government AgenciesDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Cardiovascular & Circulatory Disorders
Central Nervous
Genetic Diseases
Infectious Disease
Kidneys & Genito-Urinary System
Metabolic/Endocrinology Disorders
Respiratory DisordersPrimary Technology
Drug Delivery
Drug Discovery
Gene/Cell TherapyClinical Development Stage
PreClinical
Phase I
Phase II
Phase III
UC Berkeley Extension
1995 University Avenue
Berkeley, CA, United States, 94704-7000
510-642-4111
http://extension.berkeley.edu/sciences/Primary Contacts
Victoria Sharma, Ph.D.
Program Director, Biotechnology
510-642-1062
Barbara Peterson, Ph.D.
Program Director, Sciences and Mathematics
510-642-1061
Company Profile
Whether you're a biotechnology research or business professional, stay current with the industry's latest developments, and learn practical knowledge on topics of critical importance to bioscience companies. Get exposure to the latest professional trends in the pharmaceutical, biotechnology, medical device, and diagnostics industries. Build on existing skills and experience to advance or shift your career in a new direction. Courses are scheduled for working professionals and held in Berkeley, San Francisco, Belmont, and online.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
1995 University Avenue
Berkeley, CA, United States, 94704-7000
510-642-4111
http://extension.berkeley.edu/sciences/Primary Contacts
Victoria Sharma, Ph.D.
Program Director, Biotechnology
510-642-1062
Barbara Peterson, Ph.D.
Program Director, Sciences and Mathematics
510-642-1061
Company Profile
Whether you're a biotechnology research or business professional, stay current with the industry's latest developments, and learn practical knowledge on topics of critical importance to bioscience companies. Get exposure to the latest professional trends in the pharmaceutical, biotechnology, medical device, and diagnostics industries. Build on existing skills and experience to advance or shift your career in a new direction. Courses are scheduled for working professionals and held in Berkeley, San Francisco, Belmont, and online.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
UGL Services
United States, http://www.ugl-unicco.comCompany Classification
Associate/Service Providers
United States, http://www.ugl-unicco.comCompany Classification
Associate/Service Providers
UK Trade & Investment
1 Sansome Street Suite 850
San Francisco, CA, United States, 94104
http://www.uktradeinvestusa.comPrimary Contacts
Marcie Newman Reid
415-617-1374
Company Profile
UK Trade & Investment (UKTI) is the British Government's international business development organization. UKTI helps UK companies succeed in international markets and assists overseas companies to bring high quality investment to the UK. The UK's open and agile business environment, limited regulation and favorable business conditions mean it has never been easier for foreign investors to establish a UK operation. UKTI’s influence, advice and practical assistance can open the right doors for your company, maximize your resources, and save you significant amounts of time and money. Our expert teams can also also help you navigate the regulatory and reimbursement landscape in the UK to effectively gain market access and help your business succeed overseas. UKTI’s services are entirely free and confidential. Please contact us today to learn more about how we can support your business.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
Government Agencies
1 Sansome Street Suite 850
San Francisco, CA, United States, 94104
http://www.uktradeinvestusa.comPrimary Contacts
Marcie Newman Reid
415-617-1374
Company Profile
UK Trade & Investment (UKTI) is the British Government's international business development organization. UKTI helps UK companies succeed in international markets and assists overseas companies to bring high quality investment to the UK. The UK's open and agile business environment, limited regulation and favorable business conditions mean it has never been easier for foreign investors to establish a UK operation. UKTI’s influence, advice and practical assistance can open the right doors for your company, maximize your resources, and save you significant amounts of time and money. Our expert teams can also also help you navigate the regulatory and reimbursement landscape in the UK to effectively gain market access and help your business succeed overseas. UKTI’s services are entirely free and confidential. Please contact us today to learn more about how we can support your business.Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Foreign Agencies
Government Agencies
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, CA, United States, 94949
415-483-8800
www.ultragenyx.comPrimary Contacts
Emil Kakkis, MD, PhD
Chief Executive Officer
Company Profile
Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market. The company focuses on metabolic and rare diseases that may affect small numbers of patients, but for which the medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these clinically underserved diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Genetic Diseases
Musculoskeletal DisordersClinical Development Stage
PreClinical
Phase I
Phase II
60 Leveroni Court
Novato, CA, United States, 94949
415-483-8800
www.ultragenyx.comPrimary Contacts
Emil Kakkis, MD, PhD
Chief Executive Officer
Company Profile
Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market. The company focuses on metabolic and rare diseases that may affect small numbers of patients, but for which the medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these clinically underserved diseases.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Genetic Diseases
Musculoskeletal DisordersClinical Development Stage
PreClinical
Phase I
Phase II
Universal Bio Mining
Universal Bio Mining
San Francisco, CA, United States, 94107
http://universalbiomining.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
Universal Bio Mining
San Francisco, CA, United States, 94107
http://universalbiomining.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Industrial Biotechnology
University of California, Office of the President
University of California, Santa Cruz Extension
2505 Augustine Drive
Santa Clara, CA, United States, 95054
408-861-3700
http://www.ucsc-extension.edu/Primary Contacts
Andy Hou
Director of Engineering and Technology
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
2505 Augustine Drive
Santa Clara, CA, United States, 95054
408-861-3700
http://www.ucsc-extension.edu/Primary Contacts
Andy Hou
Director of Engineering and Technology
Company Classification
Education, Research Institution, Government Agency, other Non-ProfitOrganization Type
Education
Valley Fever Solutions, Inc.
175 Brookwood Rd
Woodside, CA, United States, 94062
650-454-4126
http://www.ValleyFeverSolutions.comPrimary Contacts
David Larwood
CEO
John Galgiani
Chief Medical Officer
Company Profile
Valley Fever Solutions is preparing to start Phase IIa trials on a drug candidate that is a new class of antifungal, specifically for Valley Fever, an orphan indication. We are looking at improved diagnostics for the disease, and collaborate closely with a group that is also studying vaccine candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Infectious Disease
Respiratory DisordersPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
Phase II
175 Brookwood Rd
Woodside, CA, United States, 94062
650-454-4126
http://www.ValleyFeverSolutions.comPrimary Contacts
David Larwood
CEO
John Galgiani
Chief Medical Officer
Company Profile
Valley Fever Solutions is preparing to start Phase IIa trials on a drug candidate that is a new class of antifungal, specifically for Valley Fever, an orphan indication. We are looking at improved diagnostics for the disease, and collaborate closely with a group that is also studying vaccine candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Infectious Disease
Respiratory DisordersPrimary Technology
Biomanufacturing
Drug DiscoveryClinical Development Stage
Phase II
Veeda Oncology
250 E. Broad St., Suite 1750
Columbus, OH, 43215
614-643-1480
http://www.veedaoncology.comPrimary Contacts
Matthew Bowman
CEO
614-643-1484
Dana K. Oaks
Controller
614-643-1489
Dave Colborn
Director of Data Management/Operations
614-643-1485
Mia Hurn
Director of Business Development
415-345-1479
Company Profile
Veeda Oncology provides services to pharmaceutical companies desiring to conduct clinical trials of prospective oncological drugs. As the manager of trials Veeda Oncology provides start-up, oversight, monitoring, reporting, data management and other activities.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase I
Phase III
Approved
250 E. Broad St., Suite 1750
Columbus, OH, 43215
614-643-1480
http://www.veedaoncology.comPrimary Contacts
Matthew Bowman
CEO
614-643-1484
Dana K. Oaks
Controller
614-643-1489
Dave Colborn
Director of Data Management/Operations
614-643-1485
Mia Hurn
Director of Business Development
415-345-1479
Company Profile
Veeda Oncology provides services to pharmaceutical companies desiring to conduct clinical trials of prospective oncological drugs. As the manager of trials Veeda Oncology provides start-up, oversight, monitoring, reporting, data management and other activities.Company Classification
Associate/Service ProvidersOrganization Type
Contract Research OrganizationDisease Areas of Focus
CancerPrimary Technology
Drug DeliveryClinical Development Stage
PreClinical
Phase I
Phase III
Approved
Velocity Pharmaceutical Development
400 Oyster Point Blvd, Suite 202
South San Francisco, CA, United States, 94080
650-273-5748
http://www.vpd.netCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
400 Oyster Point Blvd, Suite 202
South San Francisco, CA, United States, 94080
650-273-5748
http://www.vpd.netCompany Classification
Bioscience/R&D/Non-Profit conducting R&D
Veracyte, Inc.
7000 Shoreline Court, Suite 250
South San Francisco, CA, 94019
650-243-6300
http://www.veracyte.comPrimary Contacts
Bonnie Anderson
Chief Executive Officer
Chris Hall
Chief Commercial Officer
Richard B. Lanman
Chief Medical Officer
Company Profile
Molecular diagnostics company focused on advancing molecular cytology.Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
GenomicsClinical Development Stage
PreClinical
Approved
7000 Shoreline Court, Suite 250
South San Francisco, CA, 94019
650-243-6300
http://www.veracyte.comPrimary Contacts
Bonnie Anderson
Chief Executive Officer
Chris Hall
Chief Commercial Officer
Richard B. Lanman
Chief Medical Officer
Company Profile
Molecular diagnostics company focused on advancing molecular cytology.Company Classification
Bioscience/R&D/Non-Profit conducting R&DDisease Areas of Focus
CancerPrimary Technology
Bioinformatics
GenomicsClinical Development Stage
PreClinical
Approved
Verinata Health, Inc.
1531 Industrial Road
San Carlos, CA, 94070
650-632-1680
http://www.verinata.comPrimary Contacts
Caren L. Mason
CEO
Richard P. Rava
President & Sr. VP of R&D
Company Profile
Verinata Health is driven by a sole , extraordinary purpose - maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosome abnormalities using our proprietary technology. For more information about Artemis Health, please got to www.verinata.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Womens HealthPrimary Technology
Bioinformatics
Genomics
1531 Industrial Road
San Carlos, CA, 94070
650-632-1680
http://www.verinata.comPrimary Contacts
Caren L. Mason
CEO
Richard P. Rava
President & Sr. VP of R&D
Company Profile
Verinata Health is driven by a sole , extraordinary purpose - maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosome abnormalities using our proprietary technology. For more information about Artemis Health, please got to www.verinata.com.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Womens HealthPrimary Technology
Bioinformatics
Genomics
Versaggi Biocommunications
9 Carolyn Ct.
Mill Valley, CA, United States, 94941
415 806-6039
http://www.versaggibio.comPrimary Contacts
Charles Versaggi
President
415-806-6039
Company Profile
Versaggi Biocommunications is a full-service strategic consultancy serving the marketing and communications needs of life sciences companies.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
9 Carolyn Ct.
Mill Valley, CA, United States, 94941
415 806-6039
http://www.versaggibio.comPrimary Contacts
Charles Versaggi
President
415-806-6039
Company Profile
Versaggi Biocommunications is a full-service strategic consultancy serving the marketing and communications needs of life sciences companies.Company Classification
Associate/Service ProvidersOrganization Type
Corporate Communication
Media
Versant Ventures
United States, http://VersantVentures.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
United States, http://VersantVentures.comCompany Classification
Associate/Service ProvidersOrganization Type
Venture Capital
Versartis, Inc.
500 Ellis Street
Mountain View, CA, 94043
(650) 963-8580
http://www.versartis.comPrimary Contacts
Jeffrey L. Cleland
Chief Executive Officer
Company Profile
Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&D
500 Ellis Street
Mountain View, CA, 94043
(650) 963-8580
http://www.versartis.comPrimary Contacts
Jeffrey L. Cleland
Chief Executive Officer
Company Profile
Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.Company Classification
Bioscience/R&D/Non-Profit conducting R&D
Virobay, Inc.
1490 O'Brien Dr.
Menlo Park, CA, United States, 94025
650-833-5703
http://www.virobayinc.comPrimary Contacts
Robert Booth
CEO
David B Karpf
CMO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Central Nervous
DermatologyClinical Development Stage
PreClinical
Phase I
1490 O'Brien Dr.
Menlo Park, CA, United States, 94025
650-833-5703
http://www.virobayinc.comPrimary Contacts
Robert Booth
CEO
David B Karpf
CMO
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Central Nervous
DermatologyClinical Development Stage
PreClinical
Phase I
VistaGen Therapeutics, Inc.
United States, http://www.vistagen-inc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.vistagen-inc.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
VitaPath Genetics
348 Hatch Dr.
Foster City, CA, 94404
650-235-2020
http://www.vpgenetics.comPrimary Contacts
Bruce Cohen
CEO & President
Dennis Gilbert, Ph.D.
Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Genetic Diseases
Womens Health
348 Hatch Dr.
Foster City, CA, 94404
650-235-2020
http://www.vpgenetics.comPrimary Contacts
Bruce Cohen
CEO & President
Dennis Gilbert, Ph.D.
Chief Scientific Officer
Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Genetic Diseases
Womens Health
VytronUS, Inc.
658 N Pastoria Ave.
Sunnyvale, CA, 94085
408-730-1333
http://www.vytronus.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&D
658 N Pastoria Ave.
Sunnyvale, CA, 94085
408-730-1333
http://www.vytronus.com/Company Classification
Bioscience/R&D/Non-Profit conducting R&D
Wave 80 Biosciences, Inc.
2325 Third Street, Suite 215
San Francisco, CA, 94107
415-487-7976
http://www.wave80.comPrimary Contacts
Daniel Laser, Ph.D.
CEO & President
Richard Goozh
CFO
Laura Mazzola, Ph.D.
SVP, Global Initiatives
Company Profile
Wave 80 Biosciences, Inc. develops next-generation molecular diagnostics products for infectious disease, cancer, autoimmune disease, and other human health conditions. The company began operations in 2003, with a small team of engineers, biologists, and chemists working out of warehouse space in San Francisco’s Dogpatch neighborhood to develop new high-performance, cost-effective technologies for processing complex fluid samples. The company quickly made breakthroughs in life sciences applications ranging from immunotherapeutics to biomolecular analysis, including demonstrating in 2005 the first fully automated field-use system for quantitative multiplexed immunoassays. In 2007, Wave 80 initiated a development program combining novel nucleic acid assay methods with fluid transport technology adapted from integrated circuit thermal management to address emerging needs for viral load monitoring to accompany expanding access to antiretroviral therapy among the estimated 30 million people living with HIV in low- and middle-income countries. The first versions of the EOSCAPE-HIV system are scheduled to enter beta testing in clinics in Kenya and South Africa in 2012. Building on the EOSCAPE-HIV’s success, Wave 80 has expanded its product pipeline to include molecular diagnostic tests for a variety of infectious and non-infectious diseases, including hepatitis C, hepatitis B, cardiovascular disease, and certain autoimmune diseases and cancers. Wave 80’s first products targeting high-unmet-need areas of the U.S. clinical laboratory testing market have recently entered preliminary clinical studies.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Infectious DiseasePrimary Technology
MicrofluidicsClinical Development Stage
PreClinical
2325 Third Street, Suite 215
San Francisco, CA, 94107
415-487-7976
http://www.wave80.comPrimary Contacts
Daniel Laser, Ph.D.
CEO & President
Richard Goozh
CFO
Laura Mazzola, Ph.D.
SVP, Global Initiatives
Company Profile
Wave 80 Biosciences, Inc. develops next-generation molecular diagnostics products for infectious disease, cancer, autoimmune disease, and other human health conditions. The company began operations in 2003, with a small team of engineers, biologists, and chemists working out of warehouse space in San Francisco’s Dogpatch neighborhood to develop new high-performance, cost-effective technologies for processing complex fluid samples. The company quickly made breakthroughs in life sciences applications ranging from immunotherapeutics to biomolecular analysis, including demonstrating in 2005 the first fully automated field-use system for quantitative multiplexed immunoassays. In 2007, Wave 80 initiated a development program combining novel nucleic acid assay methods with fluid transport technology adapted from integrated circuit thermal management to address emerging needs for viral load monitoring to accompany expanding access to antiretroviral therapy among the estimated 30 million people living with HIV in low- and middle-income countries. The first versions of the EOSCAPE-HIV system are scheduled to enter beta testing in clinics in Kenya and South Africa in 2012. Building on the EOSCAPE-HIV’s success, Wave 80 has expanded its product pipeline to include molecular diagnostic tests for a variety of infectious and non-infectious diseases, including hepatitis C, hepatitis B, cardiovascular disease, and certain autoimmune diseases and cancers. Wave 80’s first products targeting high-unmet-need areas of the U.S. clinical laboratory testing market have recently entered preliminary clinical studies.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Autoimmune & Inflammatory
Cancer
Infectious DiseasePrimary Technology
MicrofluidicsClinical Development Stage
PreClinical
Wilson Sonsini Goodrich & Rosati
650 Page Mill Road
Palo Alto, CA, 94304-1050
650-493-9300
http://www.wsgr.comPrimary Contacts
Kenneth Clark
Partner
650-493-9300
Ian Edvalson
Partner
650-493-9300
Miranda Richardson
Partner
650-493-9300
Donna Petkanics
Partner
650-493-9300
Vern Norviel
Partner
650-493-9300
Jim Oettinger
Partner
650-493-9300
Company Profile
Celebrating its 50th anniversary in 2011, Wilson Sonsini Goodrich & Rosati offers a broad range of services and legal disciplines focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leader in the fields of corporate governance and finance, mergers and acquisitions, private equity, securities litigation, employment law, intellectual property, and antitrust, among many other areas of law. With long-standing roots in Silicon Valley, Wilson Sonsini Goodrich & Rosati has offices in Austin, Hong Kong, New York, Palo Alto, San Diego, San Francisco, Seattle, Shanghai, and Washington, D.C. For more information, please visit www.wsgr.com.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
650 Page Mill Road
Palo Alto, CA, 94304-1050
650-493-9300
http://www.wsgr.comPrimary Contacts
Kenneth Clark
Partner
650-493-9300
Ian Edvalson
Partner
650-493-9300
Miranda Richardson
Partner
650-493-9300
Donna Petkanics
Partner
650-493-9300
Vern Norviel
Partner
650-493-9300
Jim Oettinger
Partner
650-493-9300
Company Profile
Celebrating its 50th anniversary in 2011, Wilson Sonsini Goodrich & Rosati offers a broad range of services and legal disciplines focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leader in the fields of corporate governance and finance, mergers and acquisitions, private equity, securities litigation, employment law, intellectual property, and antitrust, among many other areas of law. With long-standing roots in Silicon Valley, Wilson Sonsini Goodrich & Rosati has offices in Austin, Hong Kong, New York, Palo Alto, San Diego, San Francisco, Seattle, Shanghai, and Washington, D.C. For more information, please visit www.wsgr.com.Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Witt Kieffer
2200 Powell St. Suite 890
Emeryville, CA, United States, 94608
510-420-1370
Primary Contacts
Steve Kirnon
Practice Leader, Life Sciences
510-420-1370
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
2200 Powell St. Suite 890
Emeryville, CA, United States, 94608
510-420-1370
Primary Contacts
Steve Kirnon
Practice Leader, Life Sciences
510-420-1370
Company Classification
Associate/Service ProvidersOrganization Type
Consulting Firms
Womble Carlyle Sandridge & Rice, LLP
10050 North Wolfe Rd.
Cupertino, CA, United States, 95014
408-341-3000
http://www.wcsr.comPrimary Contacts
Steve Bell
Chief Client Development Officer
703-394-2242
Terry Wiley
Executive Director
336-721-3745
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
10050 North Wolfe Rd.
Cupertino, CA, United States, 95014
408-341-3000
http://www.wcsr.comPrimary Contacts
Steve Bell
Chief Client Development Officer
703-394-2242
Terry Wiley
Executive Director
336-721-3745
Company Classification
Associate/Service ProvidersOrganization Type
Law Firms
Woodruff-Sawyer & Co.
United States, http://www.woodruff-sawyer.comCompany Classification
Associate/Service ProvidersOrganization Type
Insurance
United States, http://www.woodruff-sawyer.comCompany Classification
Associate/Service ProvidersOrganization Type
Insurance
Xalud Therapeutics
United States, http://www.xaludthera.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
United States, http://www.xaludthera.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
XenoPort, Inc.
3410 Central Expressway
Santa Clara, CA, 94062
408-616-7200
http://www.XenoPort.comCompany Profile
A biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
Phase III
Approved
3410 Central Expressway
Santa Clara, CA, 94062
408-616-7200
http://www.XenoPort.comCompany Profile
A biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Drug DevelopmentDisease Areas of Focus
Central NervousPrimary Technology
Drug DiscoveryClinical Development Stage
PreClinical
Phase II
Phase III
Approved
Xeris Pharmaceuticals, Inc.
1029 Lea Drive, Suite B
San Rafael, CA, 94903
415-250-8763
http://www.xerispharma.comPrimary Contacts
John Kinzell
CEO
Company Profile
XERIS is a early-stage biophrmaceutical company developing ready-to-use, patient-friendly injectable biologics using its disruptive formulation and injection platforms. It's lead product is a glucagon rescue pen (G-Pen) for severe hypoglycemia in diabetics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
Womens HealthPrimary Technology
Drug Delivery
Microfluidics
NanotechnologyClinical Development Stage
PreClinical
1029 Lea Drive, Suite B
San Rafael, CA, 94903
415-250-8763
http://www.xerispharma.comPrimary Contacts
John Kinzell
CEO
Company Profile
XERIS is a early-stage biophrmaceutical company developing ready-to-use, patient-friendly injectable biologics using its disruptive formulation and injection platforms. It's lead product is a glucagon rescue pen (G-Pen) for severe hypoglycemia in diabetics.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
TherapeuticDisease Areas of Focus
Autoimmune & Inflammatory
Metabolic/Endocrinology Disorders
Musculoskeletal Disorders
Womens HealthPrimary Technology
Drug Delivery
Microfluidics
NanotechnologyClinical Development Stage
PreClinical
Xlumena, Inc.
453 Ravendale Drive, Suite H
Mountain View, CA, 94043
650-961-9900
http://www.xlumena.comPrimary Contacts
Michael Allen
President & CEO
Company Profile
Xlumena is the leader in the development of image-guided therapeutic endoscopy products specializing in advanced implants and devices that address multiple markets. Collaborating with top physicians in the field, Xlumena focuses on technology that advances therapy to the next level. These innovations may enable numerous translumenal therapeutic procedures, helping transform complex surgeries into outpatient events.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemPrimary Technology
BiomanufacturingClinical Development Stage
PreClinical
453 Ravendale Drive, Suite H
Mountain View, CA, 94043
650-961-9900
http://www.xlumena.comPrimary Contacts
Michael Allen
President & CEO
Company Profile
Xlumena is the leader in the development of image-guided therapeutic endoscopy products specializing in advanced implants and devices that address multiple markets. Collaborating with top physicians in the field, Xlumena focuses on technology that advances therapy to the next level. These innovations may enable numerous translumenal therapeutic procedures, helping transform complex surgeries into outpatient events.Company Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Medical DevicesDisease Areas of Focus
Digestive SystemPrimary Technology
BiomanufacturingClinical Development Stage
PreClinical
XOMA, LLC
2910 Seventh Street
Berkeley, CA, 94710
510 204 7200
http://www.xoma.comPrimary Contacts
Steven B. Engle
Chairman and CEO
Fred Kurland
VP and CFO
Jim Neal
VP, Business Development
Company Profile
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. XOMA's most advanced proprietary product candidate is XOMA 052, an antibody to interleukin-1 beta that is in Phase 2 clinical development and has multi-indication potential. XOMA is developing XOMA 052 in collaboration with Les Laboratoires Servier.Company Classification
Bioscience/R&D/Non-Profit conducting R&D
2910 Seventh Street
Berkeley, CA, 94710
510 204 7200
http://www.xoma.comPrimary Contacts
Steven B. Engle
Chairman and CEO
Fred Kurland
VP and CFO
Jim Neal
VP, Business Development
Company Profile
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. XOMA's most advanced proprietary product candidate is XOMA 052, an antibody to interleukin-1 beta that is in Phase 2 clinical development and has multi-indication potential. XOMA is developing XOMA 052 in collaboration with Les Laboratoires Servier.Company Classification
Bioscience/R&D/Non-Profit conducting R&D
ZoneOne Pharma, Inc.
1700 4th St. Ste 214
San Francisco, CA, United States, 94158
415-476-9792
http://www.zoneonepharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
1700 4th St. Ste 214
San Francisco, CA, United States, 94158
415-476-9792
http://www.zoneonepharma.comCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
Therapeutic
Zyomyx, Inc.
26101 Research Road
Hayward, CA, 94545
510-265-8000
http://www.zyomyx.comPrimary Contacts
Peter Wagner
President and CEO
Frank Zaugg
Manager - Research & Development
Joe Riggs
Acting CFO
Company Profile
Biotech research and consultingCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseasePrimary Technology
Cell Biology
Micro ArraysClinical Development Stage
PreClinical
26101 Research Road
Hayward, CA, 94545
510-265-8000
http://www.zyomyx.comPrimary Contacts
Peter Wagner
President and CEO
Frank Zaugg
Manager - Research & Development
Joe Riggs
Acting CFO
Company Profile
Biotech research and consultingCompany Classification
Bioscience/R&D/Non-Profit conducting R&DOrganization Type
DiagnosticDisease Areas of Focus
Infectious DiseasePrimary Technology
Cell Biology
Micro ArraysClinical Development Stage
PreClinical





















































































